BACKGROUND OF THE INVENTION [002] The triglyceride lipase gene family plays a central role in dietary fat absorption, energy homeostasis, and plasma lipoprotein metabolism. Its members include pancreatic lipase, lipoprotein lipase (LPL), hepatic lipase, and endothelial lipase (EL) alternatively referred to as endothelial cell-derived lipase (LIPG). The latter three enzymes function in the plasma compartment and are critical to the metabolism of lipids carried on plasma lipoproteins. EL exhibits almost exclusively phospholipase A1 activity (little to no triglyceride lipase activity). Phospholipase Al activity of EL inhibited by apoCII, whereas LPL, which acts on very low density lipoprotein (VLDL), is activated by apoCII. Of different lipases tested, only EL has been shown to promote significant hydrolysis of high density lipoprotein (HDL) lipid under in vitro conditions and it was concluded that EL modulates lipoprotein metabolism, at least in part,

through its phospholipase activity. (McCoy MG, et al. J Lipid Res. 2002, 43: 921-9). Over expression of EL in the livers of wild type C56B1/6 mice or hapoAI-Tg mice induced by adenovirus exhibit dramatically reduced HDL cholesterol and apoAI concentrations and profoundly altered plasma lipoprotein levels (Jaye M, et al. Nat Genet. 1999,21 : 424-8). Another phospholipase, s- PLA2, when over expressed in hapoAI-Tg mice causes a reduction in HDL cholesterol and apoAI with reduced HDL particle size. EL is up regulated in endothelial cells in response to the cytokines, IL-lb and TNF-a, as well as in response to shear and cyclic stress, all factors implicated in the pathogenesis of atherosclerosis and plaque instability. Up regulation of EL by these factors implicates a role of this novel lipase in atherogenesis and its sequel. Although not demonstrated in animals and based on literature data available, it appears that inhibiting EL could elevate HDL and would have a beneficial effect on atherosclerosis progression. An antisense oligomer that is specific to EL could be a pharmacological agent to treat dyslipidemia and atherosclerosis.

[003] Antisense technology is emerging as an effective means for reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications for the modulation of EL expression.

SUMMARY OF THE INVENTION [004] The present invention is directed to antisense compounds, particularly oligonucleotides, which are targeted to a nucleic acid encoding EL,

and which modulate the expression of EL. Pharmaceutical and other compositions comprising the antisense compounds of the invention are also provided. Further provided are methods of modulating the expression of EL in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of EL by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the invention.

DETAILED DESCRIPTION OF THE INVENTION [005] The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid molecules encoding EL, ultimately modulating the amount of EL produced.

This is accomplished by providing antisense compounds, which specifically hybridize with one or more nucleic acids encoding EL. As used herein, the terms"target nucleic acid"and"nucleic acid encoding EL"encompass DNA encoding EL, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds, which specifically hybridize to it, is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein

translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of EL. In the context of <BR> <BR> the present invention, "modulation"means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation, of gene expression and mRNA is a preferred target.

[006] It is preferred to target specific nucleic acids for antisense.

"Targeting"an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated.

This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is a nucleic acid molecule encoding EL. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e. g. , detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene.

Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the"AUG codon, "the"start codon"or the"AUG start codon". A minority of genes have a

translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'- CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo.

Thus, the terms"translation initiation codon"and"start codon"can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular <BR> <BR> set of conditions. In the context of the invention, "start codon"and"translation initiation codon"refer to the codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding EL, regardless of the sequence (s) of such codons.

[007] It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i. e. 5'-UAA9 59-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'- TGA, respectively). The terms"start codon region"and"translation initiation codon region"refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i. e., 5'or 3') from a translation initiation codon. Similarly, the terms"stop codon region" and"translation termination codon region"refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in <BR> <BR> either direction (i. e. , 5'or 3') from a translation termination codon.<BR> <P>[008] The open reading frame (ORF) or"coding region, "which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted

effectively. Other target regions include the 5'untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5'direction from the translation initiation codon, and thus including nucleotides between the 5'cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3'untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3'direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3'end of an mRNA or corresponding nucleotides on the gene. The 5'cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5'triphosphate linkage. The 5'cap region of an mRNA is considered to include the 5'cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5'cap region may also be a preferred target region.

[009] Although some eukaryotic mRNA transcripts are directly translated, <BR> <BR> many contain one or more regions, known as"introns, "which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as"exons"and are spliced together to form a continuous <BR> <BR> mRNA sequence. mRNA splice sites, i. e. , intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

[0010] Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i. e. , hybridize sufficiently well and with sufficient specificity, to give the desired effect.

[0011] In the context of this invention, "hybridization"means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases, which pair <BR> <BR> through the formation of hydrogen bonds. "Complementary,"as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable"and "complementary"are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable.

An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the

antisense compound to non-target sequences under conditions in which specific binding is desired, i. e. , under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.

[0012] Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

[0013] The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotides have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans. In the context of this invention, the term "oligonucleotide"refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of

desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

[0014] While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 30 nucleobases (i. e. from about 8 to about 30 linked nucleo sides). Particularly preferred antisense compounds are antisense oligonucleotides, even more preferably those comprising from about 12 to about 25 nucleobases. As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base.

The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3'or 5'hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the intemucleoside backbone of the oligonucleotide. The normal I linkage or backbone of RNA and DNA is a 3'to 5'phosphodiester linkage.

[0015] Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non- natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

[0016] Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5'linkages, 2'-5'linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3'or 2'-5'to 5'-2'. Various salts, mixed salts and free acid forms are also included.

[0017] Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U. S.

3,687, 808; 4,469, 863; 4, 476, 301 ; 5,023, 243; 5,177, 196; 5,188, 897 ; 5,264, 423; 5,276, 019; 5,278, 302; 5,286, 717; 5,321, 131; 5,399, 676; 5,405, 939; 5, 4539496 ; 5,455, 233; 5,466, 677; 5,476, 925; 5,519, 126; 5,536, 821 ; 5,541, 306; 5, 550, 111 ;

5,563, 253; 5,571, 799; 5,587, 361; and 5,625, 050, each of which is herein incorporated by reference.

[0018] Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones ; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH2 component parts.

[0019] Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U. S. 5,034, 506; 5,166, 315; 5,185, 444; 5,214, 134; 5,216, 141; 5,235, 033; 5,264, 562; 5,264, 564; 5,405, 938; 5,434, 257; 5,466, 677; 5,470, 967; 5,489, 677; 5,541, 307; 5, 561, 225 ; 5,596, 086; 5,602, 240; 5,610, 289; 5,602, 240; 5,608, 046; 5,610, 289; 5, 618, 704 ; 5,623, 070; 5,663, 312; 5,633, 360; 5,677, 437; and 5,677, 439, each of which is herein incorporated by reference.

[0020] In other preferred oligonucleotide mimetics, both the sugar and the <BR> <BR> internucleoside linkage, i. e. , the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. one such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization

properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U. S. 5,539, 082; 5,714, 331 ; and 5,719, 262, each of which is herein incorporated by reference.

Further teaching of PNA compounds can be found in Nielsen et al., Science, 1991,254, 1497-1500.

[0021] Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular-CH2-NH-O-CH2-,-CH2-N (CH3)-O-CH2- [known as a methylene (methylimino) or MMI backbone],-CH2-O-N (CH3)-CH2-,- CH2N (CH3) -N (CH3)-CH2- and-0-N (CH3) -CH2-CH2- [wherein the native phosphodiester backbone is represented as-O-P-O-CH2-] of the above referenced U. S. patent 5,489, 677, and the amide backbones of the above referenced U. S. patent 5,602, 240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U. S. patent 5,034, 506.

[0022] Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2'position: OH; F; O-, S-, or N-alkyl ; O-, S-, or N-alkenyl; O-, S-or N-alkynyl ; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted Ci to Clo alkyl or C2 to CIO alkenyl and alkynyl. Particularly preferred are O [ (CH2) nO] mCH3, 0 (CH2) n, OCH3, O (CH2) nNH2, O (CH2) nCH3, O (CH2) nONH2, and O (CH2nON [(CH2) nCH3)] 2 where n and m are from 1 to

about 10. Other preferred oligonucleotides comprise one of the following at the 2'position: Ci to Clo, (lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O- alkaryl or 0-aralkyl, SH, SCH3, OCN, Cl, Br, CN, CF3, OCF3, SOCH3, S02CH3, ON02, N02, N3, NH2, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-0-CH2CH20CH3, also known as 2'-O- (2-methoxyethyl) or 2'-MOE) <BR> <BR> (Martin et al., Helv. Chim. Acta, 1995,78, 486-504) i. e. , an alkoxyalkoxy group.

A further preferred modification includes 2'-dimethylaminooxyethoxy, i. e., a O (CH2) 2ON (CH3) 2 group, also known as 2'-DMAOE, as described in examples herein below, and 2'-dimethylaminoethoxyethoxy (also known in the art as 29- O-dimethylaminoethoxyethyl or 2'-DMAEOE), i. e., 2'-O-CH2-O-CH2-N (CH2) 2, also described in examples herein below.

[0023] Other preferred modifications include 2'-methoxy (2'-O CH3), 2F- aminopropoxy (2'-O CH2 CH2 CH2NH2) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3'position of the sugar on the 3'terminal nucleotide or in 2'-5' linked oligonucleotides and the 5'position of 5'terminal nucleotide.

Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U. S. 4,981, 957 ; 5,118, 800; 5,319, 080; 5,359, 044; 5,393, 878;

5,446, 137; 5,466, 786; 5,514, 785; 5,519, 134; 5,567, 811; 5,576, 427; 5,591, 722; 5,597, 909; 5,610, 300; 5,627, 053; 5,639, 873; 5,646, 265; 5,658, 873; 5,670, 633; and 5,700, 920, each of which is herein incorporated by reference in its entirety.

[0024] Oligonucleotides may also include nucleobase (often referred to in the art simply as"base") modifications or substitutions. As used herein, "unmodified"or"natural"nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U).

Modified nucleobases include other synthetic and natural nucleobases such as 5- methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2- thiothyrnine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4- thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8- substituted adenines and guanines, 5-halo particularly 5-bromo, 5- trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylquanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7- deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in United States Patent No. 3,687, 808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858- 859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991,30, 613, and those <BR> <BR> disclosed by Sanghvi, Y. S. , Chapter 15, Antisense Research and Applications, pages 289-302, Crooke, S. T. and Lebleu, B. ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of

the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5- methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1. 2°C (Sanghvi, Y. S. , Crooke, S. T. and Lebleu, B. , eds, Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 276- 278) and are presently preferred base substitutions, even more particularly when combined with 2'-O-methoxyethyl sugar modifications.

[0025] Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U. S. 3,687, 808, as well as U. S. 4, 845, 205; 5,130, 302; 5,134, 066; 5,175, 273; 5,367, 066; 5,432, 272; 5,457, 187; 5,459, 255; 5,484, 908; 5,502, 177; 5,525, 711; 5,552, 540; 5, 587, 469 ; 5,594, 121; 5,596, 091; 5,614, 617; 5,750, 692 and 5,681, 941, each of which is herein incorporated by reference.

[0026] Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates, which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86,6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Let., 1994, <BR> <BR> 4,1053-1060), a thioether, e. g. , hexyl-S-tritylthiol (Manoharan et al., Ann. N. Y.

Acad. Sci., 1992,660, 306-309; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3,2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992,20, 533-538), an aliphatic chain, e. g. , dodecandiol or undecyl residues

(Saison-Behmoaras et al., EMBO J., 1991,10, 1111-1118; Kabanov et al., FEBS Lett., 1990,259, 327-330; Svinarchuk et al., Biochimie, 1993,75, 49-54), a phospholipid, e. g. , di-hexadecyl-rac-glycerol or triethylammonium 1, 2-di-O- hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995,36, 365'-3654 ; Shea et al., Nucl. Acids Res., 1990,18, 3777-3783), a polyamine or a polyethylene glycol chain (Mancharan et al., Nucleosides & Nucleotides, 1995,14, 969-973), or adamantan acetic acid (Manoharan et al., Tetrahedron Lett., 1995,36, 365'-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995,1264, 229-237), or an octadecylamine or <BR> <BR> hexylamino-carbonyl-oxycholesterol moiety (Crooke et al. , J. Pharmacol. Exp.

Ther., 1996,277, 923-937).

[0027] Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U. S. 4, 828, 979 ; 4,948, 882; 5,218, 105; 5,525, 465; 5,541, 313; 5,545, 730; 5,552, 538; 5, 57897179 5,580, 731; 5,580, 731; 5,591, 584; 5,109, 124; 5,118, 802; 5,138, 045; 5,414, 077; 5,486, 603; 5,512, 439; 5,578, 718; 5,608, 046; 4,587, 044; 4,605, 735; 4, 667, 025 ; 4,762, 779; 4,789, 737; 4,824, 941; 4, 835, 263; 4,876, 335; 4,904, 582; 4,958, 013; 5,082, 830; 5,112, 963; 5,214, 136; 5,082, 830; 5,112, 963; 5,214, 136; 5,245, 022 ; 5,254, 469; 5,258, 506; 5,262, 536; 5,272, 250; 5,292, 873; 5,317, 098; 5, 3719241, 5,391, 723; 5,416, 203,5, 451,463 ; 5,510, 475; 5,512, 667; 5,514, 785; 5,565, 552; 5,567, 810; 5,574, 142; 5,585, 481; 5,587, 371; 5,595, 726; 5,597, 696; 5,599, 923 ; 5,599, 928 and 5,688, 941, each of which is herein incorporated by reference.

[0028] It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single

nucleoside within an oligonucleotide. The present invention also includes antisense compounds, which are chimeric compounds."Chimeric"antisense compounds or"chimeras, "in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more <BR> <BR> chemically distinct regions, each made up of at least one monomer unit, i. e. , a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA: DNA or RNA: RNA hybrids.

By way of example, RNase H is a cellular endonuclease, which cleaves the RNA strand of RNA: DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

[0029] Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such

hybrid structures include, but are not limited to, U. S. 5,013, 830; 5,149, 797; 5,220, 007; 5,256, 775; 5,366, 878; 5,403, 711; 5,491, 133; 5,565, 350; 5,623, 065; 5,652, 355; 5, 652, 356; and 5,700, 922, each of which is herein incorporated by reference in its entirety.

[0030] The antisense compounds used in accordance with this invention may be conveniently, and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

[0031] The antisense compounds of the invention are synthesized in vitro and do not include antisense compositions of biological origin, or genetic vector constructs designed to direct the in vivo synthesis of antisense molecules. The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption assisting formulations include, but are not limited to, U. S. 5,108, 921; 5,354, 844; 5,416, 016; 5,459, 127; 5, 521, 291; 5,543, 158 ; 5,547, 932; 5,583, 020; 5, 5919721 ; 4,426, 330; 4,534, 899; 5,013, 556; 5,108, 921; 5,213, 804; 5,227, 170; 5,264, 221; 5,356, 633; 5,395, 619; 5,416, 016 ; 5,417, 978 ; 5,462, 854; 5,469, 854 ; 5, 512, 295 ; 5,527, 528; 5,534, 259; 5, 543, 152 ;

5,556, 948; 5,580, 575; and 5,595, 756, each of which is herein incorporated by reference.

[0032] The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human ; is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

[0033] The term"prodrug"indicates a therapeutic agent that is prepared in <BR> <BR> an inactive form that is converted to an active form (i. e. , drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonuclectides of the invention are prepared as SATE [ (S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published December 9,1993 or in WO 94/26764 to Imbach et al.

[0034] The term"pharmaceutically acceptable salts"refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i. e. , salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

[0035] Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines.

Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N, N'-

dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al.,"Pharmaceutical Salts,"J. of Phartna Sci., 1977,66, 119). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a"pharmaceutical addition salt"includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N- substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2- acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with

amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2- hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfoic acid, \naphthalene-2-sulfonic acid, naphthalene-1,5- disulfonic acid, 2-or 3-phosphoglycerate, glucose-6-phosphate, N- cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation.

Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

[0036] For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

[0037] The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder, which can be treated by modulating the expression of EL, is treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the antisense compounds and methods of the invention may also be useful prophylactically, e. g. , to prevent or delay infection, inflammation or tumor formation, for example.

[0038] The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding EL, enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding EL can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of EL in a sample may also be prepared.

[0039] The present invention also includes pharmaceutical compositions and formulations, which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery) s

pulmonary, e. g. , by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e. g. , intrathecal or intraventricular, administration.

Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

[0040] Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

[0041] Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

[0042] Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions, which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

[0043] Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations.

These compositions may be generated from a variety of components that

include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

[0044] The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier (s) or excipient (s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

[0045] The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non- aqueous or mixed media. Aqueous suspensions may further contain substances, which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

[0046] In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product.

The preparation of such compositions and formulations is generally known to

those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention. Emulsions [0047] The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 um in diameter. (Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and <BR> <BR> Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N. Y. , volume 1, p. 199; Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker <BR> <BR> (Eds. ), 1988, Marcel Dekker, Inc. , New York, N. Y. , Volume 1, p. 245; Block in<BR> Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds. ), 1988,<BR> Marcel Dekker, Inc. , New York, N. Y., volume 2, p. 335; Higuchi et al. , in<BR> Remington's Pharmaceutical Sciences, Mack Publishing Co. , Easton, PA, 1985, p. 301). Emulsions are often biphasic systems comprising of two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be either water-in-oil (w/o) or of the oil-in-water (o/w) variety.

When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases and the active drug, which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase.

Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti- oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases

such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil- in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous provides an o/w/o emulsion.

[0048] Emulsions are characterized by little or no thermodynamic stability.

Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion.

Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in Pharmaceutical Dosaqe Forms, Lieberman, Rieger and Banker (Eds. ), 1988, Marcel Dekker, Inc. , New York, N. Y., volume 1, p. 199).

[0049] Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger, in Pharmaceutical Dosage Forms, <BR> <BR> Lieberman, Rieger and Banker (Eds. ), 1988, Marcel Dekker, Inc., New York,<BR> N. Y. , volume 1, p. 285; Idson, in Pharmaceutiecal Dosage Forms, Lieberman,<BR> Rieger and Banker (Eds. ), Marcel Dekker, Inc., New York, N. Y. , 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of

the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds. ), 1988, Marcel Dekker, Inc. , New York, N. Y. , volume 1, p. 285).

[0050] Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

[0051] A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives, and antioxidants (Block, in Pharmaceutical <BR> <BR> Dosage Forms, Lieberman, Rieger and Banker (Eds. ), 1988, Marcel Dekker,<BR> Inc. , New York, N. Y. , volume 1, p. 335; Idson, in Pharmaceutical Dosage<BR> Forms, Lieberman, Rieger and Banker (Eds. ), 1988, Marcel Dekker, Inc., New<BR> York, N. Y. , volume 1, p. 199).

[0052] Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersedphase droplets and by increasing the viscosity of the external phase.

[0053] Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives.

Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

[0054] The application of emulsion formulations via dermatological, oral, and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and <BR> <BR> Banker (Eds. ), 1988, Marcel Dekker, Inc. , New York, N. Y. , volume 1, p. 199).

Emulsion formulations for oral delivery have been very widely used because of

reasons of ease of formulation, efficacy from an absorption and bioavailability standpoint. (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and <BR> <BR> Banker (Eds.), 1988, Marcel Dekker, Inc. , New York, N. Y. , volume 1, p. 245; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc. , New York, N. Y. , volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

[0055] In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile, which is a single optically isotropic, and thermodynamically stable liquid solution (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds. ), 1988, Marcel Dekker, Inc., New York, N. Y. , volume 1, p. 245).

Typically microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: Controlled Release of Drugs : Polymers and Aggregate Systems, Rosoff, M. , Ed. , 1989, VCH Publishers, New York, pages 1852'5).

Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte.

Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w)

type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in Remington's Pharmaceutical Sciences, Mack Publishing Co. , Easton, PA, 1985, p. 271).

[0056] The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds. ), 1988, Marcel Dekker,<BR> Inc. , New York, N. Y. , volume 1, p. 245; Block, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N. Y. , volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

[0057] Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (M0310), hexaglycerol monooleate (P0310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate (M0750), decaglycerol sequioleate (S0750), decaglycerol decaoleate (DA0750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant

molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and triglycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

[0058] Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides et al., Pharmaceutical Research, 1994, 11, 1385-1390 ; Ritschel, Meth. Find. Exp.

Clin. Pharmacol., 1993,13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides et al., Pharmaceutical Research, 1994,11, 1385; Ho et al. , J. Pharm. Sci., 1996,85, 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or oligonucleotides. Microemulsions have also

been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.

[0059] Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the oligonucleotides and nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as belonging to one of five broad categories- surfactants, fatty acids, bile salts, chelating agents, and non-chelating non- surfactants (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems7 1991, p. 92). Each of these classes has been discussed above.

Liposomes [0060] There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs.

These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term"liposome"means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

[0061] Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Noncationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages in vivo.

[0062] In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome, which is highly deformable and able to pass through such fine pores.

[0063] Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and <BR> <BR> Banker (Eds. ), 1988, Marcel Dekker, Inc. , New York, N. Y. , volume 1, P. 245).

Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

[0064] Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes. As the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

[0065] Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

[0066] Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

[0067] Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes, which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., Biochem.

Biophys. Res. Commun., 1987,147, 980-985) [0068] Liposomes, which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs.

Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the

exogenous gene was detected in the target cells (Zhou et al., Journal of Controlled Release, 1992,19, 269-274).

[0069] One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC).

Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

[0070] Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e. g. as a solution or as an emulsion) were ineffective (Weiner et al., Journal of Drug Targeting, 1992,2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis et al., Antiviral Research, 1992, 18, 259-265).

[0071] Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome TM I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-

stearyl ether) and NovasomeTM II (glyceryl distearate/ cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin- A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu et al. S. T. P. Pharma. Sci., 1994,4, 6,466).

[0072] Liposomes also include"sterically stabilized"liposomes, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside GM1, or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., FEBS Letters, 1987,223, 42; Wu et al., Cancer Research, 1993, 53, 3765).

[0073] Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (Ann. N. Y. Acad. Sci., 1987,507, 64) reported the ability of monosialoganglioside GMI, galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (Proc. Natl. Acad. Sci. U. S. A. , 1988, 85,6949). U. S. Patent No. 4,837, 028 and WO 88/04924, both to Allen et al.,

disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside Gjor a galactocerebroside sulfate ester. U. S. Patent No. 5,543, 152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn- dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al.).

[0074] Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art.

Sunamoto et al. (Bull. Chem. Soc. Jpn., 1980,53, 2778) described liposomes comprising a nonionic detergent, 2CI215G that contains a PEG moiety. Illum et al. (FEBS Lett., 1984,167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half- lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e. g. , PEG) are described by Sears (U. S. Patent Nos.

4,426, 330 and 4,534, 899). Klibanov et al. (FEBS Lett., 1990,268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume et al. (Biocllimica et Bioplzysica Acta, 1990,1029, 91) extended such observations to other <BR> <BR> PEGderivatized phospholipids, e. g. , DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B 1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle et al. (U. S. Patent Nos.

5,013, 556 and 5,356, 633) and Martin et al. (U. S. Patent No. 5,213, 804 and European Patent No. EP 0 496 813 Bl). Liposomes comprising a number of

other lipid-polymer conjugates are disclosed in WO 91/05545 and U. S. Patent No. 5,225, 212 (both to Martin et al. ) and in WO 94/20073 (Zalipsky et al.) Liposomes comprising PEG-modified ceramide lipids are described in WO <BR> <BR> 96/10391 (Choi et al. ). U. S. Patent Nos. 5,540, 935 (Miyazaki et al. ) and<BR> 5,556, 948 (Tagawa et al. ) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

[0075] A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry et al. discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U. S. Patent No. 5,264, 221 to Tagawa et al. discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense RNA. U. S. Patent No. 5,665, 710 to Rahman et al. describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love et al. discloses liposomes comprising antisense oligonucleotides targeted to the raf gene.

[0076] Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e. g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge- activators, usually surfactants, to a standard liposomal composition.

Transfersomes have been used to deliver serum albumin to the skin. The

transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

[0077] Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the"head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in Pharmaceutical Dosage Forms, Marcel Dekker, Inc., New York, NY, 1988, p. 285) [0078] If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure.

Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

[0079] If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl

sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

[0080] If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

[0081] If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N- alkylbetaines and phosphatides.

[0082] The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in Pharmaceutical Dosage Forms, Marcel Dekker, Inc. , New York, NY, 1988, p. 285). Penetration Enhancers [0083] In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

[0084] Penetration enhancers may be classified as belonging to one of five broad categories, i. e. , surfactants, fatty acids, bile salts, chelating agents, and

non-chelating nonsurfactants (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

Surfactants: [0085] In connection with the present invention, surfactants (or"surface- active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the mucosa. is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., J. Phare.

Pharmacol., 1988,40, 252).

Fatty acids : [0086] Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-. rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2- one, acylcarnitines, acylcholines, Cl 10 alkyl esters thereof (e. g., methyl, isopropyl and t-butyl), and mono-and di-glycerides thereof (i. e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc. ) (Lee et al., Critical

Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92; Muranishi, Critical <BR> Reviews in Therapeutic Drug Carrier Systems, 1990,7, 1-33 ; El Hariri et al. , J.

Phaml. Pharmacol., 1992,44, 651-654).

Bile salts: [0087] The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Hardman et al. Eds. McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers.

Thus the term"bile salts"includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucholic acid (sodium glucholate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate'and polyoxyethylene-9-lauryl ether (POE) (Lee et <BR> al. , Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92;<BR> Swinyard, Chapter 39 In: Remington's Pharmaceutical Sciences, 18th Ed. ,<BR> Gennaro, ed., Mack Publishing Co. , Easton, PA, 1990, pages 782-783; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-

33; Yamamoto et al., J. Phann. Exp. Ther., 1992,263, 25; Yamashita et al. , J.

Pharm. Sci., 1990,79, 579-583).

Chelating Agents: [0088] Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, J. Chrosnatogr., 1993, 618, 315-339). Chelating agents of the invention include but are not limited to sodium. ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e. g. , sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9, and N-amino acyl derivatives of beta-diketones (enamines) (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92; Muranishi, Critical Reviews <BR> in Therapeutic Drug Carrier Systems, 1990,7, 1-33 ; Buur et al. , J. Control Rel., 1990,14, 43-51).

Non-chelating non-surfactants: [0089] As used herein, nonchelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa (Muranishi, Critical Reviews in

Therapeutic Drug Carrier Systems, 1990,7, 1-33). This class of penetration enhancers includes, for example, unsaturated cyclic ureas, 1-alkyl-and 1- alkenylazacyclo-alkanone derivatives (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92); and non-steroidal anti- inflammatory agents such as diclofenac sodium, indomethacin, and phenylbutazone (Yamashita et al., J. Pharm. Pharmacol., 1987,39, 621-626).

[0090] Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U. S.

Patent No. 5,705, 188), cationic glycerol derivatives, and polycationic <BR> molecules, such as polylysine (Lollo et al. , PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

[0091] Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

Carriers [0092] Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, "carrier compound"or "carrier"can refer to a nucleic acid, or analog thereof, which is inert (i. e., does not possess biological activity per se) but is recognized as a nucleic acid by in vivo processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid

and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonuclectide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'isothiocyano-stilbene-2, 2'disulfonic acid (Miyao et al., Antisense Res. Dev., 1995,5, 115-121; Takakura et al., Antisense & Nucl. Acid Drug Dev., 1996,6, 177-183).

Excipients [0093] In contrast to a carrier compound, a"pharmaceutical carrier"or "excipient"is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, <BR> consistency, etc. , when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e. g. , pregelatinized maize starch,<BR> polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc. ) ; fillers (e. g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium <BR> sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc. ) ;<BR> lubricants (e. g. , magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc. ) ; disintegrants (e. g. , starch,

sodium starch glycolate, etc. ) ; and wetting agents (e. g. , sodium lauryl sulphate,<BR> etc.).

[0094] Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention.

Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

[0095] Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

[0096] Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like. Other Components [0097] The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or

anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the <BR> <BR> compositions of the present invention. 'The formulations can be sterilized and, if<BR> desired, mixed with auxiliary agents, e. g. , lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid (s) of the formulation.

[0098] Aqueous suspensions may contain substances that increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol, and/or dextran. The suspension may also contain stabilizers.

[0099] Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include, but are not limited to, anticancer drugs such as daunorubicin, dactinomycin, doxorubicin, bleomycin, mitomycin, nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine (CA), 5- fluorouracil (5-FU), floxuridine (5-FUdR), methotrexate (MTX), colchicine, vincristine, vinblastine, etoposide, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, The Merck Manual of Diagnosis and Therapy, l5th Ed., <BR> <BR> Berkow et al., eds. , 1987, Rahway, N. J. , pages 1206-1228). Anti-inflammatory

drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, The Merok Manual of Diagnosis and Therapy, <BR> <BR> 15th Ed. , Berkow et al. , eds. , 1987, Rahway, N. J. , pages 2499-2506 and 46-49, respectively). other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

[00100] In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

[00101] The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on ECsos found to be effective in in vitro and in vivo animal models. In general, dosage is from 0. 01 ug to 100 g per kg of body

weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0. 01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years.

[00102] While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

EXAMPLES Example 1 Nucleoside Phosphoramidites for Oligonucleotide Synthesis Deoxy and 2'- alkoxy amidites [00103] 2'-Deoxy and 2'-methoxy beta-cyanoethyldiisopropyl phosphoramidites are available from commercial sources (e. g. Chemgenes, Needham MA or Glen Research, Inc. Sterling VA). Other 2'-O-alkoxy substituted nucleoside amidites are prepared as described in U. S. Patent 5, 506, 351, herein incorporated by reference. For oligonucleotides synthesized using 2'-alkoxy amidites, the standard cycle for modified oligonucleotides is utilized, except the wait step after pulse delivery of tetrazole and base is increased to 360 seconds.

[00104] Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-C) nucleotides are synthesized according to published methods [Sanghvi, et. al., Nucleic Acids Research, 1993,21, 3197-3203] using commercially available phosphoramidites (Glen Research, Sterling VA or ChemGenes, Needham NM).

2'-Fluoro amidites 2'-Fluorodeoxyadenosine amidites [00105] 2'-fluoro oligonucleotides are synthesized as described previously <BR> [Kawasaki, et. al. , J. Med. Chem., 1993,36, 831-841] and United States patent 5,670, 633, herein incorporated by reference. Briefly, the protected nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine is synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material and by modifying literature procedures whereby the 2'-alpha-fluoro atom is introduced by a SN2-displacement of a 2'-beta-trityl group. Thus N6-benzoyl-9-beta-D- arabinofuranosyladenine is selectively protected in moderate yield as the 39gus'- ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N6- benzoyl groups is accomplished using standard methodologies and standard methods are used to obtain the 5'-dimethoxytrityl- (DMT) and 5'-DMT-3'- phosphoramidite intermediates.

2'-Fluorodeoxyguanosine [00106] The synthesis of 2'-deoxy-2'-fluoroguanosine is accomplished using tetraisopropyldisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate diisobutyrylarabinofuranosylguanosine. Deprotection of the TPDS group is followed by protection of the hydroxyl group with THP to give diisobutyryl di-

THP protected arabinofuranosylguanine. Selective O-deacylation and triflation is followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies are used to obtain the 5'-DMT-and 5'-DMT-3'-phosphoramidites.

2'-Fluorouridine [00107] Synthesis of 2'-deoxy-2'-fluorouridine is accomplished by the modification of a literature procedure in which 2, 2'anhydro-l-beta-D- arabinofuranosyluracil is treated with 70% hydrogen fluoride-pyridine. Standard procedures are used to obtain the 5'-DMT and 5'-DMT-3'-phosphoramidites.

2'-Fluorodeoxycytidine [00108] 2'-deoxy-2'-fluorocytidine is synthesized via amination of 2'-doxy- 2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy- 2'-fluorocytidine. Standard procedures are used to obtain the 5'-DMT and Si- DMT-3'phosphoramidites.

2'-0-(2-Methoxyethyl) modified amidites [00109] 2'-O-Methoxyethyl-substituted nucleoside amidites are prepared as follows, or alternatively, as per the methods of Martin, P., Helvetica Chimica Acta, 1995,78, 486-504.

2, 2'-Anhydro [l-(beta-D-arabinofuranosyl)-5-methyluridinel [00110] 5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) are added to DMF (300 mL). The mixture is heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution is concentrated under reduced pressure. The resulting syrup is poured

into diethylether (2.5 L), with stirring. The product formed a gum. The ether is decanted and the residue is dissolved in a minimum amount of methanol (ca.

400 mL). The solution is poured into fresh ether (2.5 L) to yield a stiff gum. The ether is decanted and the gum is dried in a vacuum oven (60°C at 1 mm Hg for 24 h) to give a solid that is crushed to a light tan powder. The material is used as is for further reactions (or it can be purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white solid.

2'-O-Methoxyethyl-5-methyluridine [00111] 2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris (2- methoxyethyl) borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) are added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel is opened and the solution evaporated to dryness and triturated with MeOH (200 mL). The residue is suspended in hot acetone (1 L). The insoluble salts are filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) is dissolved in CH3CN (600 mL) and evaporated. A silica gel column (3 kg) is packed in CH2Cl2/acetone/MeOH (20: 5: 3) containing 0. 5% Et3NH. The residue is dissolved in CH2C12 (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product is eluted with the packing solvent to give the title product. Additional material can be obtained by reworking impure fractions.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine [00112] 2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) is co- evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0. 278 M) is added and the mixture stirred at room temperature for one hour. A second aliquot of

dimethoxytrityl chloride (94.3 g, 0.278 M) is added and the reaction stirred for an additional one hour. Methanol (170 mL) is then added to stop the reaction.

The solvent is evaporated and triturated with CH3CN (200 mL) The residue is dissolved in CHC1 (1.5 L) and extracted with 2x500 mL of saturated NaXICO3 and 2x500 mL of saturated NaCl. The organic phase is dried over Na2SO4, filtered, and evaporated. The residue is purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/hexane/acetone (5: 5: 1) containing 0-5% Et3NH.

The pure fractions are evaporated to give the title product.

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylu ridine [00113] 2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3: 1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0. 258 M) are combined and stirred at room temperature for 24 hours. The reaction is monitored by TLC by first quenching the TLC sample with the addition of MeOH. Upon completion of the reaction, as judged by TLC, MeOH (50 mL) is added and the mixture evaporated at 35°C. The residue is dissolved in CHC13 (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water layers are back extracted with 200 mL of CHC13. The combined organics are dried with sodium sulfate and evaporated to a residue. The residue is purified on a 3.5 kg silica gel column and eluted using EtOAc/hexane (4: 1). Pure product fractions are evaporated to yield the title compounds.

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl- 4- triazoleuridine

[00114] A first solution is prepared by dissolving 3'-O-acetyl-2'-O- methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH3CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) is added to a solution of triazole (90 g, 1.3 M) in CH3CN (1 L), cooled to-5°C and stirred for 0.5 h using an overhead stirrer. POC13 is added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours. The first solution is added dropwise, over a 45 minute period, to the latter solution. The resulting reaction mixture is stored overnight in a cold room. Salts are filtered from the reaction mixture and the solution is evaporated. The residue is dissolved in EtOAc (1 L) and the insoluble solids are removed by filtration. The filtrate is washed with 1x300 mL of NaHC03 and 2x300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue is triturated with EtOAc to give the title compound.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine [00115] A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl- 5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and IVIOI (30 mL) is stirred at room temperature for 2 hours. The dioxane solution is evaporated and the residue azeotroped with MeOH (2x200 mL). The residue is dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with NH3 gas is added and the vessel heated to 100°C for 2 hours (TLC showed complete conversion). The vessel contents are evaporated to dryness and the residue is dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics are dried over sodium sulfate and the solvent is evaporated to give the title compound.

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcy tidine

[00116] 2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) is dissolved in DUT (800 mL) and benzoic anhydride (37.2 g, 0.165 M) is added with stirring. After stirring for 3 hours, TLC showed the reaction to be approximately 95% complete. The solvent-'is evaporated and the residue azeotroped with MeOH (200 mL). The residue is dissolved in CHC 13 (700 mL) and extracted with saturated NaHCO, (2x300 mL) and saturated NaCl (2x300 mL), dried over MgS04 and evaporated to give a residue. The residue is chromatographed on a 1.5 kg silica column using EtOAc/hexane (1 : 1) containing 0-5% Et3NH as the eluting solvent. The pure product fractions are evaporated to give the title compound. <BR> <BR> <P>N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5 -methylcytidine-39<BR> amidite [00117] N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5- methylcytidine (74 g, 0. 10 M) is dissolved in CH2C12 (1 L) Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra (isopropyl) phosphite (40.5 mL, 0.123 M) are added with stirring, under a nitrogen atmosphere. The resulting mixture is stirred for 20 hours at room temperature (TLC showed the reaction to be 95% complete). The reaction mixture is extracted with saturated NaHCO3 (1x300 mL) and saturated NaCl (3x300 mL). The aqueous washes are back-extracted with CH2C12 (300 mL), and the extracts are combined, dried over MgS04 and concentrated. The residue obtained is chromatographed on a 1.5 kg silica column using EtOAc/hexane (3: 1) as the eluting solvent. The pure fractions were combined to give the title compound.

2'-O- (Aminooxyethyl) nucleoside amidites and 2'-O- (dimethylaminooxyethyl) nucleoside amidites 2'- (Dimethylaminooxyethoxy) nucleoside amidites [00118] 2'- (Dimethylaminooxyethoxy) nucleoside amidites [also known in the art as 2'-O- (dimethylaminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine. <BR> <P>5'-O-tert-Butyldiphenylsilyl O2-2'-anhydro-5-methyluridine<BR> [00119] 02-2'-anhydro-5-methyluridine (Pro. Bio. Sint. , Varese, Italy, 100. 0g, 0.4'6 mmol), dimethylaminopyridine (0.66g, 0.013eq, 0. 0054mmol) are dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. tert-Butyldiphenylchlorosilane (125. 8g, 119. 0mL, l. leq, 0. 458mmol) is added in one portion. The reaction is stirred for 16 h at ambient temperature. TLC (Rf 0. 22, ethyl acetate) indicated a complete reaction. The solution is concentrated under reduced pressure to a thick oil. This is partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2xl L) and brine (1 L). The organic layer is dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil is dissolved in a 1: 1 mixture of ethyl acetate and ethyl ether (600mL) and the solution is cooled to-10°C. The resulting crystalline product is collected by filtration, washed with ethyl ether (3x200 mL), and dried (40°C, 1mm Hg, 24 h) to a white solid

5'-O-tert-Butyldiphenylsilyl-2'-0-(2-hydroxyethyl)-5-methylu ridine [00120] In a 2 L stainless steel, unstirred pressure reactor is added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) is added cautiously at first until the evolution of hydrogen gas subsides. 5'-O-tert-Butyldiphenylsilyl-02-2'anhydro- 5-methyluridine (149 g, 0. 3'1 mol) and sodium bicarbonate (0.074 g, 0.003 eq) are added with manual stirring. The reactor is sealed and heated in an oil bath until an internal temperature of 160°C is reached and then maintained for 16 h (pressure < 100 psig). The reaction vessel is cooled to ambient and opened. TLC (Rf 0.67 for desired product and Rf 0. 82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional side product formation, the reaction is stopped, concentrated under reduced pressure (10 to lmm, Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase. ] The residue is purified by column chromatography (2kg silica gel, ethyl acetate-hexanes gradient 1 : 1 to 4: 1). The appropriate fractions are combined, stripped and dried to product as a white crisp foam, contaminated starting material, and pure reusable starting material. <BR> <BR> <P>2'-0- ( [2-phthalimidoxy) ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine<BR> [00121] 5'-O-tert-Butyldiphenylsilyl-2'-0-(2-hydroxyethyl)-5-methylu ridine (20g, 36.98mmol) is mixed with triphenylphosphine (11. 63g, 44. 36mmol) and N-hydroxyphthalimide (7.24g, 44. 36mmol). It is then dried over P205 under high vacuum for two days at 40°C. The reaction mixture is flushed with argon

and dry THF (369.8mL, Aldrich, sure seal bottle) is added to get a clear solution. Diethyl-azodicarboxylate (6. 98mL, 44. 36mmol) is added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. After the addition is complete, the reaction is stirred for 4 hrs. By that time TLC showed the completion of the reaction (ethylacetate: hexane, 60: 40). The solvent is evaporated in vacuum. Residue obtained is placed on a flash column and eluted with ethyl acetate: hexane (60: 40), to get 2'-O- ( [2-phthalimidoxy) ethyl]-5'-t- butyldiphenylsilyl-5-methyluridine as white foam.

5'-O-tert-butyldiphenylsilyl-2'-0-[(2-formadoximinooxy) ethyl] -5- methyluridine [00122] 2'-O- ( [2-phthalimidoxy) ethyl]-5'-t-butyldiphenylsilyl-5- methyluridine (3.1g, 4. 5mmol) is dissolved in dry CH2C12 (4. 5mL) and methylhydrazine (300mL, 4. 64mmol) is added dropwise at-10°C to 0°C. After 1 h the mixture is filtered, the filtrate is washed with ice cold CH2C12 and the combined organic phase is washed with water, brine and dried over anhydrous Na2S04. The solution is concentrated to get 2'-O (aminooxyethyl) thymidine, which is then dissolved in MeOH (67. 5mL). To this formaldehyde (20% <BR> <BR> aqueous solution, w/w, 1.1 eq. ) is added and the resulting mixture is stirred for 1 h. Solvent is removed under vacuum; residue chromatographed to get 5'-O-tert- butyldiphenylsilyl-2'-0-[(2-formadoximinooxy) ethyl] -5-methyluridine as white foam.

5'-O-tert-Butyldiphenylsilyl-2'-O- [N, N-dimethylaminooxyethyl]-5- methyluridine

[00123] 5'-O-tert-butyldiphenylsilyl-2'-0-[(2-formadoximinooxy) ethyl]-5- methyluridine (1.77g, 3. 12mmol) is dissolved in a solution of 1M pyridinium p- toluenesulfonate (PPTS) in dry MeOH (30.6mL). Sodium cyanoborohydride (0.39g, 6. 13mmol) is added to this solution at 10°C under inert atmosphere. The reaction mixture is stirred for 10 minutes at 10°C. After that the reaction vessel is removed from the ice bath and stirred at room temperature for 2 h, the reaction monitored by TLC (5% MeOH in CH2C12). Aqueous NaHCO3 solution (5%, lOmL) is added and extracted with ethyl acetate (2x20mL). Ethyl acetate phase is dried over anhydrous Na2S04, evaporated to dryness. Residue is dissolved in a solution of 1M PPTS in MeOH (30.6mL). Formaldehyde (20% w/w, 30mL, 3. 37mmol) is added and the reaction mixture is stirred at room temperature for 10 minutes. Reaction mixture cooled to 10°C in an ice bath, sodium cyanoborohydride (0.39g, 6. 13mmol) is added, and reaction mixture stirred at 10°C for 10 minutes. After 10 minutes, the reaction mixture is removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5% NaHC03 (25mL) solution is added and extracted with ethyl acetate (2x25mL). Ethyl acetate layer is dried over anhydrous Na2S04 and evaporated to dryness. The residue obtained is purified by flash column chromatography and eluted with 5% MeOH in CH2C12 to get 5'-O- tertbutyldiphenylsilyl-2'-O-[N, N-dimethylaminooxyethyl]-5-methyluridine as a white foam.

2'-0- (dimethylaminooxyethyl)-5-methyluridine [00124] Triethylamine trihydrofluoride (3. 91mL, 24. 0mmol) is dissolved in dry THF and triethylamine (1.67mL, 12mmol, dry, kept over KOH). This mixture of triethylamine-2HF is then added to 5'-O-tert-butyldiphenylsilyl-2'-

0- [N, N-dimethylaminooxyethyl] -5-methyluridine (1.40g, 2. 4mmol) and stirred at room temperature for 24 hrs. Reaction is monitored by TLC (5% MeOH in CH2C12). Solvent is removed under vacuum and the residue placed on a flash column and eluted with 10% MeOH in CH2C12 to get 2'-O- (dimethylaminooxyethyl)-5-methyluridine.

5'-O-DMT-2'-O-(dimethylaminooxyethyl)-5-methyluridine [00125] 2'-O-(dimethylaminooxyethyl)-5-methyluridine (750mg, 2.17mmol) is dried over P205 under high vacuum overnight at 40°C. It is then co- evaporated with anhydrous pyridine (20mL). The residue obtained is dissolved in pyridine (1 lmL) under argon atmosphere. 4-dimethylaminopyridine (26. 5mg, 2. 60mmol), 4,4'-dimethoxytrityl chloride (880mg, 2. 60mmol) is added to the mixture and the reaction mixture is stirred at room temperature until all of the starting material disappeared. Pyridine is removed under vacuum and the residue chromatographed and eluted with 10% MeOH in CH2C12 (containing a few drops of pyridine) to get 5'-O-DMT-2'-0 (dimethylamino-oxyethyl) -5- methyluridine. <BR> <BR> <P>5'-O-DMT-2'-0-(2-N, N-dimethylaminooxyethyl)-5-methyluridine-3S-[(2n<BR> cyanoethyl) -N, N- diisopropylphosphoramidite] [00126] 5'-O-DMT-2'-O-(dimethylaminooxyethyl)-5-methyluridine (1. 08g, 1. 67mmol) is co-evaporated with toluene (20mL). To the residue N, N- diisopropylamine tetrazonide (0.29g, 1. 67mmol) is added and dried over P20, under high vacuum overnight at 40°C. Then the reaction mixture is dissolved in anhydrous acetonitrile (8. 4mL) and 2-cyanoethyl-N, N, NI, NI- tetraisopropylphosphoramidite (2. 12mL, 6. 08mmol) is added. The reaction mixture is stirred at ambient temperature for 4 hrs under inert atmosphere. The

progress of the reaction is monitored by TLC (hexane: ethyl acetate 1: 1). The solvent is evaporated, then the residue is dissolved in ethyl acetate (70mL) and washed with 5% aqueous NaHCO3 (40mL). Ethyl acetate layer is dried over anhydrous Na2S04 and concentrated. Residue obtained is chromatographed (ethyl acetate as eluent) to get 5'-O-DMT-2'-O- (2-N, N- dimethylaminooxyethyl)-5-methyluridine-3'- [ (2-cyanoethyl)-N, N- diisopropylphosphoramidite] as a foam.

2'- (Aminooxyethoxy) nucleoside amidites [00127] 2'- (Aminooxyethoxy) nucleoside amidites [also known in the art as 2'-O- (aminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared similarly.

N2-isobutyryl-6-O-diphenylcarbamoyl-2'-0- ethylacetyl)-5'-0-(4, (4, 4 dimethoxytrityl) guanosine-3'- [(2-cyanoethyl)-N, N- diisopropylphosphoramidite] [00128] The 2'-O-aminooxyethyl guanosine analog may be obtained by selective 2'-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2'-O- (2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3'-O-isomer. 2'-O- (2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2'-O- (2ethylacetyl) guanosine by treatment with adenosine <BR> <BR> deaminase. (McGee, D. P. C. , Cook, P. D., Guinosso, C. J. , WO 94/02501 AI<BR> 940203. ) Standard protection procedures should afford 2'-0- (2-ethylacetyl)-5'- 0- (4, 4'-dimethoxytrityl) guanosine and 2-N-isobutyryl-6-O-diphenylcarbamoyl- 2'-O- (2-ethylacetyl)-5'-O- (4, 4'-dimethoxytrityl) guanosine which may be

reduced to provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-0-(2- ethylacetyl)-5'-O- (4, 4'-dimethoxytrityl) guanosine. As before the hydroxyl group may be displaced by N-hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may phosphitylated as usual to yield 2-N- isobutyryl-6-0-diphenylcarbamoyl-2'-O- (2-ethylacetyl)-5'-O- (4, 4'- dimethoxytrityl) guanosine-3'- [(2-cyanoethyl)-N, N- diisopropylphosphoramiditel.

2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside amidites [00129] 2'-dimethylaminoethoxyethoxy nucleoside amidites (also known in the art as 2'-O-dimethylaminoethoxyethyl, i. e., 2'0-CH2-O-CH2-N (CH2) 2, or 2'-DMAEOE nucleoside amidites) are prepared as follows. Other nucleoside amidites are prepared similarly.

2'-O- [2 (2-N, N-dimethylaminoethoxy) ethyl]-5-methyl uridine [00130] 2 [2- (Dimethylamino) ethoxylethanol (Aldrich, 6.66 g, 50 mmol) is slowly added to a solution of borane in tetrahydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL bomb. Hydrogen gas evolves as the solid dissolves.

0-, 2'-anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium bicarbonate (2.5 mg) are added and the bomb is sealed, plaped in an oil bath and heated to 155°C for 26 hours. The bomb is cooled to room temperature and opened. The crude solution is concentrated and the residue partitioned between water (200 mL) and hexanes (200 mL). The excess phenol is extracted into the hexane layer. The aqueous layer is extracted with ethyl acetate (3x200 mL) and the combined organic layers are washed once with water, dried over anhydrous sodium sulfate and concentrated. The residue is columned on silica gel using methanol/methylene chloride 1 : 20 (which has 2% triethylamine) as the eluent.

As the column fractions are concentrated a colorless solid forms which is collected to give the title compound as a white solid.

5'-0-dimethoxytrityl-2'-O- [2 (2-N, N-dimethylaminoethoxy) ethyl)]-5- methyl uridine [00131] To 0.5 g (1.3 mmol) of 2'-O- [2 (2-N, N- dimethylaminoethoxy) ethyl) 1-5-methyl uridine in anhydrous pyridine (8 rnL), triethylamine (0.36 mL) and dimethoxytrityl chloride (DMT-C1, 0.87 g, 2 eq.) are added and stirred for 1 hour. The reaction mixture is poured into water (200 mL) and extracted with CH2C12 (2x200 mL). The combined CH2C12 layers are washed with saturated NaHC03 solution, followed by saturated NaCl solution and dried over anhydrous sodium sulfate. Evaporation of the solvent followed by silica gel chromatography using MeOH : CH2C12 : Et3N (20: 1, v/v, with 1 % triethylamine) gives the title compound.

5'-O-Dimethoxytrityl-2'-O [2 (2-N, N-dimethylaminoethoxy) ethyl)]-5-methyl uridine-3'-O- (cyanoethyl-N, N-diisopropyl) phosphoramidite [00132] Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxyN, N- diisopropyl phosphoramidite (1. 1 mL, 2 eq. ) are added to a solution of 5'-0- dimethoxytrityl-2'-O- [2 (2-N, N-dimethylaminoethoxy) ethyl)]-5-methyluridine (2.17 g, 3 mmol) dissolved in CH2C12 (20 mL) under an atmosphere of argon.

The reaction mixture is stirred overnight and the solvent evaporated. The resulting residue is purified by silica gel flash column chromatography with ethyl acetate as the eluent to give the title compound.

Example 2 Oligonucleotide synthesis

[00133] Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine.

[00134] Phosphorothioates (P=S) are synthesized as for the phosphodiester oligonucleotides except the standard oxidation bottle is replaced by 0.2 M solution of 3H-1, 2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation wait step is increased to 68 sec and is followed by the capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55°C (18 h), the oligonucleotides are purified by precipitating twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution. Phosphinate oligonucleotides are prepared as described in U. S. Patent 5,508, 270, herein incorporated by reference.

[00135] Alkyl phosphonate oligonucleotides are prepared as described in U. S. Patent 4,469, 863, herein incorporated by reference.

[00136] 3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U. S. Patents 5,610, 289 or 5,625, 050, herein incorporated by reference.

[00137] Phosphoramidite oligonucleotides are prepared as described in U. S.

Patent, 5,256, 775 or U. S. Patent 5,366, 878, herein incorporated by reference.

[00138] Alkylphosphonothioate oligonucleotides are prepared as described in WO 94/17093 and WO 94/02499 herein incorporated by reference.

[00139] 3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U. S. Patent 5,476, 925, herein incorporated by reference.

[00140] Phosphotriester oligonucleotides are prepared as described in U. S.

Patent 5,023, 243, herein incorporated by reference.

[00141] Borano phosphate oligonucleotides are prepared as described in U. S.

Patents 5,130, 302 and 5,177, 198, both herein incorporated by reference.

Example 3 Oligonucleoside Synthesis [00142] Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U. S. Patents 5, 378, 825; 5,386, 023; 5,489, 677; 5,602, 240; and 5,610, 289, all of which are herein incorporated by reference.

[00143] Formacetal and thioformacetal linked oligonucleosides are prepared as described in U. S. Patents 5,264, 562 and 5,264, 564, herein incorporated by reference.

[00144] Ethylene oxide linked oligonucleosides are prepared as described in U. S. Patent 5,223, 618, herein incorporated by reference.

Example 4 PNA Synthesis

[00145] Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, Bioorganic & Medicinal Chemistry, 1996,4, 523. They may also be prepared in accordance with U. S. Patents 5,539, 082; 5,700, 922; and 5,719, 262, herein incorporated by reference.

Example 5 Synthesis of Chimeric Oligonucleotides [00146] Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the"gap"segment of linked nucleosides is positioned between 5'and 3'"wing"segments of linked nucleosides and a second"open end"type wherein the"gap"segment is located at either the 3'or the 5'terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as"gapmers"or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as"hemimers"or"wingmers".

[2'-O-NIe]--[2'-deoxy]--[2'-O-Me] Chimeric Phosphorothioate Oligonucleotides [00147] Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 380B, as above.

Oligonucleotides are synthesized using the automated synthesizer and 2'-doxy- 5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'- dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5'and 3'wings. The

standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s repeated four times for RNA and twice for 2'-O-methyl. The fully protected oligonucleotide is cleaved from the support and the phosphate group is deprotected in 3: 1 ammonia/ethanol at room temperature overnight then lyophilized to dryness. Treatment in methanolic ammonia for 24 hrs at room temperature is then done to deprotect all bases and sample is again lyophilized to dryness. The pellet is resuspended in 1M TBAF in THF for 24 hrs at room temperature to deprotect the 2'positions. The reaction is then quenched with 1M TEAA and the sample is then reduced to 1/2 volume by rotovac before being desalted on a G25 size exclusion column. The oligo recovered is then analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

[2'-0- (2-Methoxyethyl)]-- [2'-deoxy]-- [2'-O- (Methoxyethyl)] Chimeric Phosphorothioate Oligonucleotides [00148] [2'-O- (2-methoxyethyl)]-- [2'-deoxy]- [-2'-O- (methoxyethyl)] chimeric phosphorothioate oligonucleotides are prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of phorothioate oligonucleotides are prepared as per the procedure abo 2'-O- (methoxyethyl) amidites for the 2'-O-methyl amidites. <BR> <BR> <P>[2'-0-(2-Methoxyethyl) Phosphodiester]--[2'-deoxy Phosphorothioate]" 0- (2-Methoxyethyl)] Phosphodiester] Chimeric Oligonucleotides [00149] [2'-O- (2-methoxyethyl phosphodiester]-- [2'-deoxy phosphorothioate]--[2'-O-(methcixyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution of 2'-O- (methoxyethyl) amidites

for the 2'-O-methyl amidites, oxidization with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3, H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

[00150] Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to United States patent 5,623, 065, herein incorporated by reference.

Example 6 Oligonucleotide Isolation [00151] After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55°C for 18 hours, the oligonucleotides or oligonucleosides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides are analyzed by polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis are periodically checked by"P nuclear magnetic resonance spectroscopy, and for some studies oligonuclectides are purified by HPLC, as described by Chiang et al., J. Viol. Chem. 1991,266, 18162-18171.

Example 7 Oligonucleotide Synthesis-96 Well Plate Format

[00152] Oligonucleotides are synthesized via solid phase P (IR) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages are afforded by oxidation with aqueous iodine.

Phosphorothioate internucleotide linkages are generated by sulfurization utilizing 3, H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyldiisopropyl phosphoramidites can be purchased from commercial vendors (e. g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base protected betacyanoethyldiisopropyl phosphoramidites.

[00153] Oligonucleotides are cleaved from support and deprotected with concentrated NH4OH at elevated temperature (55-60°C) for 12-16 hours and the released product then dried in vacuo. The dried product is then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

Example 8 Oligonucleotide Analysis-96 Well Plate Format [00154] The concentration of oligonucleotide in each well is assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products is evaluated by capillary electrophoresis (CE) in either the 96 well format (Beckman PLACEZ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e. g., Beckman PLACEZ 5000, ABI 270). Base and backbone composition is confirmed by mass analysis of the

compounds utilizing electrospray-mass spectroscopy. All assay test plates are diluted from the master plate using single and multi-channel robotic pipettors.

Plates are judged to be acceptable if at least 85% of the compounds on the plate are at least 85% full length.

Example 9 Cell culture and oligonucleotide treatment [001551 The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following 6 cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis, Ribonuclease protection assays, or RT-PCR.

T-24 cells: [00156] The human transitional cell bladder carcinoma cell line T-24 is obtained from the American Type Culture Collection (ATCC) (Manassas, VA).

T-24 cells are routinely cultured in complete McCoy's SA basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells are routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells are seeded into 96-well plates

(Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

[00157] For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells: [00158] The human lung carcinoma cell line A549 can be obtained from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells are routinely cultured in DMEM basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells are routinely passaged by trypsinization and dilution when they reached 90% confluence.

NHDF cells: [00159] Human neonatal dermal fibroblast (NHDF) can be obtained from the Clonetics Corporation (Walkersville MD). NHDFs are routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville MD) supplemented as recommended by the supplier. Cells are maintained for up to 10 passages as recommended by the supplier.

HEK cells: [00160] Human embryonic keratinocytes (HEK) can be obtained from the Clonetics Corporation (Walkersville MD). HEKs are routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville MD)

formulated as recommended by the supplier. Cells are routinely maintained for up to 10 passages as recommended by the supplier.

MCF-7 cells: [00161] The human breast carcinoma cell line MCF-7 is obtained from the American Type Culure Collection (Manassas, VA). MCF-7 cells are routinely cultured in DMEM low glucose (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD). Cells are routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells are seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

[00162] For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

LA4 cells: [00163] The mouse lung epithelial cell line LA4 is obtained from the American Type Culure Collection (Manassas, VA). LA4 cells are routinely cultured in F12K medium (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 15% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD). Cells are routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells are seeded into 96-well plates (Falcon-Primaria #3872) at a density of 3000-6000 cells/well for use in RT- PCR analysis.

[00164] For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

Treatment with antisense compounds: [00165] When cells reached 80% confluency, they are treated with oligonucleotide. For cells grown in 96-well plates, wells are washed once with 200 uL OPTI-MEM-1 reduced-serum medium (Gibco BRL) and then treated with 130 uL of OPTI-MEMTM-1 containing 3.75 jug/mL LIPOFECTINTM (Gibco BRL) and the desired concentration of oligonucleotide. After 4-7 hours of treatment, the medium is replaced with fresh medium. Cells are harvested 16- 24 hours after oligonucleotide treatment.

[00166] The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations.

Example 10 Analysis of oligonucleotide inhibition of EL expression [00167] Antisense modulation of EL expression can be assayed in a variety of ways known in the art. For example, EL mRNA levels can be quantitated by, e. g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred.

RNA analysis can be performed on total cellular RNA or poly (A) + mRNA.

Methods of RNA isolation are taught in, for example, Ausubel, F. M. et al.,

Current Protocols in Molecular Biology, Volume 1, pp. 4.1. 1-4.2. 9 and 4.5. 1- <BR> <BR> 4.5. 3, John Wiley & Sons, Inc. , 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F. M. et al., Current Protocols in <BR> <BR> Molecular Biology, Volume 1, pp. 4.2. 1-4.2. 9, John Wiley & Sons, Inc. , 1996.

Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISMTM 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions. Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be"multiplexed"with a GAPDH amplification reaction. In multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer- probe sets specific for GAPDH only, target gene only ("single-plexing"), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed as multiplexable. Other methods of PCR are also known in the art.

[00168] Protein levels of EL can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS).

Antibodies directed to EL can be identified and obtained from a variety of

sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for <BR> example, Ausubel, F. M. et al. , Current Protocols in Molecular Biology, Volume<BR> 2, pp. 11.12. 1-11.12. 9, John Wiley & Sons, Inc. , 1997. Preparation of monoclonal antibodies is taught in, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 11.4. 1-11.11. 5, John Wiley Sons, Inc., 1997.

[00169] Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F. M. et al., Current Protocols n Molecular Biology, Volume 2, pp. 10.16. 110.16. 11, John Wiley & Sons, Inc., 1998.

Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 10.8. 1-10.8. 21, John Wiley Sons, Inc. , 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 11.2. 1-11.2. 22, John Wiley & Sons, Inc., 1991.

Example 11 Poly (A) + mRNA isolation [00170] Poly (A) + mRNA is isolated according to Miura et al., Clin. Chez. s 1996,42, 1758-1764. Other methods for poly (A) + mRNA isolation are taught in, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 1, pp. 4.5. 1-4.5. 3, John Wiley & Sons, Inc. , 1993. Briefly, for cells grown on 96-well plates, growth medium is removed from the cells and each

well is washed with 200 uL cold PBS. 60 ! 1L lysis buffer (10 mM Tris-HCI, pH 7.6, 1 mM EDTA, 0.5 M NaCI, 0.5% NP-40,20 mM vanadyl-ribonucleoside complex) is added to each well, the plate is gently agitated and then incubated at room temperature for five minutes. 55 ML of lysate is transferred to Oligo d (T) coated 96-well plates (AGCT Inc. , Irvine CA). Plates are incubated for 60 minutes at room temperature, washed 3 times with 200 uL of wash buffer (10 mM Tris-HC1 pH 7.6, 1 mM EDTA, 0.3 M NaCI). After the final wash, the plate is blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60 pL of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C is added to each well, the plate is incubated on a 90°C hot plate for 5 minutes, and the eluate is then transferred to a fresh 96-well plate.

[00171] Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

Example 12 Total RNA Isolation [00172] Total MARNA is isolated using an RNEASY 96 kit and buffers purchased from Qiagen Inc. (Valencia CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium is removed from the cells and each well is washed with 200 PL cold PBS. 100 uL Buffer RLT is added to each well and the plate vigorously agitated for 20 seconds. 100 pL of 70% ethanol is then added to each well and the contents mixed by pipetting three times up and down. The samples are then transferred to the RNEASY 96 well plate attached to a QIAVACTM manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum is

applied for 15 seconds. 1 mL of Buffer RW1 is added to each well of the RNEASY 96 plate and the vacuum again applied for 15 seconds. 1 mL of Buffer RPE is then added to each well of the RNEASY 96 plate and the vacuum applied for a period of 15 seconds. The Buffer RPE wash is then repeated and the vacuum is applied for an additional 10 minutes. The plate is then removed from the QIAVAC manifold and blotted dry on paper towels.

The plate is then re-attached to the QIAVAC manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA is then eluted by pipetting 6011L water into each well, incubating 1 minute, and then applying the vacuum for 30 seconds. The elution step is repeated with an additional 60uL water.

[00173] The repetitive pipetting and elution steps may be automated using a <BR> <BR> QIAGEN Bio-Robot 9604 (Qiagen, Inc. , Valencia CA). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

Example 13 Real-time Quantitative PCR Analysis of EL mRNA Levels [00174] Quantitation of EL mRNA levels is determined by real-time quantitative PCR using the ABI PRISMT 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by

including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e. g. , JOE, FAM, or VIC, obtained from either Operon<BR> Technologies Inc. , Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 5'end of the probe and a quencher dye (e. g., TAMRA, obtained from either Operon Technologies Inc. , Alameda, CA or PE-Applied Biosystems, Foster City, CA) is attached to the 3'end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3'quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence- specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

[00175] PCR reagents can be obtained from PE-Applied Biosystems, Foster City, CA. RT-PCR reactions are carried out by adding 25nL PCR cocktail (lx TAQMAN buffer A, 5.5 MM MgCl2, 300 uM each of dATP, dCTP and DGTP, 600 uM of dUTP, 100 nM each of forward primer, reverse primer, and probe, 20 Units RNAse inhibitor, 1.25 Units AMPLITAQ GOLD, and 12.5

Units MuLV reverse transcriptase) to 96 well plates containing 25 uL poly (A) mRNA solution. The RT reaction is carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the AMPLITAQ GOLD, 40 cycles of a two-step PCR protocol are carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension).

[00176] Probes and primers to human EL were designed to hybridize to a human EL sequence, using published sequence, information (GenBank accession number NM_006033 is herein incorporated as Figure 1). For human EL the PCR primers were: forward primer : CCGGACGGGAGCTGAATAT SEQ ID NO : 3909 reverse primer: CAGTTTCCGCTGGGTTTCC SEQ ID NO : 3910 and the PCR probe is : FAMTM-AGGCGCATCCGGGTGAAGTCTG SEQ ID NO : 3 911- TAMRA where FAM (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye. For human cyclophilin the PCR primers were: forward primer : CCCACCGTGTTCTTCGACAT SEQ ID NO : 3912 reverse primer : TTTCTGCTGTCTTTGGGACCTT SEQ ID NO: 3913 and the PCR probe is: 5'JOE-CGCGTCTCCTTTGAGCTGTTTGCA SEQ ID NO: 3 914-TAMRA 3'where JOE (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye.

Example 14 Antisense inhibition of human EL expression by chimeric phosphorothioate oligonucleotides having 2'"MOE wings and a deoxy gap [00177] In accordance with the present invention, a series of oligonucleotides are designed to target different regions of the human EL RNA, using published sequences (NM_006033 ; incorporated herein as Figure 1). The oligonucleotides are shown in Table 1."Position"indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds.

The indicated parameters for each oligo were predicted using RNAstructure 3.7 by David H. Mathews, Michael Zuker, and Douglas H. Turner. The parameters are described either as free energy (The energy that is released when a reaction occurs. The more negative the number, the more likely the reaction will occur. <BR> <BR> <P>All free energy units are in kcal/mol. ) or melting temperature (the temperature at which two anneal strands of polynucleic acid separate. The higher the temperature, greater the affinity between the 2 strands. ) When designing an antisense oligonucleotide (oligomers) that will bind with high affinity, it is desirable to consider the structure of the target RNA strand and the antisense oligomer. Specifically, for an oligomer to bind tightly (in the table described as 'duplex formation'), it should be complementary to a stretch of target RNA that has little self-structure (in the table the free energy of which is described as 'target structure'). Also, the oligomer should have little self-structure, either intramolecular (in the table the free energy of which is described as 'intramolecular oligo') or bimolecular (in the table the free energy of which is described as'intermolecular oligo'). Breaking up any self-structure amounts to a binding penalty. All compounds in Table 1 are chimeric oligonucleotides

("gapmers") 20 nucleotides in length, composed of a central"gap"region consisting of ten 2'deoxynucleotides, which is flanked on both sides (5'and 3' directions) by four-nucleotide"wings". The wings are composed of 2'- methoxyethyl (2'-MOE) nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. Cytidine residues in the 2'-MOE wings are 5-methylcytidines. All cytidine residues are 5- methylcytidines.

Table 1 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo 'TGCATCGTCCGGAGAGAGCC 872 SEQ ID NO : 1-24. 1-28. 9 78. 2-3. 8-0. 1-10 CCGGGGTTGCGGGGTTGAGA 1555 SEQ ID NO : 2-23. 8-30. 4 80. 7-5. 3-1. 2-5. 6 ATTATTGACCGCATCCGTGT 644 SEQ ID NO : 3-23. 5-25. 6 70. 4-1. 4-0. 3-3. 6 GTATTATTGACCGCATCCGT 646 SEQ ID NO : 4-23. 3-25. 3 70-1. 4-0. 2-3. 6 TTATTGACCGCATCCGTGTA 643 SEQ ID NO : 5-23. 1-25. 3 69. 9-1. 4-0. 5-3. 6 GCATCGTCCGGAGAGAGCCT 871 SEQ ID NO : 6-23. 1-29. 8 80. 3-6 0-9 CTGCATCGTCCGGAGAGAGC 873 SEQ ID NO : 7-23. 1-27. 8 76. 6-3. 8 0-9. 6 TCCGGGGTTGCGGGGTTGAG 1556 SEQ ID NO : 8-23. 1-30. 2 81. 1-5. 3-1. 8-6. 6 GGTATTATTGACCGCATCCG 647 SEQ ID NO : 9-23-25. 3 69. 3-1. 4-0. 6-4. 6 TATTGACCGCATCCGTGTAA 642 SEQ ID NO : 10-22. 9-24. 5 67. 5-1. 6 0. 1-3. 6 ACGGCTCGCTCATGCTCACA 1066 SEQ ID NO : 11-22. 9-28. 6 78-4. 6-1-5. 9 CGGCTCGCTCATGCTCACAT 1065 SEQ ID NO : 12-22. 7-28. 4 77. 3-4. 6-1-5. 3 GGCTCGCTCATGCTCACATT 1064 SEQ ID N0 : 13-22. 4-27. 7 78-4. 6-0. 5-5 GGCGTCTTTCTCTCTTGTGT 581 SEQ ID NO : 14-22. 2-26. 9 80. 7-4. 7 0-4 TATTATTGACCGCATCCGTG 645 SEQ ID NO : 15-22. 1-24. 1 66. 9-1. 4-0. 2-3. 6 GTCCGGGGTTGCGGGGTTGA 1557 SEQ ID NO : 16-22. 1-31. 4 84. 3-7. 5-1. 8-6. 6 TCTGCATCGTCCGGAGAGAG 874 SEQ ID NO : 17-22-26. 4 74. 1-3. 8 0-8. 5 GTGTCTCAGATATTGTGTGT 2939 SEQ ID NO : 18-21. 9-22. 8 71. 5-0. 8 0-2. 8 GCATGCCTGCCCGGGTTTTT 1260 SEQ ID NO : 19-21. 8-31. 8 83. 5-8. 6-1-10. 3 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo GAATCCTTCCATTGGGTGGG 1836 SEQ ID NO : 20-21. 8-26. 5 74. 3-3. 3-1. 3-6. 4 CTGGGGCATATTGGTGGGAA 3173 SEQ ID NO : 21-21. 8-25. 5 72. 1-3. 7 0-3. 2 CTTCACCCGGATGCGCCTGA 1589 SEQ ID NO : 22-21. 6-30. 8 78. 8-8. 3-0. 7-7. 8 TGGTATTATTGACCGCATCC 648 SEQ ID NO : 23-21. 5-24. 5 69. 1-1. 6-1. 3-4. 7 GGCATGCCTGCCCGGGTTTT 1261 SEQ ID NO : 24-21. 5-32. 9 85. 6-8. 6-2. 8-12. 5 TTCACCCGGATGCGCCTGAT 1588 SEQ ID NO : 25-21. 5-29. 9 77-7. 4-0. 9-7. 8 GCGAAACCAGAGCTCCCGGC 1676 SEQ ID NO : 26-21. 5-30. 2 77-7. 9-0. 4-8. 7 ACTTCACCCGGATGCGCCTG 1590 SEQ ID NO : 27-21. 4-30. 4 78. 1-8. 3-0. 5-7. 8 GTTCCTCGTCAGGCAGAGTA 2088 SEQ ID NO : 28-21. 4-27. 3 79. 9-5-0. 7-4. 8 GGTGGCTTTTCCAAGAAGTT 2893 SEQ ID NO : 29-21. 4-24. 2 70. 6-1. 5-1. 2-5. 2 TCACCCGGATGCGCCTGATA 1587 SEQ ID NO : 30-21. 3-29. 5 76. 1-7. 4-0. 6-7. 8 TTGGCGTCTTTCTCTCTTGT 583 SEQ ID NO : 31-21. 1-25. 8 77. 2-4. 7 0-4. 6 ACGCGTGTAGGTGTGGAGGA 905 SEQ ID NO : 32-21. 1-26. 9 75. 9-5. 1 0-8. 8 CGGGGTTGCGGGGTTGAGAC 1554 SEQ ID NO : 33-21. 1-28. 6 77. 9-7. 5 0-4 ACCGCTCATCGTCCATCCGT 521 SEQ ID NO : 34-21-30. 7 80-9. 2-0. 2-3. 1 CGTCTTTCTCTCTTGTGTGC 579 SEQ ID NO : 35-21-25. 7 77. 6-4. 7 0-2. 6 GCGTCTTTCTCTCTTGTGTG 580 SEQ ID NO : 36-21-25. 7 77. 6-4. 7 0-3. 4 TGGCGTCTTTCTCTCTTGTG 582 SEQ ID NO : 37-21-25. 7 76. 6-4. 7 0-4. 6 CACCCGGATGCGCCTGATAT 1586 SEQ ID NO : 38-21-29. 1 74. 6-7. 4-0. 5-7. 4 GACTTCACCCGGATGCGCCT 1591 SEQ ID NO : 39-21-31 79. 5-9. 3-0. 5-7. 8 AGAATCCTTCCATTGGGTGG 1837 SEQ ID NO : 40-21-25. 3 72-3. 3-0. 9-5. 4 CCTCGTCAGGCAGAGTACAG 2085 SEQ ID NO : 41-21-26. 5 76. 1-5-0. 2-5. 5 TCCTCGTCAGGCAGAGTACA 2086 SEQ ID NO : 42-21-26. 9 77. 5-5-0. 7-6. 6 GTCTTTCTCTCTTGTGTGCA 578 SEQ ID NO : 43-20. 9-25. 6 79. 2-4. 7 0-5. 2 GCTCGCTCATGCTCACATTT 1063'SEQ ID NO : 44-20. 9-26. 6 75. 8-4. 6-1-4. 6 GACGGCTCGCTCATGCTCAC 1067 SEQ ID NO : 45-20. 9-28. 5 78. 2-6. 5-1-5. 9 ATTGACCGCATCCGTGTAAA 641 SEQ ID NO : 46-20. 8-24. 1 66-2. 6-0. 5-3. 6 ACTGCAGTCTTCTAAGGGCT 467 SEQ ID NO : 47-20. 7-25. 6 75. 6-3. 9 0-10 ACATTGGCGTCTTTCTCTCT 586 SEQ ID NO : 48-20. 7-25. 4 75-4. 7 0-4 1558 CGTCCGGGGTTGCGGGGTTG-20. 7-31. 6 82. 4-9. 1-1. 8-6. 6 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 49 AATCCTTCCATTGGGTGGGT 1835 SEQ ID NO : 50-20. 7-27. 1 76. 4-5-1. 3-6. 4 AGTGTCTCAGATATTGTGTG 2940 SEQ ID NO : 51-20. 7-21. 6 68-0. 8 0-2. 8 CATTGGCGTCTTTCTCTCTT 585 SEQ ID NO : 52-20. 6-25. 3 74. 8-4. 7 0-4. 6 AGGCATGCCTGCCCGGGTTT 1262 SEQ ID NO : 53-20. 6-32. 8 85. 6-8. 6-3. 6-14 CCGTCCGGGGTTGCGGGGTT 1559 SEQ ID NO : 54-20. 5-33. 6 85. 8-11. 3-1. 8-9. 4 CGTTCCTCGTCAGGCAGAGT 2089 SEQ ID NO : 55-20. 5-28. 4 80. 1-7-0. 7-4. 8 TGGGGCATATTGGTGGGAAC 3172 SEQ ID NO : 56-20. 5-24. 8 70. 8-3. 6-0. 4-4. 8 CATCGTCCGGAGAGAGCCTC 870 SEQ ID NO : 57-20. 4-28. 4 77. 7-7. 2-0. 6-8. 2 GCTGTTCCTCTTGTTCCTCA 1229 SEQ ID NO : 58-20. 4-28. 4 83. 2-8 0-2. 8 ACCCGGATGCGCCTGATATT 1585 SEQ ID NO : 59-20. 4-28. 5 74-7. 4-0. 5-7. 4 TTCCTCGTCAGGCAGAGTAC 2087 SEQ ID NO : 60-20. 4-26. 3 76. 8-5-0. 7-5. 3 GTCTCAGATATTGTGTGTAT 2937 SEQ ID NO : 61-20. 4-21. 3 67. 2-0. 8 0-2. 8 TGTCTCAGATATTGTGTGTA 2938 SEQ ID NO : 62-20. 4-21. 3 67. 1-0. 8 0-2. 8 CCCTGGTATTATTGACCGCA 651 SEQ ID NO : 63-20. 3-27 72. 9-5. 3-1. 3-4. 7 TGGTGGCTTTTCCAAGAAGT 2894 SEQ ID NO : 64-20. 3-24. 1 70. 1-2. 5-1. 2-5. 2 AACGCGTGTAGGTGTGGAGG 906 SEQ ID NO : 65-20. 2-25. 6 72. 1-4. 5 0-9. 7 CCCGTCCGGGGTTGCGGGGT 1560 SEQ ID NO : 66-20. 2-35. 5 88. 5-12. 4-2. 8-13 TACCGCTCATCGTCCATCCG 522 SEQ ID NO : 67-20. 1-29. 2 76. 3-8. 6-0. 2-3. 1 GACCGCATCCGTGTAAAGCT 638 SEQ ID NO : 68-20. 1-26. 7 71. 6-5. 9-0. 5-5. 5 GAAACCAGAGCTCCCGGCCT 1674 SEQ ID NO : 69-20. 1-30. 5 78. 3-9. 5-0. 8-8. 7 ATTGGCGTCTTTCTCTCTTG 584 SEQ ID NO : 70-19. 9-24. 6 73. 4-4. 7 0-4. 6 GTGCTTCAGAGAGTGAGCTG 2305 SEQ ID NO : 71-19. 9-24. 8 75-3. 1-1. 8-6. 5 TGTGCTTCAGAGAGTGAGCT 2306 SEQ ID NO : 72-19. 9-24. 8 75-3. 1-1. 8-5. 8 GGGGCATATTGGTGGGAACT 3171 SEQ ID NO : 73-19. 9-25. 7 72. 9-4. 5-1. 2-5. 7 TCTGGGGCATATTGGTGGGA 3174 SEQ ID NO : 74-19. 9-26. 6 76. 3-6. 7 0-4 TGACCGCATCCGTGTAAAGC 639 SEQ ID NO : 75-19. 8-25. 8 69. 7-5. 3-0. 5-4. 1 ACCCTGGTATTATTGACCGC 652 SEQ ID NO : 76-19. 8-26. 5 72. 4-5. 9-0. 6-4. 2 ATCTGCATCGTCCGGAGAGA 875 SEQ ID NO : 77-19. 8-26. 4 73. 7-6 0-8. 5 TGCGAAACCAGAGCTCCCGG 1677 SEQ ID NO : 78-19. 8-28. 4 73. 1-7. 9-0. 4-8. 6 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo CTTTCTCTCTTGTGTGCAGG 576 SEQ ID NO : 79-19. 7-25. 2 76. 5-5. 5 0-5. 3 TCTTTCTCTCTTGTGTGCAG 577 SEQ ID NO : 80-19. 7-24. 4 75. 5-4. 7 0-5. 3 TGCTGTTCCTCTTGTTCCTC 1230 SEQ ID NO : 81-19. 7-27. 7 81. 9-8 0-3. 6 AAGGCATGCCTGCCCGGGTT 1263 SEQ ID NO : 82-19. 7-32 82. 6-8. 6-3. 6-14. 8 CCAGCCGTCCCTCTGGACCA 327 SEQ ID NO : 83-19. 6-33. 8 86. 4-11. 5-2. 7-8. 7 TACATTGGCGTCTTTCTCTC 587 SEQ ID NO : 84-19. 5-24. 2 72. 3-4. 7 0-4. 6 CGCGTGTAGGTGTGGAGGAC 904 SEQ ID NO : 85-19. 5-26. 9 75. 9-7. 4 0-6. 2 CTTCCATTGGGTGGGTCCTC 1831 SEQ ID NO : 86-19. 5-29. 1 82. 9-8. 2-1. 3-6. 4 CTGGTATTATTGACCGCATC 649 SEQ ID NO : 87-19. 4-23. 4 67. 4-2. 6-1. 3-4. 7 ATCGTCCGGAGAGAGCCTCT 869 SEQ ID NO : 88-19. 4-28. 6 78. 6-7. 7-1. 4-9. 5 TTGCTGTTCCTCTTGTTCCT 1231 SEQ ID NO : 89-19. 4-27. 4 80. 3-8 0-3. 6 TCCAGCCGTCCCTCTGGACC 328 SEQ ID NO : 90-19. 3-33. 5 87. 3-11. 5-2. 7-8. 7 ATACCGCTCATCGTCCATCC 523 SEQ ID NO : 91-19. 3-28. 4 76. 5-8. 6-0. 2-3 TCTCAGATATTGTGTGTATT 2936 SEQ ID NO : 92-19. 3-20. 2 64-0. 8 0-2. 8 CTCGCTCATGCTCACATTTT 1062 SEQ ID NO : 93-19. 2-24. 9 71. 8-4. 6-1-4. 4 TCTCCCAAGTCCTCCTCGGT 1456 SEQ ID NO : 94-19. 1-31. 1 84. 5-12 0-3 GTCTCCCAAGTCCTCCTCGG 1457 SEQ ID NO : 95-19. 1-31. 1 84. 5-12 0-3 ATCTTCCAGCCGTCCCTCTG 332 SEQ ID NO : 96-19-30. 9 83. 7-11. 9 0-3. 2 TCCCAAGTCCTCCTCGGTGT 1454 SEQ ID NO : 97-19-31 84-12 0-3 AGGTACGGGGCTCCCCGCAG 305 SEQ ID NO : 98-18. 9-33. 1 85. 1-11. 2-2. 6-13. 7 GCATCCTGGCAATGCTGTGT 678 SEQ ID NO : 99-18. 9-27. 9 78. 3-7. 3-1. 7-9 AAAGGCATGCCTGCCCGGGT 1264 SEQ ID NO : 100-18. 9-31. 2 79. 9-8. 6-3. 6-14. 8 CTTGCGAAACCAGAGCTCCC 1679 SEQ ID NO : 101-18. 8-27. 4 72. 9-7. 9-0. 4-8. 4 GTCTGGGGCATATTGGTGGG 3175 SEQ ID NO : 102-18. 8-27. 2 78. 5-8. 4 0-4 AACTGCAGTCTTCTAAGGGC 468 SEQ ID NO : 103-18. 7-24 71-3. 9 0-10. 8 TCGTCCGGAGAGAGCCTCTT 868 SEQ ID NO : 104-18. 7-28. 7 79-8. 4-1. 4-10 AGGTGGGCTCAATTTCTCCC 1335 SEQ ID NO : 105-18. 7-27. 8 79-8. 3-0. 6-5. 8 CGTAAAAGGTGGGCTCAATT 1341 SEQ ID NO : 106-18. 7-21. 6 62. 3-2. 9 0-5. 8 CTCCCAAGTCCTCCTCGGTG 1455 SEQ ID NO : 107-18. 7-30. 7 82. 4-12 0-3 1553 GGGGTTGCGGGGTTGAGACA-18. 7-28. 5 79. 3-9. 1-0. 5-4. 5 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 108 TTGCGAAACCAGAGCTCCCG 1678 SEQ ID NO : 109-18. 7-27. 3 71. 2-7. 9-0. 4-8. 4 CTCGTCAGGCAGAGTACAGG 2084 SEQ ID NO : 110-18. 7-25. 7 75-7 0-5. 3 GAACGCGTGTAGGTGTGGAG 907 SEQ ID NO : 111-18. 6-25 70. 9-5. 5 0-9. 7 ACTCGGCTTGTCCTGATTCA 1109 SEQ ID NO : 112-18. 6-26. 6 75. 8-7. 4-0. 3-4. 1 CTGTTCCTCTTGTTCCTCAT 1228 SEQ ID NO : 113-18. 6-26. 6 78. 4-8 0-1. 9 TTTGCTGTTCCTCTTGTTCC 1232 SEQ ID NO : 114-18. 6-26. 6 78. 6-8 0-3. 6 TGACGTAAAAGGTGGGCTCA 1344 SEQ ID NO : 115-18. 6-23 65. 7-4. 4 0-5. 6 GGTCTCCCAAGTCCTCCTCG 1458 SEQ ID NO : 116-18. 6-31. 1 84. 5-12-0. 1-2. 7 GTTCTCAGGGTCTTCTGTAC 1640 SEQ ID NO : 117-18. 6-25. 1 78. 3-6-0. 1-4 AAACCAGAGCTCCCGGCCTG 1673 SEQ ID NO : 118-18. 6-29. 9 76. 9-9. 5-1. 8-8. 7 GATCTAGAATTGGTGGCTTT 2904 SEQ ID NO : 119-18. 6-22. 1 66. 6-3. 5 0-6. 2 AGGATTTTATGGATGGCTCT 3226 SEQ ID NO : 120-18. 6-22. 8 68. 2-4. 2 0-3. 7 TCTTCCAGCCGTCCCTCTGG 331 SEQ ID NO : 121-18. 5-32. 1 86. 3-11. 9-1. 7-5. 8 CATGCCTGCCCGGGTTTTTA 1259 SEQ ID NO : 122-18. 5-29. 7 78. 8-9. 9-0. 7-10. 3 ACTCTGCTTGCTATTCTGCT 2654 SEQ ID NO : 123-18. 5-25. 7 76-6. 5-0. 4-4 AGATCTAGAATTGGTGGCTT 2905 SEQ ID NO : 124-18. 5-22 66. 5-3. 5 0-6. 2 GGTACGGGGCTCCCCGCAGC 304 SEQ ID NO : 125-18. 4-34. 9 88. 9-12. 9-3. 5-14. 6 TCTTGTTCCTCATTTTCTTG 1221 SEQ ID NO : 126-18. 4-22. 8 69. 9-4. 4 0-1. 9 ATCCTTCCATTGGGTGGGTC 1834 SEQ ID NO : 127-18. 4-28. 2 80. 8-8. 4-1. 3-6. 4 GCTCATCGTCCATCCGTGAA 518 SEQ ID NO : 128-18. 3-27. 6 75. 2-8. 7-0. 3-3. 8 CCTGGTATTATTGACCGCAT 650 SEQ ID NO : 129-18. 3-25 69. 5-5. 3-1. 3-4. 7 GGAACGCGTGTAGGTGTGGA 908 SEQ ID NO : 130-18. 3-26. 2 73. 1-7 0-9. 7 GGTGGGCTCAATTTCTCCCA 1334 SEQ ID NO : 131-18. 3-28. 5 79. 7-8. 3-1. 9-7. 3 CCCAAGTCCTCCTCGGTGTA 1453 SEQ ID NO : 132-18. 3-30. 3 81. 7-12 0-3 GGATTTTATGGATGGCTCTA 3225 SEQ ID NO : 133-18. 3-22. 5 67. 4-4. 2 0-3. 7 CGAAACCAGAGCTCCCGGCC 1675 SEQ ID NO : 134-18. 2-30. 4 76. 3-11. 3-0. 8-7. 8 TTGACCGCATCCGTGTAAAG 640 SEQ ID NO : 135-18. 1-24. 1 66. 2-5. 3-0. 5-3. 6 CCTCTTGTTCCTCATTTTCT 1223 SEQ ID NO : 136-18. 1-25. 6 75. 7-7. 5 0-1. 8 ACGTAAAAGGTGGGCTCAAT 1342 SEQ ID NO : 137-18. 1-21. 7 62. 5-3. 6 0-5. 8 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo GTGTGCTTCAGAGAGTGAGC 2307 SEQ ID NO : 138-18. 1-25. 1 76. 6-5. 9-1-5. 2 TTGGTGGCTTTTCCAAGAAG 2895 SEQ ID NO : 139-18. 1-23 67. 2-3. 6-1. 2-5. 4 ATCTAGAATTGGTGGCTTTT 2903 SEQ ID NO : 140-18. 1-21. 6 65. 6-3. 5 0-6. 2 TCGCTCATGCTCACATTTTA 1061 SEQ ID NO : 141-18-23. 7 69. 3-4. 6-1-3. 8 GGACGGCTCGCTCATGCTCA 1068 SEQ ID NO : 142-18-29. 5 80. 2-10. 4-1-6. 1 AGACTTCACCCGGATGCGCC 1592 SEQ ID NO : 143-18-30. 1 78-11. 4-0. 5-7. 8 TCCTTCCATTGGGTGGGTCC 1833 SEQ ID NO : 144-18-30. 2 84. 5-11. 3-0. 8-6. 4 CTCTGCTTGCTATTCTGCTA 2653 SEQ ID NO : 145-18-25. 2 74. 8-6. 5-0. 4-4. 5 TACTCTGCTTGCTATTCTGC 2655 SEQ ID NO : 146-18-24. 5 73. 3-6. 5 0-4. 5 GACGTAAAAGGTGGGCTCAA 1343 SEQ ID NO : 147-17. 9-22. 3 63. 7-4. 4 0-5. 8 AAGAATCCTTCCATTGGGTG 1838 SEQ ID NO : 148-17. 9-23. 4 67. 2-5-0. 2-7 GCGTTCCTCGTCAGGCAGAG 2090 SEQ ID NO : 149-17. 9-29 80. 9-10. 3-0. 6-5. 5 AAGTGTCTCAGATATTGTGT 2941 SEQ ID NO : 150-17. 9-20. 9 65. 6-3 0-2. 8 TGCAGTCTTCTAAGGGCTGG 465 SEQ ID NO : 151-17. 8-25. 7 75. 5-6. 2-1. 7-4. 9 GATACCGCTCATCGTCCATC 524 SEQ ID NO : 152-17. 8-27 74. 4-9. 2 0. 3-3. 1 AACTCGGCTTGTCCTGATTC 1110 SEQ ID NO : 153-17. 8-25. 2 72. 2-7. 4 0-3. 8 TGTTCCTCTTGTTCCTCATT 1227 SEQ ID NO : 154-17. 8-25. 8 76. 7-8 0-1. 9 TCCCGTCCGGGGTTGCGGGG 1561 SEQ ID NO : 155-17. 8-34. 7 86. 9-13. 4-3. 4-14 TTCCATTGGGTGGGTCCTCA 1830 SEQ ID NO : 156-17. 8-28. 9 82-9. 7-1. 3-8. 8 CCGCTCATCGTCCATCCGTG 520 SEQ ID NO : 157-17. 7-30. 5 79. 3-12. 3-0. 2-3. 1 AGGAACGCGTGTAGGTGTGG 909 SEQ ID NO : 158-17. 7-25. 6 72. 1-7 0-9. 7 TTCTCAGGGTCTTCTGTACA 1639 SEQ ID NO : 159-17. 7-24. 6 75. 5-6-0. 7-6. 1 GTGGCTTTTCCAAGAAGTTC 2892 SEQ ID NO : 160-17. 7-23. 4 69. 6-4. 4-1. 2-7. 7 AAGATCTAGAATTGGTGGCT 2906 SEQ ID NO : 161-17. 7-21. 2 63. 9-3. 5 0-6. 4 AAGGTACGGGGCTCCCCGCA 306 SEQ ID NO : 162-17. 6-32. 4 82. 3-11. 2-3. 5-14. 6 AGCTGTCATGTTGAAACTGC 482 SEQ ID NO : 163-17. 6-22. 4 66. 7-3. 9-0. 8-6. 1 CGGCTTGTCCTGATTCACCA 1106 SEQ ID NO : 164-17. 6-28 76. 7-9. 8-0. 3-4. 4 TCCTCTTGTTCCTCATTTTC 1224 SEQ ID NO : 165-17. 6-25. 1 75. 4-7. 5 0-1. 9 TTCATGGAGTTTCAGAGATA 3138 SEQ ID NO : 166-17. 6-20. 4 63. 7-2. 8 0-4. 7 637 ACCGCATCCGTGTAAAGCTG-17. 5-26. 1 70. 2-8. 1-0. 2-5. 3 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 167 ATGTGGCCCACAGGCATCTG 949 SEQ ID NO : 168-17. 5-28. 8 79. 3-8. 8-2. 5-9. 2 GTGACGTAAAAGGTGGGCTC 1345 SEQ ID NO : 169-17. 5-23. 5 67. 6-6 0-5. 3 CAAGATCTAGAATTGGTGGC 2907 SEQ ID NO : 170-17. 5-21 63. 1-3. 5 0-7 CAGCCGTCCCTCTGGACCAA 326 SEQ ID NO : 171-17. 4-31. 1 80. 7-11. 5-2. 2-8. 7 AGATACCGCTCATCGTCCAT 525 SEQ ID NO : 172-17. 4-26. 6 73. 1-8. 6-0. 3-3. 5 GGCTTGTCCTGATTCACCAG 1105 SEQ ID NO : 173-17. 4-27. 2 77. 3-9. 8 0-5 GACCAGTTGTTCCCAGTGCT 1875 SEQ ID NO : 174-17. 4-29. 1 82. 1-11. 7 0-3. 7 TCCCCCAGGCCCCAGGTGCC 2509 SEQ ID NO : 175-17. 4-39 96. 1-20. 2-1. 3-8. 3 CTTCCAGCCGTCCCTCTGGA 330 SEQ ID NO : 176-17. 3-32. 3 85. 7-12. 3-2. 7-7. 8 AATCTGCATCGTCCGGAGAG 876 SEQ ID NO : 177-17. 3-25. 1 70. 2-7. 2 0-8. 5 TGTGGCCCACAGGCATCTGA 948 SEQ ID NO : 178-17. 3-29. 4 80. 7-8. 8-3. 3-9. 1 TCGGCTTGTCCTGATTCACC 1107 SEQ ID NO : 179-17. 3-27. 7 77. 4-9. 8-0. 3-4. 4 GTAAAAGGTGGGCTCAATTT 1340 SEQ ID NO : 180-17. 3-20. 9 62. 2-3. 6 0-5. 9 AGGTCTCCCAAGTCCTCCTC 1459 SEQ ID NO : 181-17. 3-30. 3 85. 6-12-0. 9-4. 6 CATCCTGGCAATGCTGTGTC 677 SEQ ID NO : 182-17. 2-26. 5 75. 6-8. 6-0. 4-7. 7 GTGTTCTCAGGGTCTTCTGT 1642 SEQ ID NO : 183-17. 2-26. 4 82. 2-8. 3-0. 7-3. 7 CCCCCAGGCCCCAGGTGCCT 2508 SEQ ID NO : 184-17. 2-39. 5 95. 9-20. 2-2. 1-9. 8 CAGCGTTCCTCGTCAGGCAG 2092 SEQ ID NO : 185-17. 1-29. 1 80. 6-11. 1-0. 7-8. 2 GATTTTATGGATGGCTCTAT 3224 SEQ ID NO : 186-17. 1-21. 3 64. 7-4. 2 0-3. 7 GTTTTAGCTGTCATGTTGAA 487 SEQ ID NO : 187-17-21. 4 66-3. 9-0. 1-6. 6 GAGCATCCTGGCAATGCTGT 680 SEQ ID NO : 188-17-27. 3 76. 6-7. 3-3-11. 2 ACTTGCGAAACCAGAGCTCC 1680 SEQ ID NO : 189-17-25. 6 70. 2-7. 9-0. 4-8. 4 AGCGTTCCTCGTCAGGCAGA 2091 SEQ ID NO : 190-17-29 80. 9-11. 1-0. 7-8. 2 TGCTATTCTGCTAGTGATCA 2646 SEQ ID NO : 191-17-23. 1 70-5. 4-0. 4-6. 9 CTGCTTGCTATTCTGCTAGT 2651 SEQ ID NO : 192-17-25. 1 74. 9-7. 6-0. 2-4. 5 AGCATCCTGGCAATGCTGTG 679 SEQ ID NO : 193-16. 9-26. 7 75. 1-7. 3-2. 5-10. 5 AAAAGGTGGGCTCAATTTCT 1338 SEQ ID NO : 194-16. 9-21. 3 63-4. 4 0-6 TCTCAGGGTCTTCTGTACAA 1638 SEQ ID NO : 195-16. 9-23. 8 72. 4-6-0. 7-6. 2 GTTCCCAGTGCTCCAGGGTC 1867 SEQ ID NO : 196-16. 9-31. 4 89. 4-13. 2-1. 2-6. 3 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo CTTTTCCAAGAAGTTCAACA 2888 SEQ ID NO : 197-16. 9-20. 1 60. 5-3. 2 0-6. 8 GGGCATATTGGTGGGAACTG 3170 SEQ ID NO : 198-16. 9-24. 5 70. 2-6. 3-1. 2-5. 7 GGTACATTTTGCTGTTCCTC 1239 SEQ ID NO : 199-16. 8-25 74. 5-8. 2 0-5. 2 CCAGTTGTTCCCAGTGCTCC 1873 SEQ ID NO : 200-16. 8-30. 7 85. 6-13. 9 0-3. 7 TGCCATCCTGACATGAGTCA 2193 SEQ ID NO : 201-16. 8-26. 2 74. 2-7. 3-2. 1-7. 1 AAGATACCGCTCATCGTCCA 526 SEQ ID NO : 202-16. 7-25. 9 70. 9-8. 6-0. 3-3. 5 CTTGTTCCTCATTTTCTTGG 1220 SEQ ID NO : 203-16. 7-23. 6 71-6. 9 0-2. 9 CATTTTGCTGTTCCTCTTGT 1235 SEQ ID NO : 204-16. 7-24. 9 74. 1-8. 2 0-3. 6 CTTCAAGAGGTCTCCCAAGT 1466 SEQ ID NO : 205-16. 7-25. 3 73. 1-7. 6-0. 9-4. 8 CCCGAGCAAGATACCAGGCC 2213 SEQ ID NO : 206-16. 7-29. 4 76. 2-12. 7 0-6. 4 ATTGGTGGCTTTTCCAAGAA 2896 SEQ ID NO : 207-16. 7-23 66. 9-4. 6-1. 7-6. 1 GTGTCAACGGCTTGCCCCAG 51 SEQ ID NO : 208-16. 6-30. 3 80. 3-12. 8-0. 8-7. 4 AGTGTCAACGGCTTGCCCCA 52 SEQ ID NO : 209-16. 6-30. 3 80. 3-12. 8-0. 8-7. 4 CTGCAGTCTTCTAAGGGCTG 466 SEQ ID NO : 210-16. 6-25. 4 74. 8-7. 4-1. 3-8. 1 GTGGCCCACAGGCATCTGAA 947 SEQ ID NO : 211-16. 6-28. 7 78. 3-8. 8-3. 3-9. 3 TGCTTCAGAGAGTGAGCTGG 2304 SEQ ID NO : 212-16. 6-24. 8 74. 1-6. 4-1. 8-6. 5 GCTATTCTGCTAGTGATCAA 2645 SEQ ID NO : 213-16. 6-22. 4 67. 7-5. 8 0-6. 7 TGGCTTTTCCAAGAAGTTCA 2891 SEQ ID NO : 214-16. 6-22. 9 67. 5-5. 3-0. 8-9. 3 CTCATCGTCCATCCGTGAAT 517 SEQ ID NO : 215-16. 5-25. 8 71. 1-8. 7-0. 3-3. 8 GTACATTTTGCTGTTCCTCT 1238 SEQ ID NO : 216-16. 5-24. 7 73. 9-8. 2 0-4. 6 GTACAAAATGTCAGTTTCCG 1624 SEQ ID NO : 217-16. 5-20. 6 61. 1-4. 1 0-5. 1 TGTACAAAATGTCAGTTTCC 1625 SEQ ID NO : 218-16. 5-19. 8 60. 5-3. 3 0-5. 9 TGTTCCCAGTGCTCCAGGGT 1868 SEQ ID NO : 219-16. 5-31 87-13. 2-1. 2-6. 3 AGACCAGTTGTTCCCAGTGC 1876 SEQ ID No : 220-16. 5-28. 2 80. 4-11. 7 0-3. 6 AGGTACATTTTGCTGTTCCT 1240 SEQ ID NO : 221-16. 4-24. 6 73. 1-8. 2 0-5. 2 AAAGGTGGGCTCAATTTCTC 1337 SEQ ID NO : 222-16. 4-22. 4 66. 7-6 0-5. 4 TCCAGTGGCAGAGTCTGGGA 1387 SEQ ID NO : 223-16. 4-28. 1 81. 5-9. 5-2. 2-9. 6 TTCCAGTGGCAGAGTCTGGG 1388 SEQ ID NO : 224-16. 4-27. 6 80. 4-9-2. 2-9. 6 TCTTCAAGAGGTCTCCCAAG 1467 SEQ ID NO : 225-16. 4-24. 5 71. 4-7. 1-0. 9-4. 8 1641 TGTTCTCAGGGTCTTCTGTA-16. 4-24. 9 77. 3-7. 6-0. 7-3. 7 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 226 CACTTGCGAAACCAGAGCTC 1681 SEQ ID NO : 227-16. 4-24. 3 67. 8-7. 9 0. 3-8 TTCCCAGTGCTCCAGGGTCA 1866 SEQ ID NO : 228-16. 4-30. 9 86. 5-13. 2-1. 2-6. 3 CCAGCGTTCCTCGTCAGGCA 2093 SEQ ID NO : 229-16. 4-31. 1 83. 7-13. 8-0. 7-8. 2 CCAAAAGGTACGGGGCTCCC 310 SEQ ID NO : 230-16. 3-28. 4 74. 1-11. 2-0. 7-7. 2 GCTTGTCCTGATTCACCAGA 1104 SEQ ID NO : 231-16. 3-26. 6 76-9. 8-0. 2-3. 8 GCCTGCCCGGGTTTTTAGGT 1256 SEQ ID NO : 232-16. 3-31. 4 84. 4-13-0. 7-12. 3 GGGTGACGTAAAAGGTGGGC 1347 SEQ ID No : 233-16. 3-24. 6 69. 2-8. 3 0-4. 7 CCAAGTCCTCCTCGGTGTAG 1452 SEQ ID NO : 234-16. 3-28. 3 78. 6-12 0-3 TCGTCAGGCAGAGTACAGGC 2083 SEQ ID NO : 235-16. 3-26. 6 77. 6-10. 3 0-5. 4 ATAGACATTTGCTCAATTAA 2359 SEQ ID NO : 236-16. 3-17. 6 55. 5-1. 2 0-3. 6 ACCGGCCATCATTCTGGCCC 2687 SEQ ID NO : 237-16. 3-32. 2 83. 3-11. 6-4. 3-11. 3 GTTTGTCTCACGTCTGGGGC 3186 SEQ ID NO : 238-16. 3-27. 9 81. 5-11. 6 0-4. 6 TCAGGCTATGTGGATAAGGT 3685 SEQ ID NO : 239-16. 3-23. 1 69-6. 8 0-4. 1 AAAGGTACGGGGCTCCCCGC 307 SEQ ID NO : 240-16. 2-31 79-11. 2-3. 5-14. 6 AAACTGCAGTCTTCTAAGGG 469 SEQ ID NO : 241-16. 2-21. 5 64. 4-3. 9 0-10. 8 TGTCAATGTGGCCCACAGGC 954 SEQ ID NO : 242-16. 2-28. 4 78. 3-10-2. 2-9. 2 GAAAGGCATGCCTGCCCGGG 1265 SEQ ID NO : 243-16. 2-30. 6 77. 9-10. 7-3. 6-14. 8 AAGTCCTCCTCGGTGTAGAC 1450 SEQ ID NO : 244-16. 2-26. 4 75. 9-10. 2 0-3. 7 CCTTCCATTGGGTGGGTCCT 1832 SEQ ID NO : 245-16. 2-30. 7 84. 5-13. 1-1. 3-6. 4 GCAAGAGCTATAGCAGCGCA 1930 SEQ ID NO : 246-16. 2-26. 1 73. 3-7. 6-2. 3-11 TAGAATTGGTGGCTTTTCCA 2900 SEQ ID NO : 247-16. 2-23. 4 68. 6-6. 1-1-5. 1 CTAGAATTGGTGGCTTTTCC 2901 SEQ ID NO : 248-16. 2-23. 6 69. 4-7. 4 0-3. 7 ATTTTATGGATGGCTCTATA 3223 SEQ ID NO : 249-16. 2-20. 4 62. 7-4. 2 0-3. 7 CATGTTGAAACTGCAGTCTT 476 SEQ ID NO : 250-16. 1-21. 4 64. 1-3. 9 0-10. 8 AAATCTGCATCGTCCGGAGA 877 SEQ ID NO : 251-16. 1-24. 4 67. 8-7. 7 0-8. 5 AAACTCGGCTTGTCCTGATT 1111 SEQ ID NO : 252-16. 1-24. 1 68. 4-7. 4-0. 3-3. 8 ATTTTGCTGTTCCTCTTGTT 1234 SEQ ID NO : 253-16. 1-24. 3 73. 3-8. 2 0-2. 9 GCCTCCCCCAGGCCCCAGGT 2512 SEQ ID NO : 254-16. 1-39. 9 98. 2-21. 4-2. 4-9. 7 TGCTTGCTATTCTGCTAGTG 2650 SEQ ID NO : 255-16. 1-24. 2 72. 6-7. 6-0. 2-4. 5 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo CAACCGGCCATCATTCTGGC 2689 SEQ ID NO : 256-16. 1-28. 2 75. 3-9. 7-2. 4-8 GCAACCGGCCATCATTCTGG 2690 SEQ ID NO : 257-16. 1-28. 2 75. 3-11. 6-0. 1-7. 4 TGTATATGCAAACATTCCAA 3602 SEQ ID NO : 258-16. 1-19. 1 57. 5-2. 5-0. 2-5. 6 CCTCAGGCTATGTGGATAAG 3687 SEQ ID NO : 259-16. 1-23. 6 68. 8-6. 8-0. 5-4. 1 CAAAAGGTACGGGGCTCCCC 309 SEQ ID NO : 260-16-28. 4 74. 1-11. 2-1. 1-9. 1 AATGTGGCCCACAGGCATCT 950 SEQ ID NO : 261-16-28. 1 77-8. 8-3. 3-9. 4 CAAAACTCGGCTTGTCCTGA 1113 SEQ ID NO : 262-16-24 67-7. 4-0. 3-3. 7 TATTTCCAGTGGCAGAGTCT 1391 SEQ ID NO : 263-16-25 74. 8-9 0-6. 8 CAAGTCCTCCTCGGTGTAGA 1451 SEQ ID NO : 264-16-26. 9 76. 3-10. 9 0-3 CCATTGGGTGGGTCCTCAGC 1828 SEQ ID NO : 265-16-30. 2 84. 6-13. 3-0. 8-5. 3 TCCATTGGGTGGGTCCTCAG 1829 SEQ ID NO : 266-16-28. 8 81. 9-11. 4-1. 3-8. 8 GTTGTTCCCAGTGCTCCAGG 1870 SEQ ID NO : 267-16-29. 9 84. 7-13. 9 0-3. 7 GCAGCGCAGTCCCCTCCCGC 1918 SEQ ID NO : 268-16-37. 1 92. 6-19. 5-1. 5-8. 5 TTGCTATTCTGCTAGTGATC 2647 SEQ ID NO : 269-16-22. 5 69. 2-5. 8-0. 4-5 TCTGCTTGCTATTCTGCTAG 2652 SEQ ID NO : 270-16-24. 3 73-7. 6-0. 4-4. 5 AGAATTGGTGGCTTTTCCAA 2899 SEQ ID NO : 271-16-23 66. 9-5. 4-1. 5-5. 8 CTCAGGCTATGTGGATAAGG 3686 SEQ ID NO : 272-16-22. 8 67. 7-6. 8 0-3. 3 GGTTTTAGCTGTCATGTTGA 488 SEQ ID NO : 273-15. 9-23. 3 71. 3-6. 8 0-8. 6 CACCCTGGTATTATTGACCG 653 SEQ ID NO : 274-15. 9-25. 4 69. 5-8. 1-1. 3-5 AAGGAACGCGTGTAGGTGTG 910 SEQ ID NO : 275-15. 9-23. 7 67. 4-7 0-9. 2 CGCTCATGCTCACATTTTAC 1060 SEQ ID NO : 276-15. 9-23. 5 68. 3-6. 5-1-4. 4 CTCGGCTTGTCCTGATTCAC 1108 SEQ ID NO : 277-15. 9-26. 6 75. 8-10. 1-0. 3-4. 4 GGCAAAACTCGGCTTGTCCT 1115 SEQ ID NO : 278-15. 9-26. 4 72. 3-9. 8-0. 5-4. 7 GGCTCAATTTCTCCCATGTT 1330 SEQ ID NO : 279-15. 9-26. 2 74. 8-10. 3 0-4. 3 ATCTTCAAGAGGTCTCCCAA 1468 SEQ ID NO : 280-15. 9-24. 5 71. 1-7. 6-0. 9-4. 8 GACACTTGCGAAACCAGAGC 1683 SEQ ID NO : 281-15. 9-23. 8 66. 3-7. 9 0-4. 1 AACCGGCCATCATTCTGGCC 2688 SEQ ID NO : 282-15. 9-29. 5 77. 6-9. 7-3. 9-10. 9 GAATTGGTGGCTTTTCCAAG 2898 SEQ ID NO : 283-15. 9-23 66. 9-5. 4-1. 7-6. 1 CGTCTGGGGCATATTGGTGG 3176 SEQ ID NO : 284-15. 9-26. 8 75. 6-10. 9 0-4 3227 TAGGATTTTATGGATGGCTC-15. 9-21. 6 65. 6-5. 7 0-3. 7 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 285 CAGTCTTCTAAGGGCTGGCT 463 SEQ ID NO : 286-15. 8-26. 6 77. 8-9. 7-1-6. 3 TGTTGAAACTGCAGTCTTCT 474 SEQ ID NO : 287-15. 8-22 66. 4-3. 9 0-12. 8 TCATGTTGAAACTGCAGTCT 477 SEQ ID NO : 288-15. 8-21. 7 65. 3-3. 9 0-12. 1 TTAGCTGTCATGTTGAAACT 484 SEQ ID NO : 289-15. 8-20. 4 62. 3-3. 9-0. 1-8. 6 CGTCCGGAGAGAGCCTCTTG 867 SEQ ID NO : 290-15. 8-28. 3 77. 1-10. 9-1. 4-10 GTCAATGTGGCCCACAGGCA 953 SEQ ID NO : 291-15. 8-29. 1 79. 6-10-3. 3-8. 7 TGGAAGTCACCCCCATTGGG 979 SEQ ID NO : 292-15. 8-28. 8 76. 7-11. 3-1. 7-8. 8 CTCAGGGTCTTCTGTACAAA 1637 SEQ ID NO : 293-15. 8-22. 7 68. 2-6-0. 7-6. 2 CTTCATGGAGTTTCAGAGAT 3139 SEQ ID NO : 294-15. 8-21. 6 66. 5-5. 8 0-5. 3 TAGCTGTCATGTTGAAACTG 483 SEQ ID NO : 295-15. 7-20. 3 61. 9-3. 9-0. 1-8. 6 TGGACGGCTCGCTCATGCTC 1069 SEQ ID NO : 296-15. 7-28. 8 78. 9-12-1-6. 1 TTCCTCTTGTTCCTCATTTT 1225 SEQ ID NO : 297-15. 7-24. 8 74-9. 1 0-1. 9 ACATTTTGCTGTTCCTCTTG 1236 SEQ ID NO : 298-15. 7-23. 9 71. 1-8. 2 0-3. 6 AAGGTGGGCTCAATTTCTCC 1336 SEQ ID NO : 299-15. 7-25. 1 72. 7-9. 4 0-5. 8 TAAAAGGTGGGCTCAATTTC 1339 SEQ ID NO : 300-15. 7-20. 1 60. 6-4. 4 0-6 TTTCCAGTGGCAGAGTCTGG 1389 SEQ ID NO : 301-15. 7-26. 5 78. 1-9-1. 8-9. 6 CAAGAGGTCTCCCAAGTCCT 1463 SEQ ID NO : 302-15. 7-27. 2 76. 4-11-0. 2-4. 8 GTATGGTCAGTGCAACCCAT 2253 SEQ ID NO : 303-15. 7-26. 3 74. 5-9. 5-1-7. 4 ATACTCTGCTTGCTATTCTG 2656 SEQ ID NO : 304-15. 7-22. 7 68. 7-7 0-4. 5 TTTTATGGATGGCTCTATAT 3222 SEQ ID NO : 305-15. 7-20. 4 62. 7-4. 2-0. 1-4. 6 ATGTTGAAACTGCAGTCTTC 475 SEQ ID NO : 306-15. 6-21. 1 64. 4-3. 9 0-11. 1 CATCGTCCATCCGTGAATGA 515 SEQ ID NO : 307-15. 6-25. 1 68. 9-9. 5 0-3 ATCCAAACCTGTGATTCGGC 812 SEQ ID NO : 308-15. 6-24. 9 68. 9-9. 3 0-3. 2 ATTTCCAGTGGCAGAGTCTG 1390 SEQ ID NO : 309-15. 6-25. 3 75. 2-9-0. 1-8. 9 TCCCAGTGCTCCAGGGTCAA 1865 SEQ ID NO : 310-15. 6-30. 1 83. 2-13. 2-1. 2-6. 3 CCATCCTGACATGAGTCAGC 2191 SEQ ID NO : 311-15 6-26. 2 74. 7-7. 3-3. 3'-9. 6 GCAGTATGGTCAGTGCAACC 2256 SEQ ID NO : 312-15. 6-26. 1 75. 6-9. 6-0. 8-7 TAGACATTTGCTCAATTAAA 2358 SEQ ID NO : 313-15. 6-16. 9 53. 7-1. 2 0-3. 6 ACTCCACTGGGTTCCAAATG 2432 SEQ ID NO : 314-15. 6-24. 7 69. 5-8. 5-0. 3-4. 8 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo TCAAGATCTAGAATTGGTGG 2908 SEQ ID NO : 315-15. 6-19. 6 60. 4-3. 5 0-8 TTCTTCCTCTCCTGCTTGGT 3331 SEQ ID NO : 316-15. 6-28. 6 83. 1-12. 5-0. 1-4. 1 GGAGTTGCTCATCCTGCCCC 245 SEQ ID NO : 317-15. 5-32 86. 8-15. 3-1. 1-5. 1 AGCCGTCCCTCTGGACCAAA 325 SEQ ID NO : 318-15. 5-29. 7 77. 4-11. 5-2. 7-8. 7 GCAGTCTTCTAAGGGCTGGC 464 SEQ ID NO : 319-15. 5-27. 5 80. 4-10. 3-1. 7-6 GTTGAAACTGCAGTCTTCTA 473 SEQ ID NO : 320-15. 5-21. 7 66-3. 9 0-12. 8 CGAGCATCCTGGCAATGCTG 681 SEQ ID NO : 321-15. 5-26. 9 73. 1-8. 4-3-11. 2 CATTTTCTTGGCATTGTAGC 1211 SEQ ID NO : 322-15. 5-22. 9 69. 1-7. 4 0-4 GTGGGCTCAATTTCTCCCAT 1333 SEQ ID NO : 323-15. 5-27. 3 77-9. 7-2. 1-7. 5 ACACTTGCGAAACCAGAGCT 1682 SEQ ID NO : 324-15. 5-24. 1 66. 9-7. 9-0. 4-5. 3 CAGTTGTTCCCAGTGCTCCA 1872 SEQ ID NO : 325-15. 5-29. 4 83-13. 9 0-3. 7 AGCAAGAGCTATAGCAGCGC 1931 SEQ ID NO : 326-15. 5-25. 4 72. 5-7. 6-2. 3-11 CTTGCTATTCTGCTAGTGAT 2648 SEQ ID NO : 327-15. 5-23 69. 6-6. 8-0. 4-4. 3 CCCTCAGGCTATGTGGATAA 3688 SEQ ID NO : 328-15. 5-25. 6 72. 1-9-1-4. 3 CCGGTAAGACCCTTCTCTCG 153 SEQ ID NO : 329-15. 4-27. 8 74. 6-11. 5-0. 7-6. 6 ACCAAAAGGTACGGGGCTCC 311 SEQ ID NO : 330-15. 4-26. 6 71. 4-11. 2 0-6. 2 TGGCCCACAGGCATCTGAAT 946 SEQ ID NO : 331-15. 4-27. 5 75-8. 8-3. 3-9. 3 TTGTTCCTCATTTTCTTGGC 1219 SEQ ID NO : 332-15. 4-24. 5 73. 5-9. 1 0-3 CTCTTGTTCCTCATTTTCTT 1222 SEQ ID NO : 333-15. 4-23. 7 72. 2-8. 3 0-1. 9 TACATTTTGCTGTTCCTCTT 1237 SEQ ID NO : 334-15. 4-23. 6 70. 7-8. 2 0-3. 6 TGCCTGCCCGGGTTTTTAGG 1257 SEQ ID NO : 335-15. 4-30. 2 80. 7-13-0. 7-11. 8 TGTGTGCTTCAGAGAGTGAG 2308 SEQ ID NO : 336-15. 4-23. 3 71. 6-7. 4-0. 2-4. 6 ATCATTCTTCCTCTCCTGCT 3335 SEQ ID NO : 337-15. 4-27. 2 79. 3-11. 8 0-3. 6 GGCTAGAAAGCAATCACAGA 3497 SEQ ID NO : 338-15. 4-21. 2 62. 5-3. 2-2. 6-6. 9 ACATTCCAAAATCTGAAAAT 3591 SEQ ID NO : 339-15. 4-15. 8 50. 2 0 0-3. 2 ATGCAAACATTCCAAAATCT 3597 SEQ ID NO : 340-15. 4-18. 4 55. 3-2. 5-0. 2-5. 6 TGTCAACGGCTTGCCCCAGA 50 SEQ ID NO : 341-15. 3-29. 7 78. 3-13. 5-0. 8-7. 1 AGGAACGGAGTTGCTCATCC 251 SEQ ID NO : 342-15. 3-25. 4 72. 1-8. 3-1. 8-6. 8 GTCCTGATTCACCAGAGAGT 1100 SEQ ID NO : 343-15. 3-25. 6 74. 9-9. 8-0. 2-3. 8 1112 AAAACTCGGCTTGTCCTGAT-15. 3-23. 3 65. 9-7. 4-0. 3-3. 7 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 344 TCCTTCCACAGGTTGTACCA 1519 SEQ ID NO : 345-15. 3-27. 7 78-10. 7-1. 7-5. 8 GGGTTGCGGGGTTGAGACAG 1552 SEQ ID NO : 346-15. 3-27. 3 77-11. 3-0. 5-3. 8 GGAAGCTCCACAGTGGGACT 1732 SEQ ID NO : 347-15. 3-27. 1 76. 4-10. 7-0. 9-9. 3 CGTCAGGCAGAGTACAGGCT 2082 SEQ ID NO : 348-15. 3-27. 1 77. 8-11. 1-0. 4-5. 5 GCCATCCTGACATGAGTCAG 2192 SEQ ID NO : 349-15. 3-26. 2 74. 7-7. 3-3. 6-9. 2 TTTTCCAAGAAGTTCAACAA 2887 SEQ ID NO : 350-15. 3-18. 5 56. 7-3. 2 0-6. 8 CCCCCATTGGGGTAGATGTC 970 SEQ ID NO : 351-15. 2-29. 5 80. 3-11. 3-3-12. 8 ATTTTCTTGGCATTGTAGCC 1210 SEQ ID NO : 352-15. 2-24. 2 71. 7-7. 4-1. 5-5. 8 TAGGTACATTTTGCTGTTCC 1241 SEQ ID NO : 353-15. 2-23. 4 70. 4-8. 2 0-5. 2 GGTTTCCCCAGACTTCACCC 1601 SEQ ID NO : 354-15. 2-30. 8 82. 9-15. 6 0-3. 8 GGGTCTTCTGTACAAAATGT 1633 SEQ ID NO : 355-15. 2-21. 2 64-6 0-6. 2 AGTATGGTCAGTGCAACCCA 2254 SEQ ID NO : 356-15. 2-26. 3 74. 8-10. 5-0. 3-6. 7 AGACATTTGCTCAATTAAAA 2357 SEQ ID NO : 357-15. 2-16. 5 52. 5-1. 2 0-3. 6 GTATATGCAAACATTCCAAA 3601 SEQ ID NO : 358-15. 2-18. 4 55. 7-2. 5-0. 5-5. 1 GTCTTCTAAGGGCTGGCTGT 461 SEQ ID NO : 359-15. 1-27. 1 79. 9-12 0-6. 3 GAAACTGCAGTCTTCTAAGG 470 SEQ ID NO : 360-15. 1-20. 9 63. 1-3. 9 0-12 ATCCTGGCAATGCTGTGTCC 676 SEQ ID NO : 361-15. 1-27. 8 78. 1-12-0. 4-7. 7 GAAGGAACGCGTGTAGGTGT 911 SEQ ID NO : 362-15. 1-24. 3 68. 8-8. 3 0-9. 7 GGAAGTCACCCCCATTGGGG 978 SEQ ID NO : 363-15. 1-30 79. 3-11. 3-3. 6-12. 4 GCTCAATTTCTCCCATGTTC 1329 SEQ ID NO : 364-15. 1-25. 4 73. 9-10. 3 0-4. 3 CTCCCGTCCGGGGTTGCGGG 1562 SEQ ID NO : 365-15. 1-34. 4 86. 3-16. 2-3-13. 4 CAAGAGCTATAGCAGCGCAG 1929 SEQ ID NO : 366-15. 1-24. 3 69. 4-7. 6-1. 5-10. 2 CCGAGCAAGATACCAGGCCT 2212 SEQ ID NO : 367-15. 1-28. 3 74. 7-12. 7 0-7. 9 TAAGTGTCTCAGATATTGTG 2942 SEQ ID NO : 368-15. 1-19. 4 61. 6-4. 3 0-2. 8 TCTGAGTCCTCTCCCTGGCT 3100 SEQ ID NO : 369-15. 1-30. 9 87. 3-14. 5-1. 2-6. 6 GCATATTGGTGGGAACTGGC 3168 SEQ ID NO : 370-15. 1-25. 1 71. 8-8. 7-1. 2-6. 1 TTTAGCTGTCATGTTGAAAC 485 SEQ ID NO : 371-15-19. 6 60. 7-3. 9-0. 1-8. 6 AGGTTTTAGCTGTCATGTTG 489 SEQ ID NO : 372-15-22. 7 70. 1-7. 7 0-4. 8 AGGCAAAACTCGGCTTGTCC 1116 SEQ ID NO : 373-15-25. 5 70. 7-9. 8-0. 5-4. 7 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo CAGACTTCACCCGGATGCGC 1593 SEQ ID NO : 374-15-28. 8 75. 8-13. 1-0. 5-7 AACCAGAGCTCCCGGCCTGG 1672 SEQ ID NO : 375-15-31. 8 81. 6-12. 8-4-9. 5 CATTGGGTGGGTCCTCAGCA 1827 SEQ ID NO : 376-15-28. 9 82. 1-13. 3-0. 3-4. 4 GCTTCAGAGAGTGAGCTGGG 2303 SEQ ID NO : 377-15-26 77. 1-9. 8-1. 1-5. 8 ATGTGTGCTTCAGAGAGTGA 2309 SEQ ID NO : 378-15-23. 3 71. 2-8. 3 0-3. 6 AATTGGTGGCTTTTCCAAGA 2897 SEQ ID NO : 379-15-23 66. 9-6. 3-1. 7-6. 1 GGGAGGCAAGGACTCGCTGC 2 SEQ ID NO : 380-14. 9-28. 6 78. 7-13. 7 0. 3-5. 7 TTTTAGCTGTCATGTTGAAA 486 SEQ ID NO : 381-14. 9-19. 5 60. 5-3. 9-0. 1-8. 6 ATCGTCCATCCGTGAATGAT 514 SEQ ID NO : 382-14. 9-24. 4 67. 8-9. 5 0-3 TGCAGCCAGTCGAGCATCCT 691 SEQ ID NO : 383-14. 9-29. 8 81. 7-14-0. 7-6. 1 CTGCAGCCAGTCGAGCATCC 692 SEQ ID NO : 384-14. 9-29. 8 81. 7-14-0. 7-7. 2 TTTTCTTGGCATTGTAGCCA 1209 SEQ ID NO : 385-14. 9-24. 9 72. 9-7. 4-2. 6-8 GGTGACGTAAAAGGTGGGCT 1346 SEQ ID NO : 386-14. 9-24. 3 68. 6-9. 4 0-5. 3 CCAGTGGCAGAGTCTGGGAA 1386 SEQ ID NO : 387-14. 9-27 76. 9-10. 5-1. 6-9. 6 AGCAGCGCAGTCCCCTCCCG 1919 SEQ ID NO : 388-14. 9-35. 3 88. 8-19. 5-0. 7-8. 5 AAGAGCTATAGCAGCGCAGT 1928 SEQ ID NO : 389-14. 9-24. 8 71. 5-7. 6-2. 3-11 AGAAACCAATCCAGTGTGCA 2049 SEQ ID NO : 390-14. 9-23. 4 66. 3-8. 5 0-5. 2 GCAAGATACCAGGCCTGCCA 2208 SEQ ID NO : 391-14. 9-29. 4 78. 3-12. 7-0. 3-11. 7 AATAGACATTTGCTCAATTA 2360 SEQ ID NO : 392-14. 9-17. 6 55. 5-2. 7 0-3. 6 AACTCCACTGGGTTCCAAAT 2433 SEQ ID NO : 393-14. 9-24 67. 4-8. 5-0. 3-5. 9 CCCCAGGCCCCAGGTGCCTT 2507 SEQ ID NO : 394-14. 9-37. 6 93. 4-20. 5-2. 2-10 AGCCTCAGGGTCCCTAATGC 2544 SEQ ID NO : 395-14. 9-29. 5 81. 5-14-0. 3-7 GGCTGCACCACTAACTAGTA 3084 SEQ ID NO : 396-14. 9-25. 1 71. 7-9. 5-0. 4-7. 1 TTTGTCTCACGTCTGGGGCA 3185 SEQ ID NO : 397-14. 9-27. 4 78. 8-11. 6-0. 8-4. 7 TTAGGATTTTATGGATGGCT 3228 SEQ ID NO : 398-14. 9-21. 3 64. 4-6. 4 0-3. 7 CTTAGGATTTTATGGATGGC 3229 SEQ ID NO : 399-14. 9-21. 3 64. 4-6. 4 0-2. 8 GCTTAGGATTTTATGGATGG 3230 SEQ ID NO : 400-14. 9-21. 3 64. 4-6. 4 0-2. 8 ATTCTTCCTCTCCTGCTTGG 3332 SEQ ID NO : 401-14. 9-27. 4 79. 3-12. 5 0-3. 8 CATTCCAAAATCTGAAAATA 3590 SEQ ID NO : 402-14. 9-15. 3 49. 2 0 0-3. 2 324 GCCGTCCCTCTGGACCAAAA-14. 8-29 74. 9-11. 5-2. 7-8 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 403 TTCCAGCCGTCCCTCTGGAC 329 SEQ ID NO : 404-14. 8-31. 6 84. 4-13. 9-2. 9-8. 4 TGTTCCTCATTTTCTTGGCA 1218 SEQ ID NO : 405-14. 8-25. 1 74. 3-10. 3 0-4 AGTTGTTCCCAGTGCTCCAG 1871 SEQ ID NO : 406-14. 8-28. 7 82. 4-13. 9 0-3. 7 GAGAAACCAATCCAGTGTGC 2050 SEQ ID NO : 407-14. 8-23. 3 66. 5-8. 5 0-3. 7 TAGCCTCCCCCAGGCCCCAG 2514 SEQ ID NO : 408-14. 8-37. 2 92. 1-19. 2-3. 2-7. 5 GCTTGCTATTCTGCTAGTGA 2649 SEQ ID NO : 409-14. 8-24. 8 74. 2-10 3. 8-4. 3 GGCTTTTCCAAGAAGTTCAA 2890 SEQ ID NO : 410-14. 8-22. 2 65. 4-6. 8-0. 3-7 TGGCTAGAAAGCAATCACAG 3498 SEQ ID NO : 411-14. 8-20. 6 61. 2-3. 2-2. 6-6. 8 TTATCTTCCAGCCGTCCCTC 334 SEQ ID NO : 412-14. 7-29. 8 81. 8-15. 1 0-3. 2 AAAGATACCGCTCATCGTCC 527 SEQ ID NO : 413-14. 7-24. 5 67. 7-9. 2-0. 3-3. 5 CTACATTGGCGTCTTTCTCT 588 SEQ ID NO : 414-14. 7-24. 7 72. 7-10 0-4. 6 CCACAGGCATCTGAATACCA 942 SEQ ID NO : 415-14. 7-25. 1 69. 7-8. 8-1. 5-4. 6 TTGTCCTGATTCACCAGAGA 1102 SEQ ID NO : 416-14. 7-24. 5 71. 3-9. 8 0-3. 8 TCAAGAGGTCTCCCAAGTCC 1464 SEQ ID NO : 417-14. 7-26. 7 76. 1-11-0. 9-4. 8 GGTGAGCTGGATCTTCAAGA 1478 SEQ ID NO : 418-14. 7-23. 9 71-9. 2 0-5. 2 GAAGAATCCTTCCATTGGGT 1839 SEQ ID NO : 419-14. 7-24 68. 6-7. 9-1. 3-6. 5 GGCCCCAGGTGCCTTTCCCC 2502 SEQ ID NO : 420-14. 7-37. 4 94. 5-21. 3-1. 3-8. 3 TGGCTGCACCACTAACTAGT 3085 SEQ ID NO : 421-14. 7-25. 4 72. 1-9. 5-1. 1-8. 3 CTGAGTCCTCTCCCTGGCTG 3099 SEQ ID NO : 422-14. 7-30. 5 85-14. 5-1. 2-6. 6 GTCTTCATGGAGTTTCAGAG 3141 SEQ ID NO : 423-14. 7-22. 6 70. 3-7. 9 0-6. 5 AGTCTTCATGGAGTTTCAGA 3142 SEQ ID NO : 424-14. 7-22. 6 70. 3-7. 9 0-6. 5 AACATTCCAAAATCTGAAAA 3592 SEQ ID NO : 425-14. 7-15. 1 48. 7 0 0-3. 2 AAACATTCCAAAATCTGAAA 3593 SEQ ID NO : 426-14. 7-15. 1 48. 7 0 0-3. 2 CGGTAAGACCCTTCTCTCGG 152 SEQ ID NO : 427-14. 6-27 73. 7-11. 5-0. 7-4 GGAACGGAGTTGCTCATCCT 250 SEQ ID NO : 428-14. 6-26. 3 73. 7-9. 9-1. 8-6. 8 TCAATGTGGCCCACAGGCAT 952 SEQ ID NO : 429-14. 6-27. 9 76. 1-10-3. 3-9. 4 GATCTTCAAGAGGTCTCCCA 1469 SEQ ID NO : 430-14. 6-25. 8 74. 9-10. 2-0. 9-5 CTTCTGTACAAAATGTCAGT 1629 SEQ ID NO : 431-14. 6-19. 5 60. 3-3. 3-1. 6-6. 5 CCAGCCATCCCGACACTTGC 1694 SEQ ID No : 432-14. 6-30. 9 79. 9-16. 3 0-3. 2 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo ACCAGTTGTTCCCAGTGCTC 1874 SEQ ID NO : 433-14. 6-28. 9 82. 6-14. 3 0-3. 7 CTGCCATCCTGACATGAGTC 2194 SEQ ID NO : 434-14. 6-26. 4 75. 1-10. 7-1-5. 2 GCCCCAGGTGCCTTTCCCCA 2501 SEQ ID NO : 435-14. 6-36. 9 92. 9-22. 3 0-6. 4 CCCAGGCCCCAGGTGCCTTT 2506 SEQ ID NO : 436-14. 6-35. 7 90. 7-18. 9-2. 2-10 TCTTCATGGAGTTTCAGAGA 3140 SEQ ID NO : 437-14. 6-22 68. 2-7. 4 0-6. 5 TTGTCTCACGTCTGGGGCAT 3184 SEQ ID NO : 438-14. 6-27. 3 78. 3-11. 6-1-4. 9 AGTCTTCTAAGGGCTGGCTG 462 SEQ ID NO : 439-14. 5-25. 9 76. 4-11. 4 0-6. 3 CCCCATTGGGGTAGATGTCA 969 SEQ ID NO : 440-14. 5-28. 2 77. 9-11. 3-2. 3-12 CTTGTCCTGATTCACCAGAG 1103 SEQ ID NO : 441-14. 5-24. 8 71. 9-9. 8-0. 2-3. 8 GCAAAACTCGGCTTGTCCTG 1114 SEQ ID NO : 442-14. 5-25. 2 69. 7-10. 1-0. 3-4. 2 TTTTGCTGTTCCTCTTGTTC 1233 SEQ ID NO : 443-14. 5-24. 7 75. 2-10. 2 0-3. 6 AGGGTGACGTAAAAGGTGGG 1348 SEQ ID NO : 444-14. 5-22. 8 65. 4-8. 3 0-5. 3 GACATTTGCTCAATTAAAAA 2356 SEQ ID NO : 445-14. 5-15. 8 50. 7-1. 2 0-3. 6 AGCCTCCCCCAGGCCCCAGG 2513 SEQ ID NO : 446-14. 5-38. 7 95-21-3. 2-9. 2 TCATGGAGTTTCAGAGATAG 3137 SEQ ID NO : 447-14. 5-20. 3 63. 6-5. 8 0-4. 7 GGCATATTGGTGGGAACTGG 3169 SEQ ID NO : 448-14. 5-24. 5 70. 2-8. 7-1. 2-5. 7 TCATTCTTCCTCTCCTGCTT 3334 SEQ ID NO : 449-14. 5-27. 3 79. 8-12. 8 0-3. 6 GAGCGAGTGTCAACGGCTTG 57 SEQ ID NO : 450-14. 4-25. 6 71. 7-9. 6-1. 6-5. 6 CGCTCATCGTCCATCCGTGA 519 SEQ ID NO : 451-14. 4-29. 1 77. 3-14. 2-0. 1-3. 6 GTCCGGAGAGAGCCTCTTGT 866 SEQ ID NO : 452-14. 4-28. 7 81. 1-12. 8-1. 3-10 GCCCACAGGCATCTGAATAC 944 SEQ ID NO : 453-14. 4-26. 2 72. 7-9. 3-2. 5-8. 7 GAAGTCACCCCCATTGGGGT 977 SEQ ID NO : 454-14. 4-30 80. 2-11. 3-4. 3-12. 8 TTGGGTGGGTCCTCAGCAGT 1825 SEQ ID NO : 455-14. 4-29. 4 85. 3-14. 1-0. 8-4. 9 CAGCAAGAGCTATAGCAGCG 1932 SEQ ID NO : 456-14. 4-24. 3 69. 4-7. 6-2. 3-11 GTCAGGCAGAGTACAGGCTC 2081 SEQ ID NO : 457-14. 4-26. 7 80. 2-11. 1-1. 1-5. 3 CAGTATGGTCAGTGCAACCC 2255 SEQ ID NO : 458-14. 4-26. 3 74. 8-11. 1-0. 6-7. 4 GCTGCACCACTAACTAGTAT 3083 SEQ ID NO : 459-14. 4-23. 9 69. 1-9. 5 0-6. 3 TGTCTCACGTCTGGGGCATA 3183 SEQ ID NO : 460-14. 4-26. 9 77. 3-11. 6-0. 8-4. 7 GTCAACGGCTTGCCCCAGAA 49 SEQ ID NO : 461-14. 3-29 76. 1-13. 8-0. 8-7. 1 246 CGGAGTTGCTCATCCTGCCC-14. 3-30. 8 82. 7-15. 3-1. 1-5. 1 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 462 CCACCCTGGTATTATTGACC 654 SEQ ID NO : 463-14. 3-26. 6 72. 9-11. 8-0. 2-4. 5 TACAAAATGTCAGTTTCCGC 1623 SEQ ID NO : 464-14. 3-21. 2 62. 1-6. 9 0-3. 6 CTGTACAAAATGTCAGTTTC 1626 SEQ ID NO : 465-14. 3-18. 7 58. 6-3. 3-1-6. 1 GGCCCGAGCAAGATACCAGG 2215 SEQ ID NO : 466-14. 3-28. 6 75. 3-12. 7-1. 5-5. 6 GGGCCCGAGCAAGATACCAG 2216 SEQ ID NO : 467-14. 3-28. 6 75. 3-12. 7-1. 5-10. 6 GCCATCATTCTGGCCCCAGC 2683 SEQ ID NO : 468-14. 3-32. 5 86. 4-16. 2-2-7. 8 GCTAGAAAGCAATCACAGAA 3496 SEQ ID NO : 469-14. 3-19. 3 58. 1-3. 2-1. 8-6. 5 GCTGGAAGTCACCCCCATTG 981 SEQ ID NO : 470-14. 2-29. 1 77. 8-14. 4-0. 1-4. 9 CCTCATTTTCTTGGCATTGT 1214 SEQ ID NO : 471-14. 2-24. 7 72. 5-10. 5 0-4 CTCAATTTCTCCCATGTTCT 1328 SEQ ID NO : 472-14. 2-24. 5 71. 4-10. 3 0-4. 3 GAGGTCTCCCAAGTCCTCCT 1460 SEQ ID NO : 473-14. 2-30. 5 85-14. 9-1. 3-6. 1 AGAGGTCTCCCAAGTCCTCC 1461 SEQ ID No : 474-14. 2-29. 6 83. 4-13. 3-2. 1-6. 4 AAGAGGTCTCCCAAGTCCTC 1462 SEQ ID NO : 475-14. 2-26. 9 77-11-1. 7-6. 5 CCTTCCACAGGTTGTACCAA 1518 SEQ ID NO : 476-14. 2-26. 6 73. 9-10. 7-1. 7-5. 3 GTTGCGGGGTTGAGACAGGT 1550 SEQ ID NO : 477-14. 2-27. 3 77. 9-12. 4-0. 5-4. 5 GGTTGCGGGGTTGAGACAGG 1551 SEQ ID NO : 478-14. 2-27. 3 77-12. 4-0. 5-4. 5 CAGGGTCTTCTGTACAAAAT 1635 SEQ ID NO : 479-14. 2-20. 7 62. 4-6-0. 1-6. 2 TCAGGGTCTTCTGTACAAAA 1636 SEQ ID NO : 480-14. 2-21. 1 63. 9-6-0. 7-6. 2 AGAGCTATAGCAGCGCAGTC 1927 SEQ ID NO : 481-14. 2-25. 9 75. 8-9. 4-2. 3-11 AGCAAGATACCAGGCCTGCC 2209 SEQ ID NO : 482-14. 2-28. 7 77. 6-12. 7-0. 6-11. 7 CCGGCCATCATTCTGGCCCC 2686 SEQ ID NO : 483-14. 2-34 85. 8-15. 5-4. 3-11. 3 ATCTGAGTCCTCTCCCTGGC 3101 SEQ ID NO : 484-14. 2-30 85. 2-14. 5-1. 2-6. 6 CATATTGGTGGGAACTGGCT 3167 SEQ ID NO : 485-14. 2-24. 2 69. 5-8. 7-1. 2-7. 4 TATCTTCCAGCCGTCCCTCT 333 SEQ ID NO : 486-14. 1-30. 6 83. 3-16. 5 0-3. 2 AAAATCTGCATCGTCCGGAG 878 SEQ ID NO : 487-14. 1-23. 1 64. 5-8. 4 0-8. 5 GTGGACGGCTCGCTCATGCT 1070 SEQ ID NO : 488-14. 1-29. 6 80. 7-14. 4-1-6. 1 TGTCCTGATTCACCAGAGAG 1101 SEQ ID NO : 489-14. 1-24. 4 71. 2-9. 8-0. 2-3. 6 TCATTTTCTTGGCATTGTAG 1212 SEQ ID NO : 490-14. 1-21. 5 66. 2-7. 4 0-4 GTTCCTCTTGTTCCTCATTT 1226 SEQ ID NO : 491-14. 1-25. 9 77. 3-11. 8 0-1. 9 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo TGAAAGGCATGCCTGCCCGG 1266 SEQ ID NO : 492-14. 1-29. 4 75. 5-11. 9-2. 8-14. 8 GGATCTTCAAGAGGTCTCCC 1470 SEQ ID NO : 493-14. 1-26. 3 76. 5-11-1. 1-5 AGGTGAGCTGGATCTTCAAG 1479 SEQ ID NO : 494-14. 1-23. 3 69. 8-9. 2 0-5. 2 TTCCGCTGGGTTTCCCCAGA 1609 SEQ ID NO : 495-14. 1-31. 5 83. 4-13. 4-4-11. 5 GAGCCAGCGTTCCTCGTCAG 2096 SEQ ID NO : 496-14. 1-29. 8 81. 8-14. 9-0. 6-4. 6 AGGGCCCGAGCAAGATACCA 2217 SEQ ID NO : 497-14. 1-28. 6 75. 3-12. 7-1. 5-11. 3 GGAGCGAGTGTCAACGGCTT 58 SEQ ID NO : 498-14-26. 8 74. 3-11. 2-1. 6-5. 6 TCCTGGCAATGCTGTGTCCC 675 SEQ ID NO : 499-14-29. 8 81. 7-15. 8 0-6. 9 GTTCCTCATTTTCTTGGCAT 1217 SEQ ID NO : 500-14-25. 1 74. 4-11. 1 0-4 CCGCTGGGTTTCCCCAGACT 1607 SEQ ID NO : 501-14-32. 1 83. 7-13. 4-4. 7-11. 5 ACAAAATGTCAGTTTCCGCT 1622 SEQ ID NO : 502-14-22. 4 64. 5-8. 4 0-3. 6 AGGGTCTTCTGTACAAAATG 1634 SEQ ID NO : 503-14-20 61. 1-6 0-6. 2 ATTGGGTGGGTCCTCAGCAG 1826 SEQ ID NO : 504-14-28. 2 81. 4-13. 3-0. 8-4. 9 CATCCTGACATGAGTCAGCT 2190 SEQ ID NO : 505-14-25. 1 73-7. 3-3. 8-9. 6 GCCTCAGGGTCCCTAATGCT 2543 SEQ ID NO : 506-14-30. 4 83. 1-15. 8-0. 3-6. 8 GTAAGTGTCTCAGATATTGT 2943 SEQ ID NO : 507-14-20. 6 65. 1-6. 6 0-2. 8 TATGCAAACATTCCAAAATC 3598 SEQ ID NO : 508-14-17. 2 53. 1-2. 5-0. 5-5. 6 ACCCTCAGGCTATGTGGATA 3689 SEQ ID NO : 509-14-26. 5 75. 1-11. 4-1-4. 3 AATTACCCTCAGGCTATGTG 3693 SEQ ID NO : 510-14-24. 1 69. 2-10. 1 0. 5-3. 7 GAGGAACGGAGTTGCTCATC 252 SEQ ID NO : 511-13. 9-24 69. 7-8. 3-1. 8-10 CTGTCATGTTGAAACTGCAG 480 SEQ ID NO : 512-13. 9-21. 3 63. 7-6. 7-0. 1-8. 7 CCAAACCTGTGATTCGGCCC 810 SEQ ID NO : 513-13. 9-28. 5 74-14. 6 0-6. 2 ATGCCTGCCCGGGTTTTTAG 1258 SEQ ID NO : 514-13. 9-29 78. 1-13. 8-0. 7-10. 3 AGTCTTGCTGCCTTGCTGGC 1775 SEQ ID NO : 515-13. 9-29. 8 85. 1-13. 8-2. 1-8 GCAGCAAGAGCTATAGCAGC 1933 SEQ ID NO : 516-13. 9-25. 3 73. 7-9. 4-1. 9-11 CCTGCCATCCTGACATGAGT 2195 SEQ ID NO : 517-13. 9-28 76. 9-14. 1 0-5. 2 CTATAGCCTCCCCCAGGCCC 2517 SEQ ID NO : 518-13. 9-35. 1 89-18. 8-2. 4-9. 3 AAGCCTCAGGGTCCCTAATG 2545 SEQ ID NO : 519-13. 9-27 74. 7-12. 5-0. 3-7 TGAGTCCTCTCCCTGGCTGC 3098 SEQ ID NO : 520-13. 9-31. 4 87. 7-16. 2-1. 2-7. 2 308 AAAAGGTACGGGGCTCCCCG-13. 8-28. 5 73-11. 2-3. 3-14. 3 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 521 TCTTCTAAGGGCTGGCTGTG 460 SEQ ID NO : 522-13. 8-25. 9 75. 9-12. 1 0-6. 3 GATCCAAACCTGTGATTCGG 813 SEQ ID NO : 523-13. 8-23. 7 66. 2-9. 3-0. 3-6. 4 GTAGATGTCAATGTGGCCCA 959 SEQ ID NO : 524-13. 8-26 73. 9-12. 2 0-6. 8 CGGGTTTTTAGGTACATTTT 1249 SEQ ID NO : 525-13. 8-21. 8 65. 4-8 0-5. 2 TCTGTACAAAATGTCAGTTT 1627 SEQ ID NO : 526-13. 8-18. 7 58. 6-3. 3-1. 6-6. 5 TTCTGTACAAAATGTCAGTT 1628 SEQ ID NO : 527-13. 8-18. 7 58. 6-3. 3-1. 6-6. 5 CTCCAGCCATCCCGACACTT 1696 SEQ ID NO : 528-13. 8-30. 4 79. 5-16. 6 0-2. 8 TTGTTCCCAGTGCTCCAGGG 1869 SEQ ID NO : 529-13. 8-29. 9 83. 6-15. 5-0. 3-5. 1 GGAGACCAGTTGTTCCCAGT 1878 SEQ ID NO : 530-13. 8-28. 2 80. 2-13. 9-0. 2-4. 1 ATGGATGGCTCTATATAAAA 3218 SEQ ID NO : 531-13. 8-18 55. 8-4. 2 0-4 AATCATTCTTCCTCTCCTGC 3336 SEQ ID NO : 532-13. 8-25. 6 74. 6-11. 8 0-2. 6 CTGAGAAACCAATCCAGTGT 2052 SEQ ID NO : 533-13. 7-22. 4 64. 3-8. 7 0-3. 7 ATCCTGACATGAGTCAGCTC 2189 SEQ ID NO : 534-13. 7-24. 8 73. 6-7. 3-3. 8-9. 4 TTAAAGCCTCAGGGTCCCTA 2548 SEQ ID NO : 535-13. 7-26. 8 74. 7-12. 5-0. 3-7 CAGGCTATGTGGATAAGGTG 3684 SEQ ID NO : 536-13. 7-22. 7 67. 3-9 0-4. 1 TCAACGGCTTGCCCCAGAAC 48 SEQ ID NO : 537-13. 6-28 73. 6-13. 8-0. 3-6. 6 TTGAAACTGCAGTCTTCTAA 472 SEQ ID NO : 538-13. 6-19. 8 60. 6-3. 9 0-12. 8 GTTTTCAAAGATACCGCTCA 533 SEQ ID NO : 539-13. 6-22. 3 64. 7-8. 7 0-3. 1 GGACATTCCCGAGAGAAAAA 723 SEQ ID NO : 540-13. 6-21 59. 6-6. 9-0. 1-3. 6 CTGCATACCCGGCCACGTGC 768 SEQ ID NO : 541-13. 6-31. 8 80. 7-16. 6-1. 5-8. 4 GCTCATGCTCACATTTTACC 1059 SEQ ID NO : 542-13. 6-24. 7 71. 9-10. 4-0. 5-4. 4 TTCAAGAGGTCTCCCAAGTC 1465 SEQ ID NO : 543-13. 6-24. 8 72. 8-10. 2-0. 9-4 CAGCTCCCGTCCGGGGTTGC 1565 SEQ ID NO : 544-13. 6-33. 7 87. 7-17. 4-2. 7-10. 5 CGACACTTGCGAAACCAGAG 1684 SEQ ID NO : 545-13. 6-22. 8 62. 9-9. 2 0-4. 1 CGGAGCCAGCGTTCCTCGTC 2098 SEQ ID NO : 546-13. 6-31. 1 82. 5-16-1. 4-5. 8 TCGGAGCCAGCGTTCCTCGT 2099 SEQ ID NO : 547-13. 6-31. 1 82. 5-16-1. 4-5. 9 GCCCGAGCAAGATACCAGGC 2214 SEQ ID NO : 548-13. 6-29. 2 76. 9-14. 7-0. 7-5. 2 TCCACTGGGTTCCAAATGGA 2430 SEQ ID NO : 549-13. 6-25. 4 70. 8-9. 4-2. 4-8. 3 CACTTAAAGCCTCAGGGTCC 2551 SEQ ID NO : 550-13. 6-26 73. 4-11. 8-0. 3-4. 3 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo CCACTTAAAGCCTCAGGGTC 2552 SEQ ID NO : 551-13. 6-26 73. 4-11. 8-0. 3-3. 6 CCAAGAAGTTCAACAAGAAA 2883 SEQ ID NO : 552-13. 6-17 52. 6-2. 7-0. 5-6. 8 CTAGAAAGCAATCACAGAAA 3495 SEQ ID NO : 553-13. 6-16. 8 52. 6-3. 2 0-4. 1 ATATGCAAACATTCCAAAAT 3599 SEQ ID NO : 554-13. 6-16. 8 52-2. 5-0. 5-5. 6 GCGAGTGTCAACGGCTTGCC 55 SEQ ID NO : 555-13. 5-28. 8 77. 7-14. 2-1-7. 3 ATCCTGCCCCGCCACACCCC 235 SEQ ID NO : 556-13. 5-37. 5 89. 2-24 0-2. 8 GACCAAAAGGTACGGGGCTC 312 SEQ ID NO : 557-13. 5-25. 2 69. 3-11. 2-0. 1-5. 2 TGAAACTGCAGTCTTCTAAG 471 SEQ ID NO : 558-13. 5-19. 7 60. 5-3. 9 0-12. 8 TGTCATGTTGAAACTGCAGT 479 SEQ ID NO : 559-13. 5-21. 6 64. 9-6. 7-0. 1-10. 7 GATGTCAATGTGGCCCACAG 956 SEQ ID NO : 560-13. 5-26 72. 8-10. 8-1. 7-9. 2 TCTGAAAGGCATGCCTGCCC 1268 SEQ ID NO : 561-13. 5-28. 7 76. 7-11. 5-3. 6-14. 8 TCCGCTGGGTTTCCCCAGAC 1608 SEQ ID NO : 562-13. 5-31. 6 83. 6-13. 4-4. 7-11. 5 GGTGTTCTCAGGGTCTTCTG 1643 SEQ ID NO : 563-13. 5-26. 4 81-12. 2-0. 4-3. 7 GAAGCTCCACAGTGGGACTG 1731 SEQ ID NO : 564-13. 5-25. 9 73. 6-10. 7-1. 7-9. 3 GTCTTGCTGCCTTGCTGGCA 1774 SEQ ID NO : 565-13. 5-30. 5 85. 7-13. 8-3. 2-10. 1 GCAACTGAGAAACCAATCCA 2056 SEQ ID NO : 566-13. 5-22 62-8. 5 0-3. 4 ATTCCAAAATCTGAAAATAA 3589 SEQ ID NO : 567-13. 5-13. 9 46. 6 0 0-3. 2 GTCGAGCATCCTGGCAATGC 683 SEQ ID NO : 568-13. 4-27. 6 76. 3-13. 2-0. 9-8. 2 TCCTCATTTTCTTGGCATTG 1215 SEQ ID NO : 569-13. 4-23. 9 70. 7-10. 5 0-4 CTCCTTCCACAGGTTGTACC 1520 SEQ ID NO : 570-13. 4-27. 9 79-13. 6-0. 8-5. 8 CCCGGATGCGCCTGATATTC 1584 SEQ ID NO : 571-13. 4-28. 7 74. 9-14. 6-0. 5-7. 4 GCAGAGTACAGGCTCGCCCA 2076 SEQ ID NO : 572-13. 4-30. 5 82. 8-14. 9-2. 2-7. 3 GGAGCCAGCGTTCCTCGTCA 2097 SEQ ID NO : 573-13. 4-31 84-16. 6-0. 9-5. 6 ATAGCCTCCCCCAGGCCCCA 2515 SEQ ID NO : 574-13. 4-37. 2 91. 6-20. 6-3. 2-7. 5 ACCACTTAAAGCCTCAGGGT 2553 SEQ ID NO : 575-13. 4-25. 8 72. 3-11. 8-0. 3-4. 4 TCTAGAATTGGTGGCTTTTC 2902 SEQ ID NO : 576-13. 4-22 67. 2-8. 6 0-5. 2 CCTCGTCCTGAGCCGCCGGG 19 SEQ ID NO : 577-13. 3-34. 8 86-20. 6-0. 8-8. 4 GCCGGTAAGACCCTTCTCTC 154 SEQ ID NO : 578-13. 3-28. 8 79-14. 4-0. 7-9. 8 AAGGTTTTAGCTGTCATGTT 490 SEQ ID NO : 579-13. 3-22 67. 8-8. 7 0-4. 8 912 CGAAGGAACGCGTGTAGGTG-13. 3-23. 9 65. 9-9. 7 0-9. 7 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 580 TTAGGTACATTTTGCTGTTC 1242 SEQ ID NO : 581-13. 3-21. 5 66. 8-8. 2 0-5. 2 TTTCCGCTGGGTTTCCCCAG 1610 SEQ ID NO : 582-13. 3-31 82. 5-13. 4-4. 3-10. 2 GTTTCCGCTGGGTTTCCCCA 1611 SEQ ID NO : 583-13. 3-32. 2 85. 7-16. 3-2. 6-7. 7 CTGGTTTCGTTTTTCATCCT 1714 SEQ ID NO : 584-13. 3-24. 7 72. 6-11. 4 0-3. 2 CTGCTAGTGATCAAACACGT 2639 SEQ ID NO : 585-13. 3-21. 9 63. 9-7-1. 6-6. 7 GATACTCTGCTTGCTATTCT 2657 SEQ ID NO : 586-13. 3-23. 3 70. 3-10 0-4. 5 CTGGCTGCACCACTAACTAG 3086 SEQ ID NO : 587-13. 3-25. 1 70. 8-10. 5-1. 2-8. 4 TCTTCCTCTCCTGCTTGGTG 3330 SEQ ID NO : 588-13. 3-28. 5 82. 5-14. 7-0. 1-4. 1 AGAAAATCATTCTTCCTCTC 3340 SEQ ID NO : 589-13. 3-20. 1 61. 6-5. 6-1. 1-3. 8 TATATGCAAACATTCCAAAA 3600. SEQ ID NO : 590-13. 3-16. 5 51. 5-2. 5-0. 5-5. 6 GGAGGCAAGGACTCGCTGCT 1 SEQ ID NO : 591-13. 2-28. 3 78. 1-13. 7-1. 3-6. 8 GGGGCTCCCCGCAGCAAAGC 299 SEQ ID NO : 592-13. 2-32. 9 84-17. 6-2. 1-9. 9 ACGAGTTTGTGCAGCCAGTT 550 SEQ ID NO : 593-13. 2-26. 5 75. 8-13. 3 0-5. 6 ATGTCAATGTGGCCCACAGG 955 SEQ ID NO : 594-13. 2-26. 6 74-11. 7-1. 7-9. 2 CTGGAAGTCACCCCCATTGG 980 SEQ ID NO : 595-13. 2-28. 5 76. 1-14. 8-0. 1-5. 2 TTTCTTGGCATTGTAGCCAA 1208 SEQ ID NO : 596-13. 2-24. 1 70. 1-7. 4-3. 5-9. 8 CCTGCCCGGGTTTTTAGGTA 1255 SEQ ID NO : 597-13. 2-29. 3 79. 5-14. 6 0-11 CAGTTTCCGCTGGGTTTCCC 1613 SEQ ID NO : 598-13. 2-30. 2 82. 7-16-0. 9-5. 5 TCCAGCCATCCCGACACTTG 1695 SEQ ID NO : 599-13. 2-29. 5 77. 5-16. 3 0-3. 2 CCCAGTGCTCCAGGGTCAAG 1864 SEQ ID No : 600-13. 2-29. 7 81. 7-15. 7-0. 6-5. 1 ACATTTGCTCAATTAAAAAA 2355 SEQ ID NO : 601-13. 2-14. 5 48-1. 2 0-3. 6 AAAGCCTCAGGGTCCCTAAT 2546 SEQ ID NO : 602-13. 2-26. 3 72. 5-12. 5-0. 3-7 TTGCTCCAAAGCAGTTATAT 2713 SEQ ID NO : 603-13. 2-21. 7 64. 4-5. 9-2. 6-7. 2 GAAAATCATTCTTCCTCTCC 3339 SEQ ID NO : 604-13. 2-22. 1 65. 1-8. 3-0. 3-2. 8 GGTAAGACCCTTCTCTCGGC 151 SEQ ID NO : 605-13. 1-28 78. 1-14. 4-0. 2-4. 7 GTTTTTAGGTACATTTTGCT 1246 SEQ ID NO : 606-13. 1-21. 3 66-8. 2 0-5. 2 TTCAGCTCCCGTCCGGGGTT 1567 SEQ ID NO : 607-13. 1-32. 4 85. 8-17. 4-1. 9-10. 7 GCTGGTGTTCTCAGGGTCTT 1646 SEQ ID NO : 608-13. 1-27. 8 84-14-0. 5-5. 2 ACCAGAGCTCCCGGCCTGGG 1671 SEQ ID NO : 609-13. 1-33. 7 86. 5-16. 2-4. 4-11. 8 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo CAAGATACCAGGCCTGCCAT 2207 SEQ ID NO : 610-13. 1-27. 6 74. 2-12. 7-0. 3-11. 7 TAGGGCCCGAGCAAGATACC 2218 SEQ ID NO : 611-13. 1-27. 6 73. 8-12. 7-1. 5-11. 3 CTCCACTGGGTTCCAAATGG 2431 SEQ ID NO : 612-13. 1-25. 7 71. 4-10. 9-1. 7-6. 9 CCTATAGCCTCCCCCAGGCC 2518 SEQ ID NO : 613-13. 1-35. 1 89-18. 8-3. 2-9. 3 CTATTCTGCTAGTGATCAAA 2644 SEQ ID NO : 614-13. 1-19. 9 61. 2-6. 8 0-6. 7 TAGTATATAAGTCTAGGCAT 3069 SEQ ID NO : 615-13. 1-19. 2 60. 8-6. 1 0-6. 1 GAGTCCTCTCCCTGGCTGCA 3097 SEQ ID NO : 616-13. 1-32. 1 88. 9-18. 3-0. 5-7. 4 CATGGAGTTTCAGAGATAGA 3136 SEQ ID NO : 617-13. 1-20. 5 63. 5-7. 4 0-3. 7 TGGATGGCTCTATATAAAAA 3217 SEQ ID NO : 618-13. 1-17. 3 54-4. 2 0-4 TTATGGATGGCTCTATATAA 3220 SEQ ID NO : 619-13. 1-19. 2 59. 3-5. 6-0. 1-4 AGCGAGTGTCAACGGCTTGC 56 SEQ ID NO : 620-13-26. 8 74. 6-12. 3-1. 4-6. 6 GGGAGCGAGTGTCAACGGCT 59 SEQ ID NO : 621-13-27. 9 76. 5-13. 4-1. 4-5. 5 TACGGGGCTCCCCGCAGCAA 302 SEQ ID NO : 622-13-32. 5 81. 6-15. 9-3. 5-14. 6 TTTAGGTACATTTTGCTGTT 1243 SEQ ID NO : 623-13-21. 2 65. 5-8. 2 0-4. 4 TTTTAGGTACATTTTGCTGT 1244 SEQ ID NO : 624-13-21. 2 65. 5-8. 2 0-5. 2 GGGTTTTTAGGTACATTTTG 1248 SEQ ID NO : 625-13-21 65-8 0-5. 2 TCAGCTCCCGTCCGGGGTTG 1566 SEQ ID NO : 626-13-32. 3 85. 2-17. 4-1. 9-10. 8 ATTCAGCTCCCGTCCGGGGT 1568 SEQ ID NO : 627-13-32. 3 85. 4-17. 4-1. 9-10. 7 TGCTGGTGTTCTCAGGGTCT 1647 SEQ ID NO : 628-13-27. 7 83. 3-14-0. 5-5. 2 AAATCTGGACTTGGTGCTCT 1996 SEQ ID NO : 629-13-23. 3 68. 6-10. 3 0-3. 6 TAAAGCCTCAGGGTCCCTAA 2547 SEQ ID NO : 630-13-26 72-12. 5-0. 2-7 TCTGCTAGTGATCAAACACG 2640 SEQ ID NO : 631-13-21. 1 62. 3-6. 5-1. 6-6. 7 GGCTTAGGATTTTATGGATG 3231 SEQ ID NO : 632-13-21. 3 64. 4-8. 3 0-3. 7 CAACCGTTGGCACAGATGTT 3275 SEQ ID NO : 633-13-24. 8 69. 2-11-0. 6-8. 4 TGTACAAGCTTCGCTTTGGC 3514 SEQ ID NO : 634-13-25 71. 8-10. 6-1. 3-7. 6 AGGGAGCGAGTGTCAACGGC 60 SEQ ID NO : 635-12. 9-27 74. 9-13. 4-0. 5-4. 4 GTACGGGGCTCCCCGCAGCA 303 SEQ ID NO : 636-12. 9-34. 4 87. 4-17. 9-3. 5-14. 6 GCTGTCATGTTGAAACTGCA 481 SEQ ID NO : 637-12. 9-23. 1 67. 6-9-1. 1-6. 7 AGTTTTCAAAGATACCGCTC 534 SEQ ID NO : 638-12. 9-21. 6 63. 7-8. 7 0-3. 1 551 CACGAGTTTGTGCAGCCAGT-12. 9-27. 1 76. 6-13. 3-0. 8-5. 6 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 639 GACATTCCCGAGAGAAAAAT 722 SEQ ID NO : 640-12. 9-19. 8 57. 3-6. 9 0-3. 2 TTCTTGGCATTGTAGCCAAT 1207 SEQ ID NO : 641-12. 9-24 69. 7-7. 4-3. 7-10. 1 CCGGATGCGCCTGATATTCA 1583 SEQ ID NO : 642-12. 9-27. 4 72. 7-13. 8-0. 5-7. 4 ACAGGAGACCAGTTGTTCCC 1881 SEQ ID NO : 643-12. 9-27. 2 77. 2-13. 2-1-4. 9 CTAGTATATAAGTCTAGGCA 3070 SEQ ID NO : 644-12. 9-20. 1 62. 9-6. 7-0. 2-6. 1 AAGTCTTCATGGAGTTTCAG 3143 SEQ ID NO : 645-12. 9-21. 3 66. 3-8. 4 0-6. 5 TTTATGGATGGCTCTATATA 3221 SEQ ID NO : 646-12. 9-20 61. 8-6. 6-0. 1-4. 6 GTTTAACAGTGATACAACTT 3407 SEQ ID NO : 647-12. 9-18. 2 57. 1-5. 3 0-4. 4 TAGAAAGCAATCACAGAAAC 3494 SEQ ID NO : 648-12. 9-16. 1 51. 3-3. 2 0-4. 1 TTCAAAGATACCGCTCATCG 530 SEQ ID NO : 649-12. 8-22. 1 62. 8-8. 7-0. 3-3. 5 GCAGGGCTGACACGAGTTTG 561 SEQ ID NO : 650-12. 8-26. 1 73. 8-13. 3 0-5. 4 TAGATGTCAATGTGGCCCAC 958 SEQ ID NO : 651-12. 8-25 71. 2-11. 7-0. 2-6. 9 CTTGGCATTGTAGCCAATGC 1205 SEQ ID NO : 652-12. 8-25. 3 71. 9-7. 4-5. 1-12. 4 TCTTGGCATTGTAGCCAATG 1206 SEQ ID NO : 653-12. 8-23. 9 69. 2-7. 4-3. 7-10. 1 TTCATCCTCCAGCCATCCCG 1702 SEQ ID NO : 654-12. 8-31. 3 81. 9-18. 5 0-3. 2 AAGTCTTGCTGCCTTGCTGG 1776 SEQ ID NO : 655-12. 8-27. 3 77. 7-13. 8-0. 4-5. 4 CAAATCTGGACTTGGTGCTC 1997 SEQ ID NO : 656-12. 8-23. 1 67. 8-10. 3 0-4. 1 AGCAACTGAGAAACCAATCC 2057 SEQ ID NO : 657-12. 8-21. 3 61. 1-8. 5 0-4. 1 TCCTGACATGAGTCAGCTCC 2188 SEQ ID NO : 658-12. 8-26. 8 77. 4-10. 2-3. 8-9. 1 GAGCAAGATACCAGGCCTGC 2210 SEQ ID NO : 659-12. 8-27. 3 75. 5-12. 7-0. 2-11. 7 CAATAGACATTTGCTCAATT 2361 SEQ ID NO : 660-12. 8-18. 6 57. 3-5. 8 0-4 CCTCCCCCAGGCCCCAGGTG 2511 SEQ ID NO : 661-12. 8-38. 1 93. 7-25. 3 0-6. 8 GCTTTTCCAAGAAGTTCAAC 2889 SEQ ID NO : 662-12. 8-21. 2 63. 4-7. 8-0. 3-6. 8 AATCAAGATCTAGAATTGGT 2910 SEQ ID NO : 663-12. 8-17. 7 55. 9-4. 4 0-8 AGTTTAACAGTGATACAACT 3408 SEQ ID NO : 664-12. 8-18. 1 57-5. 3 0-5. 2 TTGGCTAGAAAGCAATCACA 3499 SEQ ID NO : 665-12. 8-20. 7 61. 3-5. 3-2. 6-6. 9 TACCCTCAGGCTATGTGGAT 3690 SEQ ID NO : 666-12. 8-26. 5 75. 1-12. 6-1-4. 3 ACGGGGCTCCCCGCAGCAAA 301 SEQ ID NO : 667-12. 7-32. 1 79. 8-15. 8-3. 5-14. 6 CCTTCATGCTCTGGGTCCTT 421 SEQ ID NO : 668-12. 7-29. 1 82. 4-16. 4 0-4. 4 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo TTTCAAAGATACCGCTCATC 531 SEQ ID NO : 669-12. 7-21. 4 62. 7-8. 7 0-3. 1 ACATTCCCGAGAGAAAAATC 721 SEQ ID NO : 670-12. 7-19. 6 57. 3-6. 9 0-3. 2 CGTGTAGGTGTGGAGGACAT 902 SEQ ID NO : 671-12. 7-25 72. 7-11. 6-0. 5-3. 7 CCCATTGGGGTAGATGTCAA 968 SEQ ID NO : 672-12. 7-25. 5 72-11. 3-1. 4-8. 6 TGGGTGGGTCCTCAGCAGTA 1824 SEQ ID NO : 673-12. 7-29 84. 3-15. 4-0. 8-4. 9 GAGACCAGTTGTTCCCAGTG 1877 SEQ ID NO : 674-12. 7-27 77. 3-14. 3 0-3. 3 GCTATAGCAGCGCAGTCCCC 1924 SEQ ID No : 675-12. 7-31. 3 84. 4-17-1. 5-10. 7 GCCAGCGTTCCTCGTCAGGC 2094 SEQ ID NO : 676-12. 7-32. 2 87. 2-17. 2-2. 3-8. 2 CTCCCCCAGGCCCCAGGTGC 2510 SEQ ID NO : 677-12. 7-37. 9 94. 9-25. 2 0-6. 8 TATCCTATAGCCTCCCCCAG 2521 SEQ ID NO : 678-12. 7-30. 2 80. 4-17. 5 0-5 ACTTAAAGCCTCAGGGTCCC 2550 SEQ ID NO : 679-12. 7-27. 3 75. 8-14-0. 3-6. 1 ACAGAAGAGATTTGCTCCAA 2724 SEQ ID NO : 680-12. 7-21. 3 63-7. 4-1. 1-5. 7 AACAGAAGAGATTTGCTCCA 2725 SEQ ID NO : 681-12. 7-21. 3 63-7. 4-1. 1-5. 7 TCAAATCAAGATCTAGAATT 2913 SEQ ID NO : 682-12. 7-15. 7 51. 3-3 0-6. 2 AATTCAAATCAAGATCTAGA 2916 SEQ ID NO : 683-12. 7-15. 7 51. 3-3 0-6. 4 ACGTCTGGGGCATATTGGTG 3177 SEQ ID NO : 684-12. 7-25. 8 73. 6-13. 1 0-4. 4 AAATTACCCTCAGGCTATGT 3694 SEQ ID NO : 685-12. 7-23. 4 67. 1-10. 1-0. 3-4. 9 GGACCAAAAGGTACGGGGCT 313 SEQ ID NO : 686-12. 6-26 70. 2-12. 9-0. 1-5. 2 CATTCCCGAGAGAAAAATCG 720 SEQ ID NO : 687-12. 6-20. 2 57. 5-6. 9-0. 4-3. 7 CAAACCTGTGATTCGGCCCA 809 SEQ ID NO : 688-12. 6-27. 2 71. 8-14. 6 0-6. 2 CAATGTGGCCCACAGGCATC 951 SEQ ID NO : 689-12. 6-27. 9 76. 1-12-3. 3-9. 4 TGCCCGGGTTTTTAGGTACA 1253 SEQ ID NO : 690-12. 6-27. 3 75. 8-13. 5 0-10. 3 GGGCTCAATTTCTCCCATGT 1331 SEQ ID NO : 691-12. 6-27. 3 77-13. 6-1-5. 5 AAGGGTGACGTAAAAGGTGG 1349 SEQ ID NO : 692-12. 6-20. 9 61-8. 3 0-5. 3 ACTGGTTTCGTTTTTCATCC 1715 SEQ ID NO : 693-12. 6-24 71. 1-11. 4 0-3 CTTGCTGCCTTGCTGGCAAG 1772 SEQ ID NO : 694-12. 6-28. 2 77. 9-12. 5-3. 1-12. 1 ACAAATCTGGACTTGGTGCT 1998 SEQ ID NO : 695-12. 6-22. 9 66. 8-10. 3 0-5. 6 ATTCTGCTAGTGATCAAACA 2642 SEQ ID NO : 696-12. 6-20. 2 61. 6-7. 6 0-6. 7 CCATCATTCTGGCCCCAGCA 2682 SEQ ID NO : 697-12. 6-31. 4 83-17. 2-1. 5-7. 8 3166 ATATTGGTGGGAACTGGCTG-12. 6-23. 5 68. 3-9. 6-1. 2-7. 4 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 698 GCTTTGGCTAGAAAGCAATC 3502 SEQ ID NO : 699-12. 6-21. 9 64. 7-6. 5-2. 8-10. 8 CATCCTGCCCCGCCACACCC 236 SEQ ID NO : 700-12. 5-36. 2 87. 1-23. 7 0-3 TCATCGTCCATCCGTGAATG 516 SEQ ID NO : 701-12. 5-24. 9 69. 1-11. 9-0. 1-3. 6 ACTACATTGGCGTCTTTCTC 589 SEQ ID NO : 702-12. 5-24 71. 2-11. 5 0-4. 6 GTGTAGGTGTGGAGGACATC 901 SEQ ID NO : 703-12. 5-24. 6 74. 7-11. 4-0. 5-3. 7 GCTCCCGTCCGGGGTTGCGG 1563 SEQ ID NO : 704-12. 5-35 88-19. 5-3-11. 1 TCTTCTGTACAAAATGTCAG 1630 SEQ ID NO : 705-12. 5-18. 7 58. 6-4. 8-1. 3-5. 9 CAGCGCAGTCCCCTCCCGCG 1917 SEQ ID NO : 706-12. 5-36. 1 87. 7-21-2. 6-8. 5 AAGATACCAGGCCTGCCATC 2206 SEQ ID NO : 707-12. 5-27. 3 74. 8-12. 7-0. 3-12. 4 TATGGTCAGTGCAACCCATG 2252 SEQ ID NO : 708-12. 5-25. 1 71-11. 3-1. 2-7. 4 AGAAGTTCAACAAGAAAAGG 2880 SEQ ID NO : 709-12. 5-15. 5 50. 2-3 0-6. 8 TGGAGTTTCAGAGATAGACT 3134 SEQ ID NO : 710-12. 5-20. 9 64. 9-8. 4 0-3. 5 CTTTGGCTAGAAAGCAATCA 3501 SEQ ID NO : 711-12. 5-20. 8 61. 8-6. 5-1. 8-6. 2 TCCAAAACTTTTTGAGCACC 3797 SEQ ID NO : 712-12. 5-21. 8 62. 8-8. 2-1-7. 3 CTTATCTTCCAGCCGTCCCT 335 SEQ ID NO : 713-12. 4-30. 3 81. 9-17. 9 0-3. 2 TTTTCAAAGATACCGCTCAT 532 SEQ ID NO : 714-12. 4-21. 1 61. 7-8. 7 0-3. 1 GGCTGGAAGTCACCCCCATT 982 SEQ ID NO : 715-12. 4-30. 3 80. 4-17. 2-0. 5-5. 3 CATCCTCCAGCCATCCCGAC 1700 SEQ ID NO : 716-12. 4-31. 6 81. 6-19. 2 0-3. 2 CACAAATCTGGACTTGGTGC 1999 SEQ ID NO : 717-12. 4-22. 7 66. 1-10. 3 0-5. 6 AGCAGTATGGTCAGTGCAAC 2257 SEQ ID NO : 718-12. 4-24. 1 72. 1-10. 1-1. 6-5. 7 AGCAGTTATATCTGGCAACC 2704 SEQ ID NO : 719-12. 4-23. 7 69. 4-10. 4-0. 7-2. 8 GTGTATTAATTCAAATCAAG 2923 SEQ ID NO : 720-12. 4-15. 4 50. 9-3 0-4. 2 TGTGTATTAATTCAAATCAA 2924 SEQ ID NO : 721-12. 4-15. 4 50. 7-3 0-3. 9 GTCCTCTCCCTGGCTGCACC 3095 SEQ ID NO : 722-12. 4-33. 7 91. 2-21. 3 0-6. 4 CACGTCTGGGGCATATTGGT 3178 SEQ ID NO : 723-12. 4-26. 5 74. 8-14. 1 0-4. 6 GGATGGCTCTATATAAAAAA 3216 SEQ ID NO : 724-12. 4-16. 6 52. 3-4. 2 0-4. 6 CATTCTTCCTCTCCTGCTTG 3333 SEQ ID NO : 725-12. 4-26. 9 77. 7-14. 5 0-3. 6 CAAACATTCCAAAATCTGAA 3594 SEQ ID NO : 726-12. 4-16. 5 51. 3-4. 1 0-3. 2 GACACATCAATGAATTTTGT 3659 SEQ ID NO : 727-12. 4-18. 2 56. 5-5. 8 0-4. 8 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo GGGCTGGCTGTGGCCGACGG 452 SEQ ID NO : 728-12. 3-32. 8 84. 8-17. 7-2. 8-11 GTGCAGGGCTGACACGAGTT 563 SEQ ID NO : 729-12. 3-27. 2 76. 8-13. 3-1. 4-10. 1 TGGACATTCCCGAGAGAAAA 724 SEQ ID NO : 730-12. 3-21. 7 61. 3-8. 5-0. 8-4. 1 TCCAAACCTGTGATTCGGCC 811 SEQ ID NO : 731-12. 3-26. 9 72. 3-14. 6 0-5. 8 CAAAATCTGCATCGTCCGGA 879 SEQ ID NO : 732-12. 3-23. 8 65. 4-10. 9 0-8. 4 GCGTGTAGGTGTGGAGGACA 903 SEQ ID NO : 733-12. 3-26. 8 77. 3-13. 9-0. 3-4 GTCACCCCCATTGGGGTAGA 974 SEQ ID NO : 734-12. 3-30. 4 82. 2-13. 6-4. 5-12. 4 GTTTCCCCAGACTTCACCCG 1600 SEQ ID NO : 735-12. 3-30. 4 80-18. 1 0-3 CTGGTGTTCTCAGGGTCTTC 1645 SEQ ID NO : 736-12. 3-26. 4 81-14. 1 0-4. 5 GGGAAGCTCCACAGTGGGAC 1733 SEQ ID NO : 737-12. 3-27. 4 77. 1-13. 5-1. 6-9. 5 GGGGAGCAGGACGGAATGGC 2286 SEQ ID NO : 738-12. 3-27. 6 75. 3-15. 3 0-3. 9 TTTGCTCCAAAGCAGTTATA 2714 SEQ ID NO : 739-12. 3-21. 8 64. 7-6. 9-2. 6-7. 2 AAATCAAGATCTAGAATTGG 2911 SEQ ID NO : 740-12. 3-15. 8 51. 3-3 0-8 CAAATCAAGATCTAGAATTG 2912 SEQ ID NO : 741-12. 3-15. 3 50. 2-3 0-7. 2 CTGCACCACTAACTAGTATA 3082 SEQ ID NO : 742-12. 3-21. 8 64. 4-9. 5 0-6. 3 AGTCCTCTCCCTGGCTGCAC 3096 SEQ ID NO : 743-12. 3-31. 7 88. 2-19. 4 0-6. 4 AATCTGAGTCCTCTCCCTGG 3102 SEQ ID NO : 744-12. 3-27. 5 77. 9-14. 5-0. 5-6. 6 TACAAGCTTCGCTTTGGCTA 3512 SEQ ID NO : 745-12. 3-24. 4 70-10. 5-1. 5-9. 5 CCCTCGTCCTGAGCCGCCGG 20 SEQ ID NO : 746-12. 2-35. 6 86. 7-22. 5-0. 8-7. 7 TCCTGCCCCGCCACACCCCC 234 SEQ ID NO : 747-12. 2-39. 5 92-27. 3 0-3 GTCCCTCTGGACCAAAAGGT 321 SEQ ID NO : 748-12. 2-26. 8 73. 6-12. 4-2. 2-6. 9 CAGGGCTGACACGAGTTTGT 560 SEQ ID NO : 749-12. 2-25. 5 72. 8-13. 3 0-4. 7 TGCAGGGCTGACACGAGTTT 562 SEQ ID NO : 750-12. 2-26. 1 73. 8-13. 3-0. 3-5. 6 ATTCCCGAGAGAAAAATCGT 719 SEQ ID NO : 751-12. 2-20. 7 59-8-0. 2-4. 6 CCATTGGGGTAGATGTCAAT 967 SEQ ID NO : 752-12. 2-23. 5 68. 3-11. 3 0-5 TCTGCTCGATCCGCTCCACT 1410 SEQ ID NO : 753-12. 2-29. 9 80. 3-17. 2-0. 1-5. 6 CTTCCACAGGTTGTACCAAG 1517 SEQ ID NO : 754-12. 2-24. 6 70. 6-10. 7-1. 7-5. 3 AGTTTCCGCTGGGTTTCCCC 1612 SEQ ID NO : 755-12. 2-31. 5 85. 1-17. 7-1. 5-5. 9 CCGACACTTGCGAAACCAGA 1685 SEQ ID NO : 756-12. 2-24. 8 65. 9-12. 6 0-4. 3 1777 GAAGTCTTGCTGCCTTGCTG-12. 2-26. 7 76. 4-13. 8-0. 4-5. 4 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 757 GAGCTATAGCAGCGCAGTCC 1926 SEQ ID NO : 758-12. 2-27. 9 79. 2-13. 4-2. 3-11 CTAGGGCCCGAGCAAGATAC 2219 SEQ ID NO : 759-12. 2-26. 5 72. 3-12. 7-0. 7-11. 3 GATGTGTGCTTCAGAGAGTG 2310 SEQ ID NO : 760-12. 2-23. 3 71. 2-11. 1 0-3. 6 GTGTTCAATAGACATTTGCT 2366 SEQ ID NO : 761-12. 2-21 64. 2-8. 8 0-4. 4 CAGAAGAGATTTGCTCCAAA 2723 SEQ ID NO : 762-12. 2-20. 4 60. 4-7. 4-0. 6-5. 7 ATTAATTCAAATCAAGATCT 2919 SEQ ID NO : 763-12. 2-15. 2 50. 2-3 0-6. 1 AGTATATAAGTCTAGGCATG 3068 SEQ ID NO : 764-12. 2-19. 5 61. 3-7. 3 0-6. 1 GAGTGTCAACGGCTTGCCCC 53 SEQ ID NO : 765-12. 1-30. 2 80. 6-17. 2-0. 8-7. 4 CGAGTTTGTGCAGCCAGTTT 549 SEQ ID NO : 766-12. 1-26. 4 75. 6-14. 3 0-5. 6 CCGAAGGAACGCGTGTAGGT 913 SEQ ID NO : 767-12. 1-25. 9 69. 4-11. 4-2. 1-12. 5 GATCCGCTCCACTATTTCCA 1403 SEQ ID NO : 768-12. 1-27. 7 75. 7-15. 6 0-3. 3 TGGATCTTCAAGAGGTCTCC 1471 SEQ ID NO : 769-12. 1-24. 3 72. 5-11-1. 1-5 CGCTGGGTTTCCCCAGACTT 1606 SEQ ID NO : 770-12. 1-30. 2 80. 8-13. 4-4. 7-10. 7 TTTCATCCTCCAGCCATCCC 1703 SEQ ID NO : 771-12. 1-30. 6 82. 8-18. 5 0-3. 2 AGCTATAGCAGCGCAGTCCC 1925 SEQ ID NO : 772-12. 1-29. 3 81. 4-14. 9-2. 3-11 ACTGAGAAACCAATCCAGTG 2053 SEQ ID NO : 773-12. 1-21. 4 61. 9-8. 1-1. 1-5 GGCAGAGTACAGGCTCGCCC 2077 SEQ ID NO : 774-12. 1-31 84. 4-14. 9-4-9. 6 GATACCAGGCCTGCCATCCT 2204 SEQ ID NO : 775-12. 1-30. 9 82. 1-17. 1-0. 3-11. 6 AGATACCAGGCCTGCCATCC 2205 SEQ ID NO : 776-12. 1-30 80. 6-15. 6-0. 3-12. 8 AACCACTTAAAGCCTCAGGG 2554 SEQ ID NO : 777-12. 1-23. 9 67-11. 8 0-3. 7 TTCTGCTAGTGATCAAACAC 2641 SEQ ID NO : 778-12. 1-20. 4 62. 2-7. 6-0. 5-6. 7 ATGGAGTTTCAGAGATAGAC 3135 SEQ ID NO : 779-12. 1-20 62. 8-7. 9 0-2. 7 GTCCAACCGTTGGCACAGAT 3278 SEQ ID NO : 780-12. 1-27. 1 74-13. 1-1. 8-10. 8 TCAGAAGTGACCAGGATGTA 3879 SEQ ID NO : 781-12. 1-22. 4 66. 5-10. 3 0-4. 2 CACAGGCATCTGAATACCAA 941 SEQ ID NO : 782-12-22. 4 64. 1-8. 8-1. 5-4. 9 TTGGCATTGTAGCCAATGCT 1204 SEQ ID NO : 783-12-25. 3 71. 9-7. 4-5. 9-13. 3 TTCCTCATTTTCTTGGCATT 1216 SEQ ID NO : 784-12-24 71. 2-12 0-4 CCGGGTTTTTAGGTACATTT 1250 SEQ ID NO : 785-12-23. 7 68. 8-11. 7 0-5. 6 CCAGACTTCACCCGGATGCG 1594 SEQ ID NO : 786-12-29 75. 1-16. 4-0. 3-6. 4 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo AGGAGACCAGTTGTTCCCAG 1879 SEQ ID NO : 787-12-27 76. 9-13. 9-1-4. 9 CGAGCAAGATACCAGGCCTG 2211 SEQ ID NO : 788-12-26. 3 71. 3-12. 7 0-11. 4 AAAATCATTCTTCCTCTCCT 3338 SEQ ID NO : 789-12-22. 4 65. 7-10. 4 0-1. 8 GCAAACATTCCAAAATCTGA 3595 SEQ ID NO : 790-12-19 56. 5-7 0-3. 4 AACCCCTCACATAAGTTACC 3757 SEQ ID NO : 791-12-24. 6 68. 2-12. 6 0-3. 8 TTGGTGTTTCCAGCAATCCC 175 SEQ ID NO : 792-11. 9-27. 2 76. 4-15. 3 3. 6-0. 6 ATGCTGTGTCCCACCACCCT 667 SEQ ID NO : 793-11. 9-32. 2 84. 7-20. 3 0. 1-4. 2 TTTTTAGGTACATTTTGCTG 1245 SEQ ID NO : 794-11. 9-20. 1 62. 5-8. 2 0-5. 2 GAGCTGGATCTTCAAGAGGT 1475 SEQ ID NO : 795-11. 9-23. 9 71. 4-12 0-5. 1 TTCCACAGGTTGTACCAAGA 1516 SEQ ID NO : 796-11. 9-24. 3 70-10. 7-1. 7-5. 3 TGGTGTTCTCAGGGTCTTCT 1644 SEQ ID NO : 797-11. 9-26. 4 81-14. 5 0-3. 1 GAGCTCCCGGCCTGGGGATA 1667 SEQ ID NO : 798-11. 9-32. 3 84. 5-18. 2-2-11. 8 AGAAGAATCCTTCCATTGGG 1840 SEQ ID NO : 799-11. 9-22. 8 65. 8-8. 8-2. 1-6. 3 CACAGGAGACCAGTTGTTCC 1882 SEQ ID NO : 800-11. 9-25. 9 74. 6-13. 2-0. 6-4. 5 AAACCAATCCAGTGTGCACG 2047 SEQ ID NO : 801-11. 9-23. 8 65. 6-11 0-9. 8 CCTGACATGAGTCAGCTCCT 2187 SEQ ID NO : 802-11. 9-27. 3 77. 6-11. 6-3. 8-9. 1 CAGAGAGTGAGCTGGGGAGC 2299 SEQ ID NO : 803-11. 9-26. 4 77. 3-13. 8-0. 5-5 GGCCATCATTCTGGCCCCAG 2684 SEQ ID NO : 804-11. 9-31. 9 84. 6-16. 2-3. 8-10. 7 CAGGTGCCGGTTTCTGTGTA 2786 SEQ ID NO : 805-11. 9-27. 7 79. 2-15. 8 0-7 TTAATTCAAATCAAGATCTA 2918 SEQ ID NO : 806-11. 9-14. 9 49. 7-3 0-6. 4 CCTGGCTGCACCACTAACTA 3087 SEQ ID NO : 807-11. 9-27. 1 74-13. 9-1. 2-8. 4 CCAACCGTTGGCACAGATGT 3276 SEQ ID NO : 808-11. 9-26. 7 72. 3-13. 4-1. 1-10. 1 TTCCAAAATCTGAAAATAAT 3588 SEQ ID NO : 809-11. 9-13. 9 46. 6-2 0-3. 2 CTCGTCCTGAGCCGCCGGGA 18 SEQ ID NO : 810-11. 8-33. 4 84. 2-20. 6-0. 9-8. 6 GCTTATCTTCCAGCCGTCCC 336 SEQ ID NO : 811-11. 8-31. 2 84. 3-19. 4 0-4 GTCAGTTTCCGCTGGGTTTC 1615 SEQ ID NO : 812-11. 8-27. 8 81. 1-14. 7-1. 2-5. 2 CCAGAGCTCCCGGCCTGGGG 1670 SEQ ID NO : 813-11. 8-34. 7 88. 3-19. 4-3. 5-12. 4 GCTGCCTTGCTGGCAAGACT 1769 SEQ ID NO : 814-11. 8-28. 9 79. 6-13. 8-3. 3-12. 2 AACCAATCCAGTGTGCACGA 2046 SEQ ID NO : 815-11. 8-25. 1 68. 9-12. 4 0-9. 8 2516 TATAGCCTCCCCCAGGCCCC-11. 8-36. 2 90. 3-21. 2-3. 2-9. 3 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 816 TAATTCAAATCAAGATCTAG 2917 SEQ ID NO : 817-11. 8-14. 8 49. 5-3 0-6 4 GTATTAATTCAAATCAAGAT 2921 SEQ ID NO : 818-11. 8-14. 8 49. 4-3 0-4. 2 TGTATTAATTCAAATCAAGA 2922 SEQ ID NO : 819-11. 8-14. 8 49. 4-3 0-4. 2 TATGGATGGCTCTATATAAA 3219 SEQ ID NO : 820-11. 8-18. 4 57. 1-6. 6 0-4 AGAAAGCAATCACAGAAACA 3493 SEQ ID NO : 821-11. 8-17. 1 53. 1-5. 3 0-4 AGGCTATGTGGATAAGGTGT 3683 SEQ ID NO : 822-11. 8-23. 2 69. 5-11. 4 0-4. 1 TACCACAAACCATGCTTCAT 3741 SEQ ID NO : 823-11. 8-22. 9 64. 6-11. 1 0-4. 2 GACACGAGTTTGTGCAGCCA 553 SEQ ID NO : 824-11. 7-26. 7 74. 7-13. 3-1. 7-7. 3 TGTGCAGGGCTGACACGAGT 564 SEQ ID NO : 825-11. 7-27. 1 76. 3-13.. 3-2. 1-10. 7 GTGTGCAGGGCTGACACGAG 565 SEQ ID NO : 826-11. 7-27. 1 76. 3-13. 3-2. 1-11. 3 AGTCACCCCCATTGGGGTAG 975 SEQ ID NO : 827-11. 7-29. 8 81. 2-13. 6-4. 5-12. 8 TCCTGATTCACCAGAGAGTC 1099 SEQ ID NO : 828-11. 7-24. 8 73. 1-12. 6-0. 2-3. 8 TGGGCTCAATTTCTCCCATG 1332 SEQ ID NO : 829-11. 7-26. 1 73. 4-12. 7-1. 7-6. 8 TTGCGGGGTTGAGACAGGTA 1549 SEQ ID NO : 830-11. 7-25. 8 73. 8-13. 4-0. 5-4. 5 TATTCAGCTCCCGTCCGGGG 1569 SEQ ID NO : 831-11. 7-30. 8 81. 4-17. 4-1. 6-10. 7 CGGATGCGCCTGATATTCAG 1582 SEQ ID NO : 832-11. 7-25. 4 69. 6-12. 1-1. 2-10. 6 GCTGGGTTTCCCCAGACTTC 1605 SEQ ID NO : 833-11. 7-29. 8 83. 2-13. 4-4. 7-10. 7 GTCTTCTGTACAAAATGTCA 1631 SEQ ID NO : 834-11. 7-19. 9 61. 5-8. 2 0-6. 1 TGGTTTCGTTTTTCATCCTC 1713 SEQ ID NO : 835-11. 7-24. 2 72. 2-12. 5 0-3. 2 AGCTCCACAGTGGGACTGGT 1729 SEQ ID NO : 836-11. 7-28. 4 81. 1-14. 6-2. 1-9. 3 AGAGGTTTGGAGTTAGAGCT 1964 SEQ ID NO : 837-11. 7-23. 3 71. 6-11. 6 0-5 CTTCAGAGAGTGAGCTGGGG 2302 SEQ ID NO : 838-11. 7-25. 4 75. 2-13-0. 4-5. 5 AATCCCAACTCCACTGGGTT 2439 SEQ ID NO : 839-11. 7-26. 7 73. 1-12. 9-2. 1-6. 8 CTCAGATATTGTGTGTATTA 2935 SEQ ID NO : 840-11. 7-19. 5 61. 8-7. 8 0-2. 5 CCCCGCCACACCCCCTCCCA 229 SEQ ID NO : 841-11. 6-40. 4 92-28. 8 0-2. 6 GGGCTGACACGAGTTTGTGC 558 SEQ ID NO : 842-11. 6-26. 6 75. 6-13. 3-1. 7-7 TGTCCCACCACCCTGGTATT 661 SEQ ID NO : 843-11. 6-30. 5 81. 2-17. 2-1. 7-5. 7 CCCACAGGCATCTGAATACC 943 SEQ ID NO : 844-11. 6-26. 4 72-13. 2-1. 5-4. 8 AGATGTCAATGTGGCCCACA 957 SEQ ID NO : 845-11. 6-26 72. 8-12. 8-1. 5-8. 9 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo GGCATTGTAGCCAATGCTAT 1202 SEQ ID NO : 846-11. 6-24. 9 71-7. 4-5. 9-15. 3 TGGCATTGTAGCCAATGCTA 1203 SEQ ID NO : 847-11. 6-24. 9 70. 9-7. 4-5. 9-13. 3 GATATTCAGCTCCCGTCCGG 1571 SEQ ID NO : 848-11. 6-29 77. 7-17. 4 0-6. 3 GCCATCCCGACACTTGCGAA 1691 SEQ ID NO : 849-11. 6-28. 9 74. 2-17. 3 0-4. 3 CCTCCAGCCATCCCGACACT 1697 SEQ ID NO : 850-11. 6-32. 3 82. 3-20. 7 0-3. 2 CATTTGCTCAATTAAAAAAT 2354 SEQ ID NO : 851-11. 6-14. 3 47. 6-2. 7 0-3. 2 CAACTCCACTGGGTTCCAAA 2434 SEQ ID NO : 852-11. 6-24. 7 68. 6-12. 5-0. 3-6. 1 CCAAAGCAGTTATATCTGGC 2708 SEQ ID NO : 853-11. 6-22. 8 66. 6-10. 4-0. 6-2. 7 GGAGTTTCAGAGATAGACTT 3133 SEQ ID NO : 854-11. 6-21 65. 4-9. 4 0-3. 7 CGGGGCTCCCCGCAGCAAAG 300 SEQ ID NO : 855-11. 5-31. 9 79. 6-17. 6-2. 6-12. 9 TCCTTCATGCTCTGGGTCCT 422 SEQ ID NO : 856-11. 5-29. 4 84-17. 9 0-3. 8 CCTGGCAATGCTGTGTCCCA a 674 SEQ ID NO : 857-11. 5-30. 1 80. 9-17. 9-0. 4-8. 2 GCATACCCGGCCACGTGCGC 766 SEQ ID NO : 858-11. 5-33. 5 82. 6-20. 1-1. 9-10. 8 ATCCGCTCCACTATTTCCAG 1402 SEQ ID NO : 859-11. 5-27. 1 74. 8-15. 6 0-3. 1 CTGCTCGATCCGCTCCACTA 1409 SEQ ID NO : 860-11. 5-29. 2 78-17. 2-0. 1-5. 6 GTTGGTGGCATTCTGCTCGA 1421 SEQ ID NO : 861-11. 5-27. 3 78. 2-13. 9-1. 9-7. 8 TGTTGGTGGCATTCTGCTCG 1422 SEQ ID NO : 862-11. 5-26. 7 76. 6-13. 3-1. 9-8. 6 GTCCTCCTCGGTGTAGACCA 1448 SEQ ID NO : 863-11. 5-29. 8 82. 8-16. 5-1. 8-3. 1 ACCCTCAGGGAAGCTCCACA 1740 SEQ ID NO : 864-11. 5-29. 2 79-16. 1-1. 6-8. 2 GGTGCCGGTTTCTGTGTACA 2784 SEQ ID NO : 865-11. 5-27. 9 79. 4-15. 8-0. 3-6. 8 GTGTGTATTAATTCAAATCA 2925 SEQ ID NO : 866-11. 5-17. 3 55. 3-5. 8 0-4. 2 AACCGTTGGCACAGATGTTC 3274 SEQ ID NO : 867-11. 5-24. 5 69. 6-12. 2-0. 6-6. 1 TGTCCTTAGAAAACCTAAGT 3364 SEQ ID NO : 868-11. 5-20. 1 60-6. 4-2. 2-5. 7 GTACAAGCTTCGCTTTGGCT 3513 SEQ ID NO : 869-11. 5-25. 9 73. 9-12. 8-1. 5-9. 5 TCCAAAATCTGAAAATAATC 3587 SEQ ID NO : 870-11. 5-14. 2 47. 3-2. 7 0-3. 2 GTCAGAAGTGACCAGGATGT 3880 SEQ ID NO : 871-11. 5-23. 9 70. 5-10. 3-2. 1-5. 8 AAAAACAGAAGTCAGAAGTG 3890 SEQ ID NO : 872-11. 5-15. 4 50. 2-3. 9 0-2. 9 GGGCTCCCCGCAGCAAAGCA 298 SEQ ID NO : 873-11. 4-32. 4 82. 5-19-2-7. 6 GTCCCACCACCCTGGTATTA 660 SEQ ID NO : 874-11. 4-30. 2 80. 8-17. 2-1. 5-5. 5 1247 GGTTTTTAGGTACATTTTGC-11. 4-21. 6 66. 7-10. 2 0-5. 2 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 875 TTCTGCTCGATCCGCTCCAC 1411 SEQ ID NO : 876-11. 4-29. 1 78. 8-17. 2-0. 1-5. 6 TGTCAGTTTCCGCTGGGTTT 1616 SEQ ID NO : 877-11. 4-27. 4 79-14. 7-1. 2-5. 2 GAGGTTTGGAGTTAGAGCTA 1963 SEQ ID NO : 878-11. 4-23 70. 6-11. 6 0-5. 1 GAAACCAATCCAGTGTGCAC 2048 SEQ ID NO : 879-11. 4-23. 6 66. 6-11. 6 0-8. 4 AGCCAATGATGTGTGCTTCA 2317 SEQ ID NO : 880-11. 4-24. 7 71. 3-12. 6-0. 5-3. 9 TGTTCAATAGACATTTGCTC 2365 SEQ ID NO : 881-11. 4-20. 2 62. 4-8. 8 0-4 CGGTTTCTGTGTACACAGAT 2779 SEQ ID NO : 882-11. 4-23. 2 68. 6-7. 4-2. 3-17 AGGTGCCGGTTTCTGTGTAC 2785 SEQ ID NO : 883-11. 4-27. 2 78. 7-15. 8 0-6. 6 TGCACCACTAACTAGTATAT 3081 SEQ ID NO : 884-11. 4-20. 9 62. 5-9. 5 0-6. 3 AAGAAAATCATTCTTCCTCT 3341 SEQ ID NO : 885-11. 4-19 58. 2-5. 6-2-5. 7 TTTGGCTAGAAAGCAATCAC 3500 SEQ ID NO : 886.-11. 4-20. 1 60. 5-6. 1-2. 6-6. 6 TTACCCTCAGGCTATGTGGA 3691 SEQ ID NO : 887-11. 4-26. 6 75. 6-14. 1-1-3. 9 ATCCAAAACTTTTTGAGCAC 3798 SEQ ID NO : 888-11. 4-19. 8 59. 3-7. 3-1-7. 3 AGAGGAACGGAGTTGCTCAT 253 SEQ ID NO : 889-11. 3-23. 6 68. 4-9. 9-2. 4-10. 7 CGTCCCTCTGGACCAAAAGG 322 SEQ ID NO : 890-11. 3-26. 4 70. 5-12. 4-2. 7-7. 2 CTTCTAAGGGCTGGCTGTGG 459 SEQ ID NO : 891-11. 3-26. 7 76. 8-15. 4 0-6 CTGTGTCCCACCACCCTGGT 664 SEQ ID NO : 892-11. 3-32. 8 86. 5-19. 9-1. 5-5. 3 GTGGACATTCCCGAGAGAAA 725 SEQ ID NO : 893-11. 3-23. 6 66-11. 4-0. 8-4. 1 ACAGGCATCTGAATACCAAT 940 SEQ ID NO : 894-11. 3-21. 7 62. 9-8. 8-1. 5-4. 9 GCATTGTAGCCAATGCTATT 1201 SEQ ID NO : 895-11. 3-23. 8 68. 8-7. 4-5. 1-12. 4 ATGTCAGTTTCCGCTGGGTT 1617 SEQ ID NO : 896-11. 3-27. 3 78. 5-14. 7-1. 2-5. 2 ATGCTGGTGTTCTCAGGGTC 1648 SEQ ID NO : 897-11. 3-26. 8 81-14. 8-0. 5-5. 2 CTATAGCAGCGCAGTCCCCT 1923 SEQ ID NO : 898-11. 3-30. 4 82-18. 6 0. 1-8. 5 GTTTGGAGTTAGAGCTATTC 1960 SEQ ID NO : 899-11. 3-21. 7 68. 1-10. 4 0-5. 1 AATCTGGACTTGGTGCTCTG 1995 SEQ ID NO : 900-11. 3-24 70. 8-12. 7 0-3. 6 ACCAGGCCTGCCATCCTGAC 2201 SEQ ID NO : 901-11. 3-31. 4 83. 1-17. 9-2-11. 9 GGGAGCAGGACGGAATGGCT 2285 SEQ ID NO : 902-11. 3-27. 3 74. 7-15. 3-0. 5-5 AGTGTTCAATAGACATTTGC 2367 SEQ ID NO : 903-11. 3-20. 1 62. 4-8. 8 0-4. 6 CTTAAAGCCTCAGGGTCCCT 2549 SEQ ID NO : 904-11. 3-28 77. 1-16. 1-0. 3-6. 9 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo CGGCCATCATTCTGGCCCCA 2685 SEQ ID NO : 905-11. 3-32. 7 83. 6-17. 1-4. 3-11. 3 GAAGAGATTTGCTCCAAAGC 2721 SEQ ID NO : 906-11. 3-21. 5 63. 2-7. 4-2. 8-7. 3 AAACAGAAGAGATTTGCTCC 2726 SEQ ID NO : 907-11. 3-19. 9 59. 8-7. 4-1. 1-5. 7 AAGAAGTTCAACAAGAAAAG 2881 SEQ ID NO : 908-11. 3-13. 6 46. 4-1. 5-0. 5-6. 8 TTTCCAAGAAGTTCAACAAG 2886 SEQ ID NO : 909-11. 3-18. 4 56. 6-7. 1 0-6. 8 GTATATAAGTCTAGGCATG 3067 SEQ ID NO : 910-11. 3-20. 7 64. 4-9. 4 0-6. 1 CCAAAACTTTTTGAGCACCA 3796 SEQ ID NO : 911-11. 3-22. 1 62. 6-9. 7-1-7. 3 CAGAAGTCAGAAGTGACCAG 3885 SEQ ID NO : 912-11. 3-21. 5 64. 1-8. 6-1. 6-5. 2 AAAGGTTTTAGCTGTCATGT 491 SEQ ID NO : 913-11. 2-21. 2 65-10 0-4. 8 TCGTCCATCCGTGAATGATG 513 SEQ ID NO : 914-11. 2-24. 4 67. 7-12. 7-0. 2-4. 4 TGTGTGCAGGGCTGACACGA 566 SEQ ID NO : 915-11. 2-27. 1 75. 8-13. 3-2. 6-11. 7 TCTCTTGTGTGCAGGGCTGA 571 SEQ ID NO : 916-11. 2-27. 3 80. 5-15. 5-0. 3-5. 4 CTCGATCCGCTCCACTATTT 1406 SEQ ID NO : 917-11. 2-26. 7 73-15. 5 0-4. 5 TCATCCTCCAGCCATCCCGA 1701 SEQ ID NO : 918-11. 2-31. 8 82. 7-20. 6 0-3. 2 TCTTGCTGCCTTGCTGGCAA 1773 SEQ ID NO : 919-11. 2-28. 6 79. 3-14. 1-3. 3-10. 3 TCAATAGACATTTGCTCAAT 2362 SEQ ID NO : 920-11. 2-18. 9 58. 3-7. 7 0-4 CCTCAGGGTCCCTAATGCTT 2542 SEQ ID NO : 921-11. 2-28. 7 79. 1-17-0. 1-6. 4 CTATCTCTCTAAACAGAAGA 2736 SEQ ID NO : 922-11. 2-18. 2 57. 2-7 0-3. 2 TTCCAAGAAGTTCAACAAGA 2885 SEQ ID NO : 923-11. 2-18. 9 57. 5-7. 7 0-6. 8 ACCGTTGGCACAGATGTTCT 3273 SEQ ID NO : 924-11. 2-26. 1 73. 9-14. 3-0. 3-4. 6 GTCCTTAGAAAACCTAAGTA 3363 SEQ ID NO : 925-11. 2-19. 8 59. 5-6. 4-2. 2-5. 7 AATGTCCTTAGAAAACCTAA 3366 SEQ ID NO : 926-11. 2-18. 2 55. 2-6. 4-0. 3-3 CAATGTCCTTAGAAAACCTA 3367 SEQ ID NO : 927-11. 2-19. 6 58. 1-8. 4 0-2. 1 AAGTTTAACAGTGATACAAC 3409 SEQ ID NO : 928-11. 2-16. 5 53. 2-5. 3 0-4. 4 CAAGCTTCGCTTTGGCTAGA 3510 SEQ ID NO : 929-11. 2-25. 1 71. 6-12. 3-1. 5-9. 5 TAAAAACAGAAGTCAGAAGT 3891 SEQ ID NO : 930-11. 2-15. 1 49. 7-3. 9 0-2. 8 GTAAAAACAGAAGTCAGAAG 3892 SEQ ID NO : 931-11. 2-15. 1 49. 7-3. 9 0-2. 8 GAGTTGCTCATCCTGCCCCG 244 SEQ ID NO : 932-11. 1-31. 6 83. 5-19. 9-0. 3-4. 5 ACACGAGTTTGTGCAGCCAG 552 SEQ ID NO : 933-11. 1-26. 1 73. 7-13. 3-1. 7-6. 5 557 GGCTGACACGAGTTTGTGCA-11. 1-26. 1 74. 1-13. 3-1. 7-7. 8 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID No : 934 AGTGGACATTCCCGAGAGAA 726 SEQ ID No : 935-11. 1-24. 3 68. 4-12. 3-0. 8-4. 1 CCTGCATACCCGGCCACGTG 769 SEQ ID NO : 936-11. 1-32 79. 9-20. 1-0. 6-8. 4 TCACCCCCATTGGGGTAGAT 973 SEQ ID NO : 937-11. 1-29. 2 78. 7-13. 6-4. 5-12. 8 ATTTCTCCCATGTTCTTGTA 1324 SEQ ID NO : 938-11. 1-24. 2 72. 1-13. 1 0-4. 3 AGCTCCCGGCCTGGGGATAT 1666 SEQ ID NO : 939-11. 1-31. 7 83. 2-18. 2-2. 1-12. 4 CAGGAGACCAGTTGTTCCCA 1880 SEQ ID NO : 940-11. 1-27. 7 77. 6-15. 5-1-4. 9 TCACAGGAGACCAGTTGTTC 1883 SEQ ID NO : 941-11. 1-24. 3 72. 6-13. 2 0. 5-3. 3 GCCTGCCATCCTGACATGAG 2196 SEQ ID NO : 942-11. 1-28. 6 77. 7-17. 5 0-5. 2 CCAGGCCCCAGGTGCCTTTC 2505 SEQ ID NO : 943-11. 1-34. 1 89. 5-20. 8-2. 2-10 AGAAGAGATTTGCTCCAAAG 2722 SEQ ID NO : 944-11. 1-19. 7 59. 4-7. 4-1. 1-5. 7 GTCATAACTTCTATCTCTCT 2746 SEQ ID NO : 945-11. 1-21. 4 67-10. 3 0-1. 9 GCACCACTAACTAGTATATA 3080 SEQ ID NO : 946-11. 1-20. 6 62-9. 5 0-6. 3 ACATATCTTGAAATAAGACT 3448 SEQ ID NO : 947-11. 1-15. 9 51. 6-3. 9-0. 8-3. 9 GAAGTCAGAAGTGACCAGGA 3883 SEQ ID NO : 948-11. 1-22. 6 66. 6-9. 1-2. 4-6. 3 CAGGGAGCGAGTGTCAACGG 61 SEQ ID NO : 949-11-25. 9 71. 8-14. 2-0. 5-4. 6 GTTGCTCATCCTGCCCCGCC 242 SEQ ID NO : 950-11-34. 8 89. 3-23. 8 0-3. 6 AACGGAGTTGCTCATCCTGC 248 SEQ ID NO : 951-11-26. 3 73. 9-14-1. 2-6. 4 ATCCTTCATGCTCTGGGTCC 423 SEQ ID NO : 952-11-28. 5 81. 9-17. 5 0-4. 4 GTCATGTTGAAACTGCAGTC 478 SEQ ID NO : 953-11-22 66. 6-9-0. 1-12. 1 TGACACGAGTTTGTGCAGCC 554 SEQ ID NO : 954-11-26 73. 5-13. 3-1. 7-6. 8 CTCTTGTGTGCAGGGCTGAC 570 SEQ ID NO : 955-11-27. 1 79. 2-15. 5-0. 3-5. 4 CTCTCTTGTGTGCAGGGCTG 572 SEQ ID NO : 956-11-27. 6 81. 2-16-0. 3-5. 3 TTTCTCTCTTGTGTGCAGGG 575 SEQ ID NO : 957-11-25. 5 77. 2-14. 5 0-5. 3 TCGAGCATCCTGGCAATGCT 682 SEQ ID NO : 958-11-27. 3 74. 9-13. 5-2. 8-11. 2 GCAGCCAGTCGAGCATCCTG 690 SEQ ID NO : 959-11-29. 8 81. 7-17. 9-0. 7-6. 1 CCCGAGAGAAAAATCGTCCT 716 SEQ ID NO : 960-11-23. 5 63. 6-11. 6-0. 7-3. 9 TCCGGAGAGAGCCTCTTGTG 865 SEQ ID NO : 961-11-27. 5 77. 3-15-1. 4-9. 9 GGTAGATGTCAATGTGGCCC 960 SEQ ID NO : 962-11-26. 5 75. 4-15. 5 0-6. 6 TGGCTGGAAGTCACCCCCAT 983 SEQ ID NO : 963-11-30. 2 79. 8-17. 9-1. 2-5. 8 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo GGTGGACGGCTCGCTCATGC 1071 SEQ ID NO : 964-11-29. 9 81. 3-18. 2-0. 5-6. 1 GGTGTAGACCAGGAAGGTGT 1439 SEQ ID NO : 965-11-25. 5 74. 6-12. 9-1. 5-2. 9 CTGGATCTTCAAGAGGTCTC 1472 SEQ ID NO : 966-11-23. 2 70. 7-11-1. 1-5 ATATTCAGCTCCCGTCCGGG 1570 SEQ ID NO : 967-11-29. 6 78. 9-17. 4-0. 8-10. 1 AATGTCAGTTTCCGCTGGGT 1618 SEQ ID NO : 968-11-26. 5 75. 5-14. 7-0. 6-5. 2 GGTTTGGAGTTAGAGCTATT 1961 SEQ ID NO : 969-11-22. 5 69. 2-11. 5 0-5. 1 TTCGGAGCCAGCGTTCCTCG 2100 SEQ ID NO : 970-11-30 79. 5-17. 5-1. 4-5. 2 TCTATCTCTCTAAACAGAAG 2737 SEQ ID NO : 971-11-18 57. 2-7 0-2. 7 TATTAATTCAAATCAAGATC 2920 SEQ ID NO : 972-11-14 47. 8-3 0-4. 2 GATATTGTGTGTATTAATTC 2931 SEQ ID NO : 973-11-17. 3 56. 3-6. 3 0-4. 2 GAAAAGTGTAAGTGTCTCAG 2950 SEQ ID NO : 974-11-18. 7 58. 9-7. 7 0-2. 1 TGAAAAGTGTAAGTGTCTCA 2951 SEQ ID NO : 975-11-18. 7 58. 6-7. 7 0-2. 4 AAATCATTCTTCCTCTCCTG 3337 SEQ ID NO : 976-11-23. 1 67. 8-12. 1 0-1. 8 ATGTCCTTAGAAAACCTAAG 3365 SEQ ID NO : 977-11-18. 9 57. 1-6. 4-1. 4-4. 8 TTTAACAGTGATACAACTTT 3406 SEQ ID NO : 978-11-17. 1 54. 5-6. 1 0-3. 7 CCAAAATCTGAAAATAATCT 3586 SEQ ID NO : 979-11-14. 7 48-3. 7 0-3. 2 ACCACAAACCATGCTTCATG 3740 SEQ ID NO : 980-11-23. 2 65-11. 1-1-5. 3 AGAAGTCAGAAGTGACCAGG 3884 SEQ ID NO : 981-11-22 65. 5-8. 6-2. 4-6. 3 GGCCGGTAAGACCCTTCTCT 155 SEQ ID NO : 982-10. 9-29. 6 79. 8-17. 6-0. 7-9. 8 TCACAGATGGTTTGACCTCA 381 SEQ ID NO : 983-10. 9-24 70. 3-12. 3-0. 6-4. 4 CTCATGCTCACATTTTACCA 1058 SEQ ID NO : 984-10. 9-23. 6 68. 8-12-0. 4-4. 4 AGCCATCCCGACACTTGCGA 1692 SEQ ID NO : 985-10. 9-29. 6 76. 7-18. 2-0. 1-4. 3 TGCTGCCTTGCTGGCAAGAC 1770 SEQ ID NO : 986-10. 9-28 77. 5-13. 8-3. 3-12, 7 CCAACTCCACTGGGTTCCAA 2435 SEQ ID NO : 987-10. 9-27. 4 74. 1-15. 9-0. 3-6. 1 CAACAAGAAAAGGCACTGGT 2873 SEQ ID No : 988-10. 9-19. 9 58. 4-8. 2-0. 6-4. 4 CCCTGGCTGCACCACTAACT 3088 SEQ ID NO : 989-10. 9-29. 4 77. 8-17. 2-1. 2-8. 4 ACAAGCTTCGCTTTGGCTAG 3511 SEQ ID NO : 990-10. 9-24. 7 70. 9-12. 2-1. 5-9. 5 CTGTACAAGCTTCGCTTTGG 3515 SEQ ID NO : 991-10. 9-24. 1 69. 5-11. 6-1. 5-7. 8 GTCTGTGTAGCTTTGGGTTT 361 SEQ ID NO : 992-10. 8-25. 3 77. 5-14. 5 0-4. 6 693 CCTGCAGCCAGTCGAGCATC-10. 8-29. 8 81. 7-18. 1-0. 8-8. 1 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 993 TCAAGTGGACATTCCCGAGA 729 SEQ ID NO : 994-10. 8-24. 8 69. 5-13. 1-0. 8-4. 1 CTTTCACGAAGTTGCCTGCA 783 SEQ ID NO : 995-10. 8-25. 6 71. 6-14. 3-0. 2-6. 8 ACCCCCATTGGGGTAGATGT 971 SEQ ID NO : 996-10. 8-29. 3 79. 2-14. 2-4. 3-12. 8 CCTGATTCACCAGAGAGTCA 1098 SEQ ID NO : 997-10. 8-25. 1 72. 5-13. 6-0. 4-5. 4 AGTCCTCCTCGGTGTAGACC 1449 SEQ ID NO : 998-10. 8-29. 1 82. 2-17. 4-0. 7-1. 7 AAGCTCCACAGTGGGACTGG 1730 SEQ ID NO : 999-10. 8-26. 5 74. 9-13. 6-2. 1-8. 9 AGCCAGCGTTCCTCGTCAGG 2095 SEQ ID NO : 1000-10. 8-30. 4 83. 1-18. 7-0. 8-8. 2 ATGGTCAGTGCAACCCATGA 2251 SEQ ID NO : 1001-10. 8-26 72. 8-14. 2-0. 9-7. 4 CCACTGGGTTCCAAATGGAG 2429 SEQ ID NO : 1002-10. 8-25 69. 5-12. 6-1. 5-9. 1 TGCTCCAAAGCAGTTATATC 2712 SEQ ID NO : 1003-10. 8-22 65. 5-8. 8-2. 4-7. 1 TATTGGTGGGAACTGGCTGC 3165 SEQ ID NO : 1004-10. 8-25. 3 72. 5-13. 6-0. 4-9. 4 GAAGTTTAACAGTGATACAA 3410 SEQ ID NO : 1005-10. 8-16. 9 53. 9-6. 1 0-4. 6 TCGTCCTGAGCCGCCGGGAG 17 SEQ ID NO : 1006-10. 7-32. 5 82. 7-20. 6-1. 1-8. 7 GTAAGACCCTTCTCTCGGCC 150 SEQ ID NO : 1007-10. 7-28. 8 79-17. 6-0. 2-6 TTGTGTGCAGGGCTGACACG 567 SEQ ID NO : 1008-10. 7-26. 6 74. 8-13. 3-2. 6-11. 7 TTTCACGAAGTTGCCTGCAT 782 SEQ ID NO : 1009-10. 7-24. 7 69. 7-13. 3-0. 4-6. 8 GGCCCACAGGCATCTGAATA 945 SEQ ID NO : 1010-10. 7-27. 2 74. 6-13. 2-3. 3-8. 9 CACCCCCATTGGGGTAGATG 972 SEQ ID NO : 1011-10. 7-28. 8 76. 9-13. 6-4. 5-12. 8 AATTTCTCCCATGTTCTTGT 1325 SEQ ID NO : 1012-10. 7-23. 8 70. 3-13. 1 0-4. 3 AAAGGGTGACGTAAAAGGTG 1350 SEQ ID NO : 1013-10. 7-19 56. 8-8. 3 0-5. 3 TCGATCCGCTCCACTATTTC 1405 SEQ ID NO : 1014-10. 7-26. 2 72. 7-15. 5 0-4. 2 GGGTCCTCAGCAGTAACTTT 1819 SEQ ID NO : 1015-10. 7-26 76. 1-15. 3 0-4. 1 TGATGTGTGCTTCAGAGAGT 2311 SEQ ID NO : 1016-10. 7-23. 3 71. 2-12. 6 0-3. 6 TTCAATAGACATTTGCTCAA 2363 SEQ ID NO : 1017-10. 7-19 58. 6-8. 3 0-4 CTAAACAGAAGAGATTTGCT 2728 SEQ ID NO : 1018-10. 7-18. 1 56. 1-7. 4 0-5. 7 TGTAAGTGTCTCAGATATTG 2944 SEQ ID NO : 1019-10. 7-19. 4 61. 6-8. 7 0-2. 8 AAGGGCTTAGGATTTTATGG 3234 SEQ ID NO : 1020-10. 7-21. 2 63. 9-10. 5 0-3. 7 TGAGAACATATCTTGAAATA 3453 SEQ ID NO : 1021-10. 7-15. 4 50. 5-3. 9-0. 6-3. 9 AGATGGTTTGACCTCAGTCT 377 SEQ ID NO : 1022-10. 6-24. 5 73. 2-12. 3-1. 6-5. 8 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo AGGGCTGGCTGTGGCCGACG 453 SEQ ID NO : 1023-10. 6-31. 6 82. 8-17. 7-3. 3-11 CATACCCGGCCACGTGCGCT 765 SEQ ID NO : 1024-10. 6-32. 6 80. 5-20. 1-1. 3-11. 7 ACAAAATCTGCATCGTCCGG 880 SEQ ID NO : 1025-10. 6-23. 4 64. 7-12. 8 0-6 AAGTCACCCCCATTGGGGTA 976 SEQ ID NO : 1026-10. 6-29. 1 78. 4-14. 2-4. 3-12. 8 GATTCACCAGAGAGTCAACA 1095 SEQ ID NO : 1027-10. 6-22. 4 66. 4-11. 8 0-4. 8 AAGGCAAAACTCGGCTTGTC 1117 SEQ ID NO : 1028-10. 6-22. 8 65. 1-11. 5-0. 5-4. 1 GGGGATATGCTGGTGTTCTC 1654 SEQ ID NO : 1029-10. 6-26 77. 2-15. 4 0-3. 6 AGGGAAGCTCCACAGTGGGA 1734 SEQ ID NO : 1030-10. 6-27. 2 76. 8-15-1. 6-9. 5 GGAAGTCTTGCTGCCTTGCT 1778 SEQ ID NO : 1031-10. 6-27. 9 79. 3-16. 6-0. 4-5. 4 TGGGTCCTCAGCAGTAACTT 1820 SEQ ID NO : 1022-10. 6-25. 9 75. 5-15. 3 0-4. 1 CCCCAGGTGCCTTTCCCCAT 2500 SEQ ID NO : 1033-10. 6-35. 1 88. 6-24. 5 0-6. 6 CTCAGGGTCCCTAATGCTTA 2541 SEQ ID NO : 1034-10. 6-26. 4 75-15. 3-0. 1-6. 4 CAGATATTGTGTGTATTAAT 2933 SEQ ID NO : 1035-10. 6-17. 5 56. 2-6. 9 0-4 ACTAGTATATAAGTCTAGGC 3071 SEQ ID NO : 1036-10. 6-19. 6 62. 2-7. 8-1. 1-6. 3 AAGCAATCACAGAAACAAGA 3490 SEQ ID NO : 1037-10. 6-17. 1 53. 1-6. 5 0-4. 1 TGGTGTTTCCAGCAATCCCG 174 SEQ ID NO : 1038-10. 5-27. 9 75. 7-16. 3-1-6. 1 GAACGGAGTTGCTCATCCTG 249 SEQ ID NO : 1039-10. 5-25. 1 71-12. 8-1. 8-6. 8 CAGATGGTTTGACCTCAGTC 378 SEQ ID NO : 1040-10. 5-24. 3 72. 3-12. 3-1. 4-5. 3 CTCACAGATGGTTTGACCTC 382 SEQ ID NO : 1041-10. 5-24. 2 71. 2-12. 3-1. 3-5. 1 GGCTGGCTGTGGCCGACGGA 451 SEQ ID NO : 1042-10. 5-32. 2 83. 7-18. 4-3. 3-11 TCCCGAGAGAAAAATCGTCC 717 SEQ ID NO : 1043-10. 5-23 63. 2-11. 6-0. 7-3. 9 TGCATACCCGGCCACGTGCG 767 SEQ ID NO : 1044-10. 5-31. 7 78. 6-18. 6-2. 6-8. 9 CTATTTCCAGTGGCAGAGTC 1392 SEQ ID NO : 1045-10. 5-25 74. 8-14. 5 0-7. 4 GTGTTGGTGGCATTCTGCTC 1423 SEQ ID NO : 1046-10. 5-27. 1 80. 8-14. 7-1. 9-5. 6 CCCCAGACTTCACCCGGATG 1596 SEQ ID NO : 1047-10. 5-30. 4 77. 8-19. 9 0-6. 4 TTGCTGCCTTGCTGGCAAGA 1771 SEQ ID NO : 1048-10. 5-27. 9 77. 3-14. 1-3. 3-12. 7 GTGGGTCCTCAGCAGTAACT 1821 SEQ ID NO : 1049-10. 5-27 78. 8-16. 5 0-4. 1 GGGTGGGTCCTCAGCAGTAA 1823 SEQ ID NO : 1050-10. 5-28. 3 81. 6-16. 9-0. 8-4. 9 ACACACAAATCTGGACTTGG 2002 SEQ ID NO : 1051-10. 5-20. 8 61. 4-10. 3 0-4. 7 2054 AACTGAGAAACCAATCCAGT-10. 5-20. 7 60. 1-8. 7-1. 4-5. 6 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 1052 TCAGAGAGTGAGCTGGGGAG 2300 SEQ ID NO : 1053-10. 5-25 74. 4-13. 8-0. 4-5 TGCTAGTGATCAAACACGTC 2638 SEQ ID NO : 1054-10. 5-21. 4 63. 4-10-0. 8-6. 7 CCGGTTTCTGTGTACACAGA 2780 SEQ ID NO : 1055-10. 5-25. 2 72. 4-10. 3-2. 4-17 GATGGCTCTATATAAAAAAA 3215 SEQ ID NO : 1056-10. 5-14. 7 48. 5-4. 2 0-3. 7 CGTTGGCACAGATGTTCTCC 3271 SEQ ID NO : 1057-10. 5-26. 3 75-15-0. 6-6. 1 CCGTTGGCACAGATGTTCTC 3272 SEQ ID NO : 1058-10. 5-26. 3 75-15-0. 6-6. 1 TAAGTTACCACAAACCATGC 3746 SEQ ID NO : 1059-10. 5-21. 1 61-10. 1-0. 2-4. 4 TGGACCAAAAGGTACGGGGC 314 SEQ ID NO : 1060-10. 4-25. 1 68. 3-14. 2-0. 1-5. 2 AGTCGAGCATCCTGGCAATG 684 SEQ ID NO : 1061-10. 4-25. 8 72. 4-14. 5-0. 8-5. 6 CTGGCTGGAAGTCACCCCCA 984 SEQ ID NO : 1062-10. 4-31. 1 81. 7-19. 3-1. 3-5. 2 TTTCTCCCATGTTCTTGTAA 1323 SEQ ID NO : 1063-10. 4-23. 5 69. 7-13. 1 0-4. 3 TAAAGGGTGACGTAAAAGGT 1351 SEQ ID NO : 1064-10. 4-18. 7 56. 4-8. 3 0-5. 3 ACTATTTCCAGTGGCAGAGT 1393 SEQ ID NO : 1065-10. 4-24. 8 73. 6-14. 4 0-7. 4 TGATATTCAGCTCCCGTCCG 1572 SEQ ID NO : 1066-10. 4-27. 8 75. 1-17. 4 0-4. 4 GCTAGGGCCCGAGCAAGATA 2220 SEQ ID NO : 1067-10. 4-28. 1 75. 7-15. 6-1. 5-12. 1 TGGGGAGCAGGACGGAATGG 2287 SEQ ID NO : 1068-10. 4-25. 8 71. 1-15. 4 0-4. 1 CAAGAAGTTCAACAAGAAAA 2882 SEQ ID NO : 1069-10. 4-14. 3 47. 5-3. 2-0. 5-6. 8 TTGAAAAGTGTAAGTGTCTC 2952 SEQ ID NO : 1070-10. 4-18. 1 57. 7-7. 7 0-2. 3 GAAATCTGAGTCCTCTCCCT 3104 SEQ ID NO : 1071-10. 4-26. 2 74. 3-14. 5-1. 2-4. 9 TATCTTGAAATAAGACTCAA 3445 SEQ ID NO : 1072-10. 4-15. 4 50. 5-3. 6-1. 3-6 GCTTCGCTTTGGCTAGAAAG 3507 SEQ ID NO : 1073-10. 4-23. 7 68. 2-12. 3-0. 9-5. 7 TCCCTCTGGACCAAAAGGTA 320 SEQ ID NO : 1074-10. 3-25. 3 69. 9-14. 2-0. 6-6 ACAGATGGTTTGACCTCAGT 379 SEQ ID NO : 1075-10. 3-24. 1 71. 2-12. 3-1. 4-5. 2 AAACCTCACAGATGGTTTGA 386 SEQ ID NO : 1076-10. 3-21. 5 63. 2-9. 1-2. 1-7. 3 TCTAAGGGCTGGCTGTGGCC 457 SEQ ID NO : 1077-10. 3-29. 5 82. 5-17-2. 2-11 CAAAGATACCGCTCATCGTC 528 SEQ ID NO : 1078-10. 3-23. 2 65. 3-12. 3-0. 3-3. 5 TCTTGTGTGCAGGGCTGACA 569 SEQ ID NO : 1079-10. 3-26. 9 78. 3-15. 9-0. 4-6. 6 TTCCCGAGAGAAAAATCGTC 718 SEQ ID NO : 1080-10. 3-21. 1 60. 2-9. 9-0. 7-4. 1 TTCACGAAGTTGCCTGCATA 781 SEQ ID NO : 1081-10. 3-24. 3 68. 8-13. 3-0. 4-6. 8 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo CTGAAAGGCATGCCTGCCCG 1267 SEQ ID NO : 1082-10. 3-29. 1 74. 9-15. 2-3. 6-14. 3 CGCTCCACTATTTCCAGTGG 1399 SEQ ID NO : 1083-10. 3-27. 1 75. 3-14-2. 8-8. 6 CCCAGACTTCACCCGGATGC 1595 SEQ ID NO : 1084-10. 3-30. 2 78. 5-19. 9 0-6. 4 CAGAGCTCCCGGCCTGGGGA 1669 SEQ ID NO : 1085-10. 3-33. 3 86. 4-20. 6-2. 1-12. 4 TCAGGCAGAGTACAGGCTCG 2080 SEQ ID NO : 1086-10. 3-26. 3 76-13. 8-2. 2-7. 4 CACTGGGTTCCAAATGGAGA 2428 SEQ ID NO : 1087-10. 3-23. 6 67. 3-12. 7-0. 3-7. 5 GCTCCAAAGCAGTTATATCT 2711 SEQ ID NO : 1088-10. 3-22. 9 67. 6-10. 9-1. 7-5. 8 AGATATTGTGTGTATTAATT 2932 SEQ ID NO : 1089-10. 3-16. 9 55. 2-6. 6 0-4. 2 GGGCTTAGGATTTTATGGAT 3232 SEQ ID NO : 1090-10. 3-22. 5 67. 2-12. 2 0-3. 7 AAAGGGCTTAGGATTTTATG 3235 SEQ ID NO : 1091-10. 3-19. 3 59. 2-9 0-3. 8 GAAAGCAATCACAGAAACAA 3492 SEQ ID NO : 1092-10. 3-16. 4 51. 3-6. 1 0-4. 1 GGCTATGTGGATAAGGTGTA 3682 SEQ ID NO : 1093-10. 3-22. 9 68. 6-12. 6 0-4. 1 AAACTTTTTGAGCACCAACA 3793 SEQ ID NO : 1094-10. 3-20. 3 59. 7-9. 5-0. 2-4. 6 AGTAAAAACAGAAGTCAGAA 3893 SEQ ID NO : 1095-10. 3-15. 1 49. 7-4. 8 0-2. 9 CTCTTGGTGTTTCCAGCAAT 178 SEQ ID NO : 1096-10. 2-25 73-14. 8 3. 4-0. 9 TTCTCTCTTGTGTGCAGGGC 574 SEQ ID NO : 1097-10. 2-27. 2 81. 7-17 0-5. 3 ATCAAGTGGACATTCCCGAG 730 SEQ ID NO : 1098-10. 2-24. 2 68. 2-13. 1-0. 8-4. 3 GATCAAGTGGACATTCCCGA 731 SEQ ID NO : 1099-10. 2-24. 8 69. 2-13. 7-0. 8-5. 9 TGAGCTGGATCTTCAAGAGG 1476 SEQ ID NO : 1100-10. 2-22. 7 67. 8-12. 5 0-5. 1 GGATGCGCCTGATATTCAGC 1581 SEQ ID NO : 1101-10. 2-26. 4 73. 7-14. 6-1. 4-10. 6 AGCGCAGTCCCCTCCCGCGA 1916 SEQ ID NO : 1102-10. 2-36 88-23. 2-2. 6-8. 5 ATCCTATAGCCTCCCCCAGG 2520 SEQ ID NO : 1103-10. 2-31. 7 83. 4-20. 8-0. 5-5. 2 ATATCCTATAGCCTCCCCCA 2522 SEQ ID NO : 1104-10. 2-30. 2 80. 1-20 0-4. 5 AAACCACTTAAAGCCTCAGG 2555 SEQ ID NO : 1105-10. 2-22 62. 6-11. 8 0-3. 6 GGCAACCGGCCATCATTCTG 2691 SEQ ID NO : 1106-10. 2-28. 2 75. 3-15. 5-2. 5-7. 2 CAAAGCAGTTATATCTGGCA 2707 SEQ ID NO : 1107-10. 2-21. 5 64-10. 4-0. 7-2. 8 TCCAAAGCAGTTATATCTGG 2709 SEQ ID NO : 1108-10. 2-21. 4 63. 9-10. 4-0. 6-2. 7 TGTCATAACTTCTATCTCTC 2747 SEQ. ID N0 : 1109-10. 2-20. 5 64. 7-10. 3 0-2. 4 GAAGTTCAACAAGAAAAGGC 2879 SEQ ID NO : 1110-10. 2-17. 3 53. 8-6. 4-0. 5-6. 1 3144 AAAGTCTTCATGGAGTTTC-10. 2-20. 6 63. 7-9. 4-0. 9-6. 2 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 1111 TCCTTAGAAAACCTAAGTAC 3362 SEQ ID NO : 1112-10. 2-18. 8 57. 2-6. 4-2. 2-5. 7 GTGATACAACTTTGGCACGA 3399 SEQ ID NO : 1113-10. 2-22. 3 64. 4-11. 4-0. 4-5. 5 ATTACCCTCAGGCTATGTGG 3692 SEQ ID NO : 1114-10. 2-26 74. 2-15. 2-0. 3-3. 6 CCTGCCCCGCCACACCCCCT 233 SEQ ID NO : 1115-10. 1-40 91. 9-29. 9 0-3 AGTTGCTCATCCTGCCCCGC 243 SEQ ID NO : 1116-10. 1-32. 8 86. 5-22. 7 0-3. 6 ACGGAGTTGCTCATCCTGCC 247 SEQ ID NO : 1117-10. 1-29 79. 9-17. 7-1. 1-5. 1 CGTCCATCCGTGAATGATGA 512 SEQ ID NO : 1118-10. 1-24. 6 67. 5-13. 3-1. 1-4. 6 AACTACATTGGCGTCTTTCT 590 SEQ ID NO : 1119-10. 1-22. 9 67. 3-12. 8 0-4. 6 TCCCACCACCCTGGTATTAT 659 SEQ ID NO : 1120-10. 1-29 77. 5-17. 2-1. 7-5. 7 CCGCTCCACTATTTCCAGTG 1400 SEQ ID NO : 1121-10. 1-27. 9 76. 3-16. 8-0. 9-4. 9 CGATCCGCTCCACTATTTCC 1404 SEQ ID NO : 1122-10. 1-27. 8 74. 5-17. 7 0-3. 9 GGTGGCATTCTGCTCGATCC 1418 SEQ ID NO : 1123-10. 1-28. 4 79. 8-16. 4-1. 9-7. 8 GCTGGATCTTCAAGAGGTCT 1473 SEQ ID NO : 1124-10. 1-24. 6 73. 5-13. 3-1. 1-5 GGGATATGCTGGTGTTCTCA 1653 SEQ ID NO : 1125-10. 1-25. 5 75. 6-15. 4 0-3. 6 CCATCCCGACACTTGCGAAA 1690 SEQ ID NO : 1126-10. 1-26. 4 68. 5-16. 3 0-4. 3 ATCACAGGAGACCAGTTGTT 1884 SEQ ID NO : 1127-10. 1-23. 9 70. 8-13. 2-0. 3-3. 7 AAGCAGTATGGTCAGTGCAA 2258 SEQ ID NO : 1128-10. 1-23. 2 69-11. 5-1. 6-5. 7 TCAACAAGAAAAGGCACTGG 2874 SEQ ID NO : 1129-10. 1-19. 1 56. 9-8. 2-0. 6-4 ATCAAGATCTAGAATTGGTG 2909 SEQ ID NO : 1130-10. 1-18. 4 57. 8-7. 8 0-8 AAAACAGAAGTCAGAAGTGA 3889 SEQ ID NO : 1131-10. 1-16. 7 53. 1-6-0. 3-3. 2 GCCCTCGTCCTGAGCCGCCG 21 SEQ ID NO : 1132-10-36. 2 88. 3-25. 3-0. 8-5. 4 CTTGGTGTTTCCAGCAATCC 176 SEQ ID NO : 1133-10-26. 1 74. 7-16. 1 3. 4-0. 9 GCCCCGCCACACCCCCTCCC 230 SEQ ID NO : 1134-10-41. 5 95-31. 5 0-2. 5 AGCTTATCTTCCAGCCGTCC 337 SEQ ID NO : 1135-10-29. 2 81. 3-18. 3-0. 8-4. 3 GCGCCTGATATTCAGCTCCC 1577 SEQ ID NO : 1136-10-29. 9 80. 6-18. 3-1. 4-10. 6 TTTGGAGTTAGAGCTATTCA 1959 SEQ ID NO : 1137-10-21. 2 65. 8-10. 7-0. 2-5. 1 TCTGGACTTGGTGCTCTGGA 1993 SEQ ID NO : 1138-10-26. 5 77. 5-16. 5 0-3. 6 GAGTACAGGCTCGCCCAGCA 2073 SEQ ID NO : 1139-10-30. 5 82. 8-18. 4-2. 1-8. 5 TTCAGAGAGTGAGCTGGGGA 2301 SEQ ID NO : 1140-10-25. 1 74. 5-14. 4-0. 4-5. 5 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo TGATACTCTGCTTGCTATTC 2658 SEQ ID NO : 1141-10-22. 4 68. 1-12. 4 0-4. 5 TCCAACCGTTGGCACAGATG 3277 SEQ ID NO : 1142-10-25. 9 70. 7-14. 1-1. 7-10. 6 GAAATAAGACTCAACTGGTT 3439 SEQ ID NO : 1143-10-17. 9 55. 6-7. 9 0-4. 3 GAGAACATATCTTGAAATAA 3452 SEQ ID NO : 1144-10-14. 7 48. 9-3. 9-0. 6-3. 9 TGCAAACATTCCAAAATCTG 3596 SEQ ID NO : 1145-10-18. 4 55. 2-8. 4 0-4. 7 AACTTTTTGAGCACCAACAA 3792 SEQ ID NO : 1146-10-20. 3 59. 7-9. 8-0. 2-4. 6 AGGGCTGACACGAGTTTGTG 559 SEQ ID NO : 1147-9. 9-24. 8 71. 6-13. 3-1. 5-6. 7 TAGACCAGGAAGGTGTTGGT 1435 SEQ ID NO : 1148-9. 9-24. 4 71. 5-12. 9-1. 5-6. 9 GTAGACCAGGAAGGTGTTGG 1436 SEQ ID NO : 1149-9. 9-24. 4 71. 5-12. 9-1. 5-5. 8 GTGTAGACCAGGAAGGTGTT 1438 SEQ ID NO : 1150-9. 9-24. 4 72. 3-12. 9-1. 5-4. 5 ATCTGGACTTGGTGCTCTGG 1994 SEQ ID NO : 1151-9. 9-25. 9 76-16 0-3. 6 TGAGAAACCAATCCAGTGTG 2051 SEQ ID NO : 1152-9. 9-21. 5 62. 4-11. 6 0-3. 7 CATGAGTCAGCTCCTGTCGG 2182 SEQ ID NO : 1153-9. 9-27. 2 77. 7-16-1. 2-6. 2 AAGAGATTTGCTCCAAAGCA 2720 SEQ ID NO : 1154-9. 9-21. 6 63. 1-9. 3-2. 4-10. 2 ATATTGTGTGTATTAATTCA 2930 SEQ ID NO : 1155-9. 9-17. 4 56. 3-7. 5 0-4. 2 GTTGGCACAGATGTTCTCCT 3270 SEQ ID NO : 1156-9. 9-26. 4 77. 3-15. 7-0. 6-6. 1 CCTTAGAAAACCTAAGTACA 3361 SEQ ID NO : 1157-9. 9-19. 1 57. 1-7-2. 2-6. 2 TGAAATAAGACTCAACTGGT 3440 SEQ ID NO : 1158-9. 9-17. 8 55. 2-7. 9 0-2. 9 AGCTTCGCTTTGGCTAGAAA 3508 SEQ ID NO : 1159-9. 9-23. 7 68. 2-12. 3-1. 4-6. 4 AAGCTTCGCTTTGGCTAGAA 3509 SEQ ID NO : 1160-9. 9-23. 7 68. 2-12. 3-1. 4-9. 2 CATAAGTTACCACAAACCAT 3748 SEQ ID NO : 1161-9. 9-20 58. 5-10. 1 0. 6-3. 8 ACTTTTTGAGCACCAACAAG 3791 SEQ ID NO : 1162-9. 9-21 61. 8-11. 1 2. 1-3. 6 CGAGTGTCAACGGCTTGCCC 54 SEQ ID NO : 1163-9. 8-29 76. 9-18. 3-0. 8-7. 4 TCTTGGTGTTTCCAGCAATC 177 SEQ ID NO : 1164-9. 8-24. 5 72. 7-14. 7 3. 4-0. 9 CACAGATGGTTTGACCTCAG 380 SEQ ID NO : 1165-9. 8-23. 6 69-12. 3-1. 4-5. 2 CAGTTTTCAAAGATACCGCT 535 SEQ ID NO : 1166-9. 8-21. 9 63. 5-12. 1 0-3. 1 CCCACCACCCTGGTATTATT 658 SEQ ID NO : 1167-9. 8-28. 7 76. 2-17. 2-1. 7-5. 7 CATTGTAGCCAATGCTATTA 1200 SEQ ID NO : 1168-9. 8-21. 7 64. 1-9. 6-2. 3-6. 8 CTCATTTTCTTGGCATTGTA 1213 SEQ ID NO : 1169-9. 8-22. 4 68-12. 6 0-4 1385 CAGTGGCAGAGTCTGGGAAT-9. 8-25 73. 1-14. 2-0. 5-9. 6 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 1170 CAGGTGAGCTGGATCTTCAA 1480 SEQ ID NO : 1171-9. 8-24 70. 8-13. 3-0. 7-6. 7 GTTTTTCATCCTCCAGCCAT 1706 SEQ ID NO : 1172-9. 8-27. 6 78. 3-17. 8 0-3. 2 GGTTTCGTTTTTCATCCTCC 1712 SEQ ID NO : 1173-9. 8-26. 2 76. 2-16. 4 0-2. 5 ATGAGTCAGCTCCTGTCGGA 2181 SEQ ID NO : 1174-9. 8-27. 1 77. 9-16-1. 2-7. 2 GCCGGTTTCTGTGTACACAG 2781 SEQ ID NO : 1175-9. 8-26. 4 75. 4-13. 2-1. 4-15 TGCCGGTTTCTGTGTACACA 2782 SEQ ID NO : 1176-9. 8-26. 4 74. 9-14. 8 0-11. 7 TGTGTGTATTAATTCAAATC 2926 SEQ ID NO : 1177-9. 8-16. 6 54-6. 8 0-4. 2 AAATCTGAGTCCTCTCCCTG 3103 SEQ ID NO : 1178-9. 8-25. 6 72. 8-14. 5-1. 2-4. 9 GAGTTTCAGAGATAGACTTT 3132 SEQ ID NO : 1179-9. 8-19. 9 62. 9-10. 1 0-3. 7 CGCTTTGGCTAGAAAGCAAT 3503 SEQ ID NO : 1180-9. 8-22. 3 63. 6-9. 2-3. 3-11 CTGTGTAGCTTTGGGTTTGT 359 SEQ ID NO : 1181-9. 7-24. 9 75. 4-15. 2 0-4. 6 AACCTCACAGATGGTTTGAC 385 SEQ ID NO : 1182-9. 7-22. 4 65. 9-11. 5-1. 1-5. 3 TAAACCTCACAGATGGTTTG 387 SEQ ID NO : 1183-9. 7-20. 6 61. 4-8. 5-2. 4-7. 9 GAGTTTGTGCAGCCAGTTTT 548 SEQ ID NO : 1184-9. 7-25. 7 76. 3-16 0-5. 3 CAATTTCTCCCATGTTCTTG 1326 SEQ ID NO : 1185-9. 7-23. 3 68. 1-13. 6 0-4. 3 CTGGGTTTCCCCAGACTTCA 1604 SEQ ID NO : 1186-9. 7-28. 7 79. 7-15-4-9. 6 TAGGAAAGCCAATGATGTGT 2323 SEQ ID NO : 1187-9. 7-20. 9 61. 6-10-1. 1-3. 5 GTTCAATAGACATTTGCTCA 2364 SEQ ID NO : 1188-9. 7-20. 9 63. 8-11. 2 0-4 AAATCCCAACTCCACTGGGT 2440 SEQ ID NO : 1189-9. 7-25. 9 70. 5-14. 1-2. 1-6. 8 TCAGGGTCCCTAATGCTTAT 2540 SEQ ID NO : 1190-9. 7-25. 5 73-15. 3-0. 1-6. 4 AAGCAGTTATATCTGGCAAC 2705 SEQ ID NO : 1191-9. 7-21 63. 4-10. 4-0. 7-2. 8 TCACGTCTGGGGCATATTGG 3179 SEQ ID NO : 1192-9. 7-25. 7 73. 1-16 0-4. 6 ATATCTTGAAATAAGACTCA 3446 SEQ ID NO : 1193-9. 7-16. 1 52. 3-5-1. 3-5. 1 AGAACATATCTTGAAATAAG 3451 SEQ ID NO : 1194-9. 7-14. 1 47. 8-3. 9-0. 1-3. 3 CATGCTTCATGTACACAACT 3731 SEQ ID NO : 1195-9. 7-21. 7 64. 3-11. 1-0. 8-6. 7 GCAGAGGAACGGAGTTGCTC 255 SEQ ID NO : 1196-9. 6-25. 4 72. 7-14-1. 8-8. 3 TCTGTGTAGCTTTGGGTTTG 360 SEQ ID NO : 1197-9. 6-24. 1 73. 5-14. 5 0-4. 6 CTCAGTCTGTGTAGCTTTGG 365 SEQ ID NO : 1198-9. 6-24. 7 75. 5-15. 1 0-4. 6 AAGTGGACATTCCCGAGAGA 727 SEQ ID NO : 1199-9. 6-24. 3 68. 4-13. 8-0. 8-4. 2 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo CCCGGGTTTTTAGGTACATT 1251 SEQ ID NO : 1200-9. 6-25. 6 72-15. 3 0-9 AGTGGCAGAGTCTGGGAATC 1384 SEQ ID No : 1201-9. 6-24. 7 73. 7-14. 4 0. 2-8. 9 CAAAATGTCAGTTTCCGCTG 1621 SEQ ID NO : 1202-9. 6-22. 2 63. 9-11. 7-0. 8-4. 2 GTGGGACTGGTTTCGTTTTT 1720 SEQ ID NO : 1203-9. 6-24. 7 72. 9-15. 1 0-3. 2 CCACAGTGGGACTGGTTTCG 1725 SEQ ID NO : 1204-9. 6-26. 7 74. 8-15-2. 1-8. 3 CTGGACTTGGTGCTCTGGAG 1992 SEQ ID NO : 1205-9. 6-26. 1 76-16. 5 0-5. 7 ATCCCAACTCCACTGGGTTC' 2438 SEQ ID NO : 1206-9. 6-27. 8 77. 1-16. 1-2. 1-6. 8 TCATAACTTCTATCTCTCTA 2745 SEQ ID NO : 1207-9. 6-19. 9 62. 9-10. 3 0-1. 2 TCAGATATTGTGTGTATTAA 2934 SEQ ID NO : 1208-9. 6-17. 9 57. 5-8. 3 0-2. 8 TCTCACGTCTGGGGCATATT 3181 SEQ ID NO : 1209-9. 6-25. 8 74. 3-16. 2 0-4. 7 AAAAGGGCTTAGGATTTTAT 3236 SEQ ID NO : 1210-9. 6-18. 6 57. 4-9 0-3. 8 GAACATATCTTGAAATAAGA 3450 SEQ ID NO : 1211-9. 6-14. 7 48. 9-3. 9-1. 1-3. 7 GTGGATAAGGTGTAACTGAC 3676 SEQ ID NO : 1212-9. 6-20. 5 62. 5-10. 1-0. 6-2. 6 GCTTCATGTACACAACTATT 3728 SEQ ID NO : 1213-9. 6-20. 8 62. 9-11. 2 0-6. 7 AAGTTACCACAAACCATGCT 3745 SEQ ID NO : 1214-9. 6-22. 3 63. 3-12. 2-0. 2-4. 4 ACATAAGTTACCACAAACCA 3749 SEQ ID NO : 1215-9. 6-20. 2 59-10. 1-0. 2-3. 8 AGACCCTTCTCTCGGCCAGG 147 SEQ ID NO : 1216-9. 5-30. 5 82. 6-21 0-7. 2 CCCGCCACACCCCCTCCCAA 228 SEQ ID NO : 1217-9. 5-37. 7 86. 9-28. 2 0-2. 6 CAGTCTGTGTAGCTTTGGGT 363 SEQ ID NO : 1218-9. 5-25. 8 78. 2-16. 3 0-4. 6 ACCACCCTGGTATTATTGAC 655 SEQ ID NO : 1219-9. 5-24. 8 70-13. 7-1. 5-5. 3 CAGCCAGTCGAGCATCCTGG 689 SEQ ID NO : 1220-9. 5-29. 2 79. 9-17. 8-1. 9-8. 4 CACTATTTCCAGTGGCAGAG 1394 SEQ ID NO : 1221-9. 5-24. 3 71. 2-13. 9-0. 8-7. 4 CTGATATTCAGCTCCCGTCC 1573 SEQ ID NO : 1222-9. 5-27. 9 77. 2-17. 4-0. 9-4. 7 TATGCTGGTGTTCTCAGGGT 1649 SEQ ID NO : 1223-9. 5-26. 1 78. 3-15. 9-0. 5-5. 2 CATCCCGACACTTGCGAAAC 1689 SEQ ID NO : 1224-9. 5-24. 6 65. 9-15. 1 0-4. 1 AGTGGGACTGGTTTCGTTTT 1721 SEQ ID NO : 1225-9. 5-24. 6 72. 8-15. 1 0-3. 3 TAGCAGCGCAGTCCCCTCCC 1920 SEQ ID NO : 1226-9. 5-34. 2 89. 2-23. 8-0. 7-7. 7 TAAGCAGTATGGTCAGTGCA 2259 SEQ ID NO : 1227-9. 5-23. 6 70. 8-12. 5-1. 6-5. 5 AGAGAGTGAGCTGGGGAGCA 2298 SEQ ID NO : 1228-9. 5-26. 4 77. 3-15. 3-1. 6-5. 5 2436 CCCAACTCCACTGGGTTCCA-9. 5-30. 1 79. 8-19-1. 5-6. 1 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 1229 CATCATTCTGGCCCCAGCAT 2681 SEQ ID NO : 1230-9. 5-29. 4 79. 7-18. 3-1. 5-7. 8 TGGTGGGAACTGGCTGCAAA 3162 SEQ ID NO : 1231-9. 5-24. 8 69. 3-13. 9-1. 2-9. 6 AAAATTACCCTCAGGCTATG 3695 SEQ ID NO : 1232-9. 5-21. 5 62. 1-11. 4-0. 3-4. 9 TGCTTCATGTACACAACTAT 3729 SEQ ID NO : 1233-9. 5-20. 7 62. 5-11. 2 0-6. 7 AAGTCAGAAGTGACCAGGAT 3882 SEQ ID NO : 1234-9. 5-22 65. 3-10. 1-2. 4-6. 3 GGGTTTGTGGAGCTTATCTT 347 SEQ ID NO : 1235-9. 4-24. 7 74. 4-15. 3 0-5. 2 TTAAACCTCACAGATGGTTT 388 SEQ ID NO : 1236-9. 4-20. 7 61. 8-9. 1-2. 2-7. 5 TTCTAAGGGCTGGCTGTGGC 458 SEQ ID NO : 1237-9. 4-27. 6 79. 3-17. 5-0. 5-6 GTGTCCCACCACCCTGGTAT 662 SEQ ID NO : 1238-9. 4-31. 6 84. 3-20. 5-1. 7-5. 7 TGATCCCAAGACATCGTTGA 1013 SEQ ID NO : 1239-9. 4-23. 6 66. 6-14. 2 0-4. 7 CCACTATTTCCAGTGGCAGA 1395 SEQ ID NO : 1240-9. 4-26. 3 74. 6-14. 5-2. 4-7. 6 GCTCCACTATTTCCAGTGGC 1398 SEQ ID NO : 1241-9. 4-28. 1 80. 1-15. 7-3-9. 6 TCCTATAGCCTCCCCCAGGC 2519 SEQ ID NO : 1242-9. 4-33. 5 87. 7-21. 3-2. 8-8. 9 TATCTCTCTAAACAGAAGAG 2735 SEQ ID NO : 1243-9. 4-17. 3 55. 4-7-0. 7-4. 2 TTACATATGTCATAACTTCT 2754 SEQ ID NO : 1244-9. 4-18. 2 57. 8-8. 3 0-8. 2 ACAATGTCCTTAGAAAACCT 3368 SEQ ID NO : 1245-9. 4-20. 1 59. 2-10. 7 0-4 TGTGGATAAGGTGTAACTGA 3677 SEQ ID NO : 1246-9. 4-20. 3 61. 8-10. 1-0. 6-2. 6 TAGTAAAAACAGAAGTCAGA 3894 SEQ ID NO : 1247-9. 4-15. 5 50. 8-6. 1 0-2. 9 CGGCCGGTAAGACCCTTCTC 156 SEQ ID NO : 1248-9. 3-29. 5 77. 6-19. 1-0. 2-10. 2 TGGGTTTGTGGAGCTTATCT 348 SEQ ID NO : 1249-9. 3-24. 6 73. 8-15. 3 0-5. 2 AGTCTGTGTAGCTTTGGGTT 362 SEQ ID NO : 1250-9. 3-25. 2 77. 5-15. 9 0-4. 6 TCTCTCTTGTGTGCAGGGCT 573 SEQ ID NO : 1251-9. 3-28 83. 5-18. 1-0. 3-5. 3 CAGTCGAGCATCCTGGCAAT 685 SEQ ID NO : 1252-9. 3-26. 5 73. 6-16. 3-0. 8-5. 6 CCAGTCGAGCATCCTGGCAA 686 SEQ ID NO : 1253-9. 3-28. 5 77. 1-17. 7-1. 4-7. 4 ATTCACCAGAGAGTCAACAA 1094 SEQ ID NO : 1254-9. 3-21. 1 62. 9-11. 8 0-4. 8 CTGATTCACCAGAGAGTCAA 1097 SEQ ID NO : 1255-9. 3-22. 4 66. 4-12. 4-0. 5-5. 3 TGTAGACCAGGAAGGTGTTG 1437 SEQ ID NO : 1256-9. 3-23. 2 68. 6-12. 9-0. 9-4. 5 CCAGTGCTCCAGGGTCAAGG 1863 SEQ ID NO : 1257-9. 3-28. 9 80. 8-19. 6 0-3. 6 GCGCAGTCCCCTCCCGCGAG 1915 SEQ ID NO : 1258-9. 3-36 88-24. 9-1. 8-8. 2 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo ACCAATCCAGTGTGCACGAG 2045 SEQ ID NO : 1259-9. 3-25. 8 71. 3-15. 6 0-9. 8 TGGTCAGTGCAACCCATGAG 2250 SEQ ID NO : 1260-9. 3-26 73. 1-15. 9-0. 6-7. 4 AGGCCCCAGGTGCCTTTCCC 2503 SEQ ID NO : 1261-9. 3-35. 4 91. 8-24-2. 1-9. 8 ATGCTTATATCCTATAGCCT 2528 SEQ ID NO : 1262-9. 3-23. 6 69. 1-13. 6-0. 5-5 TAAACAGAAGAGATTTGCTC 2727 SEQ ID NO : 1263-9. 3-17. 6 55. 5-7. 4-0. 7-5. 7 ATCTCTCTAAACAGAAGAGA 2734 SEQ ID NO : 1264-9. 3-18. 2 57. 3-7-1. 9-6. 4 TTTGCCTCCAGGAAATCTGA 3115 SEQ ID NO : 1265-9. 3-24. 3 68. 8-13. 9-1-5 AGTCCAACCGTTGGCACAGA 3279 SEQ ID NO : 1266-9. 3-27. 1 74. 3-15. 2-2. 6-11. 5 CTCCTGCTTGGTGTCACACT 3323 SEQ ID NO : 1267-9. 3-27. 7 79. 7-17. 2-1. 1-6. 7 AAAGAAAATCATTCTTCCTC 3342 SEQ ID NO : 1268-9. 3-17. 4 54. 5-5. 6-2. 5-6. 5 AAAGCAATCACAGAAACAAG 3491 SEQ ID NO : 1269-9. 3-15. 8 50. 3-6. 5 0-4. 1 ATGAATTTTGTGTTTAGGCT 3650 SEQ ID NO : 1270-9. 3-20. 4 62. 9-11. 1 0-3. 7 GGCTCCCCGCAGCAAAGCAA 297 SEQ ID NO : 1271-9. 2-30. 5 77. 9-19. 4-1. 9-6. 2 GCCTGCATACCCGGCCACGT 770 SEQ ID NO : 1272-9. 2-33. 8 84-23. 7-0. 7-7. 2 TGTAGGTGTGGAGGACATCC 900 SEQ ID NO : 1273-9. 2-25. 4 74. 8-15. 2-0. 9-4. 7 ATTGGGGTAGATGTCAATGT 965 SEQ ID NO : 1274-9. 2-22 66. 5-12. 8 0-3. 8 TTCTCCCATGTTCTTGTAAC 1322 SEQ ID NO : 1275-9. 2-23. 6 69. 9-13. 9-0. 1-4. 3 TCCACAGGTTGTACCAAGAC 1515 SEQ ID NO : 1276-9. 2-24. 4 70. 2-13. 5-1. 7-5. 3 AGAAATCCCAACTCCACTGG 2442 SEQ ID NO : 1277-9. 2-24. 1 66. 6-14. 9 0-4. 1 TATTCTGCTAGTGATCAAAC 2643 SEQ ID NO : 1278-9. 2-19. 2 59. 8-10 0-6. 7 TCTCTCTAAACAGAAGAGAT 2733 SEQ ID NO : 1279-9. 2-18. 2 57. 3-7-2-6. 5 ATTGGTGGGAACTGGCTGCA 3164 SEQ ID NO : 1280-9. 2-26. 3 74. 2-15. 7-1. 2-9. 6 CTCACGTCTGGGGCATATTG 3180 SEQ ID NO : 1281-9. 2-25. 4 72. 5-16. 2 0-4. 7 TGTTTGTCTCACGTCTGGGG 3187 SEQ ID NO : 1282-9. 2-26. 1 76. 5-16. 9 0-4. 6 ATGGCTCTATATAAAAAAAA 3214 SEQ ID NO : 1283-9. 2-13. 4 45. 9-4. 2 0-3. 7 TTAACAGTGATACAACTTTG 3405 SEQ ID NO : 1284-9. 2-17 54. 2-7. 8 0-4. 6 TCTTGAAATAAGACTCAACT 3443 SEQ ID NO : 1285-9. 2-16. 8 53. 4-6. 7-0. 8-6 ATCTTGAAATAAGACTCAAC 3444 SEQ ID NO : 1286-9. 2-15. 9 51. 6-5. 3-1. 3-6 CCCTCACATAAGTTACCACA 3754 SEQ ID NO : 1287-9. 2-24. 7 69. 1-15-0. 2-3. 8 254 CAGAGGAACGGAGTTGCTCA-9. 1-24. 3 69. 6-12. 8-2. 4-10. 7 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 1288 AAGGGCTGGCTGTGGCCGAC 454 SEQ ID NO : 1289-9. 1-30. 1 80. 8-17. 7-3. 3-11 TGATTCACCAGAGAGTCAAC 1096 SEQ ID NO : 1290-9. 1-21. 7 65-11. 9-0. 4-4. 8 TCCTCCTCGGTGTAGACCAG 1447 SEQ ID NO : 1291-9. 1-28. 6 79. 6-17. 7-1. 8-3. 1 CGAAACTCCTTCCACAGGTT 1525 SEQ ID NO : 1292-9. 1-25 69. 2-15-0. 8-5. 2 CACACAAATCTGGACTTGGT 2001 SEQ ID NO : 1293-9. 1-21. 8 63. 8-12. 7 0-5. 6 TGAGTCAGCTCCTGTCGGAA 2180 SEQ ID NO : 1294-9. 1-26. 4 75. 4-16-1. 2-6. 7 TATAAGTCTAGGCATGTGGC 3064 SEQ ID NO : 1295-9. 1-22. 8 68. 8-13-0. 4-5. 3 GGAAATCTGAGTCCTCTCCC 3105 SEQ ID NO : 1296-9. 1-26. 5 74. 9-16. 1-1. 2-6. 9 GTCTCACGTCTGGGGCATAT 3182 SEQ ID NO : 1297-9. 1-26. 9 77. 5-17. 3-0. 1-4. 7 CCTCTCCTGCTTGGTGTCAC 3326 SEQ ID NO : 1298-9. 1-29. 2 83. 6-20. 1 0. 5-4. 1 TTCCTCTCCTGCTTGGTGTC 3328 SEQ ID NO : 1299-9. 1-28. 8 84. 3-19. 2-0. 1-4. 1 TGGATAAGGTGTAACTGACA 3675 SEQ ID NO : 1300-9. 1-20 60. 6-10. 1-0. 6-3. 8 GACCCTTCTCTCGGCCAGGG 146 SEQ ID NO : 1301-9-31. 7 84. 7-21-1. 7-10 TTGCTCATCCTGCCCCGCCA 241 SEQ ID NO : 1302-9-34. 3 86. 8-25. 3 0-3. 6 GCTCCCCGCAGCAAAGCAAT 296 SEQ ID NO : 1303-9-29. 3 75. 6-19. 4-0. 7-5. 6 ACCTCACAGATGGTTTGACC 384 SEQ ID NO : 1304-9-25. 1 71. 8-15. 4-0. 5-4. 5 CAACTACATTGGCGTCTTTC 591 SEQ ID NO : 1305-9-22. 7 66. 5-13. 7 0-4. 6 TCCTGCAGCCAGTCGAGCAT 694 SEQ ID NO : 1306-9-29. 8 81. 7-19. 9-0. 8-8. 1 TCACGAAGTTGCCTGCATAC 780 SEQ ID NO : 1307-9-24. 4 69-14. 7-0. 4-6. 8 CTGCCCGGGTTTTTAGGTAC 1254 SEQ ID NO : 1308-9-27. 5 76. 6-17. 3 0-10. 3 TCCGCTCCACTATTTCCAGT 1401 SEQ ID NO : 1309-9-28. 3 78. 2-19. 3 0-3. 1 AACTCCTTCCACAGGTTGTA 1522 SEQ ID NO : 1310-9-25. 2 72. 8-15. 3-0. 8-4. 9 TTTCCCCAGACTTCACCCGG 1599 SEQ ID NO : 1311-9-30. 4 79. 1-21. 4 0-5. 8 AGCAGTAACTTTCCTCCATG 1811 SEQ ID NO : 1312-9-24. 4 70. 8-15. 4 0-4. 1 TACACACAAATCTGGACTTG 2003 SEQ ID NO : 1313-9-19. 3 58. 4-10. 3 0-5. 1 GGCCTGCCATCCTGACATGA 2197 SEQ ID NO : 1314-9-29. 8 79. 9-20. 3 0-7. 5 ATGGCTAAGACGTAAGCAGT 2271 SEQ ID NO : 1315-9-22. 4 65. 4-11. 6-1. 8-8. 2 CAGGGTCCCTAATGCTTATA 2539 SEQ ID NO : 1316-9-24. 8 70. 8-15. 3-0. 1-6. 4 TACATATGTCATAACTTCTA 2753 SEQ ID NO : 1317-9-17. 8 56. 8-8. 3 0-8. 2 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo AGAAGTTTAACAGTGATACA 3411 SEQ ID NO : 1318-9-17. 6 56-8. 6 0-4. 6 AACATATCTTGAAATAAGAC 3449 SEQ ID NO : 1319-9-14. 3 48. 1-3. 9-1. 3-4 TGTGTTTAGGCTCGGGTCCT 3642 SEQ ID NO : 1320-9-28. 3 81. 2-18. 8-0. 2-7 CCCCTCACATAAGTTACCAC 3755 SEQ ID NO : 1321-9-26 71. 4-17 0-3. 8 GAAGTGACCAGGATGTACAG 3876 SEQ ID NO : 1322-9-22. 2 65. 6-13. 2 0-6. 7 TGCAAAGCTTCCATTAGTAA 3908 SEQ ID NO : 1323-9-21 62. 3-11. 4-0. 3-7 GGTGTTTCCAGCAATCCCGG 173 SEQ ID NO : 1324-8. 9-29. 1 78. 4-19. 6-0. 3-6. 4 CGCCACACCCCCTCCCAAGA 226 SEQ ID NO : 1325-8. 9-34. 3 82. 7-25. 4 0-2. 6 GTTTGTGGAGCTTATCTTCC 345 SEQ ID NO : 1326-8. 9-24. 7 74. 5-15. 3-0. 1-5. 2 GTTTGTGCAGCCAGTTTTCA 546 SEQ ID NO : 1327-8. 9-26. 2 77. 5-17. 3 0-4. 8 TCCGTGTAAAGCTGGTGGGC 631 SEQ ID NO : 1328-8. 9-27. 2 75. 7-17. 6-0. 4-5. 1 AAACCTGTGATTCGGCCCAC 808 SEQ ID NO : 1329-8. 9-26. 7 71. 3-17. 3-0. 1-6. 6 GGCCCCTTCAAACATGGGCC 839 SEQ ID NO : 1330-8. 9-30. 8 79. 6-18-3. 9-10. 4 CTCTGAAAGGCATGCCTGCC 1269 SEQ ID NO : 1331-8. 9-27. 6 75. 2-15. 2-3. 2-14. 8 GCTCGATCCGCTCCACTATT 1407 SEQ ID NO : 1332-8. 9-28. 4 76. 7-19. 5 0-4. 8 CCACAGGTTGTACCAAGACT 1514 SEQ ID NO : 1333-8. 9-24. 9 70. 5-15-0. 9-4. 2 AAACTCCTTCCACAGGTTGT 1523 SEQ ID NO : 1334-8. 9-24. 8 71-15. 2-0. 5-5. 4 GCGAAACTCCTTCCACAGGT 1526 SEQ ID NO : 1335-8. 9-26. 7 72. 9-16. 9-0. 8-5 AGCTCCCGTCCGGGGTTGCG 1564 SEQ ID NO : 1336-8. 9-33. 8 86-21. 1-3. 8-11. 8 GGACTGGTTTCGTTTTTCAT 1717 SEQ ID NO : 1337-8. 9-23. 4 69. 7-14. 5 0-3. 3 AGGAAGTCTTGCTGCCTTGC 1779 SEQ ID NO : 1338-8. 9-27 77. 6-18. 1 0-5. 4 TGGACTTGGTGCTCTGGAGG 1991 SEQ ID NO : 1339-8. 9-26. 4 76. 7-17. 5 0-6. 4 AGCTAGGGCCCGAGCAAGAT 2221 SEQ ID NO : 1340-8. 9-28. 4 76. 6-17. 1-1. 7-12. 8 ATGATGTGTGCTTCAGAGAG 2312 SEQ ID NO : 1341-8. 9-22. 1 67. 6-13. 2 0-3. 7 CTCTCTAAACAGAAGAGATT 2732 SEQ ID NO : 1342-8. 9-17. 9 56. 3-7-2-6. 5 GCAGGTGCCGGTTTCTGTGT 2787 SEQ ID NO : 1343-8. 9-29. 8 84. 4-20. 3-0. 2-8. 3 ATAAGTCTAGGCATGTGGCT 3063 SEQ ID NO : 1344-8. 9-24 71. 4-13. 8-1. 2-6. 1 GGTGGGAACTGGCTGCAAAA 3161 SEQ ID NO : 1345-8. 9-24. 1 67. 3-13. 9-1. 2-7. 6 CCTCACATAAGTTACCACAA 3753 SEQ ID NO : 1346-8. 9-22 63. 5-12. 6-0. 2-3. 8 3874 AGTGACCAGGATGTACAGCC-8. 9-26. 1 74. 6-17. 2 0-5. 8 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 1347 GCAAAGCTTCCATTAGTAAA 3907 SEQ ID NO : 1348-8. 9-20. 3 60. 4-11. 4 0-7 GTTAAACCTCACAGATGGTT 389 SEQ ID NO : 1349-8. 8-21. 8 64. 6-11. 5-1. 4-5. 9 GCCAGTCGAGCATCCTGGCA 687 SEQ ID NO : 1350-8. 8-31 83. 9-17. 7-4. 5-13. 6 CAAGTGGACATTCCCGAGAG 728 SEQ ID NO : 1351-8. 8-24. 4 68. 2-15. 1-0. 1-4. 2 CATTGGGGTAGATGTCAATG 966 SEQ ID NO : 1352-8. 8-21. 5 64. 4-11. 3-1. 3-5. 2 AGCTGGATCTTCAAGAGGTC 1474 SEQ ID NO : 1353-8. 8-23. 7 71. 7-14. 9 0. 1-4. 6 TGCGGGGTTGAGACAGGTAG 1548 SEQ ID NO : 1354-8. 8-25. 7 73. 7-16. 2-0. 5-4. 5 GGTCTTCTGTACAAAATGTC 1632 SEQ ID NO : 1355-8. 8-20. 4 62. 9-11. 6 0-6. 1 CACAGTGGGACTGGTTTCGT 1724 SEQ ID NO : 1356-8. 8-25. 9 74. 6-15-2. 1-6. 9 CAGCAGTAACTTTCCTCCAT 1812 SEQ ID NO : 1357-8. 8-25. 1 72-16. 3 0-4. 1 AGTCCCCTCCCGCGAGGAGT 1911 SEQ ID NO : 1358-8. 8-33. 9 87. 1-22. 2-2. 5-13. 6 TGAGCTGGGGAGCAGGACGG 2292 SEQ ID NO : 1359-8. 8-28 77. 3-17. 6-1. 6-6. 4 GTGAGCTGGGGAGCAGGACG 2293 SEQ ID NO : 1360-8. 8-28 78. 2-17. 6-1. 6-5. 9 AGGAAAGCCAATGATGTGTG 2322 SEQ ID NO : 1361-8. 8-21. 2 62-11. 2-1. 1-3. 5 AAGTGTTCAATAGACATTTG 2368 SEQ ID NO : 1362-8. 8-17. 6 56. 1-8. 8 0-4. 4 AGGGTCCCTAATGCTTATAT 2538 SEQ ID NO : 1363-8. 8-24. 1 69. 6-15. 3 0-6. 1 CAGTTATATCTGGCAACCGG 2702 SEQ ID NO : 1364-8. 8-23. 9 67. 6-14. 6-0. 2-6. 6 AAAGCAGTTATATCTGGCAA 2706 SEQ ID NO : 1365-8. 8-20. 1 60. 7-10. 4-0. 7-2. 8 TTCTATCTCTCTAAACAGAA 2738 SEQ ID NO : 1366-8. 8-18. 1 57. 4-9. 3 0-3 TATTGTGTGTATTAATTCAA 2929 SEQ ID NO : 1367-8. 8-16. 7 54. 3-7. 9 0-4. 2 ATGTGGATAAGGTGTAACTG 3678 SEQ ID NO : 1368-8. 8-19. 7 60. 5-10. 1-0. 6-2. 6 TCACATAAGTTACCACAAAC 3751 SEQ ID NO : 1369-8. 8-18. 6 56. 7-9. 3-0. 2-3. 3 TAAGACCCTTCTCTCGGCCA 149 SEQ ID NO : 1370-8. 7-28. 3 76. 7-19. 1-0. 2-7. 4 CCGTCCCTCTGGACCAAAAG 323 SEQ ID NO : 1371-8. 7-27. 2 71. 4-15. 8-2. 7-6. 6 ATACCCGGCCACGTGCGCTC 764 SEQ ID NO : 1372-8. 7-32. 3 81. 2-21. 7-1. 3-11. 7 AACCTGTGATTCGGCCCACC 807 SEQ ID NO : 1373-8. 7-29. 4 76. 8-20. 7 0. 1-6. 3 TCAATTTCTCCCATGTTCTT 1327 SEQ ID NO : 1374-8. 7-23. 7 69. 8-15 0-4. 3 TTGGTGGCATTCTGCTCGAT 1420 SEQ ID NO : 1375-8. 7-26. 1 74. 6-15. 5-1. 9-7. 8 CCAGGTGAGCTGGATCTTCA 1481 SEQ ID NO : 1376-8. 7-26. 7 77-15. 5-2. 5-7 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo CGCCTGATATTCAGCTCCCG 1576 SEQ ID NO : 1377-8. 7-28. 9 76. 2-18. 7-1. 4-6. 2 TCCTCCAGCCATCCCGACAC 1698 SEQ ID NO : 1378-8. 7-31. 8 82. 2-23. 1 0-3. 2 CTGCCTTGCTGGCAAGACTT 1768 SEQ ID NO : 1379-8. 7-27. 2 75. 7-15. 2-3. 3-12. 7 GGTCCTCAGCAGTAACTTTC 1818 SEQ ID NO : 1380-8. 7-25. 2 75. 1-16. 5 0-4. 1 GGTGGGTCCTCAGCAGTAAC 1822 SEQ ID NO : 1381-8. 7-27. 3 79. 5-18. 6 5-4. 1 GGCTAAGACGTAAGCAGTAT 2269 SEQ ID NO : 1382-8. 7-22. 1 65-11. 6-1. 8-8. 2 TGGCTAAGACGTAAGCAGTA 2270 SEQ ID NO : 1383-8. 7-22. 1 64. 9-11. 6-1. 8-8. 2 CTGGCAACCGGCCATCATTC 2693 SEQ ID NO : 1384-8. 7-28. 2 75. 3-16. 2-3. 3-8 TCTGGCAACCGGCCATCATT 2694 SEQ ID NO : 1385-8. 7-28. 2 75. 3-16. 2-3. 3-8 TTGTGTTTAGGCTCGGGTCC 3643 SEQ ID NO : 1386-8. 7-27. 5 79. 6-18. 8 0-5. 4 ACACATCAATGAATTTTGTG 3658 SEQ ID NO : 1387-8. 7-17. 6 55. 2-7. 6-1. 2-8. 6 AGTTACCACAAACCATGCTT 3744 SEQ ID NO : 1388-8. 7-23. 1 65. 6-13. 9-0. 2-4. 4 ATAAGTTACCACAAACCATG 3747 SEQ ID NO : 1389-8. 7-19. 3 57. 3-10. 1-0. 2-4. 2 ACCCCTCACATAAGTTACCA 3756 SEQ ID NO : 1390-8. 7-26 71. 4-17. 3 0-3. 8 TTTTGAGCACCAACAAGACA 3788 SEQ ID NO : 1391-8. 7-21. 3 62-12. 1-0. 2-4. 6 AAGTGACCAGGATGTACAGC 3875 SEQ ID NO : 1392-8. 7-23. 4 68. 5-14. 7 0-1. 8 GGTTTGTGGAGCTTATCTTC 346 SEQ ID NO : 1393-8. 6-23. 9 73. 4-15. 3 0-5. 2 CTCTGGGTCCTTGGAGGTGC 413 SEQ ID NO : 1394-8. 6-29. 2 84. 2-19. 8-0. 6-5 GCTCTGGGTCCTTGGAGGTG 414 SEQ ID NO : 1395-8. 6-29. 2 84. 2-19. 8-0. 6-5. 2 TGCTCTGGGTCCTTGGAGGT 415 SEQ ID NO : 1396-8. 6-29. 2 84. 2-19. 8-0. 6-5. 2 CTTGTGTGCAGGGCTGACAC 568 SEQ ID NO : 1397-8. 6-26. 7 77. 1-16. 5-1. 5-10. 3 GGCATCTGAATACCAATGCT 937 SEQ ID NO : 1398-8. 6-23. 5 66. 7-11. 9-3-7. 4 GCCCGGGTTTTTAGGTACAT 1252 SEQ ID NO : 1399-8. 6-27. 3 75. 9-17. 5 0-10. 3 GAGTCTGGGAATCTGCATTA 1377 SEQ ID NO : 1400-8. 6-23 68. 7-14. 4 0-4. 9 GTGGCAGAGTCTGGGAATCT 1383 SEQ ID NO : 1401-8. 6-25. 6 75. 5-16-0. 6-9. 6 TCCACTATTTCCAGTGGCAG 1396 SEQ ID NO : 1402-8. 6-26. 1 75-14. 5-3-8. 7 TCAGTTTCCGCTGGGTTTCC 1614 SEQ ID NO : 1403-8. 6-28. 6 81-18. 7-1. 2-5. 2 AAATGTCAGTTTCCGCTGGG 1619 SEQ ID NO : 1404-8. 6-24. 6 69. 8-14. 7-1. 2-5. 2 AGAGCTCCCGGCCTGGGGAT 1668 SEQ ID NO : 1405-8. 6-32. 6 85. 4-21. 6-2. 1-12. 4 1934 GGCAGCAAGAGCTATAGCAG-8. 6-24. 7 71. 9-13. 4-2. 7-11 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 1406 TTGGAGTTAGAGCTATTCAA 1958 SEQ ID NO : 1407-8. 6-20. 4 63. 1-11. 3-0. 2-5. 1 CAGCAACTGAGAAACCAATC 2058 SEQ ID NO : 1408-8. 6-20 58. 7-11. 4 0-4. 1 TCTTTTGAAAAGTGTAAGTG 2956 SEQ ID NO : 1409-8. 6-16. 7 54-7. 2-0. 8-5. 9 ATCTTTTGAAAAGTGTAAGT 2957 SEQ ID NO : 1410-8. 6-16. 7 54. 1-7. 2-0. 8-5. 9 CACCACTAACTAGTATATAA 3079 SEQ ID NO : 1411-8. 6-18. 1 56. 1-9. 5 0-6. 3 TCCTCTCCTGCTTGGTGTCA 3327 SEQ ID NO : 1412-8. 6-29. 4 84. 9-20. 3-0. 1-4. 1 AGCAATCACAGAAACAAGAG 3489 SEQ ID NO : 1413-8. 6-17. 8 54. 9-9. 2 0-4. 1 TCAGTCTGTGTAGCTTTGGG 364 SEQ ID NO : 1414-8. 5-25 76. 3-16. 5 0-4. 6 TCAAAGATACCGCTCATCGT 529 SEQ ID NO : 1415-8. 5-23. 2 65. 3-14. 2-0. 2-3. 1 CGCATCCGTGTAAAGCTGGT 635 SEQ ID NO : 1416-8. 5-26. 3 71. 8-17. 8 0-5. 1 CCCGGCCACGTGCGCTCCGA 761 SEQ ID NO : 1417-8. 5-35. 8 84. 7-25. 4-1. 3-11. 7 ACCCGGCCACGTGCGCTCCG 762 SEQ ID NO : 1418-8. 5-35. 4 84. 1-25. 4-0. 7-10. 9 GCCGAAGGAACGCGTGTAGG 914 SEQ ID NO : 1419-8. 5-26. 5 70. 2-15. 3-2. 1-13. 2 AGGCATCTGAATACCAATGC 938 SEQ ID NO : 1420-8. 5-22. 6 65. 1-11. 9-2. 2-6. 5 CTGAGGCTCAAAGCAGGCTG 2150 SEQ ID NO : 1421-8. 5-25. 5 72. 6-15. 7-1. 2-4. 9 ATTTTAAGTGTTCAATAGAC 2373 SEQ ID NO : 1422-8. 5-16. 7 54. 6-8. 2 0-2. 6 ATGATACTCTGCTTGCTATT 2659 SEQ ID NO : 1423-8. 5-22 66. 5-13. 5 0-4. 5 GCAGTTATATCTGGCAACCG 2703 SEQ ID NO : 1424-8. 5-24. 5 69. 2-15. 2-0. 6-2. 7 CATAACTTCTATCTCTCTAA 2744 SEQ ID NO : 1425-8. 5-18. 8 59. 3-10. 3 0-1. 2 AGGGCTTAGGATTTTATGGA 3233 SEQ ID NO : 1426-8. 5-22. 5 67. 5-14 0-3. 7 TTGAGAACATATCTTGAAAT 3454 SEQ ID NO : 1427-8. 5-15. 8 51. 3-6. 5-0. 6-3. 9 TCATTATGTATATGCAAACA 3608 SEQ ID NO : 1428-8. 5-17. 5 55-9 0-6. 2 TATGTGGATAAGGTGTAACT 3679 SEQ ID NO : 1429-8. 5-19. 4 60-10. 1-0. 6-2. 6 CCTCTTGGTGTTTCCAGCAA 179 SEQ ID NO : 1430-8. 4-27 76. 8-18. 6 3. 6-0. 6 TCATCCTGCCCCGCCACACC 237 SEQ ID NO : 1431-8. 4-34. 6 85. 9-26. 2 0-3 CAGCAAAGCAATAGCAGAGG 288 SEQ ID NO : 1432-8. 4-21. 6 63. 1-11. 5-1. 7-6. 6 AGCCAGTCGAGCATCCTGGC 688 SEQ ID NO : 1433-8. 4-30. 3 83. 3-17. 7-4. 2-13 AAATCGTCCTTCTCCTGCAG 706 SEQ ID NO : 1434-8. 4-25. 5 71. 8-16. 6 0-7. 8 GGATCCAAACCTGTGATTCG 814 SEQ ID NO : 1435-8. 4-23. 7 66. 2-14. 6-0. 3-8. 3 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo CAGGCATCTGAATACCAATG 939 SEQ ID NO : 1436-8. 4-21. 5 62. 3-12. 3-0. 6-4. 7 AGTCTGGGAATCTGCATTAG 1376 SEQ ID NO : 1437-8. 4-22. 4 67. 5-14 0-4. 9 GTGAGCTGGATCTTCAAGAG 1477 SEQ ID NO : 1438-8. 4-22. 7 68. 5-14. 3 0-5. 2 CCTGGGGATATGCTGGTGTT 1657 SEQ ID NO : 1439-8. 4-27. 2 77. 1-18. 8 0-3. 6 CTCCACAGTGGGACTGGTTT 1727 SEQ ID NO : 1440-8. 4-26. 8 77-17. 1-1. 2-9. 3 GAGAAGAATCCTTCCATTGG 1841 SEQ ID NO : 1441-8. 4-22. 2 64. 6-11. 7-2. 1-6 GAATGGCTAAGACGTAAGCA 2273 SEQ ID NO : 1442-8. 4-21. 1 61. 4-11. 6-1-7. 4 TCCAAGAAGTTCAACAAGAA 2884 SEQ ID NO : 1443-8. 4-18. 1 55. 4-9. 1-0. 3-6 CTTTTGAAAAGTGTAAGTGT 2955 SEQ ID NO : 1444-8. 4-17. 5 55. 7-8. 6-0. 2-5. 1 CTTCCTCCCGAATCTCAGCC 3305 SEQ ID NO : 1445-8. 4-29. 6 79. 1-21. 2 0-3. 2 TCGCTTTGGCTAGAAAGCAA 3504 SEQ ID NO : 1446-8. 4-22. 7 65-11-3. 3-11 TTCGCTTTGGCTAGAAAGCA 3505 SEQ ID NO : 1447-8. 4-23. 5 67. 4-11. 8-3. 3-11 CCCCGCAGCAAAGCAATAGC 293 SEQ ID NO : 1448-8. 3-27. 7 72. 1-18. 5-0. 7-6. 1 CCCTCTGGACCAAAAGGTAC 319 SEQ ID NO : 1449-8. 3-25. 1 69-16. 3-0. 1-6 CTCCTGCAGCCAGTCGAGCA 695 SEQ ID NO : 1450-8. 3-30. 7 83. 7-21. 5-0. 8-8. 1 AGGTGGACGGCTCGCTCATG 1072 SEQ ID NO : 1451-8. 3-28. 1 77. 3-19. 8 0. 3-5. 3 CAGCCATCCCGACACTTGCG 1693 SEQ ID NO : 1452-8. 3-29. 7 76. 4-20. 9-0. 1-4 TTACACACAAATCTGGACTT 2004 SEQ ID NO : 1453-8. 3-19. 4 58. 8-11. 1 0-3 CCAATCCAGTGTGCACGAGA 2044 SEQ ID NO : 1454-8. 3-26. 2 72-17 0-9. 8 CTGGGGAGCAGGACGGAATG 2288 SEQ ID NO : 1455-8. 3-25. 5 70. 5-16. 3-0. 7-4. 9 GAAAGCCAATGATGTGTGCT 2320 SEQ ID NO : 1456-8. 3-22. 7 65. 2-13. 5-0. 7-4. 2 CAGGCCCCAGGTGCCTTTCC 2504 SEQ ID NO : 1457-8. 3-34. 1 89. 5-23. 6-2. 2-10 TATATCCTATAGCCTCCCCC 2523 SEQ ID NO : 1458-8. 3-29. 2 78. 5-20. 9 0-5 TCTCTAAACAGAAGAGATTT 2731 SEQ ID NO : 1459-8. 3-17. 1 54. 7-7-1. 8-6. 2 TATATAAGTCTAGGCATGTG 3066 SEQ ID NO : 1460-8. 3-19. 5 61-11. 2 0-6. 1 AAATAAGACTCAACTGGTTA 3438 SEQ ID NO : 1461-8. 3-17 53. 8-8. 7 0-4. 7 TGACACATCAATGAATTTTG 3660 SEQ ID NO : 1462-8. 3-17 53. 6-8. 1-0. 3-4. 8 TCCCGGCCGGTAAGACCCTT 159 SEQ ID NO : 1463-8. 2-32. 2 80. 5-21-0. 7-14. 2 AAAATCGTCCTTCTCCTGCA 707 SEQ ID NO : 1464-8. 2-24. 8 69. 3-16. 6 0-4. 7 784 CCTTTCACGAAGTTGCCTGC-8. 2-26. 9 74-18-0. 4-3. 8 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 1465 CCTGGCTGGAAGTCACCCCC 985 SEQ ID NO : 1466-8. 2-32. 4 84-22. 8-1. 3-5. 2 GTCCACAGCCTGGCTGGAAG 993 SEQ ID NO : 1467-8. 2-28. 9 79. 6-17. 6-2-14. 2 AGACCAGGAAGGTGTTGGTG 1434 SEQ ID NO : 1468-8. 2-24. 7 71. 9-14. 8-1. 7-6. 7 ACAGTGGGACTGGTTTCGTT 1723 SEQ ID NO : 1469-8. 2-25. 3 73. 8-15-2. 1-6. 9 GCTCCACAGTGGGACTGGTT 1728 SEQ ID NO : 1470-8. 2-28. 5 81. 1-18. 2-2. 1-9. 3 CATCACAGGAGACCAGTTGT 1885 SEQ ID NO : 1471-8. 2-24. 5 71. 6-15. 7-0. 3-3. 7 CGAGGAGTCCCAGCCATCAC 1899 SEQ ID NO : 1472-8. 2-29. 3 79. 3-20-1-7. 5 AGGTTTGGAGTTAGAGCTAT 1962 SEQ ID NO : 1473-8. 2-22. 4 69. 1-14. 2 0-5. 1 CCAGCAACTGAGAAACCAAT 2059 SEQ ID NO : 1474-8. 2-21. 6 60. 9-12. 8-0. 3-4. 3 CAGAGTACAGGCTCGCCCAG 2075 SEQ ID NO : 1475-8. 2-28. 7 78. 8-18. 3-2. 2-7. 3 GAGTCAGCTCCTGTCGGAAG 2179 SEQ ID NO : 1496-8. 2-26. 4 75. 9-17. 3-0. 7-5. 4 GCTAAGACGTAAGCAGTATG 2268 SEQ ID NO : 1477-8. 2-20. 9 62. 3-11. 6-1-7. 6 AAAGTGTAAGTGTCTCAGAT 2948 SEQ ID NO : 1478-8. 2-19. 4 61-11. 2 0-3. 3 TCTAGGCATGTGGCTGAACC 3058 SEQ ID NO : 1479-8. 2-25. 9 73. 8-17-0. 4-8. 3 TTGTTTGTCTCACGTCTGGG 3188 SEQ ID NO : 1480-8. 2-25 74. 2-16. 8 0-4. 6 TTAATAAAAGGGCTTAGGAT 3241 SEQ ID NO : 1481-8. 2-17. 4 54. 4-9. 2 0-3. 8 TTCCTCCCGAATCTCAGCCA 3304 SEQ ID NO : 1482-8. 2-29. 4 78. 3-21. 2 0-3. 2 ATCCCGGCCGGTAAGACCCT 160 SEQ ID NO : 1483-8. 1-32. 1 80. 2-21-0. 7-14. 2 GCTCAAGCCGAAGGAACGCG 920 SEQ ID NO : 1484-8. 1-26. 3 68. 6-16. 6-1. 5-10. 1 ATCCCAAGACATCGTTGAGT 1011 SEQ ID NO : 1485-8. 1-24. 2 68. 8-16. 1 0-3. 8 GATTTTCATCTGATAATGGT 1292 SEQ ID NO : 1486-8. 1-19. 3 60. 1-11. 2 0-4. 4 CGGTGTAGACCAGGAAGGTG 1440 SEQ ID NO : 1487-8. 1-25. 1 71. 1-15. 2-1. 8-6. 3 CCCAGGTGAGCTGGATCTTC 1482 SEQ ID NO : 1488-8. 1-28 79. 6-16. 9-3-7. 3 CACCCTCAGGGAAGCTCCAC 1741 SEQ ID NO : 1489-8. 1-29. 2 79-19. 5-1. 6-8. 2 GAGGAGTCCCAGCCATCACA 1898 SEQ ID NO : 1490-8. 1-29. 2 80. 7-20-1-7. 5 ATACCAGGCCTGCCATCCTG 2203 SEQ ID NO : 1491-8. 1-30. 3 80. 7-20. 2-1. 6-11. 7 AGTGAGCTGGGGAGCAGGAC 2294 SEQ ID NO : 1492-8. 1-27. 2 78. 9-17. 6-1. 4-5. 6 GCTAGTGATCAAACACGTCA 2637 SEQ ID NO : 1493-8. 1-22. 1 64. 7-12. 4-1. 6-6. 2 AAGTTCAACAAGAAAAGGCA 2878 SEQ ID NO : 1494-8. 1-17. 4 53. 8-8. 6-0. 5-4. 5 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo TTGTGTGTATTAATTCAAAT 2927 SEQ ID NO : 1495-8. 1-16. 3 53. 1-8. 2 0-4. 2 GTGTCACACTTCCTCCCGAA 3313 SEQ ID NO : 1496-8. 1-28 76. 5-19. 3-0. 3-5. 8 CAAAATCTGAAAATAATCTA 3585 SEQ ID NO : 1497-8. 1-12. 4 44-4. 3 0-2. 7 ATGCTTCATGTACACAACTA 3730 SEQ ID NO : 1498-8. 1-20. 7 62. 5-12. 6 0-6. 7 GGATGTACAGCCAATAATAT 3866 SEQ ID NO : 1499-8. 1-20. 1 59. 9-12 0-6. 4 AGAAGTGACCAGGATGTACA 3877 SEQ ID NO : 1500-8. 1-22. 2 65. 6-14. 1 0-6. 4 CGTCCTGAGCCGCCGGGAGG 16 SEQ ID NO : 1501-8-33. 3 83. 4-24. 1-1. 1-8. 7 GGCTTGCCCCAGAACGAGAT 43 SEQ ID NO : 1502-8-28. 6 75. 4-20-0. 3-6. 5 CTGGACCAAAAGGTACGGGG 315 SEQ ID NO : 1503-8-24. 2 66. 3-15. 7-0. 1-5. 2 TGATGAAAAAGGTTTTAGCT 498 SEQ ID NO : 1504-8-17. 5 54. 8-9. 5 0. 2-6. 8 AGAAAAATCGTCCTTCTCCT 710 SEQ ID NO : 1505-8-22. 2 63. 8-14. 2 0-3. 2 CGATCAAGTGGACATTCCCG 732 SEQ ID NO : 1506-8-25 68. 1-16. 1-0. 8-6. 1 AAACATGGGCCCGGCAGGAT 830 SEQ ID NO : 1507-8-28 73. 1-18. 4-0. 7-11. 2 GTGGCATTCTGCTCGATCCG 1417 SEQ ID NO : 1508-8-28 76. 9-18. 1-1. 9-8. 7 ACTCCTTCCACAGGTTGTAC 1521 SEQ ID NO : 1509-8-26. 1 75. 9-17. 2-0. 8-5. 4 GCGGGGTTGAGACAGGTAGC 1547 SEQ ID NO : 1510-8-27. 5 78. 4-19. 5 0. 3-3. 9 GCCTGGGGATATGCTGGTGT 1658 SEQ ID NO : 1511-8-28. 9 81. 2-20. 9 0-4. 9 CAGTCCCCTCCCGCGAGGAG 1912 SEQ ID NO : 1512-8-33. 4 84. 6-22. 7-2. 4-13. 2 CTTCGGAGCCAGCGTTCCTC 2101 SEQ ID NO : 1513-8-30. 1 81. 8-20. 6-1. 4-5. 2 CCAACAGCTAGGGCCCGAGC 2226 SEQ ID NO : 1514-8-30. 7 79. 9-21-0. 9-11. 5 AGTTATATCTGGCAACCGGC 2701 SEQ ID NO : 1515-8-25 70. 6-16. 3-0. 4-6. 9 CTCCAAAGCAGTTATATCTG 2710 SEQ ID NO : 1516-8-21. 1 63. 3-12. 6-0. 2-2 ATTAATAAAAGGGCTTAGGA 3242 SEQ ID NO : 1517-8-17. 4 54. 4-9. 4 0-3. 8 CATTATGTATATGCAAACAT 3607 SEQ ID NO : 1518-8-17. 1 53. 8-8. 4-0. 5-7. 2 ACTGACACATCAATGAATTT 3662 SEQ ID NO : 1519-8-18 55. 7-9. 3-0. 4-4. 8 GGATAAGGTGTAACTGACAC 3674 SEQ ID NO : 1520-8-20. 2 61. 2-10. 1-2. 1-5. 7 CTCACATAAGTTACCACAAA 3752 SEQ ID NO : 1521-8-19. 3 58-10. 8-0. 2-3. 8 AAAACTTTTTGAGCACCAAC 3794 SEQ ID NO : 1522-8-18. 9 56. 7-10. 4-0. 2-4. 6 GCGGTGGCAGGGAGCGAGTG 68 SEQ ID NO : 1523-7. 9-30. 1 81. 7-20. 6-1. 6-6. 6 613 GCCAGGGGGAGCCAGTCAAC-7. 9-30. 2 82. 7-21-1. 2-5. 1 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 1524 CACAAAATCTGCATCGTCCG 881 SEQ ID NO : 1525-7. 9-22. 9 63. 5-15 0-4. 9 CGTTGAGTCCACAGCCTGGC 999 SEQ ID NO : 1526-7. 9-29. 6 81. 1-20. 8-0. 8-8. 8 TTCACCAGAGAGTCAACAAA 1093 SEQ ID NO : 1527-7. 9-20. 4 60. 9-12. 5 0-4. 8 ATGCGCCTGATATTCAGCTC 1579 SEQ ID NO : 1528-7. 9-25. 9 73. 4-16. 4-1. 4-10. 6 TGGGGATATGCTGGTGTTCT 1655 SEQ ID NO : 1529-7. 9-25. 6 75. 2-17. 7 0-3. 6 GGGACTGGTTTCGTTTTTCA 1718 SEQ ID NO : 1530-7. 9-24. 6 72. 5-16. 7 0-3. 3 CAGTGGGACTGGTTTCGTTT 1722 SEQ ID NO : 1531-7. 9-25. 2 73. 6-16-1. 2-5. 4 TTTCCTCCATGGGCTTGGAT 1802 SEQ ID NO : 1532-7. 9-27. 6 77. 4-18. 6-1-8. 4 GTAACTTTCCTCCATGGGCT 1807 SEQ ID NO : 1533-7. 9-27 76. 2-18. 5-0. 2-8. 3 ATAGCAGCGCAGTCCCCTCC 1921 SEQ ID NO : 1534-7. 9-32. 2 85. 8-23. 4-0. 7-8. 5 ACACAAATCTGGACTTGGTG 2000 SEQ ID NO : 1535-7. 9-21. 1 62. 6-12. 7-0. 1-5. 6 CAACTGAGAAACCAATCCAG 2055 SEQ ID NO : 1536-7. 9-20. 2 58. 5-11. 6-0. 4-3. 6 CAGGCAGAGTACAGGCTCGC 2079 SEQ ID NO : 1537-7. 9-27. 7 78. 7-17. 2-2. 6-7. 4 TAGAAACCACTTAAAGCCTC 2558 SEQ ID NO : 1538-7. 9-20. 4 59. 9-12. 5 0-3. 2 TGGCAACCGGCCATCATTCT 2692 SEQ ID NO : 1539-7. 9-28. 2 75. 3-17. 1-3. 2-7. 8 CTTCCTCTCCTGCTTGGTGT 3329 SEQ ID NO : 1540-7. 9-29. 3 84. 4-20. 9-0. 1-4. 1 AATAAGACTCAACTGGTTAT 3437 SEQ ID NO : 1541-7. 9-17. 7 55. 6-9. 8 0-4. 7 CACATCAATGAATTTTGTGT 3657 SEQ ID NO : 1542-7. 9-18. 6 57. 5-9. 9-0. 6-7. 4 CTTCATGTACACAACTATTT 3727 SEQ ID NO : 1543-7. 9-19. 1 59. 1-11. 2 0-6. 2 TTTGAGCACCAACAAGACAA 3787 SEQ ID NO : 1544-7. 9-20. 5 59. 8-12. 1-0. 2-4. 4 AGTCAGAAGTGACCAGGATG 3881 SEQ ID NO : 1545-7. 9-22. 7 67. 4-12. 4-2. 4-6. 6 AAACAGAAGTCAGAAGTGAC 3888 SEQ ID NO : 1546-7. 9-17. 6 55. 4-7. 7-2-5. 6 CCCGGCCGGTAAGACCCTTC 158 SEQ ID NO : 1547-7. 8-32. 2 80. 5-21-0. 7-14. 9 CATCCTTCATGCTCTGGGTC 424 SEQ ID NO : 1548-7. 8-27. 2 79. 3-19. 4 0-4. 4 CTAAGGGCTGGCTGTGGCCG 456 SEQ ID NO : 1549-7. 8-29. 9 80. 2-18. 8-3. 3-11 ATCCGTGTAAAGCTGGTGGG 632 SEQ ID NO : 1550-7. 8-25. 4 71. 4-17. 6 0-5. 1 GAGAAAAATCGTCCTTCTCC 711 SEQ ID NO : 1551-7. 8-21. 9 63. 2-12. 7-1. 3-5. 4 TCATGCTCACATTTTACCAC 1057 SEQ ID NO : 1552-7. 8-22. 9 67. 4-14. 4-0. 4-4. 4 ATAAAGGGTGACGTAAAAGG 1352 SEQ ID NO : 1553-7. 8-17. 5 53. 7-9. 7 0-5. 3 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo TCAGCAGTAACTTTCCTCCA 1813 SEQ ID NO : 1554-7. 8-25. 5 73. 8-17. 7 0-4. 1 GGTCAGTGCAACCCATGAGA 2249 SEQ ID NO : 1555-7. 8-26. 6 74. 6-18. 3-0. 1-6. 4 ATTTGCTCAATTAAAAAATG 2353 SEQ ID NO : 1556-7. 8-13. 6 46. 4-5. 8 0-3. 6 ATCTGGCAACCGGCCATCAT 2695 SEQ ID NO : 1557-7. 8-28. 1 75-17-3. 3-8 GTGCCGGTTTCTGTGTACAC 2783 SEQ ID NO : 1558-7. 8-26. 9 77. 4-18. 2 0-9. 6 AGTTCAACAAGAAAAGGCAC 2877 SEQ ID NO : 1559-7. 8-18. 3 56-9. 8-0. 5-4. 8 TTTTGAAAAGTGTAAGTGTC 2954 SEQ ID NO : 1560-7. 8-17 55-9. 2 0-3. 7 CTTTGCCTCCAGGAAATCTG 3116 SEQ ID NO : 1561-7. 8-24. 6 69. 4-16-0. 6-5 TGTCACACTTCCTCCCGAAT 3312 SEQ ID NO : 1562-7. 8-26. 8 73. 2-19 0-2. 8 TGATACAACTTTGGCACGAT 3398 SEQ ID NO : 1563-7. 8-21. 1 61. 4-12. 6-0. 4-4 CCTGTACAAGCTTCGCTTTG 3516 SEQ ID NO : 1564-7. 8-24. 9 70. 6-15. 5-1. 5-7. 8 ATGTATATGCAAACATTCCA 3603 SEQ ID NO : 1565-7. 8-19. 8 59. 3-11. 3-0. 5-7 TATGTATATGCAAACATTCC 3604 SEQ ID NO : 1566-7. 8-18. 8 57. 6-10. 1-0. 7-7. 4 CTGACACATCAATGAATTTT 3661 SEQ ID NO : 1567-7. 8-17. 9 55. 5-9. 4-0. 4-4. 8 CTTTTTGAGCACCAACAAGA 3790 SEQ ID NO : 1568-7. 8-21. 4 62. 5-13. 6 2. 6-2. 6 GCGGAGGTTAAACCTCACAG 395 SEQ ID NO : 1569-7. 7-24. 3 68. 3-12. 3-4. 3-11. 9 TGCGGAGGTTAAACCTCACA 396 SEQ ID NO : 1570-7. 7-24. 3 67. 9-12. 3-4. 3-13. 2 GCATCCGTGTAAAGCTGGTG 634 SEQ ID NO : 1571-7. 7-25. 5 71. 7-17. 8 0-5. 1 CACCACCCTGGTATTATTGA 656 SEQ ID NO : 1572-7. 7-25. 3 70. 5-15. 9-1. 7-5. 7 TGTGTCCCACCACCCTGGTA 663 SEQ ID NO : 1573-7. 7-31. 6 84. 1-22. 2-1. 7-6. 3 TGCTGTGTCCCACCACCCTG 666 SEQ ID NO : 1574-7. 7-32. 2 84. 6-23. 7-0. 6-4. 3 CGAAGTTGCCTGCATACCCG 777 SEQ ID NO : 1575-7. 7-27. 9 72. 7-20. 2 0-5. 8 TGGAAGGCAAAACTCGGCTT 1120 SEQ ID NO : 1576-7. 7-23 64. 4-14. 6-0. 5-4 TGGTGGCATTCTGCTCGATC 1419 SEQ ID NO : 1577-7. 7-26. 4 76-17. 5-1. 1-7. 8 CGTTTTTCATCCTCCAGCCA 1707 SEQ ID NO : 1578-7. 7-28. 4 78-20. 7 0-3. 2 GACTGGTTTCGTTTTTCATC 1716 SEQ ID NO : 1579-7. 7-22. 6 68. 7-14. 9 0-3. 3 CCCTCAGGGAAGCTCCACAG 1739 SEQ ID NO : 1580-7. 7-29 78. 8-19. 7-1. 6-7. 7 TGGTGTCACACTTCCTCCCG 3315 SEQ ID NO : 1581-7. 7-29. 3 80-20. 4-1. 1-6. 7 GTGTTTAGGCTCGGGTCCTA 3641 SEQ ID NO : 1582-7. 7-28 80. 8-19. 6-0. 5-7. 9 3651 AATGAATTTTGTGTTTAGGC-7. 7-18. 8 58. 8-11. 1 0-3. 3 kcal/kcal/kcal/ mol mol, deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 1583 TAAAATTACCCTCAGGCTAT 3696 SEQ ID NO : 1584-7. 7-21. 2 61. 7-12. 9-0. 3-4. 9 GTACACAACTATTTAAAATA 3721 SEQ ID NO : 1585-7. 7-14. 3 48. 1-6. 6 0-5 GGCGGTGGCAGGGAGCGAGT 69 SEQ ID NO : 1586-7. 6-31. 3 84. 5-22. 1-1. 6-7. 2 GAGCAGAGGAACGGAGTTGC 257 SEQ ID NO : 1587-7. 6-24. 7 70. 8-15. 3-1. 8-7. 3 CTTCATGCTCTGGGTCCTTG 420 SEQ ID NO : 1588-7. 6-27. 1 78. 6-19. 5 0-4. 4 ATGATGAAAAAGGTTTTAGC 499 SEQ ID NO : 1589-7. 6-16. 6 53-8. 3-0. 4-4. 4 AATCGTCCTTCTCCTGCAGC 705 SEQ ID NO : 1590-7. 6-28 78. 5-19. 9 0-8. 1 GTCGGCCCCTTCAAACATGG 842 SEQ ID NO : 1591-7. 6-28. 2 74. 6-20. 6 0-6. 2 CCGGAGAGAGCCTCTTGTGG 864 SEQ ID NO : 1592-7. 6-28. 3 78. 1-19. 2-1. 4-8. 2 GGGGTAGATGTCAATGTGGC 962 SEQ ID NO : 1593-7. 6-24. 9 73. 4-17. 3 0-3. 8 TTTTTCATCCTCCAGCCATC 1705 SEQ ID NO : 1594-7. 6-26. 8 76. 6-19. 2 0-3. 2 CAGGGAAGCTCCACAGTGGG 1735 SEQ ID NO : 1595-7. 6-27. 3 76. 5-18. 1-1. 6-9. 5 AATTTTAAGTGTTCAATAGA 2374 SEQ ID No : 1596-7. 6-15. 8 52. 2-8. 2 0-2. 6 CAAATCTTTTGAAAAGTGTA 2960 SEQ ID NO : 1597-7. 6-15. 5 50. 7-7. 2-0. 5-5. 3 AAAAGTCTTCATGGAGTTTC 3145 SEQ ID NO : 1598-7. 6-19. 2 60. 3-10. 1-1. 4-6. 7 TTGAGCACCAACAAGACAAA 3786 SEQ ID NO : 1599-7. 6-19. 7 57. 7-12. 1 0-4. 5 CGTGAATGATGAAAAAGGTT 504 SEQ ID NO : 1600-7. 5-16. 8 52. 1-9. 3 0-1. 8 CCAGTTTTCAAAGATACCGC 536 SEQ ID NO : 1601-7. 5-23 65. 2-15. 5 0-2. 6 AGGATCCAAACCTGTGATTC 815 SEQ ID NO : 1602-7. 5-22. 9 66. 2-14. 6-0. 3-9 CTTACACACAAATCTGGACT 2005 SEQ ID NO : 1603-7. 5-20. 2 60. 3-12. 7 0-3 TGACATGAGTCAGCTCCTGT 2185 SEQ ID NO : 1604-7. 5-25. 6 75. 3-15. 9-2. 2-8. 6 CCCCAACAGCTAGGGCCCGA 2228 SEQ ID NO : 1605-7. 5-32. 9 81. 9-23. 7-1. 1-11. 3 GTAAGCAGTATGGTCAGTGC 2260 SEQ ID NO : 1606-7. 5-24. 1 73. 3-15. 9-0. 5-4. 1 TCCCAACTCCACTGGGTTCC 2437 SEQ ID NO : 1607-7. 5-29. 8 80. 5-20. 2-2. 1-6. 8 GAAATCCCAACTCCACTGGG 2441 SEQ ID NO : 1608-7. 5-25. 3 68. 7-16. 5-1. 2-5. 6 ATAGAAACCACTTAAAGCCT 2559 SEQ ID NO : 1609-7. 5-20 58. 6-12. 5 0-3. 2 TGATCAAACACGTCACTCAT 2632 SEQ ID NO : 1610-7. 5-20. 7 61. 1-13. 2 0-6 AATGATACTCTGCTTGCTAT 2660 SEQ ID NO : 1611-7. 5-21. 2 63. 9-13. 7 0-4. 5 GGTTTCTGTGTACACAGATG 2778 SEQ ID NO : 1612-7. 5-22. 4 68. 4-10. 3-2. 6-17. 3 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo AAAAGTGTAAGTGTCTCAGA 2949 SEQ ID NO : 1613-7. 5-18. 7 58. 9-11. 2 0-2. 5 TTGGTGGGAACTGGCTGCAA 3163 SEQ ID NO : 1614-7. 5-25. 6 71. 9-16. 7-1. 2-9. 6 ACAAAGAAAATCATTCTTCC 3344 SEQ ID NO : 1615-7. 5-17 53. 3-7-2. 5-6. 5 AAACAATGTCCTTAGAAAAC 3370 SEQ ID NO : 1616-7. 5-15. 8 50. 5-8. 3 0-4. 8 ACTATTTAAAATATCGTATA 3714 SEQ ID NO : 1617-7. 5-14. 1 47. 8-6. 6 0-5 CAGAAGTGACCAGGATGTAC 3878 SEQ ID NO : 1618-7. 5-22. 2 65. 6-14. 7 0-4 GCTTGCCCCAGAACGAGATC 42 SEQ ID NO : 1619-7. 4-27. 8 74. 6-20. 4 0-4. 1 GCAGGGAGCGAGTGTCAACG 62 SEQ ID NO : 1620-7. 4-26. 5 73. 4-17. 7-1. 3-4. 7 GCCACACCCCCTCCCAAGAA 225 SEQ ID NO : 1621-7. 4-32. 8 80. 9-25. 4 0-2 CCGCCACACCCCCTCCCAAG 227 SEQ ID NO : 1622-7. 4-35. 7 84. 5-28. 3 0-2. 6 CCTCACAGATGGTTTGACCT 383 SEQ ID NO : 1623-7. 4-25. 8 73. 2-17-1. 3-5. 1 GTGAATGATGAAAAAGGTTT 503 SEQ ID NO : 1624-7. 4-16. 1 51. 5-8. 7 0-2. 3 ATCGTCCTTCTCCTGCAGCC 704 SEQ ID NO : 1625-7. 4-30. 7 84. 7-22. 8 0-8. 1 TACCCGGCCACGTGCGCTCC 763 SEQ ID NO : 1626-7. 4-34. 3 84. 2-25-1. 3-11. 7 TGCCTGCATACCCGGCCACG 771 SEQ ID NO : 1627-7. 4-32. 6 80. 6-23. 7-1. 4-8 GAAGGCAAAACTCGGCTTGT 1118 SEQ ID NO : 1628-7. 4-23 64. 9-14. 9-0. 5-4 GGCATTCTGCTCGATCCGCT 1415 SEQ ID NO : 1629-7. 4-29. 5 79. 8-19. 6-2. 5-8. 7 CTCAGCAGTAACTTTCCTCC 1814 SEQ ID NO : 1630-7. 4-25. 7 74. 6-18. 3 0-4. 1 GGACTTGGTGCTCTGGAGGT 1990 SEQ ID NO : 1631-7. 4-27. 6 80. 6-20. 2 0-6. 4 GCCCAGCAACTGAGAAACCA 2061 SEQ ID NO : 1632-7. 4-26. 1 69. 9-18. 1-0. 3-4. 3 CGCCCAGCAACTGAGAAACC 2062 SEQ ID NO : 1633-7. 4-26. 2 68. 9-18. 1-0. 4-4. 3 CTGACATGAGTCAGCTCCTG 2186 SEQ ID NO : 1634-7. 4-25. 3 73. 7-14. 6-3. 3-8. 2 AGGCCTGCCATCCTGACATG 2198 SEQ ID NO : 1635-7. 4-29. 2 78. 9-21. 1-0. 3-8. 2 CCCAGGTGCCTTTCCCCATG 2499 SEQ ID NO : 1636-7. 4-33. 1 85. 3-25. 7 0-6. 6 GAAACCACTTAAAGCCTCAG 2556 SEQ ID NO : 1637-7. 4-21. 4 61. 5-14 0-3. 2 CTTCTATCTCTCTAAACAGA 2739 SEQ ID NO : 1638-7. 4-19. 7 61. 4-12. 3 0-2. 5 ATTACATATGTCATAACTTC 2755 SEQ ID NO : 1639-7. 4-17. 3 55. 7-9. 4 0-8. 2 TTCAACAAGAAAAGGCACTG 2875 SEQ ID NO : 1640-7. 4-18 54. 9-8. 2-2. 4-5. 4 AGTGATACAACTTTGGCACG 3400 SEQ ID NO : 1641-7. 4-21. 7 63. 3-13. 2-1-6. 2 3488 GCAATCACAGAAACAAGAGA-7. 4-18. 4 56-11 0-3. 4 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 1642 TGTTTAGGCTCGGGTCCTAT 3640 SEQ ID NO : 1643-7. 4-26. 8 77. 1-18. 3-1-8. 5 AAAACCCCTCACATAAGTTA 3759 SEQ ID NO : 1644-7. 4-21 60. 4-13. 6 0-3. 5 GCCCCAGAACGAGATCTGCC 38 SEQ ID NO : 1645-7. 3-29. 7 77. 5-21-1. 3-6. 3 ACCCTTCTCTCGGCCAGGGG 145 SEQ ID NO : 1646-7. 3-32. 3 85. 9-22. 9-2. 1-10. 5 GATGAAAAAGGTTTTAGCTG 497 SEQ ID NO : 1647-7. 3-17. 5 54. 8-9. 5-0. 4-8. 1 CCGCATCCGTGTAAAGCTGG 636 SEQ ID NO : 1648-7. 3-27. 1 72-19. 3-0. 2-5. 3 CCGAGAGAAAAATCGTCCTT 715 SEQ ID NO : 1649-7. 3-21. 6 60. 7-13. 4-0. 7-3. 9 TGCTCAAGCCGAAGGAACGC 921 SEQ ID NO : 1650-7. 3-25. 5 68. 4-16. 6-1. 5-6. 3 CCCAAGACATCGTTGAGTCC 1009 SEQ ID NO : 1651-7. 3-26. 2 72. 4-18. 9 0. 1-4. 4 GATGCGCCTGATATTCAGCT 1580 SEQ ID NO : 1652-7. 3-26. 1 73. 1-17. 2-1. 4-10. 6 CTGGGGATATGCTGGTGTTC 1656 SEQ ID NO : 1653-7. 3-25. 6 75. 2-18. 3 0-3. 6 TATAGCAGCGCAGTCCCCTC 1922 SEQ ID NO : 1654-7. 3-29. 9 81. 9-21. 7-0. 7-8. 5 CAGGCCTGCCATCCTGACAT 2199 SEQ ID NO : 1655-7. 3-29. 9 80. 1-20. 7-1. 5-11. 5 TCAGTGCAACCCATGAGAAC 2247 SEQ ID NO : 1656-7. 3-23. 7 67. 2-15. 9-0. 2-5. 4 ATAGGAAAGCCAATGATGTG 2324 SEQ ID NO : 1657-7. 3-19. 7 58. 7-11. 2-1. 1-3. 5 CCCAGCATGAATGATACTCT 2669 SEQ ID NO : 1658-7. 3-23. 8 67. 4-16. 5 0-4. 6 AACTAGTATATAAGTCTAGG 3072 SEQ ID NO : 1659-7. 3-17. 1 55. 7-8. 6-1. 1-6. 3 TTCAGAGATAGACTTTGCCT 3128 SEQ ID NO : 1660-7. 3-22. 7 67. 9-14. 9-0. 1-3. 8 CTCTCCTGCTTGGTGTCACA 3325 SEQ ID NO : 1661-7. 3-27. 9 81-20. 1-0. 1-5 CAAAGAAAATCATTCTTCCT 3343 SEQ ID NO : 1662-7. 3-17. 7 54. 6-7. 9-2. 5-6. 5 CAAAACTTTTTGAGCACCAA 3795 SEQ ID NO : 1663-7. 3-19. 4 57. 4-11. 4-0. 5-6. 5 CGGCTTGCCCCAGAACGAGA 44 SEQ ID NO : 1664-7. 2-29. 4 75. 2-21. 3-0. 8-7. 1 TTTGGGTTTGTGGAGCTTAT 350 SEQ ID NO : 1665-7. 2-23. 5 70. 7-16. 3 0-5. 2 GCTGGCTGTGGCCGACGGAG 450 SEQ ID NO : 1666-7. 2-31 81. 6-20. 5-3. 3-8. 4 CCGTGAATGATGAAAAAGGT 505 SEQ ID NO : 1667-7. 2-18. 7 55. 2-11. 5 0-3 GGCCAGGGGGAGCCAGTCAA 614 SEQ ID NO : 1668-7. 2-31. 2 84. 6-22. 3-1. 7-8. 6 AAGCTGGTGGGCCAGGGGGA 623 SEQ ID NO : 1669-7. 2-30. 7 83. 6-20. 3-3. 2-9. 4 CACGAAGTTGCCTGCATACC 779 SEQ ID NO : 1670-7. 2-26 71-18. 1-0. 4-6. 8 GATCCCAAGACATCGTTGAG 1012 SEQ ID NO : 1671-7. 2-23. 6 67-16. 4 0-3. 8 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo GGATTTTCATCTGATAATGG 1293 SEQ ID NO : 1672-7. 2-19. 3 59. 6-11. 2-0. 7-4. 5 GGTGTTGGTGGCATTCTGCT 1424 SEQ ID NO : 1673-7. 2-27. 9 81. 7-18. 8-1. 9-5. 6 TGCGCCTGATATTCAGCTCC 1578 SEQ ID NO : 1674-7. 2-27. 9 77-19. 1-1. 3-10. 6 GTTTCGTTTTTCATCCTCCA 1711 SEQ ID NO : 1675-7. 2-25. 7 74. 6-18. 5 0-3 CCTTGCTGGCAAGACTTGCC 1765 SEQ ID NO : 1676-7. 2-28. 3 77. 3-17. 3-3. 8-12. 9 GTCCTCAGCAGTAACTTTCC 1817 SEQ ID NO : 1677-7. 2-26 76. 2-18. 8 0-4. 1 GGCTCGCCCAGCAACTGAGA 2066 SEQ ID NO : 1678-7. 2-29. 7 79-20. 4-2. 1-6. 9 GGAAAGCCAATGATGTGTGC 2321 SEQ ID NO : 1679-7. 2-23 65. 8-15. 2-0. 3-3. 4 GATCAAACACGTCACTCATA 2631 SEQ ID NO : 1680-7. 2-20. 4 60. 6-13. 2 0-4. 7 AAGTGTAAGTGTCTCAGATA 2947 SEQ ID NO : 1681-7. 2-19. 8 62. 6-12. 6 0-3. 3 CTAGGCATGTGGCTGAACCT 3057 SEQ ID NO : 1682-7. 2-26. 4 74. 1-17. 9-1. 2-8. 3 TAATAAAAGGGCTTAGGATT 3240 SEQ ID NO : 1683-7. 2-17. 4 54. 4-10. 2 0-3. 8 GGCACAGATGTTCTCCTGGT 3267 SEQ ID NO : 1684-7. 2-27. 5 79. 6-19. 5-0. 6-5 CAGAAGTTTAACAGTGATAC 3412 SEQ ID NO : 1685-7. 2-17. 6 56-10. 4 0-4. 6 AATCTGAAAATAATCTAAAA 3582 SEQ ID NO : 1686-7. 2-11 41. 5-3. 8 0-3. 2 AAATCTGAAAATAATCTAAA 3583 SEQ ID NO : 1687-7. 2-11 41. 5-3. 8 0-3. 2 TGCCCTCGTCCTGAGCCGCC 22 SEQ ID NO : 1688-7. 1-35. 4 88. 9-26. 8-1. 4-5. 4 AACGGCTTGCCCCAGAACGA 46 SEQ ID NO : 1689-7. 1-28. 3 72. 3-20. 3-0. 8-7. 1 TGTGTAGCTTTGGGTTTGTG 358 SEQ ID NO : 1690-7. 1-24 73-16. 9 0-4. 3 GCATCCTTCATGCTCTGGGT 425 SEQ ID NO : 1691-7. 1-28. 6 82-19. 4-2. 1-5. 7 ATTGTAGCCAATGCTATTAC 1199 SEQ ID NO : 1692-7. 1-21. 2 63. 5-12-2. 1-8. 5 TGGGTTTCCCCAGACTTCAC 1603 SEQ ID NO : 1693-7. 1-28 78. 4-18. 3-2. 6-7. 6 AGGCAGCAAGAGCTATAGCA 1935 SEQ ID NO : 1694-7. 1-24. 7 71. 9-14. 9-2. 7-11 AATGGCTAAGACGTAAGCAG 2272 SEQ ID NO : 1695-7. 1-20. 5 60. 4-11. 6-1. 8-8. 2 AGCTGGGGAGCAGGACGGAA 2290 SEQ ID NO : 1696-7. 1-27. 3 75-18. 6-1. 6-6. 4 AATGATGTGTGCTTCAGAGA 2313 SEQ ID NO : 1697-7. 1-21. 4 65-14. 3 0-3. 7 TAAGTGTTCAATAGACATTT 2369 SEQ ID NO : 1698-7. 1-17. 3 55. 6-10. 2 0-3. 3 GGTCCCTAATGCTTATATCC 2536 SEQ ID NO : 1699-7. 1-25. 3 72-18. 2 0-3. 6 GTTCAACAAGAAAAGGCACT 2876 SEQ ID NO : 1700-7. 1-19. 2 57. 7-11. 1-0. 9-4. 8 3311 GTCACACTTCCTCCCGAATC-7. 1-27. 2 74. 9-20. 1 0-2. 8 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 1701 GATGTACAGCCAATAATATG 3865 SEQ ID NO : 1702-7. 1-18. 9 57. 4-11. 8 0-6. 7 ACGGCTTGCCCCAGAACGAG 45 SEQ ID NO : 1703-7-29 74. 6-21. 1-0. 8-7. 1 CAACGGCTTGCCCCAGAACG 47 SEQ ID NO : 1704-7-28. 4 72. 1-20. 5-0. 8-7. 1 TTTGTGCAGCCAGTTTTCAA 545 SEQ ID NO : 1705-7-24. 3 71. 3-17. 3 0-5. 3 CGGCCCCTTCAAACATGGGC 840 SEQ ID NO : 1706-7-29. 6 76. 2-19. 7-2. 9-9 TCCACAGCCTGGCTGGAAGT 992 SEQ ID NO : 1707-7-28. 9 79. 6-18. 3-2. 9-15. 1 CTGGAAGGCAAAACTCGGCT 1121 SEQ ID NO : 1708-7-23. 8 65. 8-16. 1-0. 5-4 ACTCTGAAAGGCATGCCTGC 1270 SEQ ID NO : 1709-7-25. 8 72. 3-15. 5-1. 4-14. 8 TCTCCCATGTTCTTGTAACT 1321 SEQ ID NO : 1710-7-24. 4 71. 6-16. 4-0. 9-3. 8 AGGAAGGTGTTGGTGGCATT 1429 SEQ ID NO : 1711-7-25 73. 3-18 0-4 GGGGTTGAGACAGGTAGCTG 1545 SEQ ID NO : 1712-7-25. 8 76-17. 4-1. 3-3. 2 TTCCCCAGACTTCACCCGGA 1598 SEQ ID NO : 1713-7-30. 9 79. 9-23. 9 0-6. 4 CATGGGCTTGGATAGCAGGA 1795 SEQ ID NO : 1714-7-25. 7 73. 5-17. 2-1. 4-7. 3 AGTAACTTTCCTCCATGGGC 1808 SEQ ID NO : 1715-7-26. 1 74. 6-18. 5-0. 2-8. 3 AAAGCCAATGATGTGTGCTT 2319 SEQ ID NO : 1716-7-22. 2 64. 2-13. 5-1. 7-6. 2 TGGCTCTATATAAAAAAAAA 3213 SEQ ID NO : 1717-7-12. 7 44. 5-5. 7 0-3. 7 AAGTCCAACCGTTGGCACAG 3280 SEQ ID NO : 1718-7-25. 8 70. 8-16. 2-2. 6-11. 5 TCCTCCCGAATCTCAGCCAT 3303 SEQ ID NO : 1719-7-29. 3 77. 9-22. 3 0-3. 2 CTGCTTGGTGTCACACTTCC 3320 SEQ ID NO : 1720-7-26. 9 78. 1-18. 7-1. 1-6. 7 CGGTGGCAGGGAGCGAGTGT 67 SEQ ID NO : 1721-6. 9-29. 5 80. 9-21. 7-0. 8-4. 3 CTCCCCGCAGCAAAGCAATA 295 SEQ ID NO : 1722-6. 9-27. 2 71. 3-19. 4-0. 7-4. 9 ACCTCAGTCTGTGTAGCTTT 367 SEQ ID NO : 1723-6. 9-25. 7 77. 5-18. 8 0-4. 6 TTCCTTTCACGAAGTTGCCT 786 SEQ ID NO : 1724-6. 9-25. 6 72-18-0. 4-3. 8 CAGGATCCAAACCTGTGATT 816 SEQ ID NO : 1725-6. 9-23. 2 65. 9-14. 6-1. 7-9 GTCTGGGAATCTGCATTAGT 1375 SEQ ID NO : 1726-6. 9-23. 6 70. 7-16. 7 0-4. 9 ATCCTCCAGCCATCCCGACA 1699 SEQ ID NO : 1727-6. 9-31. 6 81. 6-24. 7 0-3. 2 TTCCTCCATGGGCTTGGATA 1801 SEQ ID NO : 1728-6. 9-27. 2 76. 4-19-1. 2-8. 4 GTCCCCTCCCGCGAGGAGTC 1910 SEQ ID NO : 1729-6. 9-34. 3 88. 6-24. 7-2. 4-13. 1 TCTACACAGGGCCTCTTCGG 2115 SEQ ID NO : 1730-6. 9-27. 7 77. 6-20. 8 0-7. 3 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo ACTGAGGCTCAAAGCAGGCT 2151 SEQ ID NO : 1731-6. 9-25. 7 73. 3-16. 8-2-6. 9 TACCAGGCCTGCCATCCTGA 2202 SEQ ID NO : 1732-6. 9-30. 9 82-21. 8-2-11. 9 CATGAATGATACTCTGCTTG 2664 SEQ ID NO : 1733-6. 9-20. 1 60. 8-13. 2 0-3. 7 TTGGCACAGATGTTCTCCTG 3269 SEQ ID NO : 1734-6. 9-25. 2 73. 5-17. 5-0. 6-6. 1 TCTCCTGCTTGGTGTCACAC 3324 SEQ ID NO : 1735-6. 9-27. 2 79. 5-19. 7-0. 3-6. 6 TAACAGTGATACAACTTTGG 3404 SEQ ID NO : 1736-6. 9-18. 1 56. 3-11. 2 0-4. 6 CTTCGCTTTGGCTAGAAAGC 3506 SEQ ID NO : 1737-6. 9-23. 7 68. 2-14. 6-2. 2-9. 6 TATCTCATTATGTATATGCA 3612 SEQ ID NO : 1738-6. 9-19 59. 9-12. 1 0-5. 8 ATCAATGAATTTTGTGTTTA 3654 SEQ ID NO : 1739-6. 9-16. 9 54. 5-10 0-4. 8 GCTATGTGGATAAGGTGTAA 3681 SEQ ID NO : 1740-6. 9-21 63. 6-14. 1 0-2. 8 ACAACTATTTAAAATATCGT 3717 SEQ ID NO : 1741-6. 9-14. 9 49-8 0-5 TGTACACAACTATTTAAAAT 3722 SEQ ID NO : 1742-6. 9-14. 6 48. 6-7. 7 0-5. 9 GTGACCAGGATGTACAGCCA 3873 SEQ ID NO : 1743-6. 9-26. 8 75. 4-19. 3-0. 3-7. 1 CCATTAGTAAAAACAGAAGT 3898 SEQ ID NO : 1744-6. 9-16. 6 52. 3-9. 7 0-3. 9 GAACGAGATCTGCCCTCGTC 32 SEQ ID NO : 1745-6. 8-26. 9 73. 5-16. 7-3. 4-9. 2 CTCATCCTGCCCCGCCACAC 238 SEQ ID NO : 1746-6. 8-33. 5 84. 6-26. 7 0-3 TCTGGACCAAAAGGTACGGG 316 SEQ ID NO : 1747-6. 8-23. 4 65. 3-16. 6 0. 4-5. 2 ATGCTCTGGGTCCTTGGAGG 416 SEQ ID NO : 1748-6. 8-28 80. 4-20. 6-0. 3-5. 2 AAAAATCGTCCTTCTCCTGC 708 SEQ ID NO : 1749-6. 8-23. 4 66. 1-16. 6 0-3 TCCTTTCACGAAGTTGCCTG 785 SEQ ID NO : 1750-6. 8-25. 5 71. 5-18-0. 4-3. 8 GGGTAGATGTCAATGTGGCC 961 SEQ ID NO : 1751-6. 8-25. 7 74. 4-18. 9 0-6. 2 GCCTGATATTCAGCTCCCGT 1575 SEQ ID NO : 1752-6. 8-29. 3 79. 8-21-1. 4-6. 2 CTTGCTGGCAAGACTTGCCC 1764 SEQ ID NO : 1753-6. 8-28. 3 77. 3-17. 3-4. 2-13. 3 TAACTTTCCTCCATGGGCTT 1806 SEQ ID NO : 1754-6. 8-25. 9 73. 2-18. 5-0. 2-8. 3 CCGCGAGGAGTCCCAGCCAT 1902 SEQ ID NO : 1755-6. 8-32. 6 82. 9-24. 7-1-8. 5 CCAATGATGTGTGCTTCAGA 2315 SEQ ID NO : 1756-6. 8-23. 5 68. 4-16. 7 0-3. 7 TTAATTTTAAGTGTTCAATA 2376 SEQ ID NO : 1757-6. 8-15 50. 5-8. 2 0-2. 7 ACTGGGTTCCAAATGGAGAG 2427 SEQ ID NO : 1758-6. 8-22. 9 66. 4-15. 5-0. 3-7. 5 AGTGTAAGTGTCTCAGATAT 2946 SEQ ID NO : 1759-6. 8-20. 5 65-13. 7 0-3. 3 2953 TTTGAAAAGTGTAAGTGTCT-6. 8-17. 8 56. 6-11 0-2. 3 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 1760 GTCTAGGCATGTGGCTGAAC 3059 SEQ ID NO : 1761-6. 8-25. 1 73. 6-17-1. 2-5. 6 CTCCAGGAAATCTGAGTCCT 3110 SEQ ID NO : 1762-6. 8-24. 8 71. 1-16. 9-1-7. 2 TTTGTGTTTAGGCTCGGGTC 3644 SEQ ID NO : 1763-6. 8-25. 6 76. 2-18. 8 0-4. 3 GAAAACCCCTCACATAAGTT 3760 SEQ ID NO : 1764-6. 8-21. 9 62-15. 1 0-3. 1 TGAGCACCAACAAGACAAAA 3785 SEQ ID NO : 1765-6. 8-18. 9 55. 7-12. 1 0-4. 1 AAGACCCTTCTCTCGGCCAG 148 SEQ ID NO : 1766-6. 7-28. 6 77. 5-21. 4-0. 2-7. 4 CTGACACGAGTTTGTGCAGC 555 SEQ ID NO : 1767-6. 7-24. 9 71. 8-15. 3-2. 9-7. 4 TCGTCCTTCTCCTGCAGCCA 703 SEQ ID NO : 1768-6. 7-31. 4 85. 7-24. 2 0-8. 1 TTGCCTGCATACCCGGCCAC 772 SEQ ID NO : 1769-6. 7-31. 9 81. 4-23. 7-1. 4-8 ACATGGGCCCGGCAGGATCC 828 SEQ ID NO : 1770-6. 7-31. 8 82. 6-23. 5-0. 7-11. 2 CTCGGTGTAGACCAGGAAGG 1442 SEQ ID NO : 1771-6. 7-25. 2 71. 5-16. 7-1. 8-3. 1 TCCCAGGTGAGCTGGATCTT 1483 SEQ ID NO : 1772-6. 7-28 79. 6-18. 3-3-7. 3 GGCCCCCTCCCAGGTGAGCT 1490 SEQ ID NO : 1773-6. 7-36. 7 94. 1-28. 8-1. 1-8. 1 TGGGACTGGTTTCGTTTTTC 1719 SEQ ID NO : 1774-6. 7-23. 9 71. 1-17. 2 0-3. 3 CCCAGCAACTGAGAAACCAA 2060 SEQ ID NO : 1775-6. 7-23. 6 64. 2-16. 3-0. 3-4. 3 TGAGGCTCAAAGCAGGCTGA 2149 SEQ ID NO : 1776-6. 7-25. 2 71. 9-16. 5-2-7 CAGCTAGGGCCCGAGCAAGA 2222 SEQ ID NO : 1777-6. 7-29. 1 77. 6-20-1. 7-12. 8 CAATGATGTGTGCTTCAGAG 2314 SEQ ID NO : 1778-6. 7-21. 5 64. 9-14. 8 0-3. 7 TAATTTTAAGTGTTCAATAG 2375 SEQ ID NO : 1779-6. 7-14. 9 50. 3-8. 2 0-2. 7 AATCTTTTGAAAAGTGTAAG 2958 SEQ ID NO : 1780-6. 7-14. 8 49. 5-7. 2-0. 8-5. 9 TAAGTCTAGGCATGTGGCTG 3062 SEQ ID NO : 1781-6. 7-24 71. 3-16-1. 2-6. 1 ATAAAAGGGCTTAGGATTTT 3238 SEQ ID NO : 1782-6. 7-18. 6 57. 4-11. 9 0-3. 8 TCCTGCTTGGTGTCACACTT 3322 SEQ ID NO : 1783-6. 7-26. 9 78. 1-19-1. 1-6. 7 CATATCTTGAAATAAGACTC 3447 SEQ ID NO : 1784-6. 7-16. 1 52. 3-8-1. 3-4 ATAAAATTACCCTCAGGCTA 3697 SEQ ID NO : 1785-6. 7-21. 2 61. 7-13. 9-0. 3-4. 9 TTCATGTACACAACTATTTA 3726 SEQ ID NO : 1786-6. 7-17. 9 56. 6-11. 2 0-6. 7 GTTACCACAAACCATGCTTC 3743 SEQ ID NO : 1787-6. 7-23. 5 66. 8-16. 8 0-4. 2 AAACCCCTCACATAAGTTAC 3758 SEQ ID NO : 1788-6. 7-21. 9 62. 7-15. 2 0-3. 8 CTTTGGGTTTGTGGAGCTTA 351 SEQ ID NO : 1789-6. 6-24. 4 72. 8-17. 8 0-5. 2 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo GATGGTTTGACCTCAGTCTG 376 SEQ ID NO : 1790-6. 6-24. 5 72. 7-16. 3-1. 6-5. 5 AGTTTGTGCAGCCAGTTTTC 547 SEQ ID NO : 1791-6. 6-25. 5 76. 7-18. 9 0-5. 3 ACGAAGTTGCCTGCATACCC 778 SEQ ID NO : 1792-6. 6-27. 3 73. 3-20. 2-0. 2-6. 8 AAGACATCGTTGAGTCCACA 1006 SEQ ID NO : 1793-6. 6-23. 1 66. 9-15. 6-0. 7-4. 4 TCCCAAGACATCGTTGAGTC 1010 SEQ ID NO : 1794-6. 6-24. 6 70. 4-17. 4-0. 3-4. 4 TTGTAGCCAATGCTATTACA 1198 SEQ ID NO : 1795-6. 6-21. 9 64. 7-13. 2-2. 1-8. 5 CAGGTGCCTTTCCCCATGCA 2497 SEQ ID NO : 1796-6. 6-31. 6 84-24. 3-0. 5-6. 6 CCTAATGCTTATATCCTATA 2532 SEQ ID NO : 1797-6. 6-20. 8 61. 9-14. 2 0-3. 6 ATCATTCTGGCCCCAGCATG 2680 SEQ ID NO : 1798-6. 6-28. 7 78. 4-20. 5-1. 5-7. 8 ACTTTGCCTCCAGGAAATCT 3117 SEQ ID NO : 1799-6. 6-24. 8 70. 1-18. 2 0-5 GATAGACTTTGCCTCCAGGA 3122 SEQ ID NO : 1800-6. 6-25. 8 73. 6-19. 2 0-4. 7 CACACTTCCTCCCGAATCTC 3309 SEQ ID NO : 1801-6. 6-26. 9 73. 5-20. 3 0-2. 8 AACAATGTCCTTAGAAAACC 3369 SEQ ID NO : 1802-6. 6-18. 5 55. 6-11. 9 0-4. 8 AAAACAATGTCCTTAGAAAA 3371 SEQ ID NO : 1803-6. 6-14. 9 48. 5-8. 3 0-4. 8 CAGTGATACAACTTTGGCAC 3401 SEQ ID NO : 1804-6. 6-21. 6 64. 1-15 0-4. 9 CTCATTATGTATATGCAAAC 3609 SEQ ID NO : 1805-6. 6-17. 7 55. 7-11. 1 0-6. 2 ACATCAATGAATTTTGTGTT 3656 SEQ ID NO : 1806-6. 6-18 56. 6-10. 8-0. 3-5. 5 ATAAGGTGTAACTGACACAT 3672 SEQ ID NO : 1807-6. 6-19. 1 58. 6-10. 1-2. 4-6. 4 CTATTTAAAATATCGTATAA 3713 SEQ ID NO : 1808-6. 6-13. 2 45. 8-6. 6 0-5 CCGGCCGGTAAGACCCTTCT 157 SEQ ID NO : 1809-6. 5-31. 1 79. 2-21. 4-0. 7-14. 6 AATCCCGGCCGGTAAGACCC 161 SEQ ID NO : 1810-6. 5-30. 5 76. 3-21-0. 7-14. 2 CCTCAGTCTGTGTAGCTTTG 366 SEQ ID NO : 1811-6. 5-25. 5 76. 6-19 0-4. 6 CGGAGGTTAAACCTCACAGA 394 SEQ ID NO : 1812-6. 5-23. 1 65. 5-12. 3-4. 3-11. 9 GTAGGTGTGGAGGACATCCA 899 SEQ ID NO : 1813-6. 5-26. 1 76. 2-17. 4-2. 2-6. 9 AGACATCGTTGAGTCCACAG 1005 SEQ ID NO : 1814-6. 5-23. 8 69. 5-16. 4-0. 7-4. 4 TGGCATTCTGCTCGATCCGC 1416 SEQ ID NO : 1815-6. 5-28. 6 77. 7-19. 6-2. 5-8. 7 GCTCCCGGCCTGGGGATATG 1665 SEQ ID NO : 1816-6. 5-31. 7 82. 6-22. 8-2. 1-12. 4 TCCACAGTGGGACTGGTTTC 1726 SEQ ID NO : 1817-6. 5-26. 3 76. 8-17. 7-2. 1-9. 3 GTGCTCTGGAGGTGTGGACA 1983 SEQ ID NO : 1818-6. 5-27. 3 80-20. 2-0. 3-6. 4 2352 TTTGCTCAATTAAAAAATGA-6. 5-14. 2 47. 5-7. 7 0-3. 6 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 1819 TGGGTTCCAAATGGAGAGGC 2425 SEQ ID NO : 1820-6. 5-24. 8 70. 6-17. 8-0. 2-7. 2 TATGTCATAACTTCTATCTC 2749 SEQ ID NO : 1821-6. 5-18. 9 60. 4-12. 4 0-3. 1 TTCAAATCAAGATCTAGAAT 2914 SEQ ID NO : 1822-6. 5-15. 7 51. 3-9. 2 0-6. 6 ATTCAAATCAAGATCTAGAA 2915 SEQ ID NO : 1823-6. 5-15. 7 51. 3-9. 2 0-6. 6 TTTCAGAGATAGACTTTGCC 3129 SEQ ID NO : 1824-6. 5-21. 9 66. 3-14. 9-0. 1-3. 8 AAAAGTCCTTGTTTGTCTCA 3196 SEQ ID NO : 1825-6. 5-21. 5 65. 1-15 0-3. 2 TAAAACAATGTCCTTAGAAA 3372 SEQ ID NO : 1826-6. 5-15. 3 49. 5-8. 8 0-4. 8 GATACAACTTTGGCACGATA 3397 SEQ ID NO : 1827-6. 5-20. 8 61-13. 6-0. 4-4 ACTTCTGGTTCCAAGCATTT 3554 SEQ ID NO : 1828-6. 5-24. 1 70. 7-17. 6 0-4. 8 TACACAACTATTTAAAATAT 3720 SEQ ID NO : 1829-6. 5-13. 1 45. 6-6. 6 0-5 GACCTCAGTCTGTGTAGCTT 368 SEQ ID NO : 1830-6. 4-26. 2 78. 6-18. 8-0. 9-6. 4 CCGTGTAAAGCTGGTGGGCC 630 SEQ ID NO : 1831-6. 4-28. 8 77. 4-21. 5-0. 8-6. 4 CCTTCTCCTGCAGCCAGTCG 699 SEQ ID NO : 1832-6. 4-31 84. 2-23. 7-0. 8-8. 1 ACGTGCGCTCCGAGGCTGTA 754 SEQ ID NO : 1833-6. 4-30. 1 79. 7-22. 8-0. 6-9. 3 AGTCCACAGCCTGGCTGGAA 994 SEQ ID NO : 1834-6. 4-28. 9 79. 6-18. 9-2. 9-15. 1 ATGCAATTGATCCCAAGACA 1020 SEQ ID NO : 1835-6. 4-22. 4 63. 7-15. 3-0. 5-7. 6 CAGGAAGGTGTTGGTGGCAT 1430 SEQ ID NO : 1836-6. 4-25. 6 74. 1-19. 2 0-4 GGGTTTCCCCAGACTTCACC 1602 SEQ ID NO : 1837-6. 4-30 82. 1-21. 7-1. 9-6. 4 CCCGCGAGGAGTCCCAGCCA 1903 SEQ ID NO : 1838-6. 4-34. 6 86-26. 8-1. 3-8. 9 AGAGTACAGGCTCGCCCAGC 2074 SEQ ID NO : 1839-6. 4-29. 8 82. 1-21. 2-2. 2-7. 3 TTCTACACAGGGCCTCTTCG 2116 SEQ ID NO : 1840-6. 4-26. 6 75. 4-20. 2 0-7. 3 GACATGAGTCAGCTCCTGTC 2184 SEQ ID NO : 1841-6. 4-26 77. 3-16. 7-2. 9-8. 6 GCAGGACGGAATGGCTAAGA 2281 SEQ ID NO : 1842-6. 4-23. 9 67-17. 5 0-3. 9 ATTAATTTTAAGTGTTCAAT 2377 SEQ ID NO : 1843-6. 4-15. 3 51-8. 9 0-3. 8 TGCTTATATCCTATAGCCTC 2527 SEQ ID NO : 1844-6. 4-24 70. 7-16. 9-0. 5-5 CCCTAATGCTTATATCCTAT 2533 SEQ ID NO : 1845-6. 4-23. 1 66. 1-16. 7 0-3. 6 ATCAAACACGTCACTCATAG 2630 SEQ ID NO : 1846-6. 4-19. 8 59. 6-13. 4 0-4. 6 TATCTGGCAACCGGCCATCA 2696 SEQ ID NO : 1847-6. 4-27. 8 74. 5-18. 1-3. 3-8. 8 AGTTTCAGAGATAGACTTTG 3131 SEQ ID NO : 1848-6. 4-19. 3 61. 4-12. 9 0-4 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo AAAAAAGTCCTTGTTTGTCT 3198 SEQ ID No : 1849-6. 4-19 58. 3-12. 6 0-3. 9 ATAAGACTCAACTGGTTATG 3436 SEQ ID NO : 1850-6. 4-18. 4 57. 4-12 0-4. 7 CTTCTGGTTCCAAGCATTTT 3553 SEQ ID NO : 1851-6. 4-24 70. 5-17. 6 0-5 GATAAGGTGTAACTGACACA 3673 SEQ ID NO : 1852-6. 4-19. 7 59. 9-10. 1-3. 2-6. 9 CACATAAGTTACCACAAACC 3750 SEQ ID NO : 1853-6. 4-20. 2 59-13. 3-0. 2-3. 8 CAAAGCTTCCATTAGTAAAA 3906 SEQ ID NO : 1854-6. 4-17. 8 54. 7-11. 4 0-7 GGTGGCAGGGAGCGAGTGTC 66 SEQ ID NO : 1855-6. 3-29. 1 83. 4-21. 2-1. 6-4. 5 ACAACTACATTGGCGTCTTT 592 SEQ ID NO : 1856-6. 3-22. 5 65. 6-15. 2-0. 9-5. 2 AACATGGGCCCGGCAGGATC 829 SEQ ID NO : 1857-6. 3-29. 1 76. 9-21. 4-0. 7-10. 5 CAAGACATCGTTGAGTCCAC 1007 SEQ ID NO : 1858-6. 3-23. 1 66. 9-15. 9-0. 7-4. 4 AAAATGTCAGTTTCCGCTGG 1620 SEQ ID NO : 1859-6. 3-22. 7 65. 2-15. 1-1. 2-5. 8 CAGGGTCAAGGCTGAGAAGA 1854 SEQ ID NO : 1860-6. 3-23. 7 69. 1-16. 6-0. 6-4. 5 TGGAGTTAGAGCTATTCAAG 1957 SEQ ID NO : 1861-6. 3-20. 3 63-13. 5-0. 2-5. 1 CGTAAGCAGTATGGTCAGTG 2261 SEQ ID NO : 1862-6. 3-23. 1 68. 7-16. 3-0. 2-3. 8 TAGAAATCCCAACTCCACTG 2443 SEQ ID NO : 1863-6. 3-22. 6 63. 8-16. 3 0-2. 2 TCCCTAATGCTTATATCCTA 2534 SEQ ID NO : 1864-6. 3-23. 5 67. 6-17. 2 0-3. 6 ATGAATGATACTCTGCTTGC 2663 SEQ ID NO : 1865-6. 3-21. 2 63. 7-14. 9 0-3. 6 ATACACAAATCTTTTGAAAA 2965 SEQ ID NO : 1866-6. 3-14. 2 47. 6-7. 2-0. 5-4. 3 CTTGTTTGTCTCACGTCTGG 3189 SEQ ID NO : 1867-6. 3-24. 7 73. 5-18. 4 0-4. 6 CATTAATAAAAGGGCTTAGG 3243 SEQ ID NO : 1868-6. 3-17. 5 54. 4-11. 2 0-4. 2 TTAAAACAATGTCCTTAGAA 3373 SEQ ID NO : 1869-6. 3-16. 1 51. 4-9. 8 0-4. 3 ATTATGTATATGCAAACATT 3606 SEQ ID NO : 1870-6. 3-16. 5 52. 9-9. 3-0. 7-7. 4 AACTGACACATCAATGAATT 3663 SEQ ID NO : 1871-6. 3-17. 2 53. 6-10. 2-0. 4-4. 8 CCATGCTTCATGTACACAAC 3732 SEQ ID NO : 1872-6. 3-22. 8 66-15. 1-1. 3-6. 7 AACAGAAGTCAGAAGTGACC 3887 SEQ ID NO : 1873-6. 3-20. 3 61. 1-11. 6-2. 4-6 CCCTTCTCTCGGCCAGGGGC 144 SEQ ID NO : 1874-6. 2-33. 9 89. 7-26. 2-1. 4-9 TGCTCATCCTGCCCCGCCAC 240 SEQ ID NO : 1875-6. 2-34. 4 87-28. 2 0-3. 6 GGAGAGGTAGCATCCTTCAT 434 SEQ ID NO : 1876-6. 2-25. 5 75. 1-18. 1-1. 1-6. 9 GCTGACACGAGTTTGTGCAG 556 SEQ ID NO : 1877-6. 2-24. 9 71. 8-15. 3-3. 4-8. 4 935 CATCTGAATACCAATGCTCA-6. 2-21. 6 62. 9-15. 4 0-3. 6 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 1878 TGCTCGATCCGCTCCACTAT 1408 SEQ ID NO : 1879-6. 2-28. 3 76. 2-21. 6-0. 1-5. 6 CAGGCTCGCCCAGCAACTGA 2068 SEQ ID NO : 1880-6. 2-29. 8 78. 7-21. 5-2. 1-7. 7 GAGAGTGAGCTGGGGAGCAG 2297 SEQ ID NO : 1881-6. 2-26. 4 77. 3-18. 6-1. 6-5. 5 GCTTATATCCTATAGCCTCC 2526 SEQ ID NO : 1882-6. 2-26 74. 6-19. 8 0-5 CATATGTCATAACTTCTATC 2751 SEQ ID NO : 1883-6. 2-18. 3 58. 2-12. 1 0-5 TGCAAAAGTCTTCATGGAGT 3148 SEQ ID NO : 1884-6. 2-21. 1 63. 5-14. 9 0-6. 5 GTGGGAACTGGCTGCAAAAG 3160 SEQ ID NO : 1885-6. 2-22. 9 65. 1-16-0. 4-7. 8 ACACTTCCTCCCGAATCTCA 3308 SEQ ID NO : 1886-6. 2-26. 9 73. 5-20. 7 0-2. 8 ATCTGAAAATAATCTAAAAT 3581 SEQ ID NO : 1887-6. 2-11. 7 42. 8-5. 5 0-3. 2 ATATCTCATTATGTATATGC 3613 SEQ ID NO : 1888-6. 2-18. 3 58. 6-12. 1 0-3. 2 GTAACTGACACATCAATGAA 3665 SEQ ID NO : 1889-6. 2-18 55. 5-11. 3-0. 2-4. 8 TAAGGTGTAACTGACACATC 3671 SEQ ID NO : 1890-6. 2-19. 5 60-10. 1-3. 2-6. 9 CACAACTACATTGGCGTCTT 593 SEQ ID NO : 1891-6. 1-23. 1 66. 4-16-0. 9-5. 2 AATGCTGTGTCCCACCACCC 668 SEQ ID NO : 1892-6. 1-30. 6 80. 4-23. 7-0. 6-4. 3 GACATCGTTGAGTCCACAGC 1004 SEQ ID NO : 1893-6. 1-25. 6 73. 5-19. 5 0-4 TTTTCATCCTCCAGCCATCC 1704 SEQ ID NO : 1894-6. 1-28. 7 79. 8-22. 6 0-3. 2 GGGTCAAGGCTGAGAAGAAT 1852 SEQ ID NO : 1895-6. 1-22. 3 65. 4-15. 4-0. 6-4. 5 AGGGTCAAGGCTGAGAAGAA 1853 SEQ ID NO : 1896-6. 1-22. 3 65. 7-15. 4-0. 6-4. 5 GCAGTCCCCTCCCGCGAGGA 1913 SEQ ID NO : 1897-6. 1-35. 2 88. 3-26. 7-2. 4-10 GGTGCTCTGGAGGTGTGGAC 1984 SEQ ID NO : 1898-6. 1-27. 8 81. 7-21. 7 0-6. 4 AGCAGGACGGAATGGCTAAG 2282 SEQ ID NO : 1899-6. 1-23. 3 66-16. 7-0. 2-4. 6 TTAAGTGTTCAATAGACATT 2370 SEQ ID NO : 1900-6. 1-17. 3 55. 6-11. 2 0-3. 2 ACGTCACTCATAGGGGAGGT 2623 SEQ ID NO : 1901-6. 1-25. 8 74. 7-18. 9-0. 6-5. 3 ACTTCTATCTCTCTAAACAG 2740 SEQ ID NO : 1902-6. 1-19. 3 60. 6-13. 2 0-1. 6 AAGTCTAGGCATGTGGCTGA 3061 SEQ ID NO : 1903-6. 1-24. 9 73. 3-17. 5-1. 2-6. 1 AAAAAGTCCTTGTTTGTCTC 3197 SEQ ID NO : 1904-6. 1-20. 1 61. 7-14 0-3. 2 AAAAAAAGTCCTTGTTTGTC 3199 SEQ ID NO : 1905-6. 1-17. 4 54. 6-11. 3 0-4. 4 GCACAGATGTTCTCCTGGTT 3266 SEQ ID NO : 1906-6. 1-26. 4 77. 3-19. 5-0. 6-4. 6 TGGCACAGATGTTCTCCTGG 3268 SEQ ID NO : 1907-6. 1-26. 3 75. 8-19. 5-0. 4-5 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo GGTGTCACACTTCCTCCCGA 3314 SEQ ID NO : 1908-6. 1-29. 9 81. 5-22. 6-1. 1-7. 5 CTTAGAAAACCTAAGTACAA 3360 SEQ ID NO : 1909-6. 1-16. 4 51. 9-8. 6-1. 7-6. 2 GTTTAGGCTCGGGTCCTATT 3639 SEQ ID NO : 1910-6. 1-26. 9 77. 7-19. 7-1-8. 5 CATCAATGAATTTTGTGTTT 3655 SEQ ID NO : 1911-6. 1-17. 9 56. 4-11. 8 0-4. 8 GAGCACCAACAAGACAAAAA 3784 SEQ ID NO : 1912-6. 1-18. 2 54. 1-12. 1 0-4. 1 AAAACCACCTCTTGGTGTTT 186 SEQ ID NO : 1913-6-23. 1 66. 1-13. 9-3. 2-8. 9 CAAAAACCACCTCTTGGTGT 188 SEQ ID NO : 1914-6-22. 9 64. 5-13. 9-3-7. 4 GCAGCAAAGCAATAGCAGAG 289 SEQ ID NO : 1915-6-22. 2 64. 6-14. 5-1. 7-7. 2 CTGGGTCCTTGGAGGTGCGG 411 SEQ ID NO : 1916-6-29. 9 82. 3-23. 1-0. 6 0-5. 9 TCCTTCTCCTGCAGCCAGTC 700 SEQ ID NO : 1917-6-30. 6 86. 9-23. 7-0. 8-8. 1 GAGAGAAAAATCGTCCTTCT 713 SEQ ID NO : 1918-6-20. 1 59. 7-13. 6-0. 2-3. 7 ATTTTCATCTGATAATGGTA 1291 SEQ ID NO : 1919-6-18. 4 58. 2-12. 4 0-4. 4 AGAGTCTGGGAATCTGCATT 1378 SEQ ID NO : 1920-6-23. 3 69. 5-16. 5-0. 6-5. 4 GACCAGGAAGGTGTTGGTGG 1433 SEQ ID NO : 1921-6-25. 9 74. 2-18. 2-1. 7-6. 7 TCGGTGTAGACCAGGAAGGT 1441 SEQ ID NO : 1922-6-25. 5 72. 9-17. 7-1. 8-6. 5 TCGTTTTTCATCCTCCAGCC 1708 SEQ ID NO : 1923-6-28. 1 78. 7-22. 1 0-3. 2 TTGCTGGCAAGACTTGCCCG 1763 SEQ ID NO : 1924-6-28. 2 75. 2-18. 7-3. 5-12. 6 GAGGCAGCAAGAGCTATAGC 1936 SEQ ID NO : 1925-6-24. 6 72. 2-17-1. 6-9. 7 GCTCGCCCAGCAACTGAGAA 2065 SEQ ID NO : 1926-6-27. 8 74. 2-20. 4-1. 3-5. 8 ACGTAAGCAGTATGGTCAGT 2262 SEQ ID NO : 1927-6-23. 3 69. 4-16. 8-0. 2-4. 7 GAGCAGGACGGAATGGCTAA 2283 SEQ ID NO : 1928-6-23. 9 67-17-0. 7-4. 9 GAGCTGGGGAGCAGGACGGA 2291 SEQ ID NO : 1929-6-28. 6 78. 8-21-1. 6-6. 4 GGGTTCCAAATGGAGAGGCT 2424 SEQ ID NO : 1930-6-25. 7 72. 7-19. 2-0. 2-7. 5 ATATGTCATAACTTCTATCT 2750 SEQ ID NO : 1931-6-18. 5 58. 9-12. 5 0-3. 6 GTTTCTGTGTACACAGATGT 2777 SEQ ID NO : 1932-6-22. 4 69. 1-11. 8-2. 6-17. 3 GTGTAAGTGTCTCAGATATT 2945 SEQ ID NO : 1933-6-20. 6 65. 1-14. 6 0-3. 3 AAATCTTTTGAAAAGTGTAA 2959 SEQ ID NO : 1934-6-14. 1 47. 8-7. 2-0. 8-5. 9 ATATAAGTCTAGGCATGTGG 3065 SEQ ID NO : 1935-6-21 64. 3-15 0-6. 1 AGATAGACTTTGCCTCCAGG 3123 SEQ ID NO : 1936-6-25. 2 72. 6-19. 2 0-4. 1 3150 GCTGCAAAAGTCTTCATGGA-6-22. 6 66. 2-16. 6 0-5. 8 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 1937 CTTGAGAACATATCTTGAAA 3455 SEQ ID NO : 1938-6-16. 7 53. 1-9. 9-0. 6-3. 9 CCACAAACCATGCTTCATGT 3739 SEQ ID NO : 1939-6-24. 2 67. 5-16. 8-1. 3-5. 7 ATGTACAGCCAATAATATG 3864 SEQ ID NO : 1940-6-19. 5 58. 6-12. 8-0. 5-7. 6 TGCCCCGCCACACCCCCTCC 231 SEQ ID NO : 1941-5. 9-39. 5 92-33. 6 0-3 GGTTAAACCTCACAGATGGT 390 SEQ ID NO : 1942-5. 9-22. 9 66. 8-15. 4-1. 6-6. 5 GGGTCCTTGGAGGTGCGGAG 409 SEQ ID NO : 1943-5. 9-29. 6 82. 3-22. 9-0. 6-5. 9 AAAGCTGGTGGGCCAGGGGG 624 SEQ ID NO : 1944-5. 9-29. 4 79. 7-20. 3-3. 2-9. 4 GCTGTGTCCCACCACCCTGG 665 SEQ ID NO : 1945-5. 9-33. 4 87. 3-26. 6-0. 8-5 CCTGTGATTCGGCCCACCGT 805 SEQ ID NO : 1946-5. 9-31. 9 81. 3-23. 5-2. 5-9. 2 GGCCCGGCAGGATCCAAACC 823 SEQ ID NO : 1947-5. 9-31. 2 78. 8-24. 2-0. 7-9. 7 TTGGGGTAGATGTCAATGTG 964 SEQ ID NO : 1948-5. 9-22 66. 4-16. 1 0-3. 8 ACATGGATTTTCATCTGATA 1297 SEQ ID NO : 1949-5. 9-19. 7 60. 9-13. 8 0. 1-5. 5 GGAAGGTGTTGGTGGCATTC 1428 SEQ ID NO : 1950-5. 9-25. 4 74. 8-19. 5 0-4 GCGAGGAGTCCCAGCCATCA 1900 SEQ ID NO : 1951-5. 9-30. 9 82. 9-23. 9-1-7. 8 TACAGGCTCGCCCAGCAACT 2070 SEQ ID NO : 1952-5. 9-29. 1 77. 7-21. 8-1. 3-7. 3 AGGCAGAGTACAGGCTCGCC 2078 SEQ ID NO : 1953-5. 9-29 81. 2-18. 7-4. 4-10. 4 CTTATATCCTATAGCCTCCC 2525 SEQ ID NO : 1954-5. 9-26. 2 73. 9-20. 3 0-5 AATAGAAACCACTTAAAGCC 2560 SEQ ID NO : 1955-5. 9-18. 4 55. 1-12. 5 0-3. 2 GTATTAAAGTAAAATATTTC 2855 SEQ ID NO : 1956-5. 9-12. 4 44. 7-6. 5 0-6. 6 AGGCACTGGTATTAAAGTAA 2863 SEQ ID NO : 1957-5. 9-19. 5 59. 6-13. 1-0. 2-4 ACTCTAATTAGGCAATGCAT 2983 SEQ ID NO : 1958-5. 9-20. 7 62-13. 9-0. 7-8 ACTAACTAGTATATAAGTCT 3075 SEQ ID NO : 1959-5. 9-17 55. 4-11. 1 0-6. 3 TCAGAGATAGACTTTGCCTC 3127 SEQ ID NO : 1960-5. 9-23 69. 2-16. 6-0. 1-4. 5 CTGCAAAAGTCTTCATGGAG 3149 SEQ ID NO : 1961-5. 9-20. 8 62. 3-14. 9 0-5. 9 AAAAAAAAGTCCTTGTTTGT 3200 SEQ ID NO : 1962-5. 9-16. 3 51. 7-10. 4 0-4. 4 GCTTGAGAACATATCTTGAA 3456 SEQ ID NO : 1963-5. 9-19. 2 58. 9-13. 3 0-3. 9 TGCCCCAGAACGAGATCTGC 39 SEQ ID NO : 1964-5. 8-27. 7 74. 1-21-0. 8-6. 3 AAACCACCTCTTGGTGTTTC 185 SEQ ID NO : 1965-5. 8-24. 2 69. 8-15. 4-3-8. 8 AGAGCAGAGGAACGGAGTTG 258 SEQ ID NO : 1966-5. 8-22. 9 66. 8-15. 3-1. 8-7. 3 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo AGCATCCTTCATGCTCTGGG 426 SEQ ID NO : 1967-5. 8-27. 4 78. 6-18. 7-2. 9-7. 5 AATGATGAAAAAGGTTTTAG 500 SEQ ID NO : 1968-5. 8-14. 1 47. 6-7. 6-0. 4-4. 4 TGAATGATGAAAAAGGTTTT 502 SEQ ID NO : 1969-5. 8-15 49. 2-8. 7-0. 2-4. 1 GTCCATCCGTGAATGATGAA 511 SEQ ID NO : 1970-5. 8-23. 1 65. 2-16. 1-1. 1-4. 6 CCGATCAAGTGGACATTCCC 733 SEQ ID NO : 1971-5. 8-26. 2 71. 4-19. 5-0. 8-6. 1 GCATCTGAATACCAATGCTC 936 SEQ ID NO : 1972-5. 8-22. 7 65. 7-14. 7-2. 2-6. 5 GAGTCCACAGCCTGGCTGGA 995 SEQ ID NO : 1973-5. 8-30. 2 83. 6-20. 8-2. 9-15. 1 GCCAATGCTATTACAACGGT 1193 SEQ ID NO : 1974-5. 8-23. 6 66-17. 2-0. 3-4. 1 TGAGAAGAATCCTTCCATTG 1842 SEQ ID NO : 1975-5. 8-21 62-13. 1-2. 1-7 CGCGAGGAGTCCCAGCCATC 1901 SEQ ID NO : 1976-5. 8-31 81. 4-24. 1-1-8. 3 ACAGGCTCGCCCAGCAACTG 2069 SEQ ID NO : 1977-5. 8-29. 4 78-21. 5-2. 1-7. 8 CCAGGCCTGCCATCCTGACA 2200 SEQ ID NO : 1978-5. 8-31. 9 83. 5-23. 9-2-11. 9 AAGCCAATGATGTGTGCTTC 2318 SEQ ID NO : 1979-5. 8-23. 3 67. 9-16-1. 4-5. 6 CATTCTAATTAATTTTAAGT 2384 SEQ ID NO : 1980-5. 8-14. 7 49. 6-8. 9 0-6. 2 CCAGGTGCCTTTCCCCATGC 2498 SEQ ID NO : 1981-5. 8-32. 9 86. 3-27. 1 0-6. 6 ACATAATAACTAAGAAGAAA 2578 SEQ ID NO : 1982-5. 8-12. 1 43. 5-6. 3 0-2. 2 CCCCAGCATGAATGATACTC 2670 SEQ ID NO : 1983-5. 8-24. 9 69. 1-19. 1 0-4. 8 ATAGTTGCCCTTCTCCCCCT 3003 SEQ ID NO : 1984-5. 8-32. 4 86. 2-26. 6 0-3 GCAAAAGTCTTCATGGAGTT 3147 SEQ ID NO : 1985-5. 8-21. 2 64-14. 9-0. 2-6. 5 TCCATTAGTAAAAACAGAAG 3899 SEQ ID NO : 1986-5. 8-15. 8 50. 8-10 0-3. 9 ACCTCTTGGTGTTTCCAGCA 180 SEQ ID NO : 1987-5. 7-27. 9 80-20. 9-1. 2-6. 2 ATGGTTTGACCTCAGTCTGT 375 SEQ ID NO : 1988-5. 7-25. 1 75-17. 8-1. 6-6. 2 GGAGGTTAAACCTCACAGAT 393 SEQ ID NO : 1989-5. 7-22. 3 65. 3-12. 3-4. 3-11. 9 CCACCACCCTGGTATTATTG 657 SEQ ID NO : 1990-5. 7-26. 7 72. 7-19. 3-1. 7-5. 7 TCCCCTCCCGCGAGGAGTCC 1909 SEQ ID NO : 1991-5. 7-35. 1 88. 2-26. 5-2. 5-13. 6 CACTGAGGCTCAAAGCAGGC 2152 SEQ ID NO : 1992-5. 7-25. 5 72. 5-17. 8-2-6. 1 AGACGTAAGCAGTATGGTCA 2264 SEQ ID NO : 1993-5. 7-22. 7 67. 4-16-0. 9-5. 6 GGAGCAGGACGGAATGGCTA 2284 SEQ ID NO : 1994-5. 7-25. 8 71. 7-19. 2-0. 7-4. 9 AATAGGAAAGCCAATGATGT 2325 SEQ ID NO : 1995-5. 7-19 56. 9-12. 1-1. 1-3. 9 2496 AGGTGCCTTTCCCCATGCAT-5. 7-30. 9 83-24. 3-0. 7-6. 4 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 1996 AATGCTTATATCCTATAGCC 2529 SEQ ID NO : 1997-5. 7-22 64. 9-15. 6-0. 5-5 CGTCACTCATAGGGGAGGTG 2622 SEQ ID NO : 1998-5. 7-25. 6 73. 9-19. 9 0. 1-4. 6 GGCACTGGTATTAAAGTAAA 2862 SEQ ID NO : 1999-5. 7-18. 8 57. 5-13. 1 0-4 GGCAATGCATACACAAATCT 2973 SEQ ID NO : 2000-5. 7-20. 9 61-14. 3-0. 7-8 CTCTCCCTGGCTGCACCACT 3092 SEQ ID NO : 2001-5. 7-31. 9 85. 7-24. 9-1. 2-8. 4 GTTTCAGAGATAGACTTTGC 3130 SEQ ID NO : 2002-5. 7-21. 1 65. 7-14. 9-0. 1-3. 4 TAAAAGGGCTTAGGATTTTA 3237 SEQ ID NO : 2003-5. 7-18. 3 56. 8-12. 6 0-3. 8 CCTCCCGAATCTCAGCCATA 3302 SEQ ID NO : 2004-5. 7-28. 6 75. 8-22. 9 0-3. 2 CTTGAAATAAGACTCAACTG 3442 SEQ ID NO : 2005-5. 7-16. 4 52. 2-10. 1-0. 3-3. 5 ACCTGTACAAGCTTCGCTTT 3517 SEQ ID No : 2006-5. 7-25. 1 71. 3-17. 8-1. 5-7. 8 TCAATGAATTTTGTGTTTAG 3653 SEQ ID NO : 2007-5. 7-16. 9 54. 7-11. 2 0-4. 1 CACAAACCATGCTTCATGTA 3738 SEQ ID NO : 2008-5. 7-21. 9 63. 4-14. 8-1. 3-5. 7 GACCAGGATGTACAGCCAAT 3871 SEQ ID NO : 2009-5. 7-24. 9 69. 9-19. 2 0. 1-6. 3 CCACAACTACATTGGCGTCT 594 SEQ ID NO : 2010.-5. 6-25 69. 6-18. 4-0. 9-5. 2 CATGGGCCCGGCAGGATCCA 827 SEQ ID NO : 2011-5. 6-32. 3 82. 9-24. 9-1-5-11. 2 CAAACATGGGCCCGGCAGGA 831 SEQ ID NO : 2012-5. 6-28. 7 74. 1-21. 5-0. 7-11. 2 CATGCTCACATTTTACCACC 1056 SEQ ID NO : 2013-5. 6-24. 5 69. 5-18. 2-0. 4-3. 6 CCCTCCCAGGTGAGCTGGAT 1486 SEQ ID NO : 2014-5. 6-31. 5 84. 3-23. 4-2. 5-7. 6 GCCCCCTCCCAGGTGAGCTG 1489 SEQ ID NO : 2015-5. 6-35. 5 91. 4-29-0. 8-5. 8 GAAACTCCTTCCACAGGTTG 1524 SEQ ID NO : 2016-5. 6-24. 2 69-17. 7-0. 8-5. 4 CTGGAGGTGTGGACAGAGGT 1978 SEQ ID NO : 2017-5. 6-26 76. 5-19. 8-0. 3-4 GCTGGGGAGCAGGACGGAAT 2289 SEQ ID NO : 2018-5. 6-27. 3 74. 7-20. 2-1. 4-6. 2 GTCCCTAATGCTTATATCCT 2535 SEQ ID NO : 2019-5. 6-25 71. 4-19. 4 0-3. 6 CTAACTAGTATATAAGTCTA 3074 SEQ ID NO : 2020-5. 6-16. 5 54. 3-10. 9 0-6. 3 TCCTTGTTTGTCTCACGTCT 3191 SEQ ID NO : 2021-5. 6-25. 9 76. 6-20. 3 0-4. 6 AAAGTCCTTGTTTGTCTCAC 3195 SEQ ID NO : 2022-5. 6-22. 4 68-16. 8 0-3. 2 GGCTCTATATAAAAAAAAAA 3212 SEQ ID NO : 2023-5. 6-12 43. 1-6. 4 0-3. 7 TTATGTATATGCAAACATTC 3605 SEQ ID NO : 2024-5. 6-16. 9 54. 1-10. 4-0. 7-7. 4 GGCTCGGGTCCTATTCCCAA 3634 SEQ ID NO : 2025-5. 6-30. 2 80. 9-23. 1-1. 4-6. 7 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo ATCGTATAAAATTACCCTCA 3702 SEQ ID NO : 2026-5. 6-19. 7 58. 2-14. 1 0-3. 2 AAATCCAAAACTTTTTGAGC 3800 SEQ ID NO : 2027-5. 6-17. 5 54-11. 2-0. 5-6. 8 ACAGAAGTCAGAAGTGACCA 3886 SEQ ID NO : 2028-5. 6-21. 7 64. 5-13. 7-2. 4-6 CCCCTCCCAAGAAACAGAAG 218 SEQ ID NO : 2029-5. 5-25. 3 67. 1-19. 8 0-1. 8 AACCACAACTACATTGGCGT 596 SEQ ID NO : 2030-5. 5-23. 2 64. 8-17-0. 4-4. 7 CCAGGGGGAGCCAGTCAACC 612 SEQ ID NO : 2031-5. 5-30. 4 81. 7-23. 5-1. 3-4. 4 AGAGAAAAATCGTCCTTCTC 712 SEQ ID No : 2032-5. 5-19. 9 59. 8-12. 7-1. 7-6. 2 GTTCCTTTCACGAAGTTGCC 787 SEQ ID NO : 2033-5. 5-25. 9 73. 4-19. 7-0. 4-3. 8 CATCGTTGAGTCCACAGCCT 1002 SEQ ID NO : 2034-5. 5-27. 7 77. 2-22. 2 0-0. 7 ACATCGTTGAGTCCACAGCC 1003 SEQ ID NO : 2035-5. 5-27 75. 8-21. 5 0-3. 8 ATTGATCCCAAGACATCGTT 1015 SEQ ID NO : 2036-5. 5-23. 1 65. 8-16. 9-0. 5-4. 3 TGTGATTGTTCCATATGCAA 1034 SEQ ID NO : 2037-5. 5-21. 8 64. 7-16. 3 0-5. 8 TTGAAGCGATTGGAGTCAGT 1144 SEQ ID NO : 2038-5. 5-22. 6 66. 8-17. 1 0-5 AAACTCTGAAAGGCATGCCT 1272 SEQ ID NO : 2039-5. 5-22. 6 64. 2-13. 9-0. 2-14. 5 TCCCGACACTTGCGAAACCA 1687 SEQ ID NO : 2040-5. 5-26. 6 69-21. 1 0-4. 3 CCATGGGCTTGGATAGCAGG 1796 SEQ ID NO : 2041-5. 5-27. 1 75. 7-19. 4-2. 2-10. 8 GGACAGAGGTTTGGAGTTAG 1968 SEQ ID NO : 2042-5. 5-22. 7 69. 2-17. 2 0-3. 8 AGTCAGCTCCTGTCGGAAGG 2178 SEQ ID NO : 2043-5. 5-27 77. 2-20. 6-0. 7-5. 5 ATGTCATAACTTCTATCTCT 2748 SEQ ID NO : 2044-5. 5-20. 1 63. 1-14. 6 0-2. 5 TACACAAATCTTTTGAAAAG 2964 SEQ ID NO : 2045-5. 5-14. 2 47. 7-7. 2-1. 4-5. 7 GCAATGCATACACAAATCTT 2972 SEQ ID NO : 2046-5. 5-19. 8 58. 9-14. 3 0-7. 4 AATAAAAGGGCTTAGGATTT 3239 SEQ ID NO : 2047-5. 5-17. 8 55. 2-12. 3 0-3. 7 TTGGTGTCACACTTCCTCCC 3316 SEQ ID NO : 2048-5. 5-28. 6 80. 8-21. 9-1. 1-6. 7 GCTTGGTGTCACACTTCCTC 3318 SEQ ID NO : 2049-5. 5-27. 3 80. 2-21. 2-0. 3-5. 9 CAAAATCCAAAACTTTTTGA 3802 SEQ ID NO : 2050-5. 5-15. 7 49. 9-9. 1-1-7. 3 AACGAGATCTGCCCTCGTCC 31 SEQ ID NO : 2051-5. 4-28. 3 75. 6-19. 5-3. 4-9. 2 AAAAACCACCTCTTGGTGTT 187 SEQ ID NO : 2052-5. 4-22. 3 63. 7-13. 9-3-7. 9 GCTCATCCTGCCCCGCCACA 239 SEQ ID NO : 2053-5. 4-35. 1 88. 1-29. 7 0-3. 1 GTAGCCGATCAAGTGGACAT 737 SEQ ID NO : 2054-5. 4-24. 4 69. 4-19 0-4. 9 1021 TATGCAATTGATCCCAAGAC-5. 4-21. 4 62. 1-15. 3-0. 5-7. 6 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 2055 ATGGATTTTCATCTGATAAT 1295 SEQ ID NO : 2056-5. 4-18. 1 57-11. 8-0. 7-4. 5 CATGGATTTTCATCTGATAA 1296 SEQ ID NO : 2057-5. 4-18. 8 58. 3-12. 5-0. 7-4. 5 GGTTGTACCAAGACTGAGAG 1509 SEQ ID NO : 2058-5. 4-22. 5 66. 7-16. 1-0. 9-4. 7 TCCCCAGACTTCACCCGGAT 1597 SEQ ID NO : 2059-5. 4-30. 8 79. 6-25. 4 0-6. 4 TCAGGGAAGCTCCACAGTGG 1736 SEQ ID NO : 2060-5. 4-26. 5 75. 6-19. 5-1. 6-9. 5 TCCTCAGCAGTAACTTTCCT 1816 SEQ ID NO : 2061-5. 4-25. 7 74. 6-20. 3 0-4. 1 CCCCTCCCGCGAGGAGTCCC 1908 SEQ ID NO : 2062-5. 4-36. 7 89. 4-28. 4-2. 5-13. 6 TGGAGGTGTGGACAGAGGTT 1977 SEQ ID No : 2063-5. 4-25. 2 74. 8-19. 8 0. 3-4 GTACAGGCTCGCCCAGCAAC 2071 SEQ ID No : 2064-5. 4-29. 4 79. 2-21. 9-2. 1-7. 8 CCCAACAGCTAGGGCCCGAG 2227 SEQ ID NO : 2065-5. 4-30. 9 79. 1-23. 6-0. 9-11. 8 GCTCAATTAAAAAATGAACA 2349 SEQ ID NO : 2066-5. 4-14. 2 47. 1-8. 8 0-3 CTGGGTTCCAAATGGAGAGG 2426 SEQ ID NO : 2067-5. 4-23. 9 68. 3-17. 9-0. 3-7. 5 CTAGTGATCAAACACGTCAC 2636 SEQ ID NO : 2068-5. 4-20. 5 61. 2-13. 5-1. 6-6. 7 ACATATGTCATAACTTCTAT 2752 SEQ ID NO : 2069-5. 4-18. 1 57. 4-12. 2 0-7. 6 CTGTATTAAATCTTAGAACC 2818 SEQ ID NO : 2070-5. 4-17. 4 54. 9-12 0-2. 8 TATTAAAGTAAAATATTTCA 2854 SEQ ID NO : 2071-5. 4-11. 9 43. 5-6. 5 0-6. 6 TACTCTAATTAGGCAATGCA 2984 SEQ ID NO : 2072-5. 4-20. 4 61. 4-14. 1-0. 7-8 AATAATAGTTGCCCTTCTCC 3007 SEQ ID NO : 2073-5. 4-23. 8 68. 4-18. 4 0-3 CTCCCTGGCTGCACCACTAA 3090 SEQ ID NO : 2074-5. 4-29. 6 78. 9-23. 1-1-8. 2 GAGATAGACTTTGCCTCCAG 3124 SEQ ID NO : 2075-5. 4-24. 6 71. 3-19. 2 0-3. 4 ATTAAAACAATGTCCTTAGA 3374 SEQ ID NO : 2076-5. 4-16. 8 53. 1-11. 4 0-4. 8 ATCACAGAAACAAGAGAAGC 3485 SEQ ID No : 2077-5. 4-17. 7 54. 9-12. 3 0-2. 9 TCTGAAAATAATCTAAAATT 3580 SEQ ID NO : 2078-5. 4-11. 8 43. 1-6. 4 0-2. 9 AAAATCTGAAAATAATCTAA 3584 SEQ ID NO : 2079-5. 4-11 41. 5-5. 6 0-3. 2 ATGTACACAACTATTTAAAA 3723 SEQ ID NO : 2080-5. 4-14. 6 48. 6-9. 2 0-6. 7 AATCCAAAACTTTTTGAGCA 3799 SEQ ID NO : 2081-5. 4-18. 9 56. 9-12. 4-1-7. 3 CCAAAATCCAAAACTTTTTG 3803 SEQ ID NO : 2082-5. 4-17. 1 52. 2-10. 5-1. 1-6. 7 TCCAAAATCCAAAACTTTTT 3804 SEQ ID NO : 2083-5. 4-17. 5 53. 3-12. 1 0-3. 2 CCCCCTCCCAAGAAACAGAA 219 SEQ ID NO : 2084-5. 3-27. 3 70-22 0-1. 8 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo GAGCTTATCTTCCAGCCGTC 338 SEQ ID NO : 2085-5. 3-27. 8 79-21. 6-0. 8-5. 2 GAGGTTAAACCTCACAGATG 392 SEQ ID NO : 2086-5. 3-21. 1 62. 6-12. 3-3. 5-11. 3 TTCATGCTCTGGGTCCTTGG 419 SEQ ID NO : 2087-5. 3-27. 4 79. 3-22. 1 0-4. 4 GAGAGGTAGCATCCTTCATG 433 SEQ ID NO : 2088-5. 3-24. 3 72. 1-18. 1-0. 6-8. 6 AAAAAGGTTTTAGCTGTCAT 493 SEQ ID NO : 2089-5. 3-18. 6 57. 7-13. 3 0-6. 8 GAAAAAGGTTTTAGCTGTCA 494 SEQ ID NO : 2090-5. 3-19. 2 59-13. 2-0. 4-8. 1 TCGGCCCCTTCAAACATGGG 841 SEQ ID NO : 2091-5. 3-28. 2 73. 8-22. 1-0. 6-7. 8 TGTCGGCCCCTTCAAACATG 843 SEQ ID NO : 2092-5. 3-27 72. 1-21. 7 0-6. 2 AGCCGAAGGAACGCGTGTAG 915 SEQ ID NO : 2093-5. 3-25. 3 68. 1-17. 3-2. 1-13. 2 GTGATTGTTCCATATGCAAT 1033 SEQ ID NO : 2094-5. 3-21. 8 64. 7-15. 7-0. 6-7. 4 GGAAGGCAAAACTCGGCTTG 1119 SEQ ID NO : 2095-5. 3-23 64. 4-17. 7 0. 3-4 TAAACTCTGAAAGGCATGCC 1273 SEQ ID NO : 2096-5. 3-21. 4 61. 8-13. 9 0-12. 5 ACTTGGTGCTCTGGAGGTGT 1988 SEQ ID NO : 2097-5. 3-27 80-21. 7 0-6. 4 AGTACAGGCTCGCCCAGCAA 2072 SEQ ID NO : 2098-5. 3-29. 2 78. 9-21. 8-2. 1-8. 5 TCTAATTAATTTTAAGTGTT 2381 SEQ ID NO : 2099-5. 3-15. 2 51. 1-9. 9 0-6. 2 GTCCATTACCACATTCTAAT 2395 SEQ ID NO : 2100-5. 3-22. 3 65. 3-17 0-2. 1 TGTCCATTACCACATTCTAA 2396 SEQ ID NO : 2101-5. 3-22. 3 65. 2-17 0-2. 8 AGAAACCACTTAAAGCCTCA 2557 SEQ ID NO : 2102-5. 3-21. 4 61. 5-16. 1 0-3. 2 TATTAAATCTTAGAACCAGC 2815 SEQ ID NO : 2103-5. 3-17. 8 55. 5-12. 5 0-3 CAAAAGTCTTCATGGAGTTT 3146 SEQ ID NO : 2104-5. 3-19. 5 60. 1-12. 9-1. 2-6. 5 TAAGACTCAACTGGTTATGT 3435 SEQ ID NO : 2105-5. 3-19. 6 60. 5-14. 3 0-4. 7 AAAATCCAAAACTTTTTGAG 3801 SEQ ID NO : 2106-5. 3-15 48. 9-8. 6-1-7. 3 AGAACGAGATCTGCCCTCGT 33 SEQ ID NO : 2107-5. 2-26. 5 72. 2-18. 1-3. 2-9 TGGGTCCTTGGAGGTGCGGA 410 SEQ ID NO : 2108-5. 2-29. 6 81. 7-23. 9-0. 1-5. 9 TCTCCTGCAGCCAGTCGAGC 696 SEQ ID NO : 2109-5. 2-30. 4 84. 6-24-1. 1-8. 1 ACCTGTGATTCGGCCCACCG 806 SEQ ID NO : 2110-5. 2-30. 9 78. 7-23. 5-2. 2-9. 2 GCAGGATCCAAACCTGTGAT 817 SEQ ID NO : 2111-5. 2-24. 9 69. 6-17. 3-2. 4-9 GCCTGGCTGGAAGTCACCCC 986 SEQ ID NO : 2112-5. 2-32. 2 85-25. 6-1. 3-9. 4 GAGGTGGACGGCTCGCTCAT 1073 SEQ ID NO : 2113-5. 2-28. 7 78. 8-22. 8-0. 5-6. 1 1688 ATCCCGACACTTGCGAAACC-5. 2-25. 9 68-20. 7 0-4. 3 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 2114 CTCTTCGGAGCCAGCGTTCC 2103 SEQ ID NO : 2115-5. 2-30. 1 81. 8-24-0. 7-5. 1 GCCAATGATGTGTGCTTCAG 2316 SEQ ID NO : 2116-5. 2-24. 7 71. 3-19. 5 0-3. 8 GGGTCCCTAATGCTTATATC 2537 SEQ ID NO : 2117-5. 2-24. 5 71-19. 3 0-5. 3 GTATTAAATCTTAGAACCAG 2816 SEQ ID NO : 2118-5. 2-17. 2 54. 5-12 0-3 TGTATTAAATCTTAGAACCA 2817 SEQ ID NO : 2119-5. 2-17. 2 54. 3-12 0-3 CCACTAACTAGTATATAAGT 3077 SEQ ID NO : 2120-5. 2-18. 4 57. 4-13. 2 0-6. 3 CCTCCAGGAAATCTGAGTCC 3111 SEQ ID NO : 2121-5. 2-25. 9 72. 7-19. 6-1-5. 8 GCCTCCAGGAAATCTGAGTC 3112 SEQ ID NO : 2122-5. 2-25. 7 73. 4-19. 7-0. 6-5 CCTTGTTTGTCTCACGTCTG 3190 SEQ ID NO : 2123-5. 2-25. 5 74. 6-20. 3 0-4. 6 CCTGGTTATACATTAATAAA 3253 SEQ ID NO : 2124-5. 2-17. 1 53. 6-11. 9 0-4. 2 TACAAAGAAAATCATTCTTC 3345 SEQ ID NO : 2125-5. 2-14. 7 49. 1-7-2. 5-6. 5 ACACTTCTGGTTCCAAGCAT 3556 SEQ ID NO : 2126-5. 2-24. 8 71. 7-19. 6 0-5 TTTTTGAGCACCAACAAGAC 3789 SEQ ID NO : 2127-5. 2-20. 7 61. 2-15-0. 2-4. 6 CTCCAAAATCCAAAACTTTT 3805 SEQ ID NO : 2128-5. 2-18. 3 54. 7-13. 1 0-2. 7 TTCCATTAGTAAAAACAGAA 3900 SEQ ID NO : 2129-5. 2-15. 9 51-10. 7 0-3. 4 CCTCTGGACCAAAAGGTACG 318 SEQ ID NO : 2130-5. 1-23. 9 65. 8-18. 3-0. 1-5. 2 GTGGAGCTTATCTTCCAGCC 341 SEQ ID NO : 2131-5. 1-27. 8 80. 1-21. 1-1. 6-6. 1 GTGGGCCAGGGGGAGCCAGT 617 SEQ ID NO : 2132-5. 1-33. 2 90. 7-25. 6-2. 5-9. 1 TAAAGCTGGTGGGCCAGGGG 625 SEQ ID NO : 2133-5. 1-27. 9 76. 6-20. 3-2. 5-8. 7 GCCCCTTCAAACATGGGCCC 838 SEQ ID NO : 2134-5. 1-31. 6 80. 4-24-2. 5-9. 8 CCAAGACATCGTTGAGTCCA 1008 SEQ ID NO : 2135-5. 1-24. 9 70-18. 9-0. 7-4. 4 AGAGGTGGACGGCTCGCTCA 1074 SEQ ID NO : 2136-5. 1-28. 7 79. 2-22. 2-1. 3-6. 1 ACTGGAAGGCAAAACTCGGC 1122 SEQ ID NO : 2137-5. 1-23. 1 64. 6-17. 5-0. 2-4. 1 TCCTCCATGGGCTTGGATAG 1800 SEQ ID NO : 2138-5. 1-27. 1 76. 4-20. 7-1. 2-9. 5 GGTCAAGGCTGAGAAGAATC 1851 SEQ ID NO : 2139-5. 1-21. 5 64. 3-15. 6-0. 6-4. 3 CCATCACAGGAGACCAGTTG 1886 SEQ ID NO : 2140-5. 1-25. 3 71. 9-19. 6-0. 3-3. 7 GAGGCTCAAAGCAGGCTGAG 2148 SEQ ID NO : 2141-5. 1-25. 2 72. 4-18. 1-2-7. 6 TTGCTCAATTAAAAAATGAA 2351 SEQ ID NO : 2142-5. 1-13. 4 45. 8-8. 3 0-3. 6 TTCTAATTAATTTTAAGTGT 2382 SEQ ID NO : 2143-5. 1-15. 2 51. 1-10. 1 0-6. 2 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo ATTCTAATTAATTTTAAGTG 2383 SEQ ID NO : 2144-5. 1-14 48. 3-8. 9 0-5. 9 CTAGAAATCCCAACTCCACT 2444 SEQ ID NO : 2145-5. 1-23. 5 65. 7-18. 4 0-3 TTTCCCCATGCATATACACA 2489 SEQ ID NO : 2146-5. 1-25 69. 7-19. 9 0-6. 8 GAATGATACTCTGCTTGCTA 2661 SEQ ID NO : 2147-5. 1-21. 8 65. 2-16. 7 0-4. 5 TCTCCCTGGCTGCACCACTA 3091 SEQ ID NO : 2148-5. 1-30. 7 83. 2-24. 3-1. 2-8. 4 AAAGTCCAACCGTTGGCACA 3281 SEQ ID NO : 2149-5. 1-25. 1 68. 4-17. 4-2. 6-11. 5 AACAGTGATACAACTTTGGC 3403 SEQ ID NO : 2150-5. 1-20. 2 60. 9-15. 1 0-4. 6 TATAAAATTACCCTCAGGCT 3698 SEQ ID NO : 2151-5. 1-21. 2 61. 7-15. 5-0. 3-4. 9 CCCAGAACGAGATCTGCCCT 36 SEQ ID NO : 2152-5-28. 8 75. 3-22. 4-1. 3-6. 3 AGCAGAGGAACGGAGTTGCT 256 SEQ ID NO : 2153-5-25 71. 4-17. 7-2. 3-7. 7 TGGAGCTTATCTTCCAGCCG 340 SEQ ID NO : 2154-5-27. 4 76. 2-21. 1-1. 2-5. 8 TTGGGTTTGTGGAGCTTATC 349 SEQ ID NO : 2155-5-23. 8 72. 1-18. 8 0-5. 2 TCATGCTCTGGGTCCTTGGA 418 SEQ ID NO : 2156-5-27. 9 80. 3-22. 9 0-5 GGGCCAGGGGGAGCCAGTCA 615 SEQ ID NO : 2157-5-33. 1 90. 1-25. 6-2. 5-9. 2 CCCCTTCAAACATGGGCCCG 837 SEQ ID NO : 2158-5-30. 6 76. 3-24-0. 9-11. 2 TTTGAAGCGATTGGAGTCAG 1145 SEQ ID NO : 2159-5-21. 5 63. 9-16. 5 0-5 GGTGTGGACAGAGGTTTGGA 1973 SEQ ID NO : 2160-5-25. 3 74. 8-19. 7-0. 3-4 CTACACAGGGCCTCTTCGGA 2114 SEQ ID NO : 2161-5-27. 9 77. 2-22. 4 0-7. 7 TTCCCCATGCATATACACAT 2488 SEQ ID NO : 2162-5-24. 9 69. 3-19. 9 0-6. 8 ATTAAAGTAAAATATTTCAA 2853 SEQ ID NO : 2163-5-11. 5 42. 6-6. 5 0-6. 6 CTCCCCCTACTCTAATTAGG 2991 SEQ ID NO : 2164-5-26. 3 72. 9-21. 3 0. 2-7. 5 AGACTTTGCCTCCAGGAAAT 3119 SEQ ID No : 2165-5-24. 1 68. 3-19. 1 0-5 TTAGAAAACCTAAGTACAAA 3359 SEQ ID NO : 2166-5-14. 8 48. 6-9. 2-0. 3-6. 2 TCAGAAGTTTAACAGTGATA 3413 SEQ ID NO : 2167-5-17. 8 56. 8-12. 8 0-4. 6 AGGCTCGGGTCCTATTCCCA 3635 SEQ ID NO : 2168-5-30. 9 83. 8-24-1. 9-6. 9 CAACTATTTAAAATATCGTA 3716 SEQ ID NO : 2169-5-14. 4 48-9. 4 0-5 CACAACTATTTAAAATATCG 3718 SEQ ID NO : 2170-5-14. 4 47. 7-9. 4 0-5 ACAAACCATGCTTCATGTAC 3737 SEQ ID NO : 2171-5-21. 4 62. 8-15-1. 3-5. 7 CTTCCATTAGTAAAAACAGA 3901 SEQ ID NO : 2172-5-17. 5 54. 5-12. 5 0-3. 9 369 TGACCTCAGTCTGTGTAGCT-4. 9-26. 1 77. 9-19. 6-1. 6-7 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 2173 TGTAGCCGATCAAGTGGACA 738 SEQ ID NO : 2174-4. 9-24. 4 69. 3-19. 5 0-4. 9 GCCCGGCAGGATCCAAACCT 822 SEQ ID NO : 2175-4. 9-30. 9 78. 3-25. 2-0. 3-9 CCACAAAATCTGCATCGTCC 882 SEQ ID NO : 2176-4. 9-24. 1 66. 6-19. 2 0-4. 9 AATTGATCCCAAGACATCGT 1016 SEQ ID NO : 2177-4. 9-22. 3 63. 5-16. 7-0. 5-4. 3 CAATTGATCCCAAGACATCG 1017 SEQ ID NO : 2178-4. 9-21. 8 61. 7-16. 2-0. 5-6. 7 GCAATTGATCCCAAGACATC 1018 SEQ ID NO : 2179-4. 9-22. 8 65. 2-17. 2-0. 5-7. 1 CTGTGATTGTTCCATATGCA 1035 SEQ ID NO : 2180-4. 9-23. 4 68. 9-18. 5 0-5. 7 TGCGAAACTCCTTCCACAGG 1527 SEQ ID NO : 2181-4. 9-25. 5 69. 7-19. 9-0. 5-5 GGGTTGAGACAGGTAGCTGC 1544 SEQ ID NO : 2182-4. 9-26. 4 77. 9-19. 9-1. 5-3. 5 ATGGGCTTGGATAGCAGGAA 1794 SEQ ID NO : 2183-4. 9-24. 3 70-17. 2-2. 2-6 GTCCCAGCCATCACAGGAGA 1893 SEQ ID NO : 2184-4. 9-29. 2 80. 7-23. 8-0. 1-3. 7 GACAGAGGTTTGGAGTTAGA 1967 SEQ ID NO : 2185-4. 9-22. 1 67. 8-17. 2 0-3. 8 GGAGGTGTGGACAGAGGTTT 1976 SEQ ID NO : 2186-4. 9-25. 3 75. 4-19. 8-0. 3-3. 5 ACAGCTAGGGCCCGAGCAAG 2223 SEQ ID NO : 2187-4. 9-28. 7 76. 9-21. 4-1. 7-12. 8 CAGGACGGAATGGCTAAGAC 2280 SEQ ID NO : 2188-4. 9-22. 3 63. 7-17. 4 0-3. 7 AATTAATTTTAAGTGTTCAA 2378 SEQ ID NO : 2189-4. 9-14. 6 49. 3-9. 7 0-5. 8 GGCAGGTGCCGGTTTCTGTG 2788 SEQ ID NO : 2190-4. 9-29. 8 83. 3-23. 2-1. 7-10. 3 AAGGCACTGGTATTAAAGTA 2864 SEQ ID NO : 2191-4. 9-19. 5 59. 6-13. 8-0. 6-4. 1 TAGTTGCCCTTCTCCCCCTA 3002 SEQ ID NO : 2192-4. 9-32. 1 85. 6-27. 2 0-2. 3 TAACTAGTATATAAGTCTAG 3073 SEQ ID NO : 2193-4. 9-15. 6 52. 4-9. 8-0. 7-6. 3 ATTGGCTTGAGAACATATCT 3460 SEQ ID NO : 2194-4. 9-20. 5 62. 2-14. 9-0. 4-6. 2 CAAACCATGCTTCATGTACA 3736 SEQ ID NO : 2195-4. 9-21. 9 63. 4-16. 1-0. 8-6. 4 CCAGAACGAGATCTGCCCTC 35 SEQ ID NO : 2196-4. 8-27. 2 73. 6-21-1. 3-6. 3 GGGCTGGGGGACTGGAGGCA 128 SEQ ID NO : 2197-4. 8-31. 1 85. 4-25. 4-0. 8-5. 2 TTGTGCAGCCAGTTTTCAAA 544 SEQ ID NO : 2198-4. 8-23. 5 68. 6-18. 7 0-5. 3 ACCACAACTACATTGGCGTC 595 SEQ ID NO : 2199-4. 8-24. 3 68. 3-18. 5-0. 9-5. 5 GTGATTCGGCCCACCGTTCC 802 SEQ ID NO : 2200-4. 8-31. 5 81. 8-24. 2-2. 5-9. 2 TCTGATAATGGTAAACTCTG 1284 SEQ ID NO : 2201-4. 8-18 56. 4-13. 2 0-2. 6 GACATGGATTTTCATCTGAT 1298 SEQ ID NO : 2202-4. 8-20. 6 62. 8-14. 9-0. 7-5. 5 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo GAAGGTGTTGGTGGCATTCT 1427 SEQ ID NO : 2203-4. 8-25. 1 74. 1-20. 3 0-4 CGGGGTTGAGACAGGTAGCT 1546 SEQ ID NO : 2204-4. 8-26. 6 75. 9-21. 1-0. 5-4. 9 ACCCCAACAGCTAGGGCCCG 2229 SEQ ID N0 : 2205-4. 8-32. 5 81. 2-26-1. 2-11. 3 TAGTGATCAAACACGTCACT 2635 SEQ ID NO : 2206-4. 8-20. 5 61. 2-13. 7-2-7. 3 CCAGCATGAATGATACTCTG 2668 SEQ ID No : 2207-4. 8-21. 8 63. 8-17 0-4. 8 ATATCTGGCAACCGGCCATC 2697 SEQ ID NO : 2208-4. 8-27. 1 73. 4-19. 2-3. 1-10 TATTACATATGTCATAACTT 2756 SEQ ID NO : 2209-4. 8-16. 6 53. 9-11. 3 0-8. 2 CACAAATCTTTTGAAAAGTG 2962 SEQ ID NO : 2210-4. 8-15. 5 50. 3-9. 2-1. 4-6 AGGCAATGCATACACAAATC 2974 SEQ ID NO : 2211-4. 8-20 59. 4-14. 3-0. 7-8 CTACTCTAATTAGGCAATGC 2985 SEQ ID NO : 2212-4. 8-20. 6 62. 1-15. 8 0-6. 9 CACTAACTAGTATATAAGTC 3076 SEQ ID NO : 2213-4. 8-16. 8 54. 7-12 0-5. 8 CTCCCGAATCTCAGCCATAA 3301 SEQ ID NO : 2214-4. 8-25. 9 70. 3-21. 1 0-3. 2 CCTGCTTGGTGTCACACTTC 3321 SEQ ID NO : 2215-4. 8-26. 9 78. 1-20. 9-1. 1-6. 7 TGGTTCCAAGCATTTTGGAT 3549 SEQ ID NO : 2216-4. 8-23. 5 68. 4-15. 6-3. 1-8. 3 CACTTCTGGTTCCAAGCATT 3555 SEQ ID NO : 2217-4. 8-24. 7 71. 5-19. 9 0-5 AACACTTCTGGTTCCAAGCA 3557 SEQ ID NO : 2218-4. 8-24. 1 69. 4-19. 3 0-5 TGTAACTGACACATCAATGA 3666 SEQ ID NO : 2219-4. 8-18. 7 57. 3-13. 2-0. 4-4. 7 AGCACCAACAAGACAAAAAA 3783 SEQ ID NO : 2220-4. 8-16. 9 51. 5-12. 1 0-4. 1 GCTCCAAAATCCAAAACTTT 3806 SEQ ID NO : 2221-4. 8-20 57. 9-15. 2 0-2. 8 CGGGCGGTGGCAGGGAGCGA 71 SEQ ID NO : 2222-4. 7-32. 1 82. 6-25. 8-1. 6-7. 2 CCCTCCCAAGAAACAGAAGT 217 SEQ ID NO : 2223-4. 7-24. 5 66. 7-19. 8 0-2. 8 AGAGGTAGCATCCTTCATGC 432 SEQ ID NO : 2224-4. 7-25. 5 75. 3-18. 7-2. 1-8. 6 CGGAGAGGTAGCATCCTTCA 435 SEQ ID NO : 2225-4. 7-26. 3 74. 9-20. 4-1. 1-6. 9 CAAGCCGAAGGAACGCGTGT 917 SEQ ID NO : 2226-4. 7-25. 6 67. 5-18. 3-1. 5-13. 2 CACAGCCTGGCTGGAAGTCA 990 SEQ ID NO : 2227-4. 7-27. 6 77. 1-19. 3-2. 9-15. 1 TTTACCACCTCTGTGATTGT 1045 SEQ ID NO : 2228-4. 7-24. 3 70. 8-18. 8-0. 6-3. 7 CCAATGCTATTACAACGGTT 1192 SEQ ID NO : 2229-4. 7-21. 9 62. 5-17. 2 0-4. 5 TGGATTTTCATCTGATAATG 1294 SEQ ID NO : 2230-4. 7-18. 1 57-12. 5-0. 7-4. 5 CTCCACTATTTCCAGTGGCA 1397 SEQ ID NO : 2231-4. 7-27 76. 7-19. 3-3-8. 7 1412 ATTCTGCTCGATCCGCTCCA-4. 7-28. 9 78. 2-24. 2 0. 4-4. 9 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 2232 CCTCCTCGGTGTAGACCAGG 1446 SEQ ID NO : 2233-4. 7-29. 4 80. 4-22. 2-2. 5-5. 3 CGCAGTCCCCTCCCGCGAGG 1914 SEQ ID NO : 2234-4. 7-35. 4 86. 4-28. 7-2-8. 2 TGAGAACCCCAACAGCTAGG 2234 SEQ ID NO : 2235-4. 7-25. 2 69. 1-20. 5 0-4. 6 TCTAGAAATCCCAACTCCAC 2445 SEQ ID NO : 2236-4. 7-23 65. 2-18. 3 0-5. 2 ATTTGCTCCAAAGCAGTTAT 2715 SEQ ID NO : 2237-4. 7-22. 1 65. 3-14. 8-2. 6-7. 2 AGTCTAGGCATGTGGCTGAA 3060 SEQ ID NO : 2238-4. 7-24. 9 73. 3-18. 9-1. 2-6. 1 TAGACTTTGCCTCCAGGAAA 3120 SEQ ID NO : 2239-4. 7-23. 8 67. 8-19. 1 0-5 CTTGGTGTCACACTTCCTCC 3317 SEQ ID No : 2240-4. 7-27. 5 79. 2-21. 6-1. 1-6. 7 TCACAGAAACAAGAGAAGCA 3484 SEQ ID NO : 2241-4. 7-18. 4 56. 1-13. 7 0-4. 1 AACCACCTCTTGGTGTTTCC 184 SEQ ID NO : 2242-4. 6-26. 9 75. 8-19. 3-3-8. 1 AGCAAAGCAATAGCAGAGGC 287 SEQ ID NO : 2243-4. 6-22. 7 65. 9-16. 4-1. 7-7. 3 GCTTTGGGTTTGTGGAGCTT 352 SEQ ID NO : 2244-4. 6-26. 5 78. 1-21. 3-0. 3-5. 2 GTGCGGAGGTTAAACCTCAC 397 SEQ ID NO : 2245-4. 6-24. 8 69. 9-16. 7-3. 5-13. 2 TAAGGGCTGGCTGTGGCCGA 455 SEQ ID NO : 2246-4. 6-29. 6 79. 6-21. 7-3. 3-11 AAAAGGTTTTAGCTGTCATG 492 SEQ ID NO : 2247-4. 6-19. 3 59. 6-14. 7 0-4. 8 GCCAGTTTTCAAAGATACCG 537 SEQ ID NO : 2248-4. 6-23 65. 2-18. 4 0-2. 6 GAAAAATCGTCCTTCTCCTG 709 SEQ ID NO : 2249-4. 6-22. 2 63. 4-17. 6 0-3 GCTGTAGCCGATCAAGTGGA 740 SEQ ID NO : 2250-4. 6-26. 2 73. 8-21. 6 0-4. 9 GATTCGGCCCACCGTTCCTT 800 SEQ ID NO : 2251-4. 6-31. 3 80. 9-24. 2-2. 5-9. 2 TGATTCGGCCCACCGTTCCT 801 SEQ ID NO : 2252-4. 6-31. 2 80. 3-24. 2-2. 4-9. 2 GGGCCCGGCAGGATCCAAAC 824 SEQ ID NO : 2253-4. 6-30. 4 78-24. 2-1. 5-10. 6 TGCAATTGATCCCAAGACAT 1019 SEQ ID NO : 2254-4. 6-22. 4 63. 7-17. 8 0-7. 1 CATTCTGCTCGATCCGCTCC 1413 SEQ ID NO : 2255-4. 6-28. 9 78. 2-23. 8-0. 1-5. 6 TCTTCGGAGCCAGCGTTCCT 2102 SEQ ID NO : 2256-4. 6-30. 1 81. 8-24. 5-0. 9-4. 7 TCATTCTGGCCCCAGCATGA 2679 SEQ ID NO : 2257-4. 6-29. 3 79. 8-23. 1-1. 5-7. 6 GTTGCCCTTCTCCCCCTACT 3000 SEQ ID NO : 2258-4. 6-33. 5 88. 3-28. 9 0-3 TCGGGTCCTATTCCCAAAAT 3631 SEQ ID NO : 2259-4. 6-24. 9 68. 1-18. 4-1. 9-5. 6 GCTCGGGTCCTATTCCCAAA 3633 SEQ ID NO : 2260-4. 6-28. 3 76-21. 8-1. 9-5. 8 GGAAAACCCCTCACATAAGT 3761 SEQ ID NO : 2261-4. 6-23 64-18. 4 0-2. 5 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo CCGGGCGGTGGCAGGGAGCG 72 SEQ ID NO : 2262-4. 5-33. 5 84. 5-27. 4-1. 6-8. 7 ATCGTTGAGTCCACAGCCTG 1001 SEQ ID NO : 2263-4. 5-27 75. 9-22. 5 0-3. 7 ATATGCAATTGATCCCAAGA 1022 SEQ ID NO : 2264-4. 5-21. 2 61. 5-16-0. 5-7. 6 CTCCCATGTTCTTGTAACTG 1320 SEQ ID NO : 2265-4. 5-24 69. 8-18. 5-0. 9-4. 3 CCAGGAAGGTGTTGGTGGCA 1431 SEQ ID NO : 2266-4. 5-27. 6 77. 8-23. 1 0-4 TCCTCGGTGTAGACCAGGAA 1444 SEQ ID NO : 2267-4. 5-26. 4 73. 8-18. 5-3. 4-7. 1 CCTCAGGGAAGCTCCACAGT 1738 SEQ ID NO : 2268-4. 5-28. 2 78. 8-22. 1-1. 6-7 GGAGTTAGAGCTATTCAAGA 1956 SEQ ID NO : 2269-4. 5-20. 9 64. 5-15. 9-0. 2-5. 1 GACTTGGTGCTCTGGAGGTG 1989 SEQ ID NO : 2270-4. 5-26. 4 77. 6-21. 9 0-6. 4 AATGAACAGAAAAATAGGAA 2337 SEQ ID NO : 2271-4. 5-12. 7 44. 3-8. 2 0'-2. 4 AAATGAACAGAAAAATAGGA 2338 SEQ ID NO : 2272-4. 5-12. 7 44. 3-8. 2 0-2. 4 TCTAAACAGAAGAGATTTGC 2729 SEQ ID NO : 2273-4. 5-17. 6 55. 5-13. 1 0-5. 7 CTCTAAACAGAAGAGATTTG 2730 SEQ ID NO : 2274-4. 5-16. 7 53. 5-11. 3-0. 7-4 TTGCCTCCAGGAAATCTGAG 3114 SEQ ID NO : 2275-4. 5-24. 2 68. 8-18. 6-1-4. 9 ATAGACTTTGCCTCCAGGAA 3121 SEQ ID NO : 2276-4. 5-24. 5 70-20 0-5 TCCCGAATCTCAGCCATAAA 3300 SEQ ID NO : 2277-4. 5-24. 3 66. 5-19. 8 0-3. 2 GTACAAAGAAAATCATTCTT 3346 SEQ ID NO : 2278-4. 5-15. 5 50. 6-9. 2-1. 8-7. 7 GGTTCCAAGCATTTTGGATA 3548 SEQ ID NO : 2279-4. 5-23. 2 67. 9-15. 6-3. 1-8. 3 TAACTGACACATCAATGAAT 3664 SEQ ID NO : 2280-4. 5-16. 8 52. 8-11. 6-0. 4-4. 8 GTGTAACTGACACATCAATG 3667 SEQ ID NO : 2281-4. 5-19. 3 59-12. 4-2. 4-6. 8 GTGGCAGGGAGCGAGTGTCA 65 SEQ ID NO : 2282-4. 4-28. 6 81. 7-22. 6-1. 6-5. 3 GTGTAGCTTTGGGTTTGTGG 357 SEQ ID No : 2283-4. 4-25. 2 76. 1-20. 8 0-4. 6 GTAAAGCTGGTGGGCCAGGG 626 SEQ ID NO : 2284-4. 4-27. 9 77. 5-20. 3-3. 2-9. 4 TCAAACATGGGCCCGGCAGG 832 SEQ ID NO : 2285-4. 4-28. 5 74. 5-22. 5-0. 7-11. 2 CTCAAGCCGAAGGAACGCGT 919 SEQ ID NO : 2286-4. 4-25. 7 67. 8-19. 3-1. 5-12 ATGCTCACATTTTACCACCT 1055 SEQ ID NO : 2287-4. 4-24. 7 70. 3-19. 8-0. 2-3. 6 TTTTGAAGCGATTGGAGTCA 1146 SEQ ID NO : 2288-4. 4-21. 6 64. 1-17. 2 0-5 AGGCCCCCTCCCAGGTGAGC 1491 SEQ ID NO : 2289-4. 4-35. 8 92. 7-30. 6-0. 5-8. 5 TGCCTTGCTGGCAAGACTTG 1767 SEQ ID NO : 2290-4. 4-26. 3 73. 6-18. 7-3. 2-12. 7 1780 CAGGAAGTCTTGCTGCCTTG-4. 4-25. 9 74. 3-21. 5 0-5. 4 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 2291 AGTCCCAGCCATCACAGGAG 1894 SEQ ID NO : 2292-4. 4-28. 6 79. 7-23. 7-0. 1-3. 7 TCTGGAGGTGTGGACAGAGG 1979 SEQ ID NO : 2293-4. 4-25. 2 74. 6-19. 8-0. 9-4. 9 GCTTACACACAAATCTGGAC 2006 SEQ ID NO : 2294-4. 4-21. 1 62. 4-16. 7 0-3 GTCAGTGCAACCCATGAGAA 2248 SEQ ID NO : 2295-4. 4-24. 7 69. 7-19. 8-0. 2-4. 9 GGTGCCTTTCCCCATGCATA. 2495 SEQ ID NO : 2296-4. 4-30. 6 82-25. 3-0. 7-6. 8 TAATAGTTGCCCTTCTCCCC 3005 SEQ ID NO : 2297-4. 4-28. 5 77. 8-24. 1 0-3 TCCAGGAAATCTGAGTCCTC 3109 SEQ ID NO : 2298-4. 4-24. 3 70. 7-18. 7-1. 1-7. 4 GCTCTATATAAAAAAAAAAG 3211 SEQ ID NO : 2299-4. 4-10. 8 41. 1-6. 4 0-3. 3 ATACATTAATAAAAGGGCTT 3246 SEQ ID NO : 2300-4. 4-16. 5 52. 3-12. 1 0-4. 2 TATTTAAAATATCGTATAAA 3712 SEQ ID NO : 2301-4. 4-11. 6 42. 6-7. 2 0-5 GTCCTGAGCCGCCGGGAGGC 15 SEQ ID NO : 2302-4. 3-34. 3 88. 2-26. 9-3. 1-12 GGGCGGTGGCAGGGAGCGAG 70 SEQ ID NO : 2303-4. 3-31. 3 83. 5-25. 4-1. 6-7. 2 AAACTTGGCGGCACGGAGCC 91 SEQ ID NO : 2304-4. 3-27. 9 73-21. 6-2-9. 3 CGCAGCAAAGCAATAGCAGA 290 SEQ ID NO : 2305-4. 3-23 64. 7-17-1. 7-7. 4 GAAGTTGCCTGCATACCCGG 776 SEQ ID NO : 2306-4. 3-28. 3 75. 1-24 0-5. 8 TTTTCATCTGATAATGGTAA 1290 SEQ ID NO : 2307-4. 3-17. 7 56. 2-13. 4 0-4. 2 ACCAGGAAGGTGTTGGTGGC 1432 SEQ ID NO : 2308-4. 3-27. 1 77. 3-21. 6-1 : 1-6e5 GCACCCTCAGGGAAGCTCCA 1742 SEQ ID NO : 2309-4. 3-30. 8 82. 7-24. 3-2. 2-8. 9 TCGCCCAGCAACTGAGAAAC 2063 SEQ ID NO : 2310-4. 3-24. 6 67-19. 6-0. 4-4. 1 ACATGAGTCAGCTCCTGTCG 2183 SEQ ID NO : 2311-4. 3-26. 2 75. 6-20. 1-1. 8-7 CCCATGAGAACCCCAACAGC 2238 SEQ ID NO : 2312-4. 3-28. 1 72. 8-23. 8 0-4. 5 CCTCTCCCTGGCTGCACCAC 3093 SEQ ID NO : 2313-4. 3-33 87. 1-27. 4-1. 2-8. 4 TGCCTCCAGGAAATCTGAGT 3113 SEQ ID NO : 2314-4. 3-25. 3 71. 6-19. 9-1-5 AATTGGCTTGAGAACATATC 3461 SEQ ID NO : 2315-4. 3-18. 9 58. 2-14. 6 0-4. 5 AACCTGTACAAGCTTCGCTT 3518 SEQ ID NO : 2316-4. 3-24. 3 68. 7-18. 6-1. 3-7. 8 TCTCATTATGTATATGCAAA 3610 SEQ ID NO : 2317-4. 3-17. 9 56. 4-13. 6 0-6. 2 CAGAACGAGATCTGCCCTCG 34 SEQ ID NO : 2318-4. 2-26 70. 2-20. 4-1. 3-6. 4 GTGTTTCCAGCAATCCCGGC 172 SEQ ID NO : 2319-4. 2-29. 7 80. 1-25. 5 0-6. 1 GTGCGCTCCGAGGCTGTAGC 752 SEQ ID NO : 2320-4. 2-30. 9 84. 3-25. 9-0. 6-8 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo CCCTTCAAACATGGGCCCGG 836 SEQ ID NO : 2321-4. 2-29. 8 75. 5-24-0. 4-11. 2 ATCCCCTTTTTGAAGCGATT 1153 SEQ ID NO : 2322-4. 2-24. 9 68. 9-20. 1-0. 3-5. 4 TGGCAGAGTCTGGGAATCTG 1382 SEQ ID NO : 2323-4. 2-24. 4 71. 7-17. 7-2. 5-9. 6 CTCCTCGGTGTAGACCAGGA 1445 SEQ ID NO : 2324-4. 2-28 78. 2-20. 4-3. 4-7. 1 AACTTTCCTCCATGGGCTTG 1805 SEQ ID NO : 2325-4. 2-26. 2 73. 6-21. 4-0. 2-8. 3 GGTTCCAAATGGAGAGGCTC 2423 SEQ ID NO : 2326-4. 2-24. 9 71. 7-20. 2-0. 2-7. 5 AGGTGGCACATAATAACTAA 2607 SEQ ID NO : 2327-4. 2-19. 1 57. 9-14-0. 8-4. 8 GTATTACATATGTCATAACT 2757 SEQ ID NO : 2328-4. 2-17. 7 56. 5-13 0-7. 9 ATAATAGTTGCCCTTCTCCC 3006 SEQ ID NO : 2329-4. 2-26. 5 74. 3-22. 3 0-3 TGGGAACTGGCTGCAAAAGT 3159 SEQ ID NO : 2330-4. 2-22. 9 65. 1-18. 2-0. 2-7. 6 AAGTCCTTGTTTGTCTCACG 3194 SEQ ID NO : 2331-4. 2-23. 9 70. 5-19. 7 0-3 ATAAAAAAAAAAGTCCTTGT 3204 SEQ ID NO : 2332-4. 2-13. 2 45. 3-9 0-3. 2 CTCGGGTCCTATTCCCAAAA 3632 SEQ ID NO : 2333-4. 2-25. 8 69. 9-19. 7-1. 9-5. 6 CTATGTGGATAAGGTGTAAC 3680 SEQ ID NO : 2334-4. 2-19. 4 60-15. 2 0-1. 9 ACCAGGATGTACAGCCAATA 3870 SEQ ID NO : 2335-4. 2-24 68. 1-19. 2-0. 3-7. 1 AACTTGGCGGCACGGAGCCC 90 SEQ ID NO : 2336-4. 1-30. 6 78. 4-24. 1-2. 4-9. 3 ACAAAAACCACCTCTTGGTG 189 SEQ ID NO : 2337-4. 1-21. 9 62. 2-15. 1-2. 7-7 GAATGATGAAAAAGGTTTTA 501 SEQ ID NO : 2338-4. 1-14. 7 48. 7-9. 9-0. 4-4. 4 TCCATCCGTGAATGATGAAA 510 SEQ ID NO : 2339-4. 1-21. 2 60. 5-15. 9-1. 1-4. 6 CCCACCGTTCCTTTCACGAA 793 SEQ ID NO : 2340-4. 1-28. 5 73. 9-23. 9-0. 1-3. 7 ATTCGGCCCACCGTTCCTTT 799 SEQ ID NO : 2341-4. 1-30. 8 80-24. 2-2. 5-6. 6 CCCGGCAGGATCCAAACCTG 821 SEQ ID NO : 2342-4. 1-29. 1 74. 3-23. 5-1. 4-9 ATGTCGGCCCCTTCAAACAT 844 SEQ ID NO : 2343-4. 1-27 72. 2-22. 9 0-5. 7 CGGAGAGAGCCTCTTGTGGA 863 SEQ ID NO : 2344-4. 1-26. 9 75. 9-21. 3-1. 4-8. 2 AGGTGTGGACAGAGGTTTGG 1974 SEQ ID NO : 2345-4. 1-24. 7 73. 7-20-0. 3-4 CCTCACTAAGCCTCAGTTTT 3040 SEQ ID NO : 2346-4. 1-25. 4 73. 3-21. 3 0-3. 2 CAGAGATAGACTTTGCCTCC 3126 SEQ ID NO : 2347-4. 1-24. 6 71. 3-20. 5 0-3. 8 TACATTAATAAAAGGGCTTA 3245 SEQ ID NO : 2348-4. 1-16. 2 51. 8-12. 1 0-4. 2 CACTTCCTCCCGAATCTCAG 3307 SEQ ID NO : 2349-4. 1-26. 7 73. 3-22. 6 0-2. 8 3351 CCTAAGTACAAAGAAAATCA-4. 1-15. 9 50. 6-11. 8 0-4. 5 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 2350 CAATCACAGAAACAAGAGAA 3487 SEQ ID NO : 2351-4. 1-15. 9 50. 6-11. 8 0-2. 9 TGACCAGGATGTACAGCCAA 3872 SEQ ID NO : 2352-4. 1-24. 9 69. 8-20. 2-0. 3-7. 1 CTTGCCCCAGAACGAGATCT 41 SEQ ID NO : 2353-4-26. 9 72. 4-22. 9 0-6. 3 TTTGTGGAGCTTATCTTCCA 344 SEQ ID NO : 2354-4-24. 2 72-18. 7-1. 4-5. 9 TCTGGGTCCTTGGAGGTGCG 412 SEQ ID NO : 2355-4-29. 1 81. 6-24. 3-0. 6-5. 9 TCCGTGAATGATGAAAAAGG 506 SEQ ID NO : 2356-4-17. 9 53. 8-13. 9 0-3. 3 CACGTGCGCTCCGAGGCTGT 755 SEQ ID NO : 2357-4-31. 1 81. 2-26. 2-0. 6-9. 3 CTGTGATTCGGCCCACCGTT 804 SEQ ID NO : 2358-4-30 78. 5-23. 5-2. 5-9. 2 CCTTCAAACATGGGCCCGGC 835 SEQ ID NO : 2359-4-29. 6 76. 2-24 0-11. 2 TCAAGCCGAAGGAACGCGTG 918 SEQ ID NO : 2360-4-24. 8 66-18. 3-0. 8-13. 2 TTGATCCCAAGACATCGTTG 1014 SEQ ID NO : 2361-4-23. 1 65. 7-19. 1 0-4. 3 TGTAGCCAATGCTATTACAA 1197 SEQ ID NO : 2362-4-21. 1 62. 3-15-2. 1-8. 5 TCCCATGTTCTTGTAACTGA 1319 SEQ ID NO : 2363-4-23. 7 69. 2-18. 7-0. 9-4. 3 CTGCGAAACTCCTTCCACAG 1528 SEQ ID NO : 2364-4-25. 2 69. 1-20. 7-0. 1-4. 3 CCCGACACTTGCGAAACCAG 1686 SEQ ID NO : 2365-4-26. 2 67. 9-22. 2 0-4. 3 TTCGTTTTTCATCCTCCAGC 1709 SEQ ID NO : 2366-4-26. 2 75. 5-22. 2 0-3 AGCAGGAAGTCTTGCTGCCT 1782 SEQ ID NO : 2367-4-27. 6 78. 9-20. 7-2. 9-9. 4 GACGTAAGCAGTATGGTCAG 2263 SEQ ID NO : 2368-4-22. 7 67. 4-18. 2-0. 2-5. 6 TAATTAATTTTAAGTGTTCA 2379 SEQ ID NO : 2369-4-15 50. 5-11 0-6. 2 TTATATCCTATAGCCTCCCC 2524 SEQ ID NO : 2370-4-27. 3 75. 5-23. 3 0-5 AACTTCTATCTCTCTAAACA 2741 SEQ ID NO : 2371-4-18. 6 58. 4-14. 6 0-0. 9 CCCCCTACTCTAATTAGGCA 2989 SEQ ID NO : 2372-4-27. 5 74. 6-22. 8-0. 5-7. 5 TCCTGGTTATACATTAATAA 3254 SEQ ID NO : 2373-4-18. 2 56. 6-14. 2 0-4. 6 CACAGATGTTCTCCTGGTTA 3265 SEQ ID NO : 2374-4-24. 3 72. 1-19. 5-0. 6-4. 6 GAATTTTGTGTTTAGGCTCG 3648 SEQ ID No : 2375-4-21. 6 64. 9-17. 6 0-3. 7 GCACCAACAAGACAAAAAAT 3782 SEQ ID NO : 2376-4-16. 9 51. 4-12. 9 0-3. 4 ACCACCTCTTGGTGTTTCCA 183 SEQ ID NO : 2377-3. 9-28. 3 79. 4-21. 4-3-7. 4 AAGTTGCCTGCATACCCGGC 775 SEQ ID NO : 2378-3. 9-29. 5 77. 9-25-0. 3-6. 9 AAGCCGAAGGAACGCGTGTA 916 SEQ ID NO : 2379-3. 9-24. 6 66-18-2. 1-13. 2 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo TCGTTGAGTCCACAGCCTGG 1000 SEQ ID NO : 2380-3. 9-28. 2 78. 5-23. 5-0. 6-4. 8 ATTGGAGTCAGTGCACTGGA 1136 SEQ ID NO : 2381-3. 9-24. 8 73. 5-17. 8-0. 4-14. 4 GCGATTGGAGTCAGTGCACT 1139 SEQ ID NO : 2382-3. 9-26. 2 75. 3-21. 2-0. 1-10. 1 TCCCCTTTTTGAAGCGATTG 1152 SEQ ID NO : 2383-3. 9-24. 9 68. 8-20. 2-0. 6-5. 3 CATAAAGGGTGACGTAAAAG 1353 SEQ ID NO : 2384-3. 9-17 52. 6-13. 1 0-5. 3 AGTGCCATAAAGGGTGACGT 1358 SEQ ID NO : 2385-3. 9-24. 4 68. 9-19. 8-0. 4-8. 2 GGATATGCTGGTGTTCTCAG 1652 SEQ ID NO : 2386-3. 9-24. 3 73. 1-19. 9-0. 1-4. 8 CCAGGGTCAAGGCTGAGAAG 1855 SEQ ID NO : 2387-3. 9-25. 1 71. 4-20. 5-0. 5-4. 1 TAAGACGTAAGCAGTATGGT 2266 SEQ ID NO : 2388-3. 9-20. 6 61. 9-15. 8-0. 8-6. 2 GGTATTAAAGTAAAATATTT 2856 SEQ ID NO : 2389-3. 9-13. 2 46. 1-9. 3 0-6. 4 CTCCTGGTTATACATTAATA 3255 SEQ ID NO : 2390-3. 9-19. 8 60. 5-15. 9 0-4. 6 TTCAGAAGTTTAACAGTGAT 3414 SEQ ID NO : 2391-3. 9-18. 2 57. 7-14. 3 0-4. 6 ATGGGAAAACCCCTCACATA 3764 SEQ ID NO : 2392-3. 9-23. 7 65. 1-17. 5-2. 3-5. 8 CTGCCCCGCCACACCCCCTC 232 SEQ ID NO : 2393-3. 8-38. 4 90. 9-34. 6 0-3 ACAGAGCAGAGGAACGGAGT 260 SEQ ID NO : 2394-3. 8-23. 7 68. 3-19. 2-0. 5-4. 3 GCTCACATTTTACCACCTCT 1053 SEQ ID NO : 2395-3. 8-26 74-22. 2 0-2. 8 CTTTTTGAAGCGATTGGAGT 1148 SEQ ID NO : 2396-3. 8-21. 5 63. 7-17. 2-0. 1-5. 3 AAGGTGTTGGTGGCATTCTG 1426 SEQ ID NO : 2397-3. 8-24. 5 72. 5-20. 7 0-4 AGGTTGTACCAAGACTGAGA 1510 SEQ ID NO : 2398-3. 8-22. 5 66. 7-17-1. 7-5 GGCTGAGAAGAATCCTTCCA 1845 SEQ ID NO : 2399-3. 8-24. 8 70. 2-18. 9-2. 1-8. 1 CCCTCCCGCGAGGAGTCCCA 1907 SEQ ID NO : 2400-3. 8-35. 4 87. 3-28. 7-2. 5-13. 6 ATGAGAACCCCAACAGCTAG 2235 SEQ ID NO : 2401-3. 8-24 66. 7-20. 2 0-4. 6 CTGTGTACACAGATGTGTAT 2773 SEQ ID NO : 2402-3. 8-21. 5 65. 9-14. 5-1. 7-14. 6 GCTCTGTCTGGCAGGTGCCG 2797 SEQ ID NO : 2403-3. 8-31. 2 86. 6-25-2. 4-10. 9 ACTGTATTAAATCTTAGAAC 2819 SEQ ID NO : 2404-3. 8-15. 6 51. 5-11. 8 0-3 GCACTGGTATTAAAGTAAAA 2861 SEQ ID NO : 2405-3. 8-16. 9 53. 3-13. 1 0-3. 4 CAATGCATACACAAATCTTT 2971 SEQ ID NO : 2406-3. 8-18. 1 55. 5-14. 3 0-7. 3 CCTTCTCCCCCTACTCTAAT 2995 SEQ ID NO : 2407-3. 8-28. 7 77. 6-24. 9 0-0. 9 GACTTTGCCTCCAGGAAATC 3118 SEQ ID NO : 2408-3. 8-24. 5 69. 5-20. 7 0-5 3210 CTCTATATAAAAAAAAAAGT-3. 8-10. 2 40-6. 4 0-3. 3 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 2409 TCATGTACACAACTATTTAA 3725 SEQ ID NO : 2410-3. 8-17. 1 54. 4-13. 3 0-6. 7 TTACCACAAACCATGCTTCA 3742 SEQ ID NO : 2411-3. 8-23 64. 9-19. 2 0-4. 2 CAGAGCAGAGGAACGGAGTT 259 SEQ ID NO : 2412-3. 7-23. 6 68. 1-18. 3-1. 6-7. 3 CCCGCAGCAAAGCAATAGCA 292 SEQ ID NO : 2413-3. 7-26. 4 69. 9-21-1. 7-7. 4 CATCCGTGTAAAGCTGGTGG 633 SEQ ID NO : 2414-3. 7-24. 9 70-21. 2 0-5. 1 CGTGCGCTCCGAGGCTGTAG 753 SEQ ID NO : 2415-3. 7-29. 9 79. 4-25. 5-0. 5-8. 2 TGGGGTAGATGTCAATGTGG 963 SEQ ID NO : 2416-3. 7-23. 1 68. 7-19. 4 0-3. 8 ACAGCCTGGCTGGAAGTCAC 989 SEQ ID NO : 2417-3. 7-27. 1 76. 7-19. 8-2. 9-15. 1 CCACAGCCTGGCTGGAAGTC 991 SEQ ID NO : 2418-3. 7-28. 9 79. 6-21. 6-2. 9-15. 1 AAGAGGTGGACGGCTCGCTC 1075 SEQ ID NO : 2419-3. 7-27. 3 75. 6-22. 2-1. 3-5. 5 CAGAGTCTGGGAATCTGCAT 1379 SEQ ID NO : 2420-3. 7-23. 9 70. 3-18. 2-2-8. 3 CCTCCCAGGTGAGCTGGATC 1485 SEQ ID NO : 2421-3. 7-29. 9 82. 8-23. 2-3-7. 3 CCCCTCCCAGGTGAGCTGGA 1487 SEQ ID No : 2422-3. 7-33. 5 87. 6-26. 8-3-7. 6 GTAGCTGCGAAACTCCTTCC 1532 SEQ ID NO : 2423-3. 7-26. 3 73-22. 6 0-7. 2 GGCCTGGGGATATGCTGGTG 1659 SEQ ID NO : 2424-3. 7-28. 9 80. 2-24. 7-0. 1-6. 4 CTCCCGGCCTGGGGATATGC 1664 SEQ ID NO : 2425-3. 7-31. 7 82. 6-25. 6-2. 1-12. 4 CAGTAACTTTCCTCCATGGG 1809 SEQ ID NO : 2426-3. 7-25 71. 4-20. 7-0. 2-8. 3 AGCTCTGTCTGGCAGGTGCC 2798 SEQ ID NO : 2427-3. 7-30. 4 87. 9-25-1. 7-9. 5 ATTAAATCTTAGAACCAGCT 2814 SEQ ID NO : 2428-3. 7-19 57. 9-15. 3 0-4. 3 CAAGAAAAGGCACTGGTATT 2870 SEQ ID NO : 2429-3. 7-19. 5 58. 4-15-0. 6-4 TCCCCCTACTCTAATTAGGC 2990 SEQ ID NO : 2430-3. 7-27. 2 75. 2-22. 8-0. 5-7. 5 AGTTGCCCTTCTCCCCCTAC 3001 SEQ ID NO : 2431-3. 7-32. 6 86. 8-28. 9 0-3 CAATTGGCTTGAGAACATAT 3462 SEQ ID NO : 2432-3. 7-19. 2 58. 1-15. 5 0-5. 7 AATTTTGTGTTTAGGCTCGG 3647 SEQ ID NO : 2433-3. 7-22. 2 66. 2-18. 5 0-3. 7 CATGTACACAACTATTTAAA 3724 SEQ ID NO : 2434-3. 7-16 51. 5-12. 3 0-6. 7 GGAGCTTATCTTCCAGCCGT 339 SEQ ID NO : 2435-3. 6-28. 6 79. 9-24. 1-0. 8-5. 2 TGGGCCAGGGGGAGCCAGTC 616 SEQ ID NO : 2436-3. 6-32. 4 88. 9-26. 3-2. 5-9. 2 CTGGTGGGCCAGGGGGAGCC 620 SEQ ID NO : 2437-3. 6-33. 4 89. 8-26. 5-3. 3-8. 9 GTGTAAAGCTGGTGGGCCAG 628 SEQ ID NO : 2438-3. 6-26. 7 75. 6-20. 3-2. 8-8. 7 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo TGAAGCGATTGGAGTCAGTG 1143 SEQ ID NO : 2439-3. 6-22. 5 66. 3-18. 9 0-5 AACTCTGAAAGGCATGCCTG 1271 SEQ ID NO : 2440-3. 6-23. 3 66. 1-16. 4-0. 4-14. 8 GTGCCATAAAGGGTGACGTA 1357 SEQ ID NO : 2441-3. 6-24. 1 68. 1-19. 8-0. 4-8. 2 CCTCAGCAGTAACTTTCCTC 1815 SEQ ID NO : 2442-3. 6-25. 7 74. 6-22. 1 0-3. 3 CCTCTTCGGAGCCAGCGTTC 2104 SEQ ID NO : 2443-3. 6-30. 1 81. 8-25. 2-1. 2-5. 6 AAGACGTAAGCAGTATGGTC 2265 SEQ ID NO : 2444-3. 6-21. 3 63. 9-17. 2-0. 2-5. 6 CTAAGACGTAAGCAGTATGG 2267 SEQ ID NO : 2445-3. 6-20. 3 60. 8-16. 2-0. 2-5 AGAGTGAGCTGGGGAGCAGG 2296 SEQ ID NO : 2446-3. 6-27 78. 6-21. 8-1. 6-5. 5 CTCAATTAAAAAATGAACAG 2348 SEQ ID NO : 2447-3. 6-12. 4 43. 9-8. 8 0-2. 9 ACCACATTCTAATTAATTTT 2388 SEQ ID NO : 2448-3. 6-17. 6 55. 1-14 0-6. 2 CTTTCCCCATGCATATACAC 2490 SEQ ID NO : 2449-3. 6-25. 2 70. 4-21. 6 0-6. 8 TGGCAGGTGCCGGTTTCTGT 2789 SEQ ID NO : 2450-3. 6-29. 8 83. 3-23. 8-2. 4-10. 9 AGAACCAGCTCTGTCTGGCA 2804 SEQ ID NO : 2451-3. 6-27 77. 2-21. 2-2. 2-7. 1 CACTGTATTAAATCTTAGAA 2820 SEQ ID NO : 2452-3. 6-16. 1 52. 3-12. 5 0-3 ACAAGAAAAGGCACTGGTAT 2871 SEQ ID NO : 2453-3. 6-19. 6 58. 5-15. 2-0. 6-4. 1 CAGTTTTGTAAAATAGGGAT 3027 SEQ ID NO : 2454-3. 6-17. 7 55. 7-13. 6-0. 1-4. 2 TCACACTTCCTCCCGAATCT 3310 SEQ ID NO : 2455-3. 6-26. 9 73. 5-23. 3 0-2. 8 ACCTAAGTACAAAGAAAATC 3352 SEQ ID NO : 2456-3. 6-15. 4 49. 8-11. 8 0-5. 3 TTCTGGTTCCAAGCATTTTG 3552 SEQ ID NO : 2457-3. 6-23. 1 68. 4-19. 5 0-5 CTGAAAATAATCTAAAATTT 3579 SEQ ID NO : 2458-3. 6-11. 5 42. 4-7. 9 0-4. 9 ATCTCATTATGTATATGCAA 3611 SEQ ID NO : 2459-3. 6-18. 6 58. 4-15 0-6. 2 CAATCCCGGCCGGTAAGACC 162 SEQ ID NO : 2460-3. 5-29. 2 74. 2-22. 9-0. 3-13. 7 GTTTCCAGCAATCCCGGCCG 170 SEQ ID NO : 2461-3. 5-31. 3 79. 8-26. 7-0. 1-10. 2 CACCTCTTGGTGTTTCCAGC 181 SEQ ID NO : 2462-3. 5-27. 9 80-21. 9-2. 5-7. 8 GGTTTGACCTCAGTCTGTGT 373 SEQ ID NO : 2463-3. 5-26. 3 78. 8-21. 8-0. 9-5. 8 CTGGCTGTGGCCGACGGAGA 449 SEQ ID NO : 2464-3. 5-29. 8 78. 7-23-3. 3-8. 4 GGTGGGCCAGGGGGAGCCAG 618 SEQ ID NO : 2465-3. 5-33. 2 89. 5-27. 2-2. 5-9. 2 TGGTGGGCCAGGGGGAGCCA 619 SEQ ID NO : 2466-3. 5-33. 2 88. 8-26. 5-3. 2-8. 4 GGCTGTAGCCGATCAAGTGG 741 SEQ ID NO : 2467-3. 5-26. 8 75-21. 6-1. 7-9. 8 773 GTTGCCTGCATACCCGGCCA-3. 5-32. 9 84. 1-27. 9-1. 4-8 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 2468 TCGGCCCACCGTTCCTTTCA 797 SEQ ID NO : 2469-3. 5-31. 8 82. 3-25. 8-2. 5-6. 6 AGACATGGATTTTCATCTGA 1299 SEQ ID NO : 2470-3. 5-20. 6 63. 1-16. 2-0. 7-5. 5 CCGGGCACCCTCAGGGAAGC 1746 SEQ ID NO : 2471-3. 5-32 82. 5-26. 3-2. 2-11. 2 GCCTTGCTGGCAAGACTTGC 1766 SEQ ID NO : 2472-3. 5-28. 1 78. 1-22-2. 5-12. 7 GTCAAGGCTGAGAAGAATCC 1850 SEQ ID NO : 2473-3. 5-22. 3 65. 5-18-0. 6-3. 9 CAGTGCTCCAGGGTCAAGGC 1862 SEQ ID NO : 2474-3. 5-28. 7 81. 8-25. 2 0-3. 9 GCCATCACAGGAGACCAGTT 1887 SEQ ID NO : 2475-3. 5-27. 1 76. 4-23-0. 3-3. 8 TCCCGCGAGGAGTCCCAGCC 1904 SEQ ID NO : 2476-3. 5-34. 3 86. 9-29. 3-1. 3-10 AACAGCTAGGGCCCGAGCAA 2224 SEQ ID NO : 2477-3. 5-28 74. 3-22. 1-1. 7-12. 8 AAATAGGAAAGCCAATGATG 2326 SEQ ID NO : 2478-3. 5-17. 1 52. 6-13-0. 3-3. 2 CATAATAACTAAGAAGAAAT 2577 SEQ ID NO : 2479-3. 5-11. 9 43. 1-8. 4 0-2. 2 GATTTGCTCCAAAGCAGTTA 2716 SEQ ID NO : 2480-3. 5-22. 7 66. 6-16. 6-2. 6-10. 2 AGATTTGCTCCAAAGCAGTT 2717 SEQ ID NO : 2481-3. 5-23 67. 4-17. 2-2. 3-10. 2 ATTGTGTGTATTAATTCAAA 2928 SEQ ID NO : 2482-3. 5-16. 3 53. 1-12. 8 0-4. 2 ACTTCCTCCCGAATCTCAGC 3306 SEQ ID NO : 2483-3. 5-27. 8 76. 4-24. 3 0-2. 8 ATACAACTTTGGCACGATAC 3396 SEQ ID NO : 2484-3. 5-20. 4 60. 2-16. 2-0. 4-4 AATGGGAAAACCCCTCACAT 3765 SEQ ID NO : 2485-3. 5-23. 3 63. 7-17. 5-2. 3-5. 8 ATGAAAAAGGTTTTAGCTGT 496 SEQ ID NO : 2486-3. 4-18. 1 56. 4-14-0. 4-8. 1 GCCGATCAAGTGGACATTCC 734 SEQ ID NO : 2487-3. 4-26 72-21. 9-0. 4-5. 9 CGGCCCACCGTTCCTTTCAC 796 SEQ ID NO : 2488-3. 4-31. 6 81. 2-26. 3-1. 9-6. 2 ATCTGAATACCAATGCTCAA 934 SEQ ID NO : 2489-3. 4-20. 2 59. 8-16. 8 0-3. 6 GCTATTACAACGGTTCTTGC 1187 SEQ ID NO : 2490-3. 4-23. 1 67. 4-19. 7 0-4. 7 GATATGCTGGTGTTCTCAGG 1651 SEQ ID NO : 2491-3. 4-24. 3 73. 1-20. 2-0. 5-5. 2 CGGGCACCCTCAGGGAAGCT 1745 SEQ ID NO : 2492-3. 4-30. 9 81. 1-24. 5-3-9. 8 TGGACAGAGGTTTGGAGTTA 1969 SEQ ID NO : 2493-3. 4-22. 7 68. 7-19. 3 0-3. 8 AGGCTCGCCCAGCAACTGAG 2067 SEQ ID NO : 2494-3. 4-29. 1 78-23. 6-2. 1-7. 7 GGAATGGCTAAGACGTAAGC 2274 SEQ ID NO : 2495-3. 4-21. 6 62. 7-17. 3-0. 7-7 ATGAACAGAAAAATAGGAAA 2336 SEQ ID No : 2496-3. 4-12. 7 44. 3-9. 3 0-2. 4 TTTAAGTGTTCAATAGACAT 2371 SEQ ID NO : 2497-3. 4-17. 3 55. 6-13. 9 0-6. 2 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo CACGTCACTCATAGGGGAGG 2624 SEQ ID NO : 2498-3. 4-25. 3 72. 4-21. 1-0. 6-5. 5 TAGAACCAGCTCTGTCTGGC 2805 SEQ ID NO : 2499-3. 4-26 75. 4-21. 2-1. 3-6. 2 CATACACAAATCTTTTGAAA 2966 SEQ ID NO : 2500-3. 4-15. 6 50. 4-10. 7-1. 4-5. 2 CTTCTCCCCCTACTCTAATT 2994 SEQ ID NO : 2501-3. 4-26. 8 74. 6-23. 4 0-2. 5 TTATACATTAATAAAAGGGC 3248 SEQ ID NO : 2502-3. 4-15. 3 50-11. 9 0-4. 2 AAAAGTCCAACCGTTGGCAC 3282 SEQ ID NO : 2503-3. 4-23. 7 65. 4-18. 2-2. 1-10. 9 TAGAAAACCTAAGTACAAAG 3358 SEQ ID NO : 2504-3. 4-14. 7 48. 4-11. 3 0-5. 6 GATTAAAACAATGTCCTTAG 3375 SEQ ID NO : 2505-3. 4-16. 8 53. 1-13. 4 0-4. 8 GTCCTTGGAGGTGCGGAGGT 407 SEQ ID NO : 2506-3. 3-29. 6 83. 3-25. 5-0. 6-5. 9 CGTGTAAAGCTGGTGGGCCA 629 SEQ ID NO : 2507-3. 3-27. 5 75. 1-23-1. 1-7. 6 CTGGCAATGCTGTGTCCCAC 673 SEQ ID NO : 2508-3. 3-28. 3 78. 1-23. 5-0. 4-11 CGAGAGAAAAATCGTCCTTC 714 SEQ ID NO : 2509-3. 3-20 58. 5-16. 2-0. 2-3. 5 GCCCACCGTTCCTTTCACGA 794 SEQ ID NO : 2510-3. 3-31 80-26. 9-0. 6-3. 8 ATGGGCCCGGCAGGATCCAA 826 SEQ ID NO : 2511-3. 3-30. 9 79. 6-25. 8-1. 5-11. 2 GAGAGCCTCTTGTGGATGTC 859 SEQ ID NO : 2512-3. 3-25. 9 76. 9-22. 6 0-5. 8 GATCCCCTTTTTGAAGCGAT 1154 SEQ ID NO : 2513-3. 3-25. 4 69. 8-21. 2-0. 7-4. 9 GGGAATCTGCATTAGTGCCA 1371 SEQ ID NO : 2514-3. 3-25. 6 72. 9-20. 4-1. 9-8. 8 GGCACCCTCAGGGAAGCTCC 1743 SEQ ID NO : 2515-3. 3-31. 3 84. 3-25-3-9. 8 CTCCAGGGTCAAGGCTGAGA 1857 SEQ ID NO : 2516-3. 3-27. 1 77. 3-23. 1-0. 5-7. 9 AGAAAAATAGGAAAGCCAAT 2330 SEQ ID NO : 2517-3. 3-15. 7 49. 7-11. 2-1. 1-3. 8 CAGAAAAATAGGAAAGCCAA 2331 SEQ ID NO : 2518-3. 3-16. 4 50. 8-11. 9-1. 1-3. 5 TCAATTAAAAAATGAACAGA 2347 SEQ ID NO : 2519-3. 3-12. 1 43. 3-8. 8 0-3 TTTTAAGTGTTCAATAGACA 2372 SEQ ID NO : 2520-3. 3-17. 4 55. 9-14. 1 0-6. 2 ACATTCTAATTAATTTTAAG 2385 SEQ ID NO : 2521-3. 3-13. 7 47. 4-10. 4 0-6. 2 TCAAACACGTCACTCATAGG 2629 SEQ ID NO : 2522-3. 3-21 62. 1-17. 7 0-4. 6 AAAGGCACTGGTATTAAAGT 2865 SEQ ID NO : 2523-3. 3-19. 1 58. 2-15-0. 6-4. 1 AGAAAAGGCACTGGTATTAA 2868 SEQ ID NO : 2524-3. 3-18. 5 56. 6-14. 7-0. 1-4 TCTCCCCCTACTCTAATTAG 2992 SEQ ID NO : 2525-3. 3-25. 5 72-22. 2 0-6. 9 CTGGTTATACATTAATAAAA 3252 SEQ ID NO : 2526-3. 3-14. 4 48. 3-11. 1 0-4. 2 3699 GTATAAAATTACCCTCAGGC-3. 3-21. 5 62. 8-17. 6-0. 3-4. 9 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 2527 GCTTCCATTAGTAAAAACAG 3902 SEQ ID NO : 2528-3. 3-18. 7 57-15. 4 0-3. 9 TGTAAAGCTGGTGGGCCAGG 627 SEQ ID NO : 2529-3. 2-26. 7 74. 8-20. 3-3. 2-9. 4 GCGCTCCGAGGCTGTAGCCG 750 SEQ ID NO : 2530-3. 2-32. 5 83. 7-26. 8-2. 5-11. 3 TTTTACCACCTCTGTGATTG 1046 SEQ ID NO : 2531-3. 2-23. 2 67. 9-18. 8-1. 1-3. 7 TTGGAGTCAGTGCACTGGAA 1135 SEQ ID NO : 2532-3. 2-24. 1 71-17. 8-0. 4-14. 4 CCTTTTTGAAGCGATTGGAG 1149 SEQ ID NO : 2533-3. 2-22. 3 64. 3-18. 3-0. 6-5. 3 GTAGCCAATGCTATTACAAC 1196 SEQ ID NO : 2534-3. 2-21. 3 62. 9-16-2. 1-8. 5 ACTTTCCTCCATGGGCTTGG 1804 SEQ ID NO : 2535-3. 2-28. 1 78. 7-24. 3-0. 1-8. 3 CTGAGAAGAATCCTTCCATT 1843 SEQ ID NO : 2536-3. 2-21. 9 63. 9-16. 6-2. 1-6. 3 TCAAGAGAGGCAGCAAGAGC 1942 SEQ ID NO : 2537-3. 2-23. 5 69-19. 5-0. 6-5. 3 CCATGAGAACCCCAACAGCT 2237 SEQ ID NO : 2538-3. 2-27 71. 4-23. 8 0-4. 5 AAAATGAACAGAAAAATAGG 2339. SEQ ID NO : 2539-3. 2-11. 4 41. 9-8. 2 0-2. 4 AAATAGAAACCACTTAAAGC 2561 SEQ ID NO : 2540-3. 2-15. 7 50. 1-12. 5 0-3 CTCTGTCTGGCAGGTGCCGG 2796 SEQ ID NO : 2541-3. 2-30. 6 84. 7-25-2. 4-11. 3 AACAAGAAAAGGCACTGGTA 2872 SEQ ID NO : 2542-3. 2-18. 9 56. 7-14. 9-0. 6-4. 5 TTGCCCTTCTCCCCCTACTC 2999 SEQ ID NO : 2543-3. 2-32. 7 86. 6-29. 5 0-3 ACTGGCTGCAAAAGTCTTCA 3154 SEQ ID NO : 2544-3. 2-23. 1 67. 4-19. 2-0. 4-6. 4 GGAACTGGCTGCAAAAGTCT 3157 SEQ ID NO : 2545-3. 2-23 66. 1-19. 1-0. 4-6. 4 TGCTTGGTGTCACACTTCCT 3319 SEQ ID NO : 2546-3. 2-26. 9 78. 1-22. 5-1. 1-6. 7 CTTCAGAAGTTTAACAGTGA 3415 SEQ ID NO : 2547-3. 2-19. 1 59. 7-15. 9 0-5. 9 AAATATCTCATTATGTATAT 3615 SEQ ID No : 2548-3. 2-15. 1 50. 6-11. 9 0-3 ATTTTGTGTTTAGGCTCGGG 3646 SEQ ID NO : 2549-3. 2-24. 1 71. 2-20. 9 0-3. 7 TGGGAAAACCCCTCACATAA 3763 SEQ ID NO : 2550-3. 2-23 63. 3-17. 5-2. 3-5. 8 AACAAAAACCACCTCTTGGT 190 SEQ ID NO : 2551'-3. 1-21. 2 60. 4-16. 1-2-5. 5 GCAAAGCAATAGCAGAGGCT 286 SEQ ID NO : 2552-3. 1-23. 6 67. 6-19. 1-1. 3-7. 1 TTGACCTCAGTCTGTGTAGC 370 SEQ ID NO : 2553-3. 1-25. 3 76. 2-20. 6-1. 6-5. 4 AGGTTAAACCTCACAGATGG 391 SEQ ID NO : 2554-3. 1-21. 7 63. 9-17-1. 6-7. 2 GGTCCTTGGAGGTGCGGAGG 408 SEQ ID NO : 2555-3. 1-29. 6 82. 3-25. 7-0. 6-5. 9 GTTGAGTCCACAGCCTGGCT 998 SEQ ID NO : 2556-3. 1-29. 7 83. 7-25. 1-1. 2-10. 3 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo CCCTTTTTGAAGCGATTGGA 1150 SEQ ID NO : 2557-3. 1-24. 3 67. 5-20. 4-0. 6-5. 3 ACAGATCCCCTTTTTGAAGC 1157 SEQ ID NO : 2558-3. 1-24. 9 70. 4-21-0. 6-5. 6 AGGCTGAGAAGAATCCTTCC 1846 SEQ ID NO : 2559-3. 1-24. 1 69. 3-18. 9-2. 1-7. 5 AGTGCAACCCATGAGAACCC 2245 SEQ ID NO : 2560-3. 1-26. 6 71. 5-23-0. 2-5. 4 TGGTATTAAAGTAAAATATT 2857 SEQ ID NO : 2561-3. 1-13. 1 45. 8-10 0-4. 4 GCATACACAAATCTTTTGAA 2967 SEQ ID NO : 2562-3. 1-18. 1 55. 8-13. 5-1. 4-5. 9 AAGACTCAACTGGTTATGTC 3434 SEQ ID NO : 2563-3. 1-20. 3 62. 5-16. 7 0-7. 5 TTGAAATAAGACTCAACTGG 3441 SEQ ID No : 2564-3. 1-16. 7 52. 8-13. 1-0. 1-3. 4 CAATGAATTTTGTGTTTAGG 3652 SEQ ID NO : 2565-3. 1-17. 7 56-14. 6 0-3 GGCTGGGGGACTGGAGGCAG 127 SEQ ID NO : 2566-3-29. 9 83. 2-25. 5-1. 3-6. 3 GTCAACCACAACTACATTGG 599 SEQ ID NO : 2567-3-21. 7 63. 1-17. 7-0. 9-3. 9 GGCAGGATCCAAACCTGTGA 818 SEQ ID NO : 2568-3-26. 1 72-20. 7-2. 4-9 CAGCCTGGCTGGAAGTCACC 988 SEQ ID NO : 2569-3-28. 9 79. 6-23. 1-2-13. 6 TCACATTTTACCACCTCTGT 1051 SEQ ID NO : 2570-3-24. 5 71-21. 5 0-2. 5 TCACCAGAGAGTCAACAAAG 1092 SEQ ID NO : 2571-3-20. 3 60. 7-17. 3 0-4. 8 GTTGTACCAAGACTGAGAGG 1508 SEQ ID NO : 2572-3-22. 5 66. 7-19. 5 0-4. 2 CGGCCTGGGGATATGCTGGT 1660 SEQ ID NO : 2573-3-29. 7 80-26. 2-0. 1-6. 7 GGGCACCCTCAGGGAAGCTC 1744 SEQ ID NO : 2574-3-30. 5 83. 4-24. 5-3-10 CAAGAGAGGCAGCAAGAGCT 1941 SEQ ID NO : 2575-3-24 69. 4-19. 5-1. 4-5. 3 GTCAGCTCCTGTCGGAAGGA 2177 SEQ ID NO : 2576-3-27. 6 78. 2-23. 5-1-7. 3 CCATTACCACATTCTAATTA 2393 SEQ ID NO : 2577-3-20. 5 60. 7-17. 5 0-3. 5 TCCCCATGCATATACACATA 2487 SEQ ID NO : 2578-3-24. 5 68. 4-21. 5 0-6. 6 CACATAATAACTAAGAAGAA 2579 SEQ ID NO : 2579-3-13. 5 46. 1-10. 5 0-2. 2 GGCACATAATAACTAAGAAG 2581 SEQ ID NO : 2580-3-16. 6 52. 4-13. 6 0-4 GGTGGCACATAATAACTAAG 2606 SEQ ID NO : 2581-3-19. 1 57. 9-15. 2-0. 8-4. 8 CTGTCTGGCAGGTGCCGGTT 2794 SEQ ID NO : 2582-3-30. 6 84. 9-25. 2-2. 4-11. 6 AGTTTTGTAAAATAGGGATA 3026 SEQ ID NO : 2583-3-16. 7 53. 8-13. 2-0. 2-4. 9 AAAAAAAAAGTCCTTGTTTG 3201 SEQ ID NO : 2584-3-14. 4 47. 7-11. 4 0-4. 4 TTTAGGCTCGGGTCCTATTC 3638 SEQ ID NO : 2585-3-26. 1 75. 9-22-1-8. 5 3645 TTTTGTGTTTAGGCTCGGGT-3-25. 3 74. 8-22. 3 0-3. 7 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 2586 CAACCACAACTACATTGGCG 597 SEQ ID NO : 2587-2. 9-22. 7 63. 1-18. 8-0. 9-5. 2 CCCCTTTTTGAAGCGATTGG 1151 SEQ ID NO : 2588-2. 9-25. 7 69. 7-22-0. 6-5. 3 GCATTCTGCTCGATCCGCTC 1414. SEQ ID NO : 2589-2. 9-28. 7 79-23. 9-1. 9-6. 6 CCTGATATTCAGCTCCCGTC 1574 SEQ ID NO : 2590-2. 9-27. 9 77. 2-23. 5-1. 4-5. 6 CTTTCCTCCATGGGCTTGGA 1803 SEQ ID NO : 2591-2. 9-28. 5 79. 4-24. 5-1-8. 3 CAATCCAGTGTGCACGAGAG 2043 SEQ ID NO : 2592-2. 9-24. 2 68. 8-20. 4 0-9. 8 CTAATTAATTTTAAGTGTTC 2380 SEQ ID NO : 2593-2. 9-15. 2 51. 1-12. 3 0-6. 2 GCCCCAGCATGAATGATACT 2671 SEQ ID NO : 2594-2. 9-26. 3 71. 6-22. 5-0. 7-4. 8 ACAAATCTTTTGAAAAGTGT 2961 SEQ ID NO : 2595-2. 9-16 51. 7-11. 6-1. 4-6 TCCTCTCCCTGGCTGCACCA 3094 SEQ ID NO : 2596-2. 9-33. 2 88. 4-29. 1-1. 1-8. 3 AAGGTGTAACTGACACATCA 3670 SEQ ID NO : 2597-2. 9-20. 5 61. 8-14. 4-3. 2-7 ACACAACTATTTAAAATATC 3719 SEQ ID NO : 2598-2. 9-13. 8 47. 1-10. 9 0-5 GTGGAAAATGAAAACTTGGC 102 SEQ ID NO : 2599-2. 8-17. 6 53. 8-14. 8 0-2. 8 CCTTCTCTCGGCCAGGGGCT 143 SEQ ID NO : 2600-2. 8-32. 8 88. 3-27. 8-2. 2-7. 4 TGGTTTGACCTCAGTCTGTG 374 SEQ ID NO : 2601-2. 8-25. 1 74. 8-20. 7-1. 6-6. 2 TGAAAAAGGTTTTAGCTGTC 495 SEQ ID NO : 2602-2. 8-18. 5 57. 7-15-0. 4-8. 1 CTGTAGCCGATCAAGTGGAC 739 SEQ ID NO : 2603-2. 8-24. 6 70. 1-21. 8 0-4. 9 AGTTGCCTGCATACCCGGCC 774 SEQ ID NO : 2604-2. 8-32. 2 83. 6-27. 9-1. 4-8 GGCCCACCGTTCCTTTCACG 795 SEQ ID NO : 2605-2. 8-31. 6 81. 2-28. 1-0. 5-6 GATGTCGGCCCCTTCAAACA 845 SEQ ID NO : 2606-2. 8-27. 6 73. 4-24. 8 0-6. 2 TGAGTCCACAGCCTGGCTGG 996 SEQ ID No : 2607-2. 8-29. 6 82-23. 2-2. 9-15. 1 CATATGCAATTGATCCCAAG 1023 SEQ ID NO : 2608-2. 8-21. 3 61. 5-17. 8-0. 5-7. 6 TAGCCAATGCTATTACAACG 1195 SEQ ID NO : 2609-2. 8-20. 9 60. 4-16. 5-1. 6-6. 2 ATATGCTGGTGTTCTCAGGG 1650 SEQ ID No : 2610-2. 8-24. 9 74. 5-22. 1 0. 2-4. 5 TCACTGAGGCTCAAAGCAGG 2153 SEQ ID NO : 2611-2. 8-24. 1 69. 8-19. 3-2-6. 1 CATGAGAACCCCAACAGCTA 2236 SEQ ID NO : 2612-2. 8-24. 7 67. 6-21. 9 0-4. 6 GTGCAACCCATGAGAACCCC 2244 SEQ ID NO : 2613-2. 8-28. 6 74. 5-25. 8 0-5. 4 ACAGAAAAATAGGAAAGCCA 2332 SEQ ID NO : 2614-2. 8-17. 3 52. 8-13. 3-1. 1-3. 5 AACAGAAAAATAGGAAAGCC 2333 SEQ ID NO : 2615-2. 8-15. 9 50. 1-13. 1 0-3. 2 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo TGTGTACACAGATGTGTATT 2772 SEQ ID NO : 2616-2. 8-20. 7 64. 2-15. 6-2. 2-11. 7 TTAAATCTTAGAACCAGCTC 2813 SEQ ID NO : 2617-2. 8-19. 4 59. 2-16. 6 0-4. 4 CCAGGAAATCTGAGTCCTCT 3108 SEQ ID NO : 2618-2. 8-24. 8 71. 1-20. 8-1. 1-7. 4 ACATTAATAAAAGGGCTTAG 3244 SEQ ID NO : 2619-2. 8-16. 5 52. 5-13. 7 0-4. 2 GTTATACATTAATAAAAGGG 3249 SEQ ID NO : 2620-2. 8-14. 7 49-11. 9 0-4. 2 CAGAAACAAGAGAAGCACAC 3481 SEQ ID NO : 2621-2. 8-18. 2 55. 4-15. 4 0-4. 1 TGAATTTTGTGTTTAGGCTC 3649 SEQ ID NO : 2622-2. 8-20. 8 64. 4-18 0-3. 7 GGTGTAACTGACACATCAAT 3668 SEQ ID NO : 2623-2. 8-20. 5 61. 6-14. 5-3. 2-7. 1 AACTATTTAAAATATCGTAT 3715 SEQ ID NO : 2624-2. 8-13. 7 46. 8-10. 9 0-4. 5 AAATGGGAAAACCCCTCACA 3766 SEQ ID NO : 2625-2. 8-22. 6 61. 9-17. 5-2. 3-5. 8 TTCCAGCAATCCCGGCCGGT 168 SEQ ID NO : 2626-2. 7-32. 4 81. 8-26. 7-0. 1-14. 2 CTTCAAACATGGGCCCGGCA 834 SEQ ID NO : 2627-2. 7-28. 3 74-24-0. 7-11. 2 GGAGAGAGCCTCTTGTGGAT 862 SEQ ID NO : 2628-2. 7-26. 1 76. 1-21. 9-1. 4-8. 2 AATGCTCAAGCCGAAGGAAC 923 SEQ ID NO : 2629-2. 7-22. 2 62. 5-17. 9-1. 5-6. 3 TGATTGTTCCATATGCAATT 1032 SEQ ID NO : 2630-2. 7-20. 7 62-17. 1-0. 8-7. 6 CAACAAAGAGGTGGACGGCT 1080 SEQ ID NO : 2631-2. 7-23. 2 65-20. 5 0-3. 7 GTAAACTCTGAAAGGCATGC 1274 SEQ ID No : 2632-2. 7-20. 6 61. 2-17. 2 0-8. 9 AGGTGTTGGTGGCATTCTGC 1425 SEQ ID NO : 2633-2. 7-27 79. 9-23. 1-1. 1-4. 7 ACAGGTTGTACCAAGACTGA 1512 SEQ ID NO : 2634-2. 7-22. 8 66. 9-18. 4-1. 7-6. 5 TGCTGGCAAGACTTGCCCGG 1762 SEQ ID NO : 2635-2. 7-29. 3 77. 2-22. 4-4. 2-13. 3 GAGTCCCAGCCATCACAGGA 1895 SEQ ID NO : 2636-2. 7-29. 2 80. 7-26. 5 0-3. 8 ATTCAAGAGAGGCAGCAAGA 1944 SEQ ID NO : 2637-2. 7-21. 8 64. 8-19. 1 0-6. 3 ACCCATGAGAACCCCAACAG 2239 SEQ ID NO : 2638-2. 7-26. 5 69. 6-23. 8 0-4. 5 GAGTGAGCTGGGGAGCAGGA 2295 SEQ ID NO : 2639-2. 7-27. 6 79. 7-23. 3-1. 6-5. 5 CATTCTGGCCCCAGCATGAA 2678 SEQ ID NO : 2640-2. 7-28. 2 75. 7-23. 9-1. 5-7. 8 ATGTGTATTACATATGTCAT 2761 SEQ ID NO : 2641-2. 7-18. 8 59. 6-15-1-8. 2 TTCTCCCCCTACTCTAATTA 2993 SEQ ID NO : 2642-2. 7-25. 6 72. 1-22. 9 0-3. 5 TGCCCTTCTCCCCCTACTCT 2998 SEQ ID NO : 2643-2. 7-33. 5 88. 1-30. 8 0-3 GGCTGCAAAAGTCTTCATGG 3151 SEQ ID NO : 2644-2. 7-23. 2 67. 4-20. 5 0-6. 4 3205 TATAAAAAAAAAAGTCCTTG-2. 7-11. 7 42. 6-9 0-3. 2 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 2645 ATATAAAAAAAAAAGTCCTT 3206 SEQ ID NO : 2646-2. 7-11. 7 42. 6-9 0-2. 9 ACAGTGATACAACTTTGGCA 3402 SEQ ID NO : 2647-2. 7-21. 6 64. 1-18. 9 0-4. 6 CCCCAGAACGAGATCTGCCC 37 SEQ ID NO : 2648-2. 6-29. 9 76. 8-25. 9-1. 3-6. 3 TGAAAACTTGGCGGCACGGA 94 SEQ ID No : 2649-2. 6-24 64. 9-19. 5-1. 9-6. 5 TCCCCGCAGCAAAGCAATAG 294 SEQ ID NO : 2650-2. 6-26. 3 69. 8-22. 8-0. 7-4. 4 TGGCAATGCTGTGTCCCACC 672 SEQ ID NO : 2651-2. 6-29. 4 79. 6-25. 2-0. 6-11 TAGTGCCATAAAGGGTGACG 1359 SEQ ID NO : 2652-2. 6-22. 9 65. 3-19. 8-0. 1-4. 4 AGAGGCAGCAAGAGCTATAG 1937 SEQ ID NO : 2653-2. 6-22. 8 68-18. 6-1. 5-6. 6 AGGACGGAATGGCTAAGACG 2279 SEQ ID NO : 2654-2. 6-22. 4 62. 9-19. 8 0-3. 7 AAGAAAAGGCACTGGTATTA 2869 SEQ ID NO : 2655-2. 6-18. 5 56. 6-15. 1-0. 6-4 ACACAAATCTTTTGAAAAGT 2963 SEQ ID NO : 2656-2. 6-15. 7 50. 8-11. 6-1. 4-6 ACCACTAACTAGTATATAAG 3078 SEQ ID NO : 2657-2. 6-17. 4 55-14. 8 0-6. 3 AGTACAAAGAAAATCATTCT 3347 SEQ ID NO : 2658-2. 6-15. 4 50. 4-11. 4-1. 3-7. 9 TGCTCCAAAATCCAAAACTT 3807 SEQ ID NO : 2659-2. 6-19. 9 57. 6-17. 3 0-3. 6 ATTAGTAAAAACAGAAGTCA 3896 SEQ ID NO : 2660-2. 6-15 49. 7-12. 4 0-3. 9 ATGAAAACTTGGCGGCACGG 95 SEQ ID NO : 2661-2. 5-23. 4 63. 8-19-1. 9-6. 5 AAACAGAGCAGAGGAACGGA 262 SEQ ID NO : 2662-2. 5-21. 1 60. 9-18. 6 0-4. 1 GAAACAGAGCAGAGGAACGG 263 SEQ ID NO : 2663-2. 5-21. 1 60. 9-18. 6 0-4. 1 TAGCATCCTTCATGCTCTGG 427 SEQ ID NO : 2664-2. 5-25. 9 75. 3-20. 3-3. 1-7. 7 CAGCCAGTTTTCAAAGATAC 539 SEQ ID NO : 2665-2. 5-20. 9 62. 6-18. 4 0-3. 2 GTACCAAGACTGAGAGGCCC 1505 SEQ ID NO : 2666-2. 5-27 74. 7-24. 5 0-6. 8 AGCTGCGAAACTCCTTCCAC 1530 SEQ ID NO : 2667-2. 5-26. 3 72-23. 8 0-5. 8 CGGAATGGCTAAGACGTAAG 2275 SEQ ID NO : 2668-2. 5-20. 6 59. 4-18. 1 0-5. 3 TATATCTGGCAACCGGCCAT 2698 SEQ ID NO : 2669-2. 5-26. 4 71. 4-20. 6-3. 3-10. 3 TCTTAGAACCAGCTCTGTCT 2808 SEQ ID NO : 2670-2. 5-24. 4 72. 6-21. 9 0-4. 4 TAAATCTTAGAACCAGCTCT 2812 SEQ ID NO : 2671-2. 5-20. 2 60. 8-17. 7 0-4. 4 ATTAGGCAATGCATACACAA 2977 SEQ ID NO : 2672-2. 5-20. 1 59. 8-17. 6 0. 1-7. 3 ACAGATGTTCTCCTGGTTAT 3264 SEQ ID NO : 2673-2. 5-23. 6 70. 8-20. 3-0. 6-4. 6 AACCTAAGTACAAAGAAAAT 3353 SEQ ID NO : 2674-2. 5-14. 3 47. 3-11. 8 0-5. 3 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo AAACACTTCTGGTTCCAAGC 3558 SEQ ID NO : 2675-2. 5-22. 7 66-20. 2 0-5 CGGGTCCTATTCCCAAAATA 3630 SEQ ID NO : 2676-2. 5-24. 2 66. 2-19. 8-1. 9-5. 6 TTAGGCTCGGGTCCTATTCC 3637 SEQ ID NO : 2677-2. 5-28 79. 1-24. 4-1-8. 5 ATTTAAAATATCGTATAAAA 3711 SEQ ID NO : 2678-2. 5-11. 2 41. 8-8. 7 0-5 CCTTGGAGGTGCGGAGGTTA 405 SEQ ID NO : 2679-2. 4-27. 8 77. 7-25. 4 0-5. 2 CCGGCAGGATCCAAACCTGT 820 SEQ ID NO : 2680-2. 4-28. 3 74. 2-23. 5-2. 4-9 ATGCTCAAGCCGAAGGAACG 922 SEQ ID NO : 2681-2. 4-23. 7 64. 7-19. 7-1. 5-6. 3 TTTCATCTGATAATGGTAAA 1289 SEQ ID NO : 2682-2. 4-16. 9 54-14. 5 0-4. 4 ACGAGAGGCCCCAGGCACCC 2030 SEQ ID NO : 2683-2. 4-33. 8 85. 1-28. 9-2. 5-7. 5 TGTGTATTACATATGTCATA 2760 SEQ ID NO : 2684-2. 4-18. 5 59-15. 5-0. 2-8. 2 AATCTTAGAACCAGCTCTGT 2810 SEQ ID NO : 2685-2. 4-22. 4 66. 5-20 0-4. 4 CTGGTATTAAAGTAAAATAT 2858 SEQ ID NO : 2686-2. 4-13. 9 47. 3-11. 5 0-3 ACGAGATCTGCCCTCGTCCT 30 SEQ ID NO : 2687-2. 3-29. 9 79. 8-24. 7-2. 9-8. 4 ACTTGGCGGCACGGAGCCCG 89 SEQ ID NO : 2688-2. 3-32. 1 80. 3-27. 4-2. 4-9. 3 TGTTTCCAGCAATCCCGGCC 171 SEQ ID NO : 2689-2. 3-30. 5 80. 1-27. 7-0. 1-6. 1 CCACACCCCCTCCCAAGAAA 224 SEQ ID NO : 2690-2. 3-30. 3 75. 1-28 0-1. 8 TTCTCCTGCAGCCAGTCGAG 697 SEQ ID NO : 2691-2. 3-28. 7 80. 5-25. 4-0. 9-7. 6 TAGGTGTGGAGGACATCCAC 898 SEQ ID NO : 2692-2. 3-25. 1 73. 2-19. 7-3. 1-9 TGCTCACATTTTACCACCTC 1054 SEQ ID NO : 2693-2. 3-25. 1 71. 9-22. 8 0-3. 6 GCTGCGAAACTCCTTCCACA 1529 SEQ ID NO : 2694-2. 3-27 72. 7-24. 7 0 0 TTTCGTTTTTCATCCTCCAG 1710 SEQ ID NO : 2695-2. 3-24. 5 71. 5-22. 2 0-3 TCCATGGGCTTGGATAGCAG 1797 SEQ ID NO : 2696-2. 3-26. 3 74. 9-21. 8-2. 2-11. 4 CCTCCATGGGCTTGGATAGC 1799 SEQ ID NO : 2697-2. 3-28. 5 79-24. 6-1. 2-10. 7 AGTGCTCCAGGGTCAAGGCT 1861 SEQ ID NO : 2698-2. 3-28. 9 82. 8-26. 6 0-4. 7 AACCCCAACAGCTAGGGCCC 2230 SEQ ID NO : 2699-2. 3-31 79. 3-27. 3-1. 2-10 TGCTCAATTAAAAAATGAAC 2350 SEQ ID NO : 2700-2. 3-13. 5 46-11. 2 0-3. 6 CACATTCTAATTAATTTTAA 2386 SEQ ID NO : 2701-2. 3-14. 4 48. 6-12. 1 0-6. 2 TCCATTACCACATTCTAATT 2394 SEQ ID NO : 2702-2. 3-21. 2 62. 6-18. 9 0-2. 5 TGGCACATAATAACTAAGAA 2582 SEQ ID NO : 2703-2. 3-16. 6 52. 3-13. 6-0. 4-4 2809 ATCTTAGAACCAGCTCTGTC-2. 3-23. 5 70. 5-21. 2 0-4. 4 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 2704 TGCATACACAAATCTTTTGA 2968 SEQ ID No : 2705-2. 3-18. 8 57. 6-15-1. 4-7. 2 TAATAATAGTTGCCCTTCTC 3008 SEQ ID NO : 2706-2. 3-21. 5 64. 2-19. 2 0-3 GTTTTGTAAAATAGGGATAA 3025 SEQ ID NO : 2707-2. 3-16 51. 9-13. 2-0. 2-4. 9 CTGGCTGCAAAAGTCTTCAT 3153 SEQ ID NO : 2708-2. 3-22. 9 66. 8-19. 9-0. 4-6. 4 TCTCTCGGCCAGGGGCTGGG 140 SEQ ID NO : 2709-2. 2-32. 2 87. 6-27. 7-2. 3-10. 4 TCCTTGGAGGTGCGGAGGTT 406 SEQ ID NO : 2710-2. 2-28. 5 80. 1-25. 5-0. 6-5. 9 CAATGCTCAAGCCGAAGGAA 924 SEQ ID NO : 2711-2. 2-22. 7 63. 1-18. 9-1. 5-6. 3 TCAACAAAGAGGTGGACGGC 1081 SEQ ID NO : 2712-2. 2-22. 7 64. 6-20. 5 0-3. 5 CACCAGAGAGTCAACAAAGA 1091 SEQ ID NO : 2713-2. 2-20. 5 60. 6-18. 3 0-4. 8 AGGTAGCTGCGAAACTCCTT 1534 SEQ ID NO : 2714-2. 2-25. 1 70. 7-22. 9 0-7 TCCCGGCCTGGGGATATGCT 1663 SEQ ID NO : 2715-2. 2-31. 7 82. 6-27. 1-2. 1-12. 4 GTGTGGACAGAGGTTTGGAG 1972 SEQ ID NO : 2716-2. 2-24. 1 72. 4-21. 9 0-4 TCTCACTGAGGCTCAAAGCA 2155 SEQ ID NO : 2717-2. 2-24. 2 70. 5-20-2-9 CAGTGCAACCCATGAGAACC 2246 SEQ ID NO : 2718-2. 2-25. 3 69. 2-22. 6-0. 2-5. 4 GAAAAATAGGAAAGCCAATG 2329 SEQ ID NO : 2719-2. 2-15. 7 49. 6-12. 3-1. 1-3. 9 ATGCATATACACATACACCA 2482 SEQ ID NO : 2720-2. 2-21. 2 62. 1-19 0-6. 4 GAGGTGGCACATAATAACTA 2608 SEQ ID NO : 2721-2. 2-20. 4 61. 1-17. 3-0. 8-4. 8 TCTGGCCCCAGCATGAATGA 2675 SEQ ID NO : 2722-2. 2-28 75. 4-24. 2-1. 5-7. 8 GAGATTTGCTCCAAAGCAGT 2718 SEQ ID NO : 2723-2. 2-23. 5 68. 4-18. 7-2. 6-10. 2 GCACTGTATTAAATCTTAGA 2821 SEQ ID NO : 2724-2. 2-18. 6 58. 2-16. 4 0-3. 4 TCTCCTGGTTATACATTAAT 3256 SEQ ID NO : 2725-2. 2-20. 5 62. 5-18. 3 0-4. 6 TAGGCTCGGGTCCTATTCCC 3636'SEQ ID NO : 2726-2. 2-29. 9 82. 3-26. 8-0. 8-8 AGGTGTAACTGACACATCAA 3669 SEQ ID NO : 2727-2. 2-20. 5 61. 8-15. 1-3. 2-7 CCTCCCAAGAAACAGAAGTT 216 SEQ ID NO : 2728-2. 1-22. 6 63. 7-19. 8-0. 5-3. 8 TGTGGAGCTTATCTTCCAGC 342 SEQ ID NO : 2729-2. 1-25. 8 76. 2-22. 1-1. 6-6. 1 CCATCCGTGAATGATGAAAA 509 SEQ ID NO : 2730-2. 1-20. 1 57. 6-16. 8-1. 1-4. 6 AGTCAACCACAACTACATTG 600 SEQ ID NO : 2731-2. 1-20. 5 60. 8-17. 7-0. 5-3. 3 GGGAGCCAGTCAACCACAAC 607 SEQ ID NO : 2732-2. 1-26. 4 72. 8-23. 7-0. 3-4. 3 CAGGGGGAGCCAGTCAACCA 611 SEQ ID NO : 2733-2. 1-29. 1 79. 3-25. 6-1. 3-4. 7 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo AGCCGATCAAGTGGACATTC 735 SEQ ID NO : 2734-2. 1-24 68. 7-21. 9 0-4. 9 GTTCCATATGCAATTGATCC 1027 SEQ ID NO : 2735-2. 1-23 66. 9-20. 9 0-6. 8 TTACCACCTCTGTGATTGTT 1044 SEQ ID NO : 2736-2. 1-24. 3 70. 8-21-1. 1-3. 8 CAAAGAGGTGGACGGCTCGC 1077 SEQ ID NO : 2737-2. 1-26 71-22. 5-1. 3-5. 5 CGATTGGAGTCAGTGCACTG 1138 SEQ ID NO : 2738-2. 1-24. 4 70. 7-19. 5 0-13. 8 GGAATCTGCATTAGTGCCAT 1370 SEQ ID NO : 2739-2. 1-24. 4 70. 3-20. 4-1. 9-8. 8 TTGGTGCTCTGGAGGTGTGG 1986 SEQ ID NO : 2740-2. 1-27. 1 79. 8-25 0-6. 4 GCACATAATAACTAAGAAGA 2580 SEQ ID NO : 2741-2. 1-16 51. 3-13. 9 0-3. 4 CACAGATGTGTATTACATAT 2766 SEQ ID NO : 2742-2. 1-18. 7 58. 5-15. 5-1-7. 1 TAGGCAATGCATACACAAAT 2975 SEQ ID NO : 2743-2. 1-19. 3 57. 6-16. 3-0. 7-8 GGGAACTGGCTGCAAAAGTC 3158 SEQ ID NO : 2744-2. 1-23. 3 66. 7-20. 7-0. 2-6. 6 ATGTTCTCCTGGTTATACAT 3260 SEQ ID NO : 2745-2. 1-22. 7 68. 5-20. 6 0-4. 6 CTAAGTACAAAGAAAATCAT 3350 SEQ ID NO : 2746-2. 1-13. 9 47-11. 8 0-5. 3 TACAACTTTGGCACGATACA 3395 SEQ ID NO : 2747-2. 1-21. 1 61. 4-18. 3-0. 4-4 AGACTCAACTGGTTATGTCT 3433 SEQ ID NO : 2748-2. 1-21. 9 66. 8-18. 9-0. 6-8. 8 TTGGCTTGAGAACATATCTT 3459 SEQ ID NO : 2749-2. 1-20. 6 62. 5-17. 7-0. 6-5. 9 ACAGAAACAAGAGAAGCACA 3482 SEQ ID NO : 2750-2. 1-18. 2 55. 4-16. 1 0-4. 1 AAAATGGGAAAACCCCTCAC 3767 SEQ ID NO : 2751-2. 1-21. 2 59. 2-17. 5-1. 6-5. 1 CCGGGAGGCAAGGACTCGCT 4 SEQ ID NO : 2752-2-29. 6 77. 7-26. 2-1. 3-7. 3 GGCAATGCTGTGTCCCACCA 671 SEQ ID NO : 2753-2-30. 1 80. 8-26. 5-0. 6-11 CGCTCCGAGGCTGTAGCCGA 749 SEQ ID NO : 2754-2-31. 3 80. 8-26. 8-2. 5-10. 5 CACATTTTACCACCTCTGTG 1050 SEQ ID NO : 2755-2-24. 1 69. 2-21. 2-0. 7-4. 5 AAAGAGGTGGACGGCTCGCT 1076 SEQ ID NO : 2756-2-26. 2 71. 7-22. 8-1. 3-5. 5 AGCGATTGGAGTCAGTGCAC 1140 SEQ ID NO : 2757-2-25. 3 73. 6-22. 3-0. 9-8. 6 GCTGAGAAGAATCCTTCCAT 1844 SEQ ID NO : 2758-2-23. 6 67. 6-19. 9-1. 7-6. 1 TGCTTACACACAAATCTGGA 2007 SEQ ID NO : 2759-2-20. 9 61. 8-18. 9 0-3. 6 GGTCTAGAAATCCCAACTCC 2447 SEQ ID NO : 2760-2-24. 5 69. 1-22. 5 0-6 GTGCCTTTCCCCATGCATAT 2494 SEQ ID NO : 2761-2-29. 4 79. 5-26. 5-0. 7-6. 8 GAAATAGAAACCACTTAAAG 2562 SEQ ID NO : 2762-2-14. 5 47. 8-12. 5 0-2. 9 2563 AGAAATAGAAACCACTTAAA-2-14. 5 47. 8-12. 5 0-2. 3 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 2763 AAGAAATAGAAACCACTTAA 2564 SEQ ID No : 2764-2-14. 5 47. 8-12. 5 0-2. 8 GTCACTCATAGGGGAGGTGG 2621 SEQ ID NO : 2765-2-26 76. 9-23. 2-0. 6-4. 8 GTCTGGCAGGTGCCGGTTTC 2792 SEQ ID NO : 2766-2-30. 2 85. 5-25. 8-2. 4-11. 6 TTAGGCAATGCATACACAAA 2976 SEQ ID NO : 2767-2-19. 4 57. 9-16. 5-0. 7-8 GTCCTTGTTTGTCTCACGTC 3192 SEQ ID NO : 2768-2-26. 2 78. 2-24. 2 0-4. 6 TATACATTAATAAAAGGGCT 3247 SEQ ID NO : 2769-2-16. 1 51. 5-14. 1 0-4 CCCGAATCTCAGCCATAAAA 3299 SEQ ID NO : 2770-2-23. 2 63. 3-21. 2 0-3. 2 CAAAATATCTCATTATGTAT 3617 SEQ ID NO : 2771-2-15. 4 50. 7-13. 4 0-2. 8 AGCTTCCATTAGTAAAAACA 3903 SEQ ID NO : 2772-2-18. 7 57-16. 7 0-4. 3 GGTGCGGAGGTTAAACCTCA 398 SEQ ID NO : 2773-1. 9-25. 8 71. 8-19. 6-4. 3-13. 2 GGAGCCAGTCAACCACAACT 606 SEQ ID NO : 2774-1. 9-26. 1 72. 2-23. 7-0. 1-3. 7 TTGAGTCCACAGCCTGGCTG 997 SEQ ID NO : 2775-1. 9-28. 5 79. 8-23. 3-2. 5-14. 6 CCACCTCTGTGATTGTTCCA 1041 SEQ ID NO : 2776-1. 9-27. 4 76. 9-24. 3-1. 1-3. 7 CTTGTAACTGAAGACATGGA 1310 SEQ ID NO : 2777-1. 9-19. 5 59. 2-17. 6 0-5. 2 CCCATGTTCTTGTAACTGAA 1318 SEQ ID NO : 2778-1. 9-22. 6 65. 4-20. 2-0. 2-4. 3 CCTCGGTGTAGACCAGGAAG 1443 SEQ ID NO : 2779-1. 9-26 72. 5-21. 8-2. 3-4. 9 GGTAGCTGCGAAACTCCTTC 1533 SEQ ID NO : 2780-1. 9-25. 5 72-23. 1 0-8 TCCAGGGTCAAGGCTGAGAA 1856 SEQ ID NO : 2781-1. 9-25. 5 72. 8-22. 9-0. 5-7. 9 AGCCATCACAGGAGACCAGT 1888 SEQ ID NO : 2782-1. 9-27 76. 3-24. 5-0. 3-3. 8 GGAGTCCCAGCCATCACAGG 1896 SEQ ID No : 2783-1. 9-29. 8 82-27. 4-0. 2-6. 3 CAGTGTGCACGAGAGGCCCC 2038 SEQ ID NO : 2784-1. 9-30. 8 82. 1-28 0-9. 8 TACACAGGGCCTCTTCGGAG 2113 SEQ ID NO : 2785-1. 9-27 75. 6-24-1-8. 6 CAACAGCTAGGGCCCGAGCA 2225 SEQ ID NO : 2786-1. 9-29. 4 77. 6-25. 5-1. 5-12 GTGGCACATAATAACTAAGA 2605 SEQ ID NO : 2787-1. 9-18. 5 56. 7-15. 7-0. 8-4. 2 GCATGAATGATACTCTGCTT 2665 SEQ ID No : 2788-1. 9-21. 9 65-19. 4-0. 3-4. 8 TAACTTCTATCTCTCTAAAC 2742 SEQ ID NO : 2789-1. 9-17. 6 56. 5-15. 7 0-0. 9 AAATCTTAGAACCAGCTCTG 2811 SEQ ID NO : 2790-1. 9-20. 5 61. 3-18. 6 0-4. 4 ACCTCACTAAGCCTCAGTTT 3041 SEQ ID NO : 2791-1. 9-25. 5 73. 5-23. 6 0-3. 2 GAACTGGCTGCAAAAGTCTT 3156 SEQ ID NO : 2792-1. 9-21. 9 63. 9-20 0. 3-6. 4 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo AGTCCTTGTTTGTCTCACGT 3193 SEQ ID NO : 2793-1. 9-25. 8 76. 7-23. 9 0-4. 4 ACAATTGGCTTGAGAACATA 3463 SEQ ID NO : 2794-1. 9-19. 4 58. 6-16. 7-0. 6-7. 2 CACACAATTGGCTTGAGAAC 3466 SEQ ID NO : 2795-1. 9-20. 6 60. 9-17. 9-0. 6-7. 2 TTTCCAGCAATCCCGGCCGG 169 SEQ ID NO : 2796-1. 8-31. 3 79-26. 7-0. 1-13. 8 TGTGATTCGGCCCACCGTTC 803 SEQ ID NO : 2797-1. 8-29. 5 78. 4-25. 2-2. 5-9. 2 TGCCCGGGCACCCTCAGGGA 1749 SEQ ID NO : 2798-1. 8-34. 7 87. 6-27. 7-2. 4-18. 6 TGCTCCAGGGTCAAGGCTGA 1859 SEQ ID NO : 2799-1. 8-28. 3 79. 9-26-0. 2-5. 9 CCTCCCGCGAGGAGTCCCAG 1906 SEQ ID NO : 2800-1. 8-33. 4 84. 6-28. 7-2. 5-13. 6 TGCTCTGGAGGTGTGGACAG 1982 SEQ ID NO : 2801-1. 8-26. 1 76. 6-23. 7-0. 3-6. 4 CTTGGTGCTCTGGAGGTGTG 1987 SEQ ID NO : 2802-1. 8-26. 8 79. 1-25 0-6. 4 GAGCAGCTGACAGCCTTCTA 2131 SEQ ID NO : 2803-1. 8-27. 1 77. 9-24. 5-0. 5-8. 7 TTCTCACTGAGGCTCAAAGC 2156 SEQ ID NO : 2804-1. 8-23. 6 69. 7-20-1. 8-8. 3 TGAACAGAAAAATAGGAAAG 2335 SEQ ID NO : 2805-1. 8-12. 7 44. 4-10. 9 0-2 TAATGCTTATATCCTATAGC 2530 SEQ ID NO : 2806-1. 8-19. 7 60. 5-17. 4-0. 1-5 GAAGAAATAGAAACCACTTA 2565 SEQ ID NO : 2807-1. 8-15. 8 50. 4-14 0-3. 1 CTGGCCCCAGCATGAATGAT 2674 SEQ ID NO : 2808-1. 8-27. 6 73. 8-24. 2-1. 5-7. 6 TTATATCTGGCAACCGGCCA 2699 SEQ ID No : 2809-1. 8-26. 5 71. 7-21. 5-3. 2-8. 5 ACACAGATGTGTATTACATA 2767 SEQ ID NO : 2810-1. 8-18. 9 59. 1-15. 5-1. 6-9. 1 TTTCTGTGTACACAGATGTG 2776 SEQ ID NO : 2811-1. 8-21. 2 65. 5-14. 8-2. 6-17. 3 AACTGGCTGCAAAAGTCTTC 3155 SEQ ID NO : 2812-1. 8-21. 7 64. 1-19. 2-0. 4-5. 6 AAACCTAAGTACAAAGAAAA 3354 SEQ ID NO : 2813-1. 8-13. 6 45. 9-11. 8 0-5. 3 AGAAAACCTAAGTACAAAGA 3357 SEQ ID NO : 2814-1. 8-15. 6 50. 1-13. 8 0-5. 3 ATGTCTTCAGAAGTTTAACA 3419 SEQ ID NO : 2815-1. 8-18. 9 59. 5-17. 1 0-7. 1 AAAATATCTCATTATGTATA 3616 SEQ ID NO : 2816-1. 8-14. 4 48. 9-12. 6 0-2. 8 TCCTGAGCCGCCGGGAGGCA 14 SEQ ID NO : 2817-1. 7-33. 8 85. 6-27. 9-4. 2-13. 3 AAAACTTGGCGGCACGGAGC 92 SEQ ID NO : 2818-1. 7-25. 2 67. 7-21. 6-1. 9-6. 9 AGCTTTGGGTTTGTGGAGCT 353 SEQ ID NO : 2819-1. 7-26. 4 78. 1-23. 5-1. 1-5 CATGCTCTGGGTCCTTGGAG 417 SEQ ID NO : 2820-1. 7-27. 5 78. 7-25. 3-0. 1-5 ATCCGTGAATGATGAAAAAG 507 SEQ ID NO : 2821-1. 7-16. 7 51. 6-15 0-3 751 TGCGCTCCGAGGCTGTAGCC-1. 7-31. 7 84. 1-28. 4-1. 4-10. 8 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 2822 AGCCTGGCTGGAAGTCACCC 987 SEQ ID NO : 2823-1. 7-30. 2 82-27-1. 3-10. 3 AGAGTCAACAAAGAGGTGGA 1085 SEQ ID NO : 2824-1. 7-20. 5 61. 9-18. 8 0-4. 8 GAGAGTCAACAAAGAGGTGG 1086 SEQ ID NO : 2825-1. 7-20. 5 61. 9-18. 8 0-4. 8 AGATCCCCTTTTTGAAGCGA 1155 SEQ ID NO : 2826-1. 7-25. 4 70-22. 9-0. 6-5. 6 AGCCAATGCTATTACAACGG 1194 SEQ ID NO : 2827-1. 7-22. 4 63. 3-19. 5-1. 1-5. 6 CCATAAAGGGTGACGTAAAA 1354 SEQ ID NO : 2828-1. 7-19 55. 9-17. 3 0-5. 3 CAGGTTGTACCAAGACTGAG 1511 SEQ ID NO : 2829-1. 7-22. 6 66. 6-19. 2-1. 7-5. 5 TAGCTGCGAAACTCCTTCCA 1531 SEQ ID NO : 2830-1. 7-25. 8 70. 9-24. 1 0-5. 8 TTGCCCGGGCACCCTCAGGG 1750 SEQ ID NO : 2831-1. 7-34. 2 86. 7-27. 7-2-17. 8 TATTCAAGAGAGGCAGCAAG 1945 SEQ ID NO : 2832-1. 7-20. 9 62. 9-19. 2 0-6. 3 ACAGAGGTTTGGAGTTAGAG 1966 SEQ ID NO : 2833-1. 7-21. 5 66. 6-19. 8 0-2. 5 GCTCTGGAGGTGTGGACAGA 1981 SEQ ID NO : 2834-1. 7-26. 7 78. 2-24-0. 9-6. 4 TAGGGGAGGTGGCACATAAT 2613 SEQ ID NO : 2835-1. 7-23. 9 69. 3-21. 3-0. 8-4. 8 TACACAGATGTGTATTACAT 2768 SEQ ID NO : 2836-1. 7-18. 9 59. 1-15. 5-1. 7-10. 3 AAAAAGTCCAACCGTTGGCA 3283 SEQ ID NO : 2837-1. 7-22. 8 63-19. 6-1. 3-10. 1 GACTCAACTGGTTATGTCTT 3432 SEQ ID NO : 2838-1. 7-22 66. 9-19. 8 0-7. 5 AACAGAGCAGAGGAACGGAG 261 SEQ ID NO : 2839-1. 6-21. 8 63. 1-20. 2 0-4. 1 TGTGCAGCCAGTTTTCAAAG 543 SEQ ID NO : 2840-1. 6-23. 4 68. 5-21. 8 0-5. 3 CTTCTCCTGCAGCCAGTCGA 698 SEQ ID NO : 2841-1. 6-29. 6 82. 1-27. 1-0. 8-8. 1 CGTCCTTCTCCTGCAGCCAG 702 SEQ ID NO : 2842-1. 6-31 84. 2-28. 7-0. 5-8. 1 ACATTTTACCACCTCTGTGA 1049 SEQ ID NO : 2843-1. 6-24 69. 4-21. 2-1. 1-3. 7 ACTGAAGACATGGATTTTCA 1304 SEQ ID NO : 2844-1. 6-19. 7 60. 1-17. 6-0. 2-5. 2 TACCAAGACTGAGAGGCCCC 1504 SEQ ID NO : 2845-1. 6-27. 8 74. 9-26. 2 0-6. 8 TAGCAGGAAGTCTTGCTGCC 1783 SEQ ID NO : 2846-1. 6-26. 4 76. 2-21. 9-2. 9-9. 9 CAGAGGTTTGGAGTTAGAGC 1965 SEQ ID NO : 2847-1. 6-23. 1 70. 7-21. 5 0-2. 8 CTCGCCCAGCAACTGAGAAA 2064 SEQ ID NO : 2848-1. 6-25. 3 68. 3-23-0. 4-4. 5 GAGAACCCCAACAGCTAGGG 2233 SEQ ID NO : 2849-1. 6-26. 4 71. 6-23. 8-0. 9-7 ATTACCACATTCTAATTAAT 2391 SEQ ID NO : 2850-1. 6-17. 1 54-15. 5 0-4. 4 AGGGGAGGTGGCACATAATA 2612 SEQ ID NO : 2851-1. 6-23. 9 69. 3-21. 4-0. 8-4. 8 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo CTCACTAAGCCTCAGTTTTG 3039 SEQ ID NO : 2852-1. 6-23. 4 69. 4-21. 8 0-3. 2 CAGGAAATCTGAGTCCTCTC 3107 SEQ ID NO : 2853-1. 6-23. 2 69-20. 4-1. 1-7. 4 CACAATTGGCTTGAGAACAT 3464 SEQ ID NO : 2854-1. 6-20. 4 60. 4-18-0. 6-7. 2 TTTAAAATATCGTATAAAAT 3710 SEQ ID NO : 2855-1. 6-11. 2 41. 8-9. 6 0-4 GGAGGTGCGGAGGTTAAACC 401 SEQ ID NO : 2856-1. 5-25. 6 71. 3-23. 3-0. 6-5. 5 AGCCAGTTTTCAAAGATACC 538 SEQ ID NO : 2857-1. 5-22. 2 65. 1-20. 7 0-3. 2 GCAGCCAGTTTTCAAAGATA 540 SEQ ID NO : 2858-1. 5-22. 5 66. 2-21 0-3. 5 CAGTCAACCACAACTACATT 601 SEQ ID NO : 2859-1. 5-21. 2 62. 1-19. 7 0-2. 8 GTCCTTCTCCTGCAGCCAGT 701 SEQ ID NO : 2860-1. 5-31. 4 88. 8-29-0. 8-8. 1 AGGCTGTAGCCGATCAAGTG 742 SEQ ID NO : 2861-1. 5-25. 6 72. 7-21. 6-2. 5-10. 5 CCCCCTCCCAGGTGAGCTGG 1488 SEQ ID NO : 2862-1. 5-34. 9 89. 5-30. 8-2. 6-6. 7 GCAGTAACTTTCCTCCATGG 1810 SEQ ID NO : 2863-1. 5-25. 6 73. 1-23. 6 0-7. 7 CAAGGCTGAGAAGAATCCTT 1848 SEQ ID NO : 2864-1. 5-21. 7 63. 2-18. 8-1. 3-4. 3 GTGGACAGAGGTTTGGAGTT 1970 SEQ ID NO : 2865-1. 5-24. 2 73-22. 7 0-2. 9 GAGGTGTGGACAGAGGTTTG 1975 SEQ ID NO : 2866-1. 5-24. 1 72. 4-22-0. 3-4 CCCAGGCACCCAGCTGCTTA 2021 SEQ ID NO : 2867-1. 5-32. 5 85. 1-30. 3-0. 5-8. 1 CACAGGGCCTCTTCGGAGCC 2111 SEQ ID NO : 2868-1. 5-30. 9 83. 3-27. 8-1. 6-7. 5 TGAGCAGCTGACAGCCTTCT 2132 SEQ ID NO : 2869-1. 5-27. 4 78. 3-24. 5-1. 3-8. 7 CTCCTGTCGGAAGGACTTCT 2172 SEQ ID NO : 2870-1. 5-26 73. 9-23. 2-1. 2-7. 6 TTACCACATTCTAATTAATT 2390 SEQ ID NO : 2871-1. 5-17. 2 54. 3-15. 7 0-6 ATGTCCATTACCACATTCTA 2397 SEQ ID NO : 2872-1. 5-23 67. 4-21. 5 0-3. 7 TATGTCCATTACCACATTCT 2398 SEQ ID NO : 2873-1. 5-23 67. 4-20. 9-0. 3-3. 8 GTTCCAAATGGAGAGGCTCA 2422 SEQ ID NO : 2874-1. 5-24. 4 70. 3-21. 7-1. 1-7. 5 GATGTGTATTACATATGTCA 2762 SEQ ID NO : 2875-1. 5-19. 4 61-16. 3-1. 6-9. 3 TTCTGTGTACACAGATGTGT 2775 SEQ ID NO : 2876-1. 5-22. 3 68. 6-16. 2-2. 6-17. 3 TGTCTGGCAGGTGCCGGTTT 2793 SEQ ID NO : 2877-1. 5-29. 8 83. 3-26-2. 3-11. 5 CAGCTCTGTCTGGCAGGTGC 2799 SEQ ID NO : 2878-1. 5-29. 1 85. 3-26. 2-1. 3-8 ATGCATACACAAATCTTTTG 2969 SEQ ID NO : 2879-1. 5-18. 2 56. 3-15. 6-1-8. 4 AAAAAAAAAAGTCCTTGTTT 3202 SEQ ID NO : 2880-1. 5-13. 7 46. 3-12. 2 0-4. 1 3391 ACTTTGGCACGATACAGATT-1. 5-21. 9 64-20. 4 0. 3-4 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 2881 GCACACAATTGGCTTGAGAA 3467 SEQ ID NO : 2882-1. 5-22. 2 64. 3-20. 1-0. 3-6. 4 ACGGAGCCCGGGCGGTGGCA 79 SEQ ID NO : 2883-1. 4-34. 5 85. 4-29. 4-3. 5-14. 9 AAACAAAAACCACCTCTTGG 191 SEQ ID NO : 2884-1. 4-19. 3 56. 1-16. 8-1-4. 1 TAGCAGAGGCTCCAGAAACA 277 SEQ ID NO : 2885-1. 4-23. 9 68. 6-20. 9-1. 5-5 TAGCCGATCAAGTGGACATT 736 SEQ ID NO : 2886-1. 4-23. 3 66. 6-21. 9 0-4. 4 GCCACGTGCGCTCCGAGGCT 757 SEQ ID NO : 2887-1. 4-33. 7 85. 3-29. 4-2. 8-13 TTCGGCCCACCGTTCCTTTC 798 SEQ ID NO : 2888-1. 4-31. 2 81. 7-27. 3-2. 5-6. 6 GTGCACTGGAAGGCAAAACT 1126 SEQ ID NO : 2889-1. 4-22. 6 64. 5-19-2. 2-8. 6 GGTTGAGACAGGTAGCTGCG 1543 SEQ ID NO : 2890-1. 4-26 74. 8-23-1. 5-3. 5 TTCAAGAGAGGCAGCAAGAG 1943 SEQ ID NO : 2891-1. 4-21. 8 65. 1-20. 4 0-6. 3 GCCTCTTCGGAGCCAGCGTT 2105 SEQ ID NO : 2892-1. 4-31. 5 84. 3-28. 7-1. 3-6. 4 CTTCTCACTGAGGCTCAAAG 2157 SEQ ID NO : 2893-1. 4-22. 7 67. 4-20. 8-0. 2-6. 7 TCTGGCAGGTGCCGGTTTCT 2791 SEQ ID NO : 2894-1. 4-29. 9 83. 8-26. 1-2. 4-11. 6 TCTATATAAAAAAAAAAGTC 3209 SEQ ID NO : 2895-1. 4-9. 7 39. 2-8. 3 0-3. 3 GATGTTCTCCTGGTTATACA 3261 SEQ ID NO : 2896-1. 4-23. 3 69. 9-21. 9 0-4. 6 GATACAGATTAAAACAATGT 3381 SEQ ID No : 2897-1. 4-14. 9 49. 1-13. 5 0-4. 6 CACAGAAACAAGAGAAGCAC 3483 SEQ ID NO : 2898-1. 4-18. 2 55. 4-16. 8 0-4. 1 AATCCAAAAATCCAAAATCC 3831 SEQ ID NO : 2899-1. 4-17 51. 5-15. 6 0-1. 1 ATCTGCCCTCGTCCTGAGCC 25 SEQ ID NO : 2900-1. 3-32. 1 85. 9-29. 9-0. 8-5. 4 TCCAGCAATCCCGGCCGGTA 167 SEQ ID NO : 2901-1. 3-32 80. 9-27. 7-0. 1-14. 2 NO : 290CAATGCTGTGTCCCA 669 SEQ ID NO : 2902CCACC-1. 3-29. 3 78. 1-27. 2-0. 6-4. 3 CCACGTGCGCTCCGAGGCTG 756 SEQ ID NO : 2903-1. 3-31. 9 81. 1-29. 7-0. 6-9. 4 TTTTTGAAGCGATTGGAGTC 1147 SEQ ID NO : 2904-1. 3-21 63. 2-19. 7 0-4. 1 CTCAGGGAAGCTCCACAGTG 1737 SEQ ID NO : 2905-1. 3-26. 2 75-24-0. 8-6. 3 AGGAGTCCCAGCCATCACAG 1897 SEQ ID NO : 2906-1. 3-28. 6 79. 7-26. 2-1-7. 5 CTGAGCAGCTGACAGCCTTC 2133 SEQ ID NO : 2907-1. 3-27. 4 78. 3-24. 5-1. 3-10. 8 AAAAATGAACAGAAAAATAG 2340 SEQ ID NO : 2908-1. 3-9. 5 38. 6-8. 2 0-1. 9 ATAATAATAGTTGCCCTTCT 3009 SEQ ID NO : 2909-1. 3-21. 1 62. 7-19. 8 0-3 GAAACAAGAGAAGCACACAA 3479 SEQ ID NO : 2910-1. 3-17. 5 53. 6-16. 2 0-4. 1 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo CGAGATCTGCCCTCGTCCTG 29 SEQ ID NO : 2911-1. 2-29. 7 79. 1-26. 9-1. 6-6. 3 TTGTGGAGCTTATCTTCCAG 343 SEQ ID NO : 2912-1. 2-24. 1 71. 9-21. 3-1. 6-6. 1 GCCAGTCAACCACAACTACA 603 SEQ ID NO : 2913-1. 2-24. 9 69. 3-23. 7 0-2. 8 TCCACAAAATCTGCATCGTC 883 SEQ ID NO : 2914-1. 2-22. 5 64. 5-21. 3 0-4. 9 ATACCAATGCTCAAGCCGAA 928 SEQ ID NO : 2915-1. 2-23. 5 64. 6-22. 3 0-5. 7 AATACCAATGCTCAAGCCGA 929 SEQ ID NO : 2916-1. 2-23. 5 64. 6-22. 3 0-5. 7 TTCCATATGCAATTGATCCC 1026 SEQ ID NO : 2917-1. 2-23. 8 67. 4-22. 6 0-6. 8 GCAGGAAGTCTTGCTGCCTT 1781 SEQ ID NO : 2918-1. 2-27. 7 78. 9-24. 4-2. 1-7. 9 TCAAGGCTGAGAAGAATCCT 1849 SEQ ID NO : 2919-1. 2-22 64. 3-20-0. 6-4. 3 CATTACCACATTCTAATTAA 2392 SEQ ID NO : 2920-1. 2-17. 8 55. 2-16. 6 0-3. 8 AGAGGGTCTAGAAATCCCAA 2451 SEQ ID NO : 2921-1. 2-22. 8 65. 9-19. 5-2. 1-9. 9 AAGAGGGTCTAGAAATCCCA 2452 SEQ ID NO : 2922-1. 2-22. 8 65. 9-19. 5-2. 1-9. 9 ACTGGTATTAAAGTAAAATA 2859 SEQ ID NO : 2923-1. 2-14. 1 47. 8-12. 9 0-3 CCCCTACTCTAATTAGGCAA 2988 SEQ ID NO : 2924-1. 2-24. 8 69-22. 9-0. 5-7. 5 AGGAAATCTGAGTCCTCTCC 3106 SEQ ID NO : 2925-1. 2-24. 5 71. 6-22-1. 2-7. 3 ATACAGATTAAAACAATGTC 3380 SEQ ID No : 2926-1. 2-14. 7 49-13. 5 0-4. 8 ATGCTCCAAAATCCAAAACT 3808 SEQ ID NO : 2927-1. 2-19. 8 57. 3-18. 6 0-3. 6 TGGAAAATGAAAACTTGGCG 101 SEQ ID NO : 2928-1. 1-17. 2 52. 1-16. 1 0-4 CACACCCCCTCCCAAGAAAC 223 SEQ ID NO : 2929-1. 1-28. 5 72. 6-27. 4 0-1. 8 TGGGCCCGGCAGGATCCAAA' 825 SEQ ID NO : 2930-1. 1-30. 2 77. 3-27. 3-1. 5-11. 2 CCTCTTGTGGATGTCGGCCC 854 SEQ ID NO : 2931-1. 1-30. 7 82. 9-29. 6 0-6. 2 CCATATGCAATTGATCCCAA 1024 SEQ ID NO : 2932-1. 1-23. 3 64. 7-21. 6-0. 3-6. 8 GTAACTGAAGACATGGATTT 1307 SEQ ID NO : 2933-1. 1-18. 7 57. 7-17. 6 0-5. 2 GGCAGAGTCTGGGAATCTGC 1381 SEQ ID NO : 2934-1. 1-26. 2 76. 4-20. 3-4. 8-13. 5 GAGTTAGAGCTATTCAAGAG 1955 SEQ ID NO : 2935-1. 1-19. 7 62-18. 1-0. 2-5. 1 AGGCTCAAAGCAGGCTGAGC 2147 SEQ ID NO : 2936-1. 1-26. 4 75. 4-22. 1-3. 2-11. 7 CCACATTCTAATTAATTTTA 2387 SEQ ID NO : 2937-1. 1-17. 1 54. 1-16 0-6. 2 TAATAACTAAGAAGGTGGCA 2597 SEQ ID NO : 2938-1. 1-18. 1 55. 8-17 0-5 TGTTCTCCTGGTTATACATT 3259 SEQ ID NO : 2939-1. 1-22. 8 68. 9-21. 7 0-4. 6 3285 ATAAAAAGTCCAACCGTTGG-1. 1-20 57. 8-17. 3-1. 5-10. 2 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 2940 CAACCTGTACAAGCTTCGCT 3519 SEQ ID NO : 2941-1. 1-24. 9 69. 4-23-0. 6-7. 8 TCAACCTGTACAAGCTTCGC 3520 SEQ ID NO : 2942-1. 1-24. 4 69. 1-23. 3 0-6. 4 CGTATAAAATTACCCTCAGG 3700 SEQ ID NO : 2943-1. 1-20. 5 59. 4-18. 9-0. 1-3. 3 AGGGGCTGGGGGACTGGAGG 130 SEQ ID NO : 2944-1-29. 8 82. 9-28. 3-0. 2-5. 1 TTCTCTCGGCCAGGGGCTGG 141 SEQ ID NO : 2945-1-31. 1 85. 3-27. 7-2. 4-10. 4 TGGCTGTGGCCGACGGAGAG 448 SEQ ID NO : 2946-1-28. 9 77. 2-24. 6-3. 3-8. 4 GTGCAGCCAGTTTTCAAAGA 542 SEQ ID NO : 2947-1-24 70-23 0-5. 3 GGAGGACATCCACAAAATCT 891 SEQ ID NO : 2948-1-21. 7 62. 7-19. 3-1. 3-6 CCAATGCTCAAGCCGAAGGA 925 SEQ ID NO : 2949-1-25. 4 68. 3-22. 8-1. 5-5. 6 GAGTCAACAAAGAGGTGGAC 1084 SEQ ID NO : 2950-1-20. 7 62. 3-18. 8-0. 8-4. 1 TGCACTGGAAGGCAAAACTC 1125 SEQ ID NO : 2951-1-21. 8 62. 9-19-1. 8-5 TGTAACTGAAGACATGGATT 1308 SEQ ID NO : 2952-1-18. 6 57. 3-17. 6 0-5. 2 TTGTAACTGAAGACATGGAT 1309 SEQ ID NO : 2953-1-18. 6 57. 3-17. 6 0-5. 2 GCCATAAAGGGTGACGTAAA 1355 SEQ ID NO : 2954-1-21. 5 61. 2-19. 8-0. 4-6 TTAGTGCCATAAAGGGTGAC 1360 SEQ ID NO : 2955-1-22. 2 65. 3-20. 5-0. 4-3. 8 CCGGCCTGGGGATATGCTGG 1661 SEQ ID NO : 2956-1-30. 5 79. 9-28. 3-1. 1-7. 8 AGGACTTCTCACTGAGGCTC 2161 SEQ ID NO : 2957-1-25. 4 75. 9-23. 9-0. 2-6. 3 GCTCCTGTCGGAAGGACTTC 2173 SEQ ID NO : 2958-1-26. 9 76. 3-24. 3-1. 6-7. 5 GACGGAATGGCTAAGACGTA 2277 SEQ ID NO : 2959-1-22. 1 62. 7-20. 2-0. 8-5. 3 GTCTAGAAATCCCAACTCCA 2446 SEQ ID NO : 2960-1-24 67. 7-23 0-6 TGAATGATACTCTGCTTGCT 2662 SEQ ID NO : 2961-1-22. 1 65. 7-21. 1 0-4. 5 TCCCTGGCTGCACCACTAAC 3089 SEQ ID NO : 2962-1-28. 9 77. 6-26. 6-1. 2-8. 4 CATAAAAAGTCCAACCGTTG 3286 SEQ ID NO : 2963-1-19. 5 56. 7-18. 5 0-6. 4 CTGGTTATGTCTTCAGAAGT 3425 SEQ ID No : 2964-1-21. 9 67. 6-20. 9 0. 2-7. 1 ACACAATTGGCTTGAGAACA 3465 SEQ ID NO : 2965-1-20. 6 60. 9-18. 8-0. 6-7. 2 CTCTGGACCAAAAGGTACGG 317 SEQ ID NO : 2966-0. 9-23. 1 64. 7-21. 7-0. 1-5. 2 GAGCCAGTCAACCACAACTA 605 SEQ ID NO : 2967-0. 9-24. 6 69. 1-23. 7 0-3. 5 TCCGAGGCTGTAGCCGATCA 746 SEQ ID NO : 2968-0. 9-28. 9 77. 9-26. 3-1. 7-9. 7 CACCGTTCCTTTCACGAAGT 791 SEQ ID NO : 2969-0. 9-25. 7 70. 7-24-0. 6-4 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo CACAGGTTGTACCAAGACTG 1513 SEQ ID NO : 2970-0. 9-22. 9 66. 8-20. 3-1. 7-6 TGCAACCCATGAGAACCCCA 2243 SEQ ID NO : 2971-0. 9-28. 1 72. 5-27. 2 0-4. 7 GTGATCAAACACGTCACTCA 2633 SEQ ID NO : 2972-0. 9-21. 9 64. 1-19. 7-1. 2-6. 7 ATTCTGGCCCCAGCATGAAT 2677 SEQ ID NO : 2973-0. 9-27. 5 74. 6-25-1. 5-7. 8 AAGTACAAAGAAAATCATTC 3348 SEQ ID NO : 2974-0. 9-13. 8 47-12. 3-0. 3-5. 9 GGCTTGAGAACATATCTTGA 3457 SEQ ID NO : 2975-0. 9-21. 1 63. 5-19. 4-0. 6-5. 9 AACCATGCTTCATGTACACA 3734 SEQ ID NO : 2976-0. 9-22. 8 66-20. 5-1. 3-6. 7 TTAGTAAAAACAGAAGTCAG 3895 SEQ ID NO : 2977-0. 9-15 49. 8-14. 1 0-2. 9 TTGTTCCATATGCAATTGAT 1029 SEQ ID NO : 2978-0. 8-20. 7 62-19. 9 0-6. 8 GATTGTTCCATATGCAATTG 1031 SEQ ID NO : 2979-0. 8-20. 7 62-19-0. 8-7. 6 GTCAACAAAGAGGTGGACGG 1082 SEQ ID NO : 2980-0. 8-22. 1 63. 7-20. 1-1. 1-4. 3 CCCCAGGCACCCAGCTGCTT 2022 SEQ ID NO : 2981-0. 8-34. 8 88. 8-32. 6-1. 3-8. 1 AGCAGCTGACAGCCTTCTAC 2130 SEQ ID NO : 2982-0. 8-26. 7 77. 2-24. 5-1. 3-8. 7 CAATTAAAAAATGAACAGAA 2346 SEQ ID NO : 2983-0. 8-11 41. 2-10. 2 0-3 GTGTACACAGATGTGTATTA 2771 SEQ ID NO : 2984-0. 8-20. 4 63. 7-17. 4-2. 2-11. 1 TTCTCCTGGTTATACATTAA 3257 SEQ ID NO : 2985-0. 8-20. 6 62. 8-19. 8 0-4. 6 CCTATTCCCAAAATATCTCA 3625 SEQ ID NO : 2986-0. 8-21. 8 62. 5-21 0-2. 6 GAGATCTGCCCTCGTCCTGA 28 SEQ ID NO : 2987-0. 7-29. 5 80. 8-28. 3-0. 2-6. 3 GGGGCTGGGGGACTGGAGGC 129 SEQ ID NO : 2988-0. 7-31. 6 87. 1-30. 4-0. 2-5. 1 CTCTTGTGGATGTCGGCCCC 853 SEQ ID NO : 2989-0. 7-30. 7 82. 9-30 0-6. 2 AACTGAAGACATGGATTTTC 1305 SEQ ID No : 2990-0. 7-18. 3 56. 9-17. 6 0-5. 2 GAGGCCCCCTCCCAGGTGAG 1492 SEQ ID NO : 2991-0. 7-34. 6 89. 6-32. 4-1. 4-8. 5 TGGTGCTCTGGAGGTGTGGA 1985 SEQ ID NO : 2992-0. 7-27. 6 80. 8-26. 9 0-5. 7 CTGCTTACACACAAATCTGG 2008 SEQ ID NO : 2993-0. 7-21. 2 62. 4-20. 5 0-3. 6 AGCAGGCTGAGCAGCTGACA 2139 SEQ ID NO : 2994-0. 7-27. 7 79. 1-25. 5-1. 4-9. 8 GTGGCACATAATAACTAAGA 2583 SEQ ID NO : 2995-0. 7-18. 5 56. 7-16. 9-0. 8-4. 2 AGAAGGTGGCACATAATAAC 2588 SEQ ID NO : 2996-0. 7-19. 1 58-17. 5-0. 8-4 ATAGGGGAGGTGGCACATAA 2614 SEQ ID NO : 2997-0. 7-23. 9 69. 3-22. 3-0. 8-4. 8 CAAACACGTCACTCATAGGG 2628 SEQ ID NO : 2998-0. 7-21. 8 63. 1-21. 1 0-4. 4 2759 GTGTATTACATATGTCATAA-0. 7-17. 8 57-16. 5-0. 2-8. 2 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 2999 CTGGCAGGTGCCGGTTTCTG 2790 SEQ ID NO : 3000-0. 7-29. 5 81. 6-26. 4-2. 4-11. 3 TCTGTCTGGCAGGTGCCGGT 2795 SEQ ID NO : 3001-0. 7-30. 9 86. 5-27. 8-2. 4-11. 6 TAAAAAAAAAAGTCCTTGTT 3203 SEQ ID NO : 3002-0. 7-13. 3 45. 5-12. 6 0-3. 2 TGGTTATACATTAATAAAAG 3251 SEQ ID NO : 3003-0. 7-13. 5 46. 6-12. 8 0-4. 2 TGGCTTGAGAACATATCTTG 3458 SEQ ID NO : 3004-0. 7-20. 5 62. 1-19-0. 6-5. 9 CCAAAATATCTCATTATGTA 3618 SEQ ID NO : 3005-0. 7-17. 4 54. 5-16. 7 0-2. 8 TTCCCAAAATATCTCATTAT 3621 SEQ ID NO : 3006-0. 7-19 57. 5-18. 3 0-2. 6 ATTCCCAAAATATCTCATTA 3622 SEQ ID NO : 3007-0. 7-19 57. 5-18. 3 0-2. 6 CATTAGTAAAAACAGAAGTC 3897 SEQ ID NO : 3008-0. 7-15 49. 7-14. 3 0-3. 9 AGGTGCGGAGGTTAAACCTC 399 SEQ ID NO : 3009-0. 6-25. 1 71-21. 3-3. 2-12. 8 GCAATGCTGTGTCCCACCAC 670 SEQ ID NO : 3010-0. 6-29. 1 78. 9-27. 7-0. 6-8. 3 CTCTGTGATTGTTCCATATG 1037 SEQ ID NO : 3011-0. 6-22. 2 66. 9-21. 6 0-54 CACTGGAAGGCAAAACTCGG 1123 SEQ ID NO : 3012-0. 6-22 62-20. 9-0. 2-4 ATTACAACGGTTCTTGCGGC 1184 SEQ ID NO : 3013-0. 6-24. 5 68. 7-23. 3-0. 3-5. 1 TCTTGTAACTGAAGACATGG 1311 SEQ ID NO : 3014-0. 6-19. 3 59. 2-18. 7 0-5. 7 GAATCTGCATTAGTGCCATA 1369 SEQ ID NO : 3015-0. 6-22. 9 67. 1-20. 4-1. 9-7. 2 AAAAAATGAACAGAAAAATA 2341 SEQ ID NO : 3016-0. 6-8. 8 37. 5-8. 2 0-2. 4 TAAAAAATGAACAGAAAAAT 2342 SEQ ID NO : 3017-0. 6-8. 8 37. 5-8. 2 0-2. 4 TACCACATTCTAATTAATTT 2389 SEQ ID NO : 3018-0. 6-17. 2 54. 3-16. 6 0-6. 2 AAAGAGGGTCTAGAAATCCC 2453 SEQ ID NO : 3019-0. 6-21. 4 62. 6-20. 3-0. 2-7. 8 GGAGGTGGCACATAATAACT 2609 SEQ ID NO : 3020-0. 6-21. 9 64. 2-20. 7-0. 3-4. 8 TGGCCCCAGCATGAATGATA 2673 SEQ ID NO : 3021-0. 6-26. 4 71. 5-24. 2-1. 5-7. 6 AGAGATTTGCTCCAAAGCAG 2719 SEQ ID NO : 3022-0. 6-22. 3 65. 4-19. 1-2. 6-10. 2 ATAACTTCTATCTCTCTAAA 2743 SEQ ID NO : 3023-0. 6-17. 4 56-16. 8 0-1. 1 AATTAGGCAATGCATACACA 2978 SEQ ID NO : 3024-0. 6-20. 1 59. 8-18. 6-0. 7-8 AGAGATAGACTTTGCCTCCA 3125 SEQ ID NO : 3025-0. 6-24. 6 71. 3-24 0-3. 8 AAACAAGAGAAGCACACAAT 3478 SEQ ID No : 3026-0. 6-16. 9 52. 4-16. 3 0-4. 1 AATCACAGAAACAAGAGAAG 3486 SEQ ID NO : 3027-0. 6-15. 2 49. 5-14. 6 0-2. 9 CAGAGGCTCCAGAAACAGAG 274 SEQ ID NO : 3028-0. 5-23 66. 5-22. 5 0-3. 8 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo CCGCAGCAAAGCAATAGCAG 291 SEQ ID NO : 3029-0. 5-24. 4 66. 9-22. 2-1. 7-7. 4 AGCCAGTCAACCACAACTAC 604 SEQ ID NO : 3030-0. 5-24. 2 68. 4-23. 7 0-3. 5 CCTCTGTGATTGTTCCATAT 1038 SEQ ID NO : 3031-0. 5-24. 2 70. 9-23. 7 0-2. 1 CAGAGAGTCAACAAAGAGGT 1088 SEQ ID NO : 3032-0. 5-20 60. 9-19. 5 0-4. 8 TTCATCTGATAATGGTAAAC 1288 SEQ ID NO : 3033-0. 5-17 54. 2-16. 5 0-4. 4 GCTGGCAAGACTTGCCCGGG 1761 SEQ ID NO : 3034-0. 5-30. 5 79. 8-25. 8-4. 2-13. 3 AGCTGACAGCCTTCTACACA 2127 SEQ ID NO : 3035-0. 5-25. 8 74. 1-23. 9-1. 3-7. 5 AATAACTAAGAAGGTGGCAC 2596 SEQ ID NO : 3036-0. 5-18. 6 56. 8-18. 1 0-5 AAAGCACTGTATTAAATCTT 2824 SEQ ID NO : 3037-0. 5-16. 9 53. 7-16. 4 0-4. 1 AGCACACAATTGGCTTGAGA 3468 SEQ ID NO : 3038-0. 5-22. 9 66. 7-21. 2-1. 1-7. 4 AATATCTCATTATGTATATG 3614 SEQ ID NO : 3039-0. 5-15. 8 52. 4-15. 3 0-3. 1 GGGTCCTATTCCCAAAATAT 3629 SEQ ID NO : 3040-0. 5-23. 4 66-21. 4-1. 4-5. 4 TCTGCCCTCGTCCTGAGCCG 24 SEQ ID NO : 3041-0. 4-32. 9 85. 2-31. 6-0. 8-5. 4 GGCGGCACGGAGCCCGGGCG 85 SEQ ID NO : 3042-0. 4-35. 9 85. 7-29. 7-5. 2-19. 4 TCTCGGCCAGGGGCTGGGGG 138 SEQ ID NO : 3043-0. 4-33. 3 88. 8-30. 3-2. 6-10. 4 CCACCTCTTGGTGTTTCCAG 182 SEQ ID NO : 3044-0. 4-28. 1 79. 1-24. 7-3-7. 4 CTTGGAGGTGCGGAGGTTAA 404 SEQ ID No : 3045-0. 4-25. 1 71. 6-24. 7 0-4 CGGCAGGATCCAAACCTGTG 819 SEQ ID NO : 3046-0. 4-26. 3 70. 8-23. 5-2. 4-9. 6 TACCACCTCTGTGATTGTTC 1043 SEQ ID NO : 3047-0. 4-24. 6 72. 1-23-1. 1-3. 8 CATGCATATACACATACACC 2483 SEQ ID NO : 3048-0. 4-21. 2 62. 1-20. 8 0-6. 8 CTAATGCTTATATCCTATAG 2531 SEQ ID NO : 3049-0. 4-18. 8 58. 4-18. 4 0-4. 7 ATAATAACTAAGAAGGTGGC 2598 SEQ ID NO : 3050-0. 4-17. 4 54. 6-17 0-5 GGGGAGGTGGCACATAATAA 2611 SEQ ID NO : 3051-0. 4-23. 2 66. 8-21. 9-0. 8-4. 8 AAGCACTGTATTAAATCTTA 2823 SEQ ID NO : 3052-0. 4-17. 3 55-16. 9 0-4. 1 GAAAAGGCACTGGTATTAAA 2867 SEQ ID NO : 3053-0. 4-17. 8 54. 7-16. 6-0. 6-4. 1 AATGCATACACAAATCTTTT 2970 SEQ ID NO : 3054-0. 4-17. 5 54. 6-17. 1 0-7. 3 AGAAACAAGAGAAGCACACA 3480 SEQ ID NO : 3055-0. 4-18. 2 55. 4-17. 8 0-4. 1 ACCATGCTTCATGTACACAA 3733 SEQ ID NO : 3056-0. 4-22. 8 66-21-1. 3-6. 7 GCGGCACGGAGCCCGGGCGG 84 SEQ ID NO : 3057-0. 3-35. 9 85. 7-29. 8-5. 2-19. 4 93 GAAAACTTGGCGGCACGGAG-0. 3-24 65. 2-21. 8-1. 9-6. 8 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 3058 AGCTGGTGGGCCAGGGGGAG 622 SEQ ID NO : 3059-0. 3-31. 4 86. 8-27. 9-3. 2-9. 4 ACCGTTCCTTTCACGAAGTT 790 SEQ ID NO : 3060-0. 3-25. 1 69. 9-24-0. 6-4. 1 AGAGCCTCTTGTGGATGTCG 858 SEQ ID NO : 3061-0. 3-26. 1 75. 2-25. 8 0-3. 7 ATTGTTCCATATGCAATTGA 1030 SEQ ID NO : 3062-0. 3-20. 7 62-19. 9-0. 2-6. 8 CGAGAGGCCCCAGGCACCCA 2029 SEQ ID NO : 3063-0. 3-34. 3 85. 4-31. 5-2. 5-7. 5 CACGAGAGGCCCCAGGCACC 2031 SEQ ID NO : 3064-0. 3-32. 5 82. 9-29. 7-2. 5-7. 5 GTGTGCACGAGAGGCCCCAG 2036 SEQ ID NO : 3065-0. 3-30. 8 82. 1-29. 6 0-9. 8 GGACTTCTCACTGAGGCTCA 2160 SEQ ID NO : 3066-0. 3-26. 1 76. 8-25. 3-0. 2-6. 3 CTGTCGGAAGGACTTCTCAC 2169 SEQ ID NO : 3067-0. 3-24 70-22. 1-1. 6-7. 6 AAAAATAGGAAAGCCAATGA 2328 SEQ ID NO : 3068-0. 3-15. 7 49. 6-14. 2-1. 1-3. 9 AGAAGAAATAGAAACCACTT 2566 SEQ ID NO : 3069-0. 3-16. 1 51. 1-15. 8 0-3. 2 ACACGTCACTCATAGGGGAG 2625 SEQ ID NO : 3070-0. 3-24. 3 70. 4-23. 5-0. 2-5 TCTGTGTACACAGATGTGTA 2774 SEQ ID NO : 3071-0. 3-21. 9 67. 6-17. 3-2. 3-16. 8 CTTTGGCACGATACAGATTA 3390 SEQ ID NO : 3072-0. 3-21. 4 62. 9-20. 4-0. 4-3. 5 TCTGGTTCCAAGCATTTTGG 3551 SEQ ID NO : 3073-0. 3-24. 2 70. 6-22-1. 9-6 AAAATATCGTATAAAATTAC 3707 SEQ ID NO : 3074-0. 3-11. 3 42-11 0-3. 2 ATCCAAAATCCGAAATGCTC 3822 SEQ ID NO : 3075-0. 3-20. 5 58. 6-20. 2 0-3. 6 CGGGAGGCAAGGACTCGCTG 3 SEQ ID NO : 3076-0. 2-27. 6 74. 3-26-1. 3-4. 5 AGTCAACAAAGAGGTGGACG- 1083 SEQ ID NO : 3077-0. 2-20. 9 61. 4-18. 8-1. 9-5. 1 GATAATGGTAAACTCTGAAA 1281 SEQ ID NO : 3078-0. 2-15. 9 51. 1-15. 7 0-2. 6 TGTGGACAGAGGTTTGGAGT 1971 SEQ ID NO : 3079-0. 2-24. 1 72. 4-23. 9 0-3. 8 AATATGTCCATTACCACATT 2400 SEQ ID NO : 3080-0. 2-21 61. 9-20. 2-0. 3-3. 8 GAGGGTCTAGAAATCCCAAC 2450 SEQ ID NO : 3081-0. 2-23 66. 2-20. 7-2. 1-9. 9 TAAGAAGGTGGCACATAATA 2590 SEQ ID NO : 3082-0. 2-18. 6 57-17. 5-0. 8-4. 8 TTTTGTAAAATAGGGATAAT 3024 SEQ ID NO : 3083-0. 2-14. 8 49. 2-14. 1-0. 2-3. 5 GCATGTGGCTGAACCTCACT 3053 SEQ ID NO : 3084-0. 2-26. 8 75. 2-25. 6-0. 9-8. 3 ACAACTTTGGCACGATACAG 3394 SEQ ID NO : 3085-0. 2-21. 4 62. 1-20. 5-0. 4-4 TTAAAATATCGTATAAAATT 3709 SEQ ID NO : 3086-0. 2-11. 2 41. 8-11 0-3 TTGCCCCAGAACGAGATCTG 40 SEQ ID NO : 3087-0. 1-26 70. 5-24. 7-1. 1-6. 3 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo ATAGCAGAGGCTCCAGAAAC 278 SEQ ID NO : 3088-0. 1-23. 2 67. 4-21. 5-1. 5-5 CCAGTCAACCACAACTACAT 602 SEQ ID NO : 3089-0. 1-23. 1 65. 3-23 0-2. 8 ACCTCTGTGATTGTTCCATA 1039 SEQ ID NO : 3090-0. 1-24. 4 71. 5-24. 3 0-2. 1 ATTTTACCACCTCTGTGATT 1047 SEQ ID NO : 3091-0. 1-23. 2 68-21. 9-1. 1-3. 7 AGAGAGTCAACAAAGAGGTG 1087 SEQ ID NO : 3092-0. 1-19. 3 59. 6-19. 2 0-4. 8 GATTGGAGTCAGTGCACTGG 1137 SEQ ID NO : 3093-0. 1-24. 8 73. 5-21. 6-0. 4-14. 4 CTATTACAACGGTTCTTGCG 1186 SEQ ID NO : 3094-0. 1-22. 1 63. 7-22 0-4. 7 ACCAAGACTGAGAGGCCCCC 1503 SEQ ID NO : 3095-0. 1-30. 1 78. 7-30 0-6. 8 CTCCCGCGAGGAGTCCCAGC 1905 SEQ ID NO : 3096-0. 1-33. 2 85. 6-30. 6-2-12. 8 GAGAGGCAGCAAGAGCTATA 1938 SEQ ID NO : 3097-0. 1-23. 4 69. 1-21. 7-1. 5-5. 8 CTATTCAAGAGAGGCAGCAA 1946 SEQ ID NO : 3098-0. 1-21. 8 64. 7-21. 7 0-6. 3 AGTTAGAGCTATTCAAGAGA 1954 SEQ ID NO : 3099-0. 1-19. 7 62-19. 6 0. 5-5. 1 ACGGAATGGCTAAGACGTA 2276 SEQ ID NO : 3100-0. 1-20. 8 59. 7-20. 2-0. 2-5. 3 TCCAAACAGAAAGAGGGTCT 2462 SEQ ID NO : 3101-0. 1-21. 3 62. 4-21. 2 0-3. 7 TGAACCTCACTAAGCCTCAG 3044 SEQ ID NO : 3102-0. 1-24 68. 3-23. 9 0-3. 2 AACAAGAGAAGCACACAATT 3477 SEQ ID NO : 3103-0. 1-17. 7 54. 4-17. 6 0-4. 1 GGGAAAACCCCTCACATAAG 3762 SEQ ID NO : 3104-0. 1-23 63. 5-21. 3-1. 6-4. 8 CTTGGCGGCACGGAGCCCGG 88 SEQ ID NO : 3105 0-33. 1 82-30. 7-2. 4-10. 1 CCGACGGAGAGGTAGCATCC 439 SEQ ID NO : 3106 0-27. 8 75. 1-27. 8 0-4. 7 TACCAATGCTCAAGCCGAAG 927 SEQ ID NO : 3107 0-23. 5 64. 8-23. 5 0-5. 7 GAATACCAATGCTCAAGCCG 930 SEQ ID NO : 3108 0-23. 5 64. 6-23. 5 0-5. 7 CAGATCCCCTTTTTGAAGCG 1156 SEQ ID NO : 3109 0-25. 5 69. 9-24. 7-0. 6-5. 6 TATTACAACGGTTCTTGCGG 1185 SEQ ID NO : 3110 0-22. 4 64. 2-21. 8-0. 3-4. 7 CAATGCTATTACAACGGTTC 1191 SEQ ID NO : 3111 0-20. 3 60. 2-20. 3 0-4. 7 CTGAAGACATGGATTTTCAT 1303 SEQ ID NO : 3112 0-19. 5 59. 6-18. 9-0. 3-5. 3 TAACTGAAGACATGGATTTT 1306 SEQ ID NO : 3113 0-17. 6 55. 1-17. 6 0-5. 2 TGCCATAAAGGGTGACGTAA 1356 SEQ ID NO : 3114 0-22. 2 63-21. 5-0. 4-8. 2 TGTACCAAGACTGAGAGGCC 1506 SEQ ID NO : 3115 0-25 71-25 0-6. 4 CCCGGGCACCCTCAGGGAAG 1747 SEQ ID NO : 3116 0-32. 2 81. 6-30. 3-1. 7-11. 5 1858 GCTCCAGGGTCAAGGCTGAG 0-28. 3 80. 4-27. 6-0. 5-7. 9 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 3117 TCCCAGCCATCACAGGAGAC 1892 SEQ ID NO : 3118 0-28. 2 77. 8-28. 2 0-3. 5 AATCCAGTGTGCACGAGAGG 2042 SEQ ID NO : 3119 0-24. 7 70. 2-23. 8 0-9. 8 ACACAGGGCCTCTTCGGAGC 2112 SEQ ID NO : 3120 0-29. 1 80. 5-27. 8-1. 2-8. 6 GCAGGCTGAGCAGCTGACAG 2138 SEQ ID NO : 3121 0-27. 7 79. 1-25. 9-1. 7-11. 1 ATAACTAAGAAGGTGGCACA 2595 SEQ ID NO : 3122 0-20 59. 9-19. 2-0. 6-5 AGCATGAATGATACTCTGCT 2666 SEQ ID NO : 3123 0-21. 8 64. 9-20. 6-1. 1-4. 8 CCCTACTCTAATTAGGCAAT 2987 SEQ ID NO : 3124 0-22. 8 65. 5-22. 1-0. 5-7. 5 GAAAACCTAAGTACAAAGAA 3356 SEQ ID NO : 3125 0-14. 9 48. 4-14. 9 0-5. 3 TCTTCAGAAGTTTAACAGTG 3416 SEQ ID NO : 3126 0-18. 9 59. 8-18. 9 0-7. 1 GCCGGGAGGCAAGGACTCGC 5 SEQ ID NO : 3127 0. 1-30. 5 80-26. 9-3. 7-10. 2 GGACTGGAGGCAGAGAAGGT 120 SEQ ID NO : 3128 0. 1-25. 3 73. 3-23. 7-1. 7-4. 7 GGGACTGGAGGCAGAGAAGG 121 SEQ ID NO : 3129 0. 1-25. 3 72. 5-23. 7-1. 7-4. 7 CACCCCCTCCCAAGAAACAG 221 SEQ ID NO : 3130 0. 1-28. 3 72. 3-28. 4 0-1. 8 AGAAACAGAGCAGAGGAACG 264 SEQ ID NO : 3131 0. 1-19. 9 58. 8-20 0-4. 1 GGACATCCACAAAATCTGCA 888 SEQ ID NO : 3132 0. 1-22. 4 63. 8-22. 5 0-5. 3 TCTGAATACCAATGCTCAAG 933 SEQ ID NO : 3133 0. 1-20. 2 60-20. 3 0-3. 6 CACCTCTGTGATTGTTCCAT 1040 SEQ ID NO : 3134 0. 1-25. 4 73. 2-24. 7-0. 6-3. 4 ACCAGAGAGTCAACAAAGAG 1090 SEQ ID NO : 3135 0. 1-19. 8 59. 6-19. 9 0-4. 8 TTACAACGGTTCTTGCGGCA 1183 SEQ ID NO : 3136 0. 1-25. 2 69. 8-24. 7-0. 3-7. 3 AATCTGCATTAGTGCCATAA 1368 SEQ ID NO : 3137 0. 1-21. 6 63. 7-20. 4-1. 2-6. 5 GTTGAGACAGGTAGCTGCGA 1542 SEQ ID NO : 3138 0. 1-25. 4 73. 5-23. 9-1. 5-3. 5 AGTGTGCACGAGAGGCCCCA 2037 SEQ ID NO : 3139 0. 1-30. 8 82. 1-30 0-9. 8 AAGGACTTCTCACTGAGGCT 2162 SEQ ID NO : 3140 0. 1-24. 3 71. 6-23. 9-0. 2-6. 3 GAACCCCAACAGCTAGGGCC 2231. SEQ ID NO : 3141 0. 1-29. 6 77. 4-28. 4-1. 2-7. 3 CTCTAATTAGGCAATGCATA 2982 SEQ ID NO : 3142 0. 1-20. 2 60. 9-19. 4-0. 7-8 GATAATAATAGTTGCCCTTC 3010 SEQ ID NO : 3143 0. 1-20. 8 62. 1-20. 9 0-3 GTTCTCCTGGTTATACATTA 3258 SEQ ID NO : 3144 0. 1-22. 5 68. 4-22. 6 0-4 CGATACAGATTAAAACAATG 3382 SEQ ID NO : 3145 0. 1-14. 5 47. 6-14. 6 0-3 AAACCATGCTTCATGTACAC 3735 SEQ ID NO : 3146 0. 1-21. 4 62. 8-20. 1-1. 3-6. 7 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo AAGCTTCCATTAGTAAAAAC 3904 SEQ ID NO : 3147 0. 1-17. 3 54-17. 4 0-6. 2 GCAATCCCGGCCGGTAAGAC 163 SEQ ID NO : 3148 0. 2-29 74. 8-26. 2 0-14. 2 CTTGCCCGGGCACCCTCAGG 1751 SEQ ID NO : 3149 0. 2-33. 9 86. 1-29. 8-1. 3-16. 7 AAGGCTGAGAAGAATCCTTC 1847 SEQ ID NO : 3150 0. 2-21. 4 63. 5-19. 9-1. 7-7. 1 CTCTGGAGGTGTGGACAGAG 1980 SEQ ID NO : 3151 0. 2-24. 9 73. 9-23. 1-2-6. 6 CCAGGCACCCAGCTGCTTAC 2020 SEQ ID NO : 3152 0. 2-30. 7 82. 4-29. 5-1. 3-8. 1 ACTTCTCACTGAGGCTCAAA 2158 SEQ ID NO : 3153 0. 2-22. 9 67. 7-22. 6-0. 2-6. 3 GAACAGAAAAATAGGAAAGC 2334 SEQ ID NO : 3154 0. 2-14. 5 47. 8-14. 7 0-2. 8 AAGAAGGTGGCACATAATAA 2589 SEQ ID NO : 3155 0. 2-18. 2 55. 7-17. 5-0. 8-4. 8 CATAGGGGAGGTGGCACATA 2615 SEQ ID NO : 3156 0. 2-25. 3 72. 8-24. 6-0. 8-4. 8 AGATGTGTATTACATATGTC 2763 SEQ ID NO : 3157 0. 2-18. 7 59. 9-17. 3-1. 6-9. 3 GATACTCAACCTGTACAAGC 3525 SEQ ID NO : 3158 0. 2-21. 8 64. 2-22 0-6. 1 GGATACTCAACCTGTACAAG 3526 SEQ ID NO : 3159 0. 2-21. 2 62. 7-21. 4 0-6. 1 CCCAAAATATCTCATTATGT 3619 SEQ ID NO : 3160 0. 2-19. 7 58. 7-19. 9 0-2. 8 TCTGTGATTGTTCCATATGC 1036 SEQ ID NO : 3161 0. 3-23. 1 69. 3-23. 4 0-5. 7 TGATAATGGTAAACTCTGAA 1282 SEQ ID NO : 3162 0. 3-16. 6 52. 8-16. 9 0-2. 6 CAGGTAGCTGCGAAACTCCT 1535 SEQ ID NO : 3163 0. 3-25. 7 71. 4-25. 2-0. 6-7 CAGCCATCACAGGAGACCAG 1889 SEQ ID NO : 3164 0. 3-26. 5 74-26. 2-0. 3-3. 8 GCTATTCAAGAGAGGCAGCA 1947 SEQ ID NO : 3165 0. 3-24. 3 71. 3-23. 7-0. 7-6. 3 TCGGAAGGACTTCTCACTGA 2166 SEQ ID NO : 3166 0. 3-23. 4 68-23-0. 5-7. 6 AGCTCCTGTCGGAAGGACTT 2174 SEQ ID NO : 3167 0. 3-26. 5 74. 9-25. 2-1. 6-7. 5 GGACGGAATGGCTAAGACGT 2278 SEQ ID NO : 3168 0. 3-23. 6 65. 6-23. 1-0. 6-5. 2 GGGTCTAGAAATCCCAACTC 24481 SEQ ID NO : 3169 0. 3-23. 7 68-22. 6-1. 3-9. 2 ACAGATGTGTATTACATATG 2765 SEQ ID NO : 3170 0. 3-18 57. 2-15. 5-2. 8-6. 6 AGGCATGTGGCTGAACCTCA 3055 SEQ ID NO : 3171 0. 3-26. 9 75. 5-25. 9-1. 2-8. 3 CAGATGTTCTCCTGGTTATA 3263 SEQ ID NO : 3172 0. 3-23. 1 69. 6-23. 4 0-4. 6 GCCGCCGGGAGGCAAGGACT 8 SEQ ID NO : 3173 0. 4-32. 1 81. 5-28. 3-4. 2-12. 6 CAGGGGCTGGGGGACTGGAG 131 SEQ ID NO : 3174 0. 4-29. 3 81. 3-29. 2-0. 2-4. 3 TAGCTTTGGGTTTGTGGAGC 354 SEQ ID NO : 3175 0. 4-25. 2 75. 3-25-0. 3-4. 6 598 TCAACCACAACTACATTGGC 0. 4-22. 3 64-21. 7-0. 9-3. 9 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 3176 GAGGCTGTAGCCGATCAAGT 743 SEQ ID NO : 3177 0. 4-26. 2 74. 2-24. 1-2. 5-10. 5 GCTCCGAGGCTGTAGCCGAT 748 SEQ ID NO : 3178 0. 4-30. 5 81. 3-28. 4-2. 5-10. 5 TCCATATGCAATTGATCCCA 1025 SEQ ID NO : 3179 0. 4-24. 4 68. 1-24. 8 0-6. 8 CTCACATTTTACCACCTCTG 1052 SEQ ID NO : 3180 0. 4-24. 2 69. 6-24. 6 0-1. 8 ATTAGTGCCATAAAGGGTGA 1361 SEQ ID NO : 3181 0. 4-22 64. 7-21. 7-0. 4-3. 8 AGAGCTATTCAAGAGAGGCA 1950 SEQ ID NO : 3182 0. 4-22. 4 67. 3-21. 7-1-5. 2 AGAACCCCAACAGCTAGGGC 2232 SEQ ID NO : 3183 0. 4-27. 6 74. 4-26. 7-1. 2-6. 8 AGGGTCTAGAAATCCCAACT 2449 SEQ ID NO : 3184 0. 4-23. 3 66. 8-21. 6-2. 1-9. 9 TTAGAACCAGCTCTGTCTGG 2806 SEQ ID NO : 3185 0. 4-24. 3 71. 4-22. 7-2-6. 8 AGCACTGTATTAAATCTTAG 2822 SEQ ID NO : 3186 0. 4-18 57. 1-18. 4 0-4. 1 AATAGTTGCCCTTCTCCCCC 3004 SEQ ID NO : 3187 0. 4-30. 8 81. 7-31. 2 0-3 TCACTAAGCCTCAGTTTTGT 3038 SEQ ID NO : 3188 0. 4-23. 7 70. 8-24. 1 0-3. 2 AACCTCACTAAGCCTCAGTT 3042 SEQ ID NO : 3189 0. 4-24. 7 70. 8-25. 1 0-3. 2 TAGGCATGTGGCTGAACCTC 3056 SEQ ID NO : 3190 0. 4-25. 9 73. 8-25-1. 2-8. 3 CCATAAAAAGTCCAACCGTT 3287 SEQ ID NO : 3191 0. 4-21. 5 60. 1-21. 9 0-2. 8 ACTCAACTGGTTATGTCTTC 3431 SEQ ID NO : 3192 0. 4-21. 8 67. 1-22. 2 0-4. 7 CTGGTTCCAAGCATTTTGGA 3550 SEQ ID NO : 3193 0. 4-24. 4 70. 3-22. 2-2. 6-7. 7 GGCAGGGAGCGAGTGTCAAC 63 SEQ ID NO : 3194 0. 5-26. 9 76. 2-25. 8-1. 6-4. 5 TTGGCGGCACGGAGCCCGGG 87 SEQ ID NO : 3195 0. 5-33. 4 82. 6-31. 2-1. 9-13. 5 ACCCCCTCCCAAGAAACAGA 220 SEQ ID NO : 3196 0. 5-28. 2 72. 5-28. 7 0-1. 8 ACACCCCCTCCCAAGAAACA 222 SEQ ID NO : 3197 0. 5-28. 5 72. 6-29 0-1. 8 CAAAGCAATAGCAGAGGCTC 285 SEQ ID NO : 3198 0. 5-22. 2 65-21-1. 7-8. 1 GGATGTCGGCCCCTTCAAAC 846 SEQ ID NO : 3199 0. 5-28. 1 74. 8-28. 6 0-6. 2 TGGAGGACATCCACAAAATC 892 SEQ ID NO : 3200 0. 5-20. 8 60. 8-19. 3-2-6 GTGCTCCAGGGTCAAGGCTG 1860 SEQ ID NO : 3201 0. 5-28. 9 82. 2-28. 9-0. 1-4. 7 CGGAAGGACTTCTCACTGAG 2165 SEQ ID NO : 3202 0. 5-23 66. 8-22. 8-0. 5-7. 6 AAAATAGGAAAGCCAATGAT 2327 SEQ ID NO : 3203 0. 5-16. 4 51. 1-15. 7-1. 1-3. 9 ATATGTCCATTACCACATTC 2399 SEQ ID NO : 3204 0. 5-22. 1 65. 5-22-0. 3-3. 8 CAGCATGAATGATACTCTGC 2667 SEQ ID NO : 3205 0. 5-21. 6 64. 1-21. 5-0. 3-4. 8 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo CTGAACCTCACTAAGCCTCA 3045 SEQ ID NO : 3206 0. 5-24. 9 70-25. 4 0-3. 2 GTCTTCAGAAGTTTAACAGT 3417 SEQ ID NO : 3207 0. 5-20. 1 63. 1-20. 6 0-7. 1 TCCAAAATCCGAAATGCTCC 3821 SEQ ID NO : 3208 0. 5-22. 5 61. 9-23 0-3. 6 CTGCCCTCGTCCTGAGCCGC 23 SEQ ID NO : 3209 0. 6-34. 3 87. 6-33. 8-1-5. 4 GCTGGTGGGCCAGGGGGAGC 621 SEQ ID NO : 3210 0. 6-33. 2 91. 1-30. 6-3. 2-9. 4 ACCACCTCTGTGATTGTTCC 1042 SEQ ID NO : 3211 0. 6-26. 9 76. 4-26. 3-1. 1-3. 7 TCTGGGAATCTGCATTAGTG 1374 SEQ ID NO : 3212 0. 6-22. 4 67. 1-23 0-4. 9 CTCACTGAGGCTCAAAGCAG 2154 SEQ ID NO : 3213 0. 6-23. 8 69. 2-22. 4-2-8. 4 TCCTGTCGGAAGGACTTCTC 2171 SEQ ID NO : 3214 0. 6-25. 5 73. 6-24. 5-1. 6-7. 6 GAGGCTCAGTAATATGTCCA 2410 SEQ ID NO : 3215 0. 6-23. 8 70. 5-23. 9-0. 1-4. 1 GAAGGTGGCACATAATAACT 2587 SEQ ID NO : 3216 0. 6-20 59. 7-20-0. 3-4. 8 TTCTGGCCCCAGCATGAATG 2676 SEQ ID NO : 3217 0. 6-27. 5 74. 5-27. 2-0. 8-7. 8 GGTTATACATTAATAAAAGG 3250 SEQ ID NO : 3218 0. 6-14. 7 49-15. 3 0-4. 2 TAAAAAGTCCAACCGTTGGC 3284 SEQ ID NO : 3219 0. 6-21. 8 61. 4-20. 7-1. 7-10. 5 TAAGTACAAAGAAAATCATT 3349 SEQ ID NO : 3220 0. 6-13. 1 45. 5-13. 7 0-5. 3 CTCGGCCAGGGGCTGGGGGA 137 SEQ ID NO : 3221 0. 7-33. 5 88. 2-31. 8-2. 4-10. 4' TGTTCCATATGCAATTGATC 1028 SEQ ID NO : 3222 0. 7-21 63. 1-21. 7 0-6. 8 GCAGAGTCTGGGAATCTGCA 1380 SEQ ID NO : 3223 0. 7-25. 7 74. 8-21. 3-5. 1-14. 1 GTGCACGAGAGGCCCCAGGC 2034 SEQ ID No : 3224 0. 7-32. 6 85. 6-31. 3-1. 4-12 GCTGACAGCCTTCTACACAG 2126 SEQ ID NO : 3225 0. 7-25. 8 74. 1-25. 8-0. 5-6. 3 AACACGTCACTCATAGGGGA 2626 SEQ ID NO : 3226 0. 7-23. 6 67. 8-24. 3 0-4. 6 AGTGATCAAACACGTCACTC 2634 SEQ ID NO : 3227 0. 7-21. 2 63. 2-19. 9-2-7. 2 ACCAGCTCTGTCTGGCAGGT 2801 SEQ ID NO : 3228 0. 7-29. 5 85-28-2. 2-7. 6 TCGTATAAAATTACCCTCAG 3701 SEQ ID NO : 3229 0. 7-19. 7 58. 3-20. 4 0-3. 2 GAAAATGAAAACTTGGCGGC 99 SEQ ID NO : 3230 0. 8-19 55. 5-19. 8 0-5. 3 GCTGGGGGACTGGAGGCAGA 126 SEQ ID NO : 3231 0. 8-29. 3 81. 9-28. 4-1. 7-5. 9 AGCAGAGGCTCCAGAAACAG 276 SEQ ID NO : 3232 0. 8-24. 2 69. 4-23. 6-1. 3-5 GTAGCATCCTTCATGCTCTG 428 SEQ ID NO : 3233 0. 8-25. 9 76. 2-23. 6-3. 1-8. 4 AGGTGTGGAGGACATCCACA 897 SEQ ID No : 3234 0. 8-26. 1 75-21. 8-5. 1-11. 7 1142 GAAGCGATTGGAGTCAGTGC 0. 8-24. 3 70. 7-25. 1 0-5 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID No : 3235 TCATCTGATAATGGTAAACT 1287 SEQ ID No : 3236 0. 8-17. 8 55. 8-18. 6 0-4. 4 GCATTAGTGCCATAAAGGGT 1363 SEQ ID NO : 3237 0. 8-23. 9 68. 9-23. 4-1. 2-6. 2 TGTGCACGAGAGGCCCCAGG 2035 SEQ ID NO : 3238 0. 8-30. 8 81. 1-30. 7 0-9. 8 CCTTTCCCCATGCATATACA 2491 SEQ ID NO : 3239 0. 8-27 73. 3-27. 8 0-6. 8 TGGCTGCAAAAGTCTTCATG 3152 SEQ ID NO : 3240 0. 8-22 64. 8-22. 1-0. 4-6. 4 CAGATTAAAACAATGTCCTT 3377 SEQ ID NO : 3241 0. 8-17. 8 54. 8-18. 6 0-4. 8 CTATTCCCAAAATATCTCAT 3624 SEQ ID NO : 3242 0. 8-19. 8 59-20. 6 0-2. 6 CCTGAGCCGCCGGGAGGCAA 13 SEQ ID NO : 3243 0. 9-32. 7 81. 5-29. 4-4. 2-12. 5 CTCTCGGCCAGGGGCTGGGG 139 SEQ ID NO : 3244 0. 9-33 88. 2-31. 3-2. 6-10. 4 GGCTGTGGCCGACGGAGAGG 447 SEQ ID NO : 3245 0. 9-30. 1 79. 8-28. 4-2. 6-8. 7 TTCAAACATGGGCCCGGCAG 833 SEQ ID NO : 3246 0. 9-27. 4 72. 5-26. 7-0. 7-11. 2 GGTAAACTCTGAAAGGCATG 1275 SEQ ID NO : 3247 0. 9-20 59. 7-20. 4 0-7. 5 CCATGTTCTTGTAACTGAAG 1317 SEQ ID NO : 3248 0. 9-20. 6 62-20. 5-0. 9-4. 3 CCCGGCCTGGGGATATGCTG 1662 SEQ ID NO : 3249 0. 9-31. 3 80. 7-30. 4-1. 5-11. 4 GAGCTATTCAAGAGAGGCAG 1949 SEQ ID NO : 3250 0. 9-22. 4 67. 3-22. 2-1-5. 1 ATCCAGTGTGCACGAGAGGC 2041 SEQ ID NO : 3251 0. 9-27. 2 76. 9-27. 2 0-9. 8 GAAGGACTTCTCACTGAGGC 2163 SEQ ID NO : 3252 0. 9-24 70. 9-24. 4-0. 2-6. 7 CAGATGTGTATTACATATGT 2764 SEQ ID NO : 3253 0. 9-19 59. 8-17. 7-2. 2-9. 3 CTCAACCTGTACAAGCTTCG 3521 SEQ ID NO : 3254 0. 9-23. 5 66. 9-24. 4 0-6. 4 GCAGAGGCTCCAGAAACAGA 275 SEQ ID NO : 3255 1-24. 8 70. 4-25. 1-0. 5-3. 9 GTTTGACCTCAGTCTGTGTA 372 SEQ ID NO : 3256 1-24. 8 75. 3-24. 2-1. 6-4. 2 GAGAGAGCCTCTTGTGGATG 861 SEQ ID NO : 3257 1-24. 9 73. 2-24. 5-1. 3-8. 2 AGTGCACTGGAAGGCAAAAC 1127 SEQ ID NO : 3258 1-21. 7 62. 9-20. 5-2. 2-10. 1 GCCTTCTACACAGGGCCTCT 2119 SEQ ID NO : 3259 1-30 83. 6-29. 9-1-7. 3 CAGCTCCTGTCGGAAGGACT 2175 SEQ ID NO : 3260 1-27. 1 75. 6-26. 5-1. 6-7. 5 GAAAGAGGGTCTAGAAATCC 2454 SEQ ID NO : 3261 1-20 60. 2-21 0-6 GCCTTTCCCCATGCATATAC 2492 SEQ ID NO : 3262 1-28. 1 76. 4-29. 1 0-6. 8 GCCCTTCTCCCCCTACTCTA 2997 SEQ ID NO : 3263 1-33. 2 87. 8-34. 2 0-2 ACAAGAGAAGCACACAATTG 3476 SEQ ID NO : 3264 1-18. 4 56. 1-19. 4 0-6. 7 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo TGGCAGGGAGCGAGTGTCAA 64 SEQ ID NO : 3265 1. 1-26. 7 75. 4-26. 2-1. 6-5 GGAAAATGAAAACTTGGCGG 100 SEQ ID NO : 3266 1. 1-18. 4 54. 3-19. 5 0-4 GGTGGAAAATGAAAACTTGG 103 SEQ ID NO : 3267 1. 1-17 52. 6-18. 1 0-2. 6 GAGGTGCGGAGGTTAAACCT 400 SEQ ID NO : 3268 1. 1-25. 3 70. 7-24. 7-1. 7-7. 7 TTGGAGGTGCGGAGGTTAAA 403 SEQ ID NO : 3269 1. 1-23. 5 67. 5-24. 6 0-4 GAGCCTCTTGTGGATGTCGG 857 SEQ ID NO : 3270 1. 1-27. 3 77. 6-28. 4 0-3. 7 GAGGACATCCACAAAATCTG 890 SEQ ID NO : 3271 1. 1-20. 5 60. 2-21-0. 3-6 CATTTTACCACCTCTGTGAT 1048 SEQ ID NO : 3272 1. 1-23. 8 68. 8-23. 7-1. 1-3. 7 CTGACAGCCTTCTACACAGG 2125 SEQ ID NO : 3273 1. 1-25. 2 72. 4-26. 3 0-3. 5. GTTATATCTGGCAACCGGCC 2700 SEQ ID NO : 3274 1. 1-27 73. 8-26-2. 1-6. 9 AGATGTTCTCCTGGTTATAC 3262 SEQ ID NO : 3275 1. 1-22. 6 69-23. 7 0-4. 6 TCCTATTCCCAAAATATCTC 3626 SEQ ID NO : 3276 1. 1-21. 5 62. 8-22. 6 0-2. 6 GAAATGCTCCAAAATCCAAA 3811 SEQ ID NO : 3277 1. 1-18. 6 54. 7-19. 7 0-2. 9 GAGCCCGGGCGGTGGCAGGG 76 SEQ ID NO : 3278 1. 2-34. 7 88. 3-32. 1-2. 7-15. 7 CCAGCAATCCCGGCCGGTAA 166 SEQ ID NO : 3279 1. 2-30. 9 77. 1-29. 1-0. 1-14. 2 GCTGTGGCCGACGGAGAGGT 446 SEQ ID NO : 3280 1. 2-30. 1 80. 7-30. 7-0. 2-8. 3 GCCTCTTGTGGATGTCGGCC 855 SEQ ID NO : 3281 1. 2-30. 5 83. 9-31-0. 4-5. 8 AACAAAGAGGTGGACGGCTC 1079 SEQ ID NO : 3282 1. 2-22. 9 65. 3-23. 6-0. 2-3. 7 TTGTACCAAGACTGAGAGGC 1507 SEQ ID NO : 3283 1. 2-23. 1 67. 7-24. 3 0-4. 2 AAAAGCACTGTATTAAATCT 2825 SEQ ID NO : 3284 1. 2-16. 1 51. 7-17. 3 0-4. 1 AATGCTCCAAAATCCAAAAC 3809 SEQ ID No : 3285 1. 2-18. 2 54-19. 4 0-3. 6 CCAAAATCCGAAATGCTCCA 3820 SEQ ID NO : 3286 1. 2-22. 8 61. 7-24 0-3. 6 AGCCCGGGCGGTGGCAGGGA 75 SEQ ID NO : 3287 1. 3-34. 7 88. 3-32. 1-3. 1-15. 7 CGGCACGGAGCCCGGGCGGT 83 SEQ ID NO : 3288 1. 3-35. 3 85-31. 2-5. 2-18. 1 GACTGGAGGCAGAGAAGGTG 119 SEQ ID NO : 3289 1. 3-24. 1 70. 5-23. 7-1. 7-4. 7 ATGCTATTACAACGGTTCTT 1189 SEQ ID NO : 3290 1. 3-21. 3 63. 3-22. 6 0-4. 7 AGAGAGGCAGCAAGAGCTAT 1939 SEQ ID NO : 3291 1. 3-23. 7 70-23. 4-1. 5-6. 6 ACAGCCTTCTACACAGGGCC 2122 SEQ ID No : 3292 1. 3-28. 7 79. 8-28. 2-1. 8-6. 4 CCTGTCGGAAGGACTTCTCA 2170 SEQ ID NO : 3293 1. 3-25. 8 73-25. 5-1. 6-7. 6 2176 TCAGCTCCTGTCGGAAGGAC 1. 3-26. 6 75. 3-26. 8-1-7. 3 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 3294 TGGCACATAATAACTAAGAA 2604 SEQ ID NO : 3295 1. 3-16. 6 52. 3-17. 2-0. 4-4 CACTGGTATTAAAGTAAAAT 2860 SEQ ID NO : 3296 1. 3-15. 1 49. 6-16. 4 0-3 CTAATTAGGCAATGCATACA 2980 SEQ ID NO : 3297 1. 3-19. 8 59. 4-20. 2-0. 7-8 GAACCTCACTAAGCCTCAGT 3043 SEQ ID NO : 3298 1. 3-25. 2 71. 7-26. 5 0-3. 2 ATACTCAACCTGTACAAGCT 3524 SEQ ID NO : 3299 1. 3-22. 1 64. 8-23. 4 0-6. 1 ATATCGTATAAAATTACCCT 3704 SEQ ID NO : 3300 1. 3-18. 3 55. 3-19. 6 0-3. 2 ATCCAAAAATCCAAAATCCG 3830 SEQ ID NO : 3301 1. 3-18. 5 53. 7-19. 8 0-2. 2 CCGCCGGGAGGCAAGGACTC 7 SEQ ID NO : 3302 1. 4-30. 7 79. 2-27. 9-4. 2-10. 4 CTTCTCTCGGCCAGGGGCTG 142 SEQ ID NO : 3303 1. 4-30. 8 84. 7-30-2. 2-7. 9 TCTTGTGGATGTCGGCCCCT 852 SEQ ID NO : 3304 1. 4-30. 7 82. 9-32. 1 0-6. 2 AGGACATCCACAAAATCTGC 889 SEQ ID NO : 3305 1. 4-21. 7 62. 9-22. 5-0. 3-6 GCCCCAGGCACCCAGCTGCT 2023 SEQ ID NO : 3306 1. 4-36. 5 92. 7-36-1. 7-11. 5 TGACAGCCTTCTACACAGGG 2124 SEQ ID NO : 3307 1. 4-25. 5 73-26. 3-0. 3-3. 5 GCTGAGCAGCTGACAGCCTT 2134 SEQ ID NO : 3308 1. 4-28. 8 81-26. 5-2. 1-15. 6 GGCTCAAAGCAGGCTGAGCA 2146 SEQ ID NO : 3309 1. 4-27. 1 76. 2-24. 2-4. 3-12. 9 ATAACTAAGAAGAAATAGAA 2573 SEQ ID NO : 3310 1. 4-11. 8 43-13. 2 0-2. 9 TCACTCATAGGGGAGGTGGC 2620 SEQ ID NO : 3311 1. 4-26. 6 77. 9-27. 2-0. 6-4. 5 GGCCCCAGCATGAATGATAC 2672 SEQ ID NO : 3312 1. 4-26. 6 72. 2-26. 4-1. 5-7. 3 TCTAATTAGGCAATGCATAC 2981 SEQ ID NO : 3313 1. 4-19. 5 59. 5-20-0. 7-8 GCTGAACCTCACTAAGCCTC 3046 SEQ ID NO : 3314 1. 4-26 73-27. 4 0-3. 6 AGATTAAAACAATGTCCTTA 3376 SEQ ID NO : 3315 1. 4-16. 8 53. 1-18. 2 0-4. 8 AAATATCGTATAAAATTACC 3706 SEQ ID NO : 3316 1. 4-14 46. 9-15. 4 0-3. 2 ACAGAAGTTTTAAAAAACAA 205 SEQ ID NO : 3317 1. 5-12. 7 44. 6-12. 3-1. 9-8. 8 AACAGAAGTTTTAAAAAACA 206 SEQ ID NO :'3318 1. 5-12. 7 44. 6-12. 3-1. 9-8. 8 TGGAGGTGCGGAGGTTAAAC 402 SEQ ID NO : 3319 1. 5-23. 6 67. 7-25. 1 0-4 CTGAATACCAATGCTCAAGC 932 SEQ ID NO : 3320 1. 5-21. 6 62. 5-23. 1 0-5. 3 CAGCCTTCTACACAGGGCCT 2121 SEQ ID NO : 3321 1. 5-29. 4 81. 1-29. 1-1. 8-7. 3 CAGCTGACAGCCTTCTACAC 2128 SEQ ID NO : 3322 1. 5-25. 8 74. 1-25. 9-1. 3-7. 6 ATAATAACTAAGAAGAAATA 2576 SEQ ID NO : 3323 1. 5-10. 9 41. 3-12. 4 0-2. 2 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo GGATAATAATAGTTGCCCTT 3011 SEQ ID NO : 3324 1. 5-21. 6 63. 2-23. 1 0-3 TTTGTAAAATAGGGATAATA 3023 SEQ ID NO : 3325 1. 5-14. 4 48. 4-15. 4-0. 2-2 GTTATGTCTTCAGAAGTTTA 3422 SEQ ID NO : 3326 1. 5-19. 7 62. 9-21. 2 0. 2-7. 1 ACTGGTTATGTCTTCAGAAG 3426 SEQ ID NO : 3327 1. 5-20. 9 64. 8-21. 7-0. 5-6. 5 GTTCCAAGCATTTTGGATAA 3547 SEQ ID NO : 3328 1. 5-21. 3 63. 2-19. 7-3. 1-8. 3 ACGGAGAGGTAGCATCCTTC 436 SEQ ID NO : 3329 1. 6-25. 8 74. 4-26. 5-0. 7-6. 4 GCCGACGGAGAGGTAGCATC 440 SEQ ID NO : 3330 1. 6-27. 6 75. 8-29. 2 0-5. 8 CATCCGTGAATGATGAAAAA 508 SEQ ID NO : 3331 1. 6-17. 4 52. 6-18. 2-0. 6-4. 2 TGGTAAACTCTGAAAGGCAT 1276 SEQ ID NO : 3332 1. 6-20 59. 7-21. 6 0-4 AATTAAAAAATGAACAGAAA 2345 SEQ ID NO : 3333 1. 6-9. 6 38. 8-11. 2 0-3 TAATATGTCCATTACCACAT 2401 SEQ ID NO : 3334 1. 6-20. 6 61-21. 7-0. 1-3. 8 CTAAGAAGAAATAGAAACCA 2569 SEQ ID NO : 3335 1. 6-14. 8 48. 3-16. 4 0-2 GGTGGCACATAATAACTAAG 2584 SEQ ID NO : 3336 1. 6-19. 1 57. 9-19. 8-0. 8-4. 8 GGCATGTGGCTGAACCTCAC 3054 SEQ ID NO : 3337 1. 6-27. 1 75. 8-27. 4-1. 2-8. 3 AATATCGTATAAAATTACCC 3705 SEQ ID NO : 3338 1. 6-16. 7 51. 9-18. 3 0-3. 2 AATCCAAAATCCGAAATGCT 3823 SEQ ID NO : 3339 1. 6-19. 4 55. 8-21 0-3. 6 CAGAAGTTTTAAAAAACAAA 204 SEQ ID NO : 3340 1. 7-11. 8 42. 8-12. 3-1. 1-8 CCACCGTTCCTTTCACGAAG 792 SEQ ID NO : 3341 1. 7-26. 5 71-27. 4-0. 6-3. 8 AGAGAGCCTCTTGTGGATGT 860 SEQ ID NO : 3342 1. 7-25. 5 75. 4-26. 3-0. 8-7. 3 CATTAGTGCCATAAAGGGTG 1362 SEQ ID NO : 3343 1. 7-22. 1 64. 6-23. 1-0. 4-3. 8 ATAGCAGGAAGTCTTGCTGC 1784 SEQ ID NO : 3344 1. 7-24. 4 72. 4-23. 6-2. 5-9. 9 GGATAGCAGGAAGTCTTGCT 1786 SEQ ID NO : 3345 1. 7-24. 4 72. 2-24. 5-1. 6-9. 5 TGCACGAGAGGCCCCAGGCA 2033 SEQ ID NO : 3346 1. 7-32. 1 83. 1-31. 3-2. 5-8. 7 ACAGGGCCTCTTCGGAGCCA 2110 SEQ ID NO : 3347 1. 7-30. 9 83. 3-29. 1-3. 5-8. 6 GCAACCCATGAGAACCCCAA 2242 SEQ ID NO : 3348 1. 7-27. 4 70. 6-29. 1 0-4. 5 AGAAAGAGGGTCTAGAAATC 2455 SEQ ID NO : 3349 1. 7-18 56. 6-19. 7 0-6 CAGAAAGAGGGTCTAGAAAT 2456 SEQ ID NO : 3350 1. 7-18. 3 56. 6-20 0-6 AAGAAGAAATAGAAACCACT 2567 SEQ ID NO : 3351 1. 7-15. 3 49. 2-17 0-2. 1 TCTCAGCCATAAAAAGTCCA 3293 SEQ ID NO : 3352 1. 7-22. 1 63. 8-23. 8 0-2. 4 3355 AAAACCTAAGTACAAAGAAA 1. 7-13. 6 45. 9-15. 3 0-5. 3 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 3353 TAAAATATCGTATAAAATTA 3708 SEQ ID NO : 3354 1. 7-10. 8 41. 1-12. 5 0-3. 2 GCAATAGCAGAGGCTCCAGA 281 SEQ ID NO : 3355 1. 8-26. 2 74. 6-26. 7-1. 2-6. 4 TAATTAGGCAATGCATACAC 2979 SEQ ID NO : 3356 1. 8-19. 1 58-20-0. 7-8 CCCTTCTCCCCCTACTCTAA 2996 SEQ ID NO : 3357 1. 8-30. 7 81-32. 5 0-0. 7 CAACTTTGGCACGATACAGA 3393 SEQ ID NO : 3358 1. 8-21. 8 62. 9-22. 9-0. 4-4 AAAAATGGGAAAACCCCTCA 3768 SEQ ID NO : 3359 1. 8-20. 3 57. 1-19. 8-2. 3-5. 8 AAAAAATGGGAAAACCCCTC 3769 SEQ ID NO : 3360 1. 8-18. 9 54. 5-18. 4-2. 3-5. 8 AGATCTGCCCTCGTCCTGAG 27 SEQ ID NO : 3361 1. 9-28. 9 79. 8-30-0. 6-6. 8 AAATGAAAACTTGGCGGCAC 97 SEQ ID NO : 3362 1. 9-20 57. 6-21. 9 0-6. 5 GTTTTAAAAAACAAAAACCA 199 SEQ ID NO : 3363 1. 9-12. 7 44. 1-13. 3-1. 2-8. 1 GTGGAGGACATCCACAAAAT 893 SEQ ID NO : 3364 1. 9-21. 6 62. 4-19. 3-4. 2-9. 9 GCACTGGAAGGCAAAACTCG 1124 SEQ ID NO : 3365 1. 9-22. 6 63. 4-23. 3-1. 1-4. 6 CATGTTCTTGTAACTGAAGA 1316 SEQ ID NO : 3366 1. 9-19. 2 59. 5-20. 1-0. 9-4. 6 TGGATAGCAGGAAGTCTTGC 1787 SEQ ID NO : 3367 1. 9-23. 5 70-24. 5-0. 8-7. 9 ATGGAGAGGCTCAGTAATAT 2415 SEQ ID NO : 3368 1. 9-21. 3 64. 7-22-1. 1-5 CCCCATGCATATACACATAC 2486 SEQ ID NO : 3369 1. 9-24. 3 67. 5-26. 2 0-6. 8 TAACTAAGAAGAAATAGAAA 2572 SEQ ID NO : 3370 1. 9-11. 1 41. 7-13 0-2. 9 CTAAGAAGGTGGCACATAAT 2591 SEQ ID NO : 3371 1. 9-19. 8 59. 4-20. 8-0. 8-4. 8 CTCATAGGGGAGGTGGCACA 2617 SEQ ID NO : 3372 1. 9-26. 9 77. 1-28-0. 6-4. 9 CCTACTCTAATTAGGCAATG 2986 SEQ ID NO : 3373 1. 9-20. 8 61. 8-22. 2 0-7. 5 CAAGCATTTTGGATAAGGGA 3543 SEQ ID NO : 3374 1. 9-20. 6 61. 3-22. 5 0-4. 1 TCCCAAAATATCTCATTATG 3620 SEQ ID NO : 3375 1. 9-18. 9 57. 1-20. 8 0-2. 6 CAGGATGTACAGCCAATAAT 3868 SEQ ID NO : 3376 1. 9-21. 1 61. 8-22. 4-0. 3-7. 1 AATGAAAACTTGGCGGCACG 96 SEQ ID NO : 3377 2-21. 5 59. 8-21. 9-1. 5-6. 5 AGCAATCCCGGCCGGTAAGA 164 SEQ ID NO : 3378 2-28. 8 74. 5-27. 8-0. 1-14. 2 CATCTGATAATGGTAAACTC 1286 SEQ ID NO : 3379 2-17. 8 55. 8-19. 8 0-4. 4 CAGGCACCCAGCTGCTTACA 2019 SEQ ID NO : 3380 2-29. 4 80-30-1. 3-8. 1 CCCATGCATATACACATACA 2485 SEQ ID NO : 3381 2-23 65. 1-25 0-6. 8 TCATAGGGGAGGTGGCACAT 2616 SEQ ID NO : 3382 2-26 75. 1-27. 1-0. 8-5. 1 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo TTAAAGTAAAATATTTCAAA 2852 SEQ ID NO : 3383 2-10. 8 41. 2-12. 8 0-6. 6 GGGATAATAATAGTTGCCCT 3012 SEQ ID NO : 3384 2-22. 7 65. 3-24-0. 5-4. 5 AGGGATAATAATAGTTGCCC 3013 SEQ ID NO : 3385 2-21. 8 63. 7-23. 1-0. 5-4. 5 GCCTCAGTTTTGTAAAATAG 3031 SEQ ID NO : 3386 2-19. 8 60. 4-21. 3-0. 2-4. 2 ACGATACAGATTAAAACAAT 3383 SEQ ID NO : 3387 2-14. 7 48. 1-16. 7 0-3. 5 TATCGTATAAAATTACCCTC 3703 SEQ ID NO : 3388 2-18. 7 56. 5-20. 7 0-3. 2 TCCGAAATGCTCCAAAATCC 3814 SEQ ID NO : 3389 2-22. 5 61. 9-24. 5'0-3. 6 TGGCGGCACGGAGCCCGGGC 86 SEQ ID NO : 3390 2. 1-35. 1 86. 1-32. 2-3. 3-18. 1 TTTGACCTCAGTCTGTGTAG 371 SEQ ID NO : 3391 2. 1-23. 6 71. 9-24. 1-1. 6-4. 2 GACATCCACAAAATCTGCAT 887 SEQ ID NO : 3392 2. 1-21. 2 61. 4-23. 3 0-4. 9 AATGCTATTACAACGGTTCT 1190 SEQ ID NO : 3393 2. 1-20. 5 60. 9-22. 6 0-4. 7 ATAATGGTAAACTCTGAAAG 1280 SEQ ID NO : 3394 2. 1-15. 3 50-17. 4 0-3. 8 TTCTTGTAACTGAAGACATG 1312 SEQ ID NO : 3395 2. 1-18. 2 57-19. 7-0. 3-5. 3 CTTGGATAGCAGGAAGTCTT 1789 SEQ ID NO : 3396 2. 1-22. 7 68. 1-24. 8 0-4. 1 TAGAGCTATTCAAGAGAGGC 1951 SEQ ID NO : 3397 2. 1-21. 4 65. 5-23-0. 2-5. 1 GGCCTCTTCGGAGCCAGCGT 2106 SEQ ID NO : 3398 2. 1-32. 6 86. 5-32-2. 7-9. 7 AAGCAGGCTGAGCAGCTGAC 2140 SEQ ID NO : 3399 2. 1-26. 3 75. 4-26. 6-1. 8-10. 4 CTCAAAGCAGGCTGAGCAGC 2144 SEQ ID NO : 3400 2. 1-25. 9 73. 9-26. 9-0. 9-9. 5 GGAAGGACTTCTCACTGAGG 2164 SEQ ID NO : 3401 2. 1-23. 4 69. 2-24. 8-0. 5-7. 6 ACAGAAAGAGGGTCTAGAAA' 2457 SEQ ID NO : 3402 2. 1-18. 5 57. 1-20. 6 0-6 CCAAACAGAAAGAGGGTCTA 2461 SEQ ID NO : 3403 2. 1-20. 6 60. 6-22. 7 0-3. 1 ACTAAGAAGAAATAGAAACC 2570 SEQ ID NO : 3404 2. 1-14. 3 47. 5-16. 4 0-2. 9 TAACTAAGAAGGTGGCACAT 2594 SEQ ID NO : 3405 2. 1-20 59. 9-20. 6-1. 4-5 GCCATAAAAAGTCCAACCGT 3288 SEQ ID NO : 3406 2. 1-23. 2 63. 3-25. 3 0-2. 6 TTTGGCACGATACAGATTAA 3389 SEQ ID NO : 3407 2. 1-19. 8 59. 1-21. 2-0. 4-4 CTCAACTGGTTATGTCTTCA 3430 SEQ ID NO : 3408 2. 1-22. 3 67. 8-24. 4 0-4. 7 CCAGGATGTACAGCCAATAA 3869 SEQ ID NO : 3409 2. 1-23. 1 65. 4-24. 6-0. 3-7. 1 GATCTGCCCTCGTCCTGAGC 26 SEQ ID NO : 3410 2. 2-30. 7 83. 9-32-0. 8-5. 6 TCGGCCAGGGGCTGGGGGAC 136 SEQ ID NO : 3411 2. 2-32. 8 86. 9-32. 6-2. 4-10. 4 429 GGTAGCATCCTTCATGCTCT 2. 2-27. 1 79. 2-26. 2-3. 1-8. 4 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 3412 CTCCGAGGCTGTAGCCGATC 747 SEQ ID NO : 3413 2. 2-29. 1 78. 8-28. 8-2. 5-10. 5 CCGGCCACGTGCGCTCCGAG 760 SEQ ID NO : 3414 2. 2-33. 8 82. 2-34. 1-1. 3-11. 7 TGGCAAGACTTGCCCGGGCA 1759 SEQ ID NO : 3415 2. 2-30. 3 79-27. 9-4. 2-17 TCCAGTGTGCACGAGAGGCC 2040 SEQ ID NO : 3416 2. 2-29. 2 80. 5-30. 5 0-9. 8 CCTTCTACACAGGGCCTCTT 2118 SEQ ID NO : 3417 2. 2-28. 3 79. 5-30. 5 0-7. 3 GTCGGAAGGACTTCTCACTG 2167 SEQ ID NO : 3418 2. 2,-24 70-25. 2-0. 9-7. 6 CCATGCATATACACATACAC 2484 SEQ ID NO : 3419 2. 2-21. 2 62. 1-23. 4 0-6. 8 TGCCTTTCCCCATGCATATA 2493 SEQ ID NO : 3420 2. 2-27. 9 75. 6-29. 5-0. 3-6. 8 TACTCAACCTGTACAAGCTT 3523 SEQ ID NO : 3421 2. 2-22. 2 65. 2-24. 4 0-6. 2 CGGAGCCCGGGCGGTGGCAG 78 SEQ ID NO : 3422 2. 3-34. 3 85. 2-32. 7-3. 3-15. 7 GTAGCTTTGGGTTTGTGGAG 355 SEQ ID NO : 3423 2. 3-24. 6 74. 3-26. 9 0-4. 6 CGACGGAGAGGTAGCATCCT 438 SEQ ID NO : 3424 2. 3-26. 7 73. 5-28. 1-0. 7-6. 2 GGGGGAGCCAGTCAACCACA 609 SEQ ID NO : 3425 2. 3-29. 3 79. 6-30. 2-1. 3-4. 8 GGCTTGGATAGCAGGAAGTC 1791 SEQ ID NO : 3426 2. 3-24. 7 72. 9-24. 8-2. 2-5. 7 CAAATGGAGAGGCTCAGTAA 2418 SEQ ID NO : 3427 2. 3-20. 9 62. 2-22-1. 1-5 ACAGATTAAAACAATGTCCT 3378 SEQ ID NO : 3428 2. 3-17. 9 55-20. 2 0-4. 8 CCGAAATGCTCCAAAATCCA 3813 SEQ ID NO : 3429 2. 3-22. 8 61. 7-25. 1 0-3. 6 CGCCGGGAGGCAAGGACTCG 6 SEQ ID NO : 3430 2. 4-29. 5 75. 7-27. 7-4. 2-10 AGTTTTAAAAAACAAAAACC 200 SEQ ID NO : 3431 2. 4-12 43-12. 4-2-8. 8 ATGGTAAACTCTGAAAGGCA 1277 SEQ ID NO : 3432 2. 4-20 59. 7-22. 4 0-4 GGGCTTGGATAGCAGGAAGT 1792 SEQ ID NO : 3433 2. 4-25 : 5 73. 8-25. 7-2. 2-6 CCAGCCATCACAGGAGACCA 1890 SEQ ID NO : 3434 2. 4-28. 5 77. 2-30. 3-0. 3-3. 8 AAGAGAGGCAGCAAGAGCTA 1940 SEQ ID NO : 3435 2. 4-23 67. 6-23. 8-1. 5-6. 6 GACAGCCTTCTACACAGGGC 2123 SEQ ID NO : 3436 2. 4-27. 3 77. 6-28. 2-1. 4-5. 4 AAATGGAGAGGCTCAGTAAT 2417 SEQ ID No : 3437 2. 4-20. 2 61-22-0. 3-4. 9 GTAAAATAGGGATAATAATA 3020 SEQ ID NO : 3438 2. 4-13. 2 45. 8-15. 6 0-1. 4 ATCTCAGCCATAAAAAGTCC 3294 SEQ ID NO : 3439 2. 4-21. 4 62. 6-23. 8 0-3. 2 TACAGATTAAAACAATGTCC 3379 SEQ ID NO : 3440 2. 4-16. 7 52. 7-19. 1 0-4. 8 CAAGAAACAGAAGTTTTAAA 211 SEQ ID NO : 3441 2. 5-13. 8 46. 8-14. 5-1. 8-5. 6 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo TCCCAAGAAACAGAAGTTTT 214 SEQ ID NO : 3442 2. 5-19. 9 59-20. 6-1. 8-5 GACGGAGAGGTAGCATCCTT 437 SEQ ID NO : 3443 2. 5-26 74-27. 6-0. 7-6. 4 CCGAGGCTGTAGCCGATCAA 745 SEQ ID NO : 3444 2. 5-27. 8 74-27. 8-2. 5-10. 5 AAGCGATTGGAGTCAGTGCA 1141 SEQ ID NO : 3445 2. 5-24. 4 70. 5-25. 9-0. 9-8 CTGATAATGGTAAACTCTGA 1283 SEQ ID NO : 3446 2. 5-18. 2 56. 4-20. 7 0-2. 6 AGACAGGTAGCTGCGAAACT 1538 SEQ ID NO : 3447 2. 5-23. 2 66. 6-24. 1-1. 5-3. 5 GCTTGGATAGCAGGAAGTCT 1790 SEQ ID NO : 3448 2. 5-24. 4 72. 2-25. 4-1. 4-5. 2 CACATAATAACTAAGAAGGT 2601 SEQ ID NO : 3449 2. 5-16 51. 4-18. 5 0-2. 5 CCTCAGTTTTGTAAAATAGG 3030 SEQ ID NO : 3450 2. 5-19. 2 58. 9-21. 2-0. 2-4. 4 AGGATGTACAGCCAATAATA 3867 SEQ ID NO : 3451 2. 5-20. 1 60. 1-22-0. 3-7. 1 AAAGCTTCCATTAGTAAAAA 3905 SEQ ID NO : 3452 2. 5-16. 4 51. 9-18. 9 0-7 CTGAGCCGCCGGGAGGCAAG 12 SEQ ID NO : 3453 2. 6-30. 7 78. 7-29. 1-4. 2-13. 3 GGCCACGTGCGCTCCGAGGC 758 SEQ ID NO : 3454 2. 6-34 85. 9-33. 7-2. 8-13 TGTGGAGGACATCCACAAAA 894 SEQ ID NO : 3455 2. 6-21. 6 62. 3-19. 3-4. 9-11. 2 CTGGGAATCTGCATTAGTGC 1373 SEQ ID NO : 3456 2. 6-23. 8 69. 9-24. 8-1. 5-8. 8 AATGGAGAGGCTCAGTAATA 2416 SEQ ID NO : 3457 2. 6-20. 6 62. 5-22-1. 1-5 TCCAAATGGAGAGGCTCAGT 2420 SEQ ID No : 3458 2. 6-24. 3 70. 2-25. 7-1. 1-6. 9 TTCCAAATGGAGAGGCTCAG 2421 SEQ ID NO : 3459 2. 6-23. 2 67. 3-24. 6-1. 1-7. 5 TATATAAAAAAAAAAGTCCT 3207 SEQ ID NO : 3460 2. 6-11. 3 41. 9-13. 9 0-3 TTATGTCTTCAGAAGTTTAA 3421 SEQ ID NO : 3461 2. 6-17. 8 57. 4-20. 4 0-7. 1 AAGCACACAATTGGCTTGAG 3469 SEQ ID NO : 3462 2. 6-21. 6 63. 3-22. 2-2-9. 3 TACAGCCAATAATATGGGTT 3861 SEQ ID NO : 3463 2. 6-20. 8 61. 4-22. 9-0. 2-4. 1 CAATAGCAGAGGCTCCAGAA 280 SEQ ID NO : 3464 2. 7-23. 7 68-24. 8-1. 5-5 GAGGTAGCATCCTTCATGCT 431 SEQ ID NO : 3465 2. 7-26. 4 77-26. 5-2. 6-8. 6 GACTGAGAGGCCCCCTCCCA 1498 SEQ ID NO : 3466 2. 7-33. 9 87-34. 4-2. 2-8. 6 CCAAGACTGAGAGGCCCCCT 1502 SEQ ID NO : 3467 2. 7-30. 8 79. 9-32. 9-0. 3-6. 8 GCTGCTTACACACAAATCTG 2009 SEQ ID NO : 3468 2. 7-21. 8 63. 9-24. 5 0-5. 2 AGGGCCTCTTCGGAGCCAGC 2108 SEQ ID NO : 3469 2. 7-31. 8 86. 5-31-3. 5-8. 7 GCAGCTGACAGCCTTCTACA 2129 SEQ ID NO : 3470 2. 7-27. 4 77. 9-28. 7-1. 3-8. 7 2458 AACAGAAAGAGGGTCTAGAA 2. 7-18. 5 57. 1-21. 2 0-6 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 3471 AATAACTAAGAAGAAATAGA 2574 SEQ ID NO : 3472 2. 7-11. 8 43-14. 5 0-2. 6 AACTAAGAAGGTGGCACATA 2593 SEQ ID NO : 3473 2. 7-20 59. 9-21. 2-1. 4-4. 8 GGGAGGTGGCACATAATAAC 2610 SEQ ID NO : 3474 2. 7-22. 2 64. 8-24-0. 8-4 GGTTATGTCTTCAGAAGTTT 3423 SEQ ID NO : 3475 2. 7-21. 2 66. 4-23. 9 0. 2-7. 1 TTCCAAGCATTTTGGATAAG 3546 SEQ ID NO : 3476 2. 7-20. 1 60. 4-19. 7-3. 1-8. 3 TATTCCCAAAATATCTCATT 3623 SEQ ID NO : 3477 2. 7-19 57. 5-21. 7 0-2. 6 AAAATGAAAACTTGGCGGCA 98 SEQ ID NO : 3478 2. 8-19. 1 55. 5-21. 9 0-6. 5 CCAGGGGCTGGGGGACTGGA 132 SEQ ID NO : 3479 2. 8-31. 3 84. 4-32. 5-1. 6-7. 1 GGGGAGCCAGTCAACCACAA 608 SEQ ID NO : 3480 2. 8-27. 4 74. 7-29. 5-0. 5-4. 3 AGGGGGAGCCAGTCAACCAC 610 SEQ ID NO : 3481 2. 8-28. 6 78. 9-30-1. 3-4. 7 GGTGTGGAGGACATCCACAA 896 SEQ ID NO : 3482 2. 8-25. 4 72. 2-22. 9-5. 3-11. 9 CAGTGCACTGGAAGGCAAAA 1128 SEQ ID NO : 3483 2. 8-22. 2 63. 5-22. 2-2. 2-13. 4 ACTGAGAGGCCCCCTCCCAG 1497 SEQ ID NO : 3484 2. 8-33. 3 86. 1-35. 6 0. 3-8. 6 GAGACAGGTAGCTGCGAAAC 1539 SEQ ID NO : 3485 2. 8-22. 9 66-24. 1-1. 5-3. 5 GCCCGGGCACCCTCAGGGAA 1748 SEQ ID NO : 3486 2. 8-34 85. 3-31. 6-2. 4-18. 5 GCACGAGAGGCCCCAGGCAC 2032 SEQ ID NO : 3487 2. 8-32. 3 83. 9-32. 6-2. 5-7. 5 CTTCTACACAGGGCCTCTTC 2117 SEQ ID NO : 3488 2. 8-26. 7 77. 7-29. 5 0-7. 3 ACTAAGAAGGTGGCACATAA 2592 SEQ ID NO : 3489 2. 8-20 59. 9-21. 3-1. 4-4. 8 AAAGTAAAATATTTCAAAGA 2850 SEQ ID NO : 3490 2. 8-11. 6 42. 7-14. 4 0-6. 6 TTGTAAAATAGGGATAATAA 3022 SEQ ID NO : 3491 2. 8-13. 6 46. 6-16. 4 0-1. 5 AAATCCAAAATCCGAAATGC 3824 SEQ ID NO : 3492 2. 8-17. 8 52. 7-20. 6 0-2. 8 CCCGGGCGGTGGCAGGGAGC 73 SEQ ID NO : 3493 2. 9-34. 7 88. 3-35. 2-2. 4-9. 8 CACGGAGCCCGGGCGGTGGC 80 SEQ ID NO : 3494 2. 9-34. 5 85. 4-33. 5-2. 4-16 TGCAGCCAGTTTTCAAAGAT 541 SEQ ID No : 3495 2. 9-22. 8 66. 7-25. 7 0-4. 7 TGGATGTCGGCCCCTTCAAA 847 SEQ ID NO : 3496 2. 9-27. 9 74. 1-30. 8 0-6. 2 AGTCAGTGCACTGGAAGGCA 1131 SEQ ID NO : 3497 2. 9-25. 9 75. 3-25. 6-2-14. 4 ATGTTCTTGTAACTGAAGAC 1315 SEQ ID NO : 3498 2. 9-18. 7 58. 8-20. 6-0. 9-4. 6 CTCCATGGGCTTGGATAGCA 1798 SEQ ID NO : 3499 2. 9-27. 2 76. 5-27. 9-2. 2-11. 4 CACCCAGCTGCTTACACACA 2015 SEQ ID NO : 3500 2. 9-27. 5 75. 2-29. 9 0-8. 1 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo AACCAGCTCTGTCTGGCAGG 2802 SEQ ID NO : 3501 2. 9-27. 6 78. 4-28. 3-2. 2-7. 6 TAAAATATTTCAAAGAGGAA 2846 SEQ ID NO : 3502 2. 9-12. 9 45. 1-15. 8 0-6. 6 AGCCTCAGTTTTGTAAAATA 3032 SEQ ID NO : 3503 2. 9-19. 8 60. 4-22. 2-0. 2-4. 2 AGGGATACTCAACCTGTACA 3528 SEQ ID NO : 3504 2. 9-23. 1 67. 3-25. 1-0. 7-6. 9 CAAAAAATGGGAAAACCCCT 3770 SEQ ID NO : 3505 2. 9-19. 2 54. 5-19. 8-2. 3-5. 8 AGCCGCCGGGAGGCAAGGAC 9 SEQ ID NO : 3506 3-31. 2 80. 1-30-4. 2-13. 3 ACAAAGAGGTGGACGGCTCG 1078 SEQ ID NO : 3507 3-24. 4 67. 6-26. 7-0. 5-5. 2 CCAGAGAGTCAACAAAGAGG 1089, SEQ ID NO : 3508 3-20. 8 61. 6-23. 8 0-4 AGACAGATCCCCTTTTTGAA 1159 SEQ ID NO : 3509 3-23. 7 67. 6-26. 7 0-3. 7 TAATGGTAAACTCTGAAAGG 1279 SEQ ID NO : 3510 3-16. 5 52. 4-19. 5 0-3. 3 ATCTGATAATGGTAAACTCT 1285 SEQ ID NO : 3511 3-18 56. 4-21 0-4 AAGACATGGATTTTCATCTG 1300 SEQ ID NO : 3512 3-19. 3 59. 6-21. 4-0. 7-5. 5 TTGAGACAGGTAGCTGCGAA 1541 SEQ ID NO : 3513 3-23. 5 67. 8-24. 9-1. 5-3. 5 TTGGATAGCAGGAAGTCTTG 1788 SEQ ID NO : 3514 3-21. 8 66-24. 8 0-4. 1 AGGCACCCAGCTGCTTACAC 2018 SEQ ID NO : 3515 3-28. 9 79. 6-30. 5-1. 3-8. 1 CAACCCATGAGAACCCCAAC 2241 SEQ ID NO : 3516 3-25. 8 67. 5-28. 8 0-4 CACGATACAGATTAAAACAA 3384 SEQ ID NO : 3517 3-15. 4 49. 3-18. 4 0-3. 5 AACTGGTTATGTCTTCAGAA 3427 SEQ ID NO : 3518 3-20. 2 62. 3-22. 5-0. 5-1. 4 GAAACACTTCTGGTTCCAAG 3559 SEQ ID NO : 3519 3-21. 5 63. 3-23-1. 4-5. 2 CCAAGAAACAGAAGTTTTAA 212 SEQ ID NO : 3520 3. 1-16. 5 52-18. 3-1. 2-5. 1 CCCAAGAAACAGAAGTTTTA 213 SEQ ID No : 3521 3. 1-19. 2 57. 3-20. 5-1. 8-5. 1 CGGCCACGTGCGCTCCGAGG 759 SEQ ID No : 3522 3. 1-33 81. 4-34. 2-1. 3-11. 7 ACCAATGCTCAAGCCGAAGG 926 SEQ ID NO : 3523 3. 1-25 67. 6-26. 9-1. 1-5. 8 GAAGACATGGATTTTCATCT 1301 SEQ ID NO : 3524 3. 1-19. 9 61-22. 1-0. 7-4. 3 GTTCTTGTAACTGAAGACAT 1313 SEQ ID NO : 3525 3. 1-19. 4 60. 1-21. 9-0. 3-3. 9 TGAGAGGCCCCCTCCCAGGT 1495 SEQ ID NO : 3526 3. 1-34. 6 89. 6-35. 5-2. 2-8. 9 AAAGCAGGCTGAGCAGCTGA 2141 SEQ ID NO : 3527 3. 1-25. 4 72. 3-26. 7-1. 8-10. 4 TCAAAGCAGGCTGAGCAGCT 2143 SEQ ID NO : 3528 3. 1-25. 9 73. 9-27. 3-1. 7-10. 4 ACATAATAACTAAGAAGGTG 2600 SEQ ID NO : 3529 3. 1-15. 3 50. 1-18. 4 0-2. 6 2770 TGTACACAGATGTGTATTAC 3. 1-19. 4 60. 9-20. 3-2. 2-11. 1 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 3530 ACCCTAATCCAAAAATCCAA 3836 SEQ ID NO : 3531 3. 1-20. 8 58. 3-23. 9 0-1. 1 AGCAATAGCAGAGGCTCCAG 282 SEQ ID NO : 3532 3. 2-25. 6 73. 5-27. 1-1. 7-7. 8 GTGGATGTCGGCCCCTTCAA 848 SEQ ID NO : 3533 3. 2-29. 8 79. 6-33 0-6. 2 ATCCACAAAATCTGCATCGT 884 SEQ ID NO : 3534 3. 2-22. 1 63. 1-25. 3 0-4. 9 TGAAGACATGGATTTTCATC 1302 SEQ ID NO : 3535 3. 2-19 59-21. 7-0. 2-5. 2 AGAGGCCCCCTCCCAGGTGA 1493 SEQ ID NO : 3536 3. 2-34. 6 89. 6-35. 6-2. 2-8. 5 GAGAGGCCCCCTCCCAGGTG 1494 SEQ ID NO : 3537 3. 2-34. 6 89. 6-35. 6-2. 2-8. 6 GTAAAATATTTCAAAGAGGA 2847 SEQ ID NO : 3538 3. 2-14. 8 49. 2-18 0-6. 6 TAAAGTAAAATATTTCAAAG 2851 SEQ ID NO : 3539 3. 2-10. 7 41-13. 9 0-6. 6 GTACAGCCAATAATATGGGT 3862 SEQ ID NO : 3540 3. 2-21. 9 64. 1-23. 8-1. 2-6. 8 AGAGGCTCCAGAAACAGAGC 273 SEQ ID NO : 3541 3. 3-24. 1 69. 6-25. 2-2. 2-6. 8 TGTAGCTTTGGGTTTGTGGA 356 SEQ ID NO : 3542 3. 3-24. 6 73. 8-27. 9 0-4. 6 CAGACAGATCCCCTTTTTGA 1160 SEQ ID NO : 3543 3. 3-25. 1 70. 9-28. 4 0-4. 5 TGGGAATCTGCATTAGTGCC 1372 SEQ ID NO : 3544 3. 3-24. 9 71. 6-26. 3-1. 9-8. 8 CTGGCAAGACTTGCCCGGGC 1760 SEQ ID NO : 3545 3. 3-30. 5 79. 8-29. 6-4. 2-14. 2 GCACCCAGCTGCTTACACAC 2016 SEQ ID No : 3546 3. 3-28. 6 78. 4-31. 2-0. 5-7. 6 CCAGCTCTGTCTGGCAGGTG 2800 SEQ ID NO : 3547 3. 3-29. 3 84. 1-31. 2-1. 3-7. 6 CATGTGGCTGAACCTCACTA 3052 SEQ ID NO : 3548 3. 3-24. 7 70. 4-27-0. 9-5. 5 TTGGCACGATACAGATTAAA 3388 SEQ ID NO : 3549 3. 3-19 57-21. 6-0. 4-4 CAAGAGAAGCACACAATTGG 3475 SEQ ID NO : 3550 3. 3-19. 4 58-22. 7 0-7. 2 GAGGCAGAGAAGGTGGAAAA 114 SEQ ID NO : 3551 3. 4-20. 9. 61. 6-24. 3 0-4 AGGTAGCATCCTTCATGCTC 430 SEQ ID NO : 3552 3. 4-26. 2 77. 5-26. 5-3. 1-8. 4 CGTTCCTTTCACGAAGTTGC 788 SEQ ID NO : 3553 3. 4-24. 7 69. 8-27. 4-0. 4-3. 8 AGACTGAGAGGCCCCCTCCC 1499 SEQ ID NO : 3554 3. 4-33. 2 86. 4-34. 4-2. 2-7. 9 ACTTGCCCGGGCACCCTCAG 1752 SEQ ID NO : 3555 3. 4-32. 9 84. 3-32. 1-1. 3-16. 6 AAACAGAAAGAGGGTCTAGA 2459 SEQ ID NO : 3556 3. 4-18. 5 57. 1-21. 9 0-5. 8 GCATATACACATACACCATC 2480 SEQ ID NO : 3557 3. 4-21. 6 63. 6-25 0-3. 4 ACTCATAGGGGAGGTGGCAC 2618 SEQ ID NO : 3558 3. 4-26. 4 76. 7-29-0. 6-4. 9 GAACCAGCTCTGTCTGGCAG 2803 SEQ ID NO : 3559 3. 4-27 77. 2-28. 2-2. 2-7. 1 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo AGAAGTTTTAAAAAACAAAA 203 SEQ ID NO : 3560 3. 5-10. 4 40. 3-12-1. 9-8. 8 CAGAAACAGAGCAGAGGAAC 265 SEQ ID NO : 3561 3. 5-19. 8 59. 4-23. 3 0-4. 1 GGCAAGACTTGCCCGGGCAC 1758 SEQ ID NO : 3562 3. 5-30. 5 79. 7-29. 4-3. 5-17. 2 TGGGCTTGGATAGCAGGAAG 1793 SEQ ID NO : 3563 3. 5-24. 3 70. 3-25. 6-2. 2-6 CAGGGCCTCTTCGGAGCCAG 2109 SEQ ID NO : 3564 3. 5-30. 7 83. 1-30. 7-3. 5-8. 6 GTACACAGATGTGTATTACA 2769 SEQ ID NO : 3565 3. 5-20. 1 62. 3-21. 4-2. 2-11. 1 AAAAGGCACTGGTATTAAAG 2866 SEQ ID NO : 3566 3. 5-17. 2 53. 6-19. 9-0. 6-4. 1 TAGGGATAATAATAGTTGCC 3014 SEQ ID NO : 3567 3. 5-19. 5 59. 4-23 0-3 AACCCTAATCCAAAAATCCA 3837 SEQ ID NO : 3568 3. 5-20. 8 58. 3-24. 3 0-1. 1 TGAATACCAATGCTCAAGCC 931 SEQ ID NO : 3569 3. 6-22. 7 64. 2-26. 3 0-5. 7 TACAACGGTTCTTGCGGCAG 1182 SEQ ID NO : 3570 3. 6-25. 1 69. 8-28. 7 0. 4-7. 7 AGCTATTCAAGAGAGGCAGC 1948 SEQ ID NO : 3571 3. 6-23. 6 70. 4-26. 1-1-6 GGCTCAGTAATATGTCCATT 2408 SEQ ID NO : 3572 3. 6-23. 3 69. 1-26. 9 0-4. 1 AAGGTGGCACATAATAACTA 2586 SEQ ID NO : 3573 3. 6-19. 1 57. 9-21. 8-0. 8-4. 8 CCAAGCATTTTGGATAAGGG 3544 SEQ ID NO : 3574 3. 6-22 63. 6-23. 9-1. 7-5. 6 GTCCTATTCCCAAAATATCT 3627 SEQ ID NO : 3575 3. 6-22. 3 64. 3-25. 9 0-2. 6 AAATGCTCCAAAATCCAAAA 3810 SEQ ID NO : 3576 3. 6-17. 3 52. 1-20. 9 0-3. 6 CCCAGCCATCACAGGAGACC 1891 SEQ ID NO : 3577 3. 7-29. 8 79. 5-33. 5 0-3. 5 ATCCAAACAGAAAGAGGGTC 2463 SEQ ID NO : 3578 3. 7-20. 4 60. 6-24. 1 0-3. 6 AACTTTGGCACGATACAGAT 3392 SEQ ID NO : 3579 3. 7-21. 1 61. 7-24. 1-0. 4-4 GGGATACTCAACCTGTACAA 3527 SEQ ID NO : 3580 3. 7-22. 4 65-25. 2-0. 7-7 CTCCCAAGAAACAGAAGTTT 215 SEQ ID NO : 3581 3. 8-20. 7 60. 5-22. 9-1. 6-4. 9 CTTAGAACCAGCTCTGTCTG 2807 SEQ ID NO : 3582 3. 8-24 70. 7-27. 8 0-4. 5 AAAATATTTCAAAGAGGAAA 2845 SEQ ID NO : 3583 3. 8-12. 5 44. 2-15. 6-0. 5-6. 6 AGTAAAATATTTCAAAGAGG 2848 SEQ ID NO : 3584 3. 8-14. 2 48-18 0-6. 6 CTCAGTTTTGTAAAATAGGG 3029 SEQ ID NO : 3585 3. 8-18. 4 57. 6-21. 7-0. 2-3. 7 GGCACATAATAACTAAGAAG 2603 SEQ ID NO : 3586 3. 9-16. 6 52. 4-20. 5 0-4 TGTCTTCAGAAGTTTAACAG 3418 SEQ ID NO : 3587 3. 9-18. 9 59. 8-22. 8 0-7. 1 CAACTGGTTATGTCTTCAGA 3428 SEQ ID NO : 3588 3. 9-21. 6 65. 8-24. 8-0. 5-6 3815 ATCCGAAATGCTCCAAAATC 3. 9-20. 5 58. 6-24. 4 0-3. 6 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 3589 AAAAACAAAAACCACCTCTT 193 SEQ ID NO : 3590 4-16. 7 51-20. 7 0-0. 9 AAACAGAAGTTTTAAAAAAC 207 SEQ ID NO : 3591 4-11. 3 42-14-1. 2-7. 5 ACAGGTAGCTGCGAAACTCC 1536 SEQ ID NO : 3592 4-25 70. 1-27. 4-1. 5-3. 5 GCTCAAAGCAGGCTGAGCAG 2145 SEQ ID NO : 3593 4-25. 9 73. 9-26. 4-3. 5-12. 3 CATATACACATACACCATCC 2479 SEQ ID NO : 3594 4-21. 8 63. 2-25. 8 0-2. 4 TGTAAAATAGGGATAATAAT 3021 SEQ ID NO : 3595 4-13. 5 46. 3-17. 5 0-1. 4 GCACGATACAGATTAAAACA 3385 SEQ ID NO : 3596 4-17. 9 54. 3-21. 9 0-3. 5 TATGTCTTCAGAAGTTTAAC 3420 SEQ ID NO : 3597 4-17. 9 57. 6-21. 9 0-6. 5 GAAAATAATCTAAAATTTGA 3577 SEQ ID NO : 3598 4-11. 2 41. 9-15. 2 0-5. 2 GGTCCTATTCCCAAAATATC 3628 SEQ ID NO : 3599 4-22. 6 64. 9-26. 6 0-2. 7 ACAGCCAATAATATGGGTTG 3860 SEQ ID NO : 3600 4-21. 1 61. 9-24. 1-0. 9-5. 5 AAAACAAAAACCACCTCTTG 192 SEQ ID NO : 3601 4. 1-17. 4 52. 4-21. 5 0-28 CTCCCAGGTGAGCTGGATCT 1484 SEQ ID NO : 3602 4. 1-28. 8 81. 2-29. 9-3-7. 3 ACCCAGCTGCTTACACACAA 2014 SEQ ID NO : 3603 4. 1-26. 1 71. 8-29. 7 0-8. 1 AACCCATGAGAACCCCAACA 2240 SEQ ID No : 3604 4. 1-25. 8 67. 5-29. 9 0-4. 5 GCTCAGTAATATGTCCATTA 2407 SEQ ID NO : 3605 4. 1-21. 8 65. 9-25. 9 0-2. 9 CATAATAACTAAGAAGGTGG 2599 SEQ ID NO : 3606 4. 1-16. 3 52-20. 4 0-2. 6 AAGTAAAATATTTCAAAGAG 2849 SEQ ID NO : 3607 4. 1-12. 3 44. 1-16. 4 0-6. 1 GAAGCACACAATTGGCTTGA 3470 SEQ ID NO : 3608 4. 1-22. 2 64. 3-23. 7-2. 6-10. 1 ACTCAACCTGTACAAGCTTC 3522 SEQ ID No : 3609 4. 1-22. 9 67. 3-27 0-6. 4 TCCAAAAATCCAAAATCCGA 3829 SEQ ID NO : 3610 4. 1-19. 1 54. 7-23. 2 0-2. 8 TGTACAGCCAATAATATGGG 3863 SEQ ID NO : 3611 4. 1-20. 7 61-23. 7-0. 9-9. 4 GGGGACTGGAGGCAGAGAAG 122 SEQ ID NO : 3612 4. 2-25. 3 72. 5-28. 6-0. 8-4. 2 CGGCCAGGGGCTGGGGGACT 135 SEQ ID NO : 3613 4. 2-33. 3 86. 9-35. 1-2. 4-9. 5 TCAGTGCACTGGAAGGCAAA 1129 SEQ ID NO : 3614 4. 2-23. 3 67-24. 3-2. 2-14. 4 GCAAGACTTGCCCGGGCACC 1757 SEQ ID NO : 3615 4. 2-31. 3 80. 5-31. 3-2. 6-16. 6 AGGTGGCACATAATAACTAA 2585 SEQ ID No : 3616 4. 2-19. 1 57. 9-22. 4-0. 8-4. 8 GGCAGAGAAGGTGGAAAATG 112 SEQ ID NO : 3617 4. 3-20. 3 60-24. 6 0-4 GGCCGACGGAGAGGTAGCAT 441 SEQ ID NO : 3618 4. 3-28. 4 76. 6-32-0. 4-7 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo AGCCTCTTGTGGATGTCGGC 856 SEQ ID NO : 3619 4. 3-28. 5 80. 7-31. 9-0. 8-5. 1 GAGTCAGTGCACTGGAAGGC 1132 SEQ ID NO : 3620 4. 3-25. 8 75. 6-27-0. 7-14. 4 AAGACTGAGAGGCCCCCTCC 1500 SEQ ID NO : 3621 4. 3-30. 5 80. 6-32. 6-2. 2-8. 6 ATTAAAAAATGAACAGAAAA 2344 SEQ ID NO : 3622 4. 3-9. 6 38. 8-13. 9 0-3 AATAGGGATAATAATAGTTG 3016 SEQ ID NO : 3623 4. 3-15 49. 9-19. 3 0-1. 4 AAATAGGGATAATAATAGTT 3017 SEQ ID NO : 3624 4. 3-14. 3 48. 2-18. 6 0-1. 4 CCGAATCTCAGCCATAAAAA 3298 SEQ ID NO : 3625 4. 3-20. 5 58. 3-24. 8 0-3. 2 AAGGGATACTCAACCTGTAC 3529 SEQ ID NO : 3626 4. 3-21. 7 64-25. 1-0. 7-5. 8 GGAGGCAGAGAAGGTGGAAA 115 SEQ ID NO : 3627 4. 4-22. 8 66. 1-27. 2 0-4 TGGAGGCAGAGAAGGTGGAA 116 SEQ ID NO : 3628 4. 4-23. 5 68. 2-27. 9 0-3. 2 TCAGACAGATCCCCTTTTTG 1161 SEQ ID NO : 3629 4. 4-24. 9 71. 2-29. 3 0-4. 5 GCTCAGACAGATCCCCTTTT 1163 SEQ ID NO : 3630 4. 4-27. 5 77. 2-31. 9 0-4. 5 TGTTCTTGTAACTGAAGACA 1314 SEQ ID NO : 3631 4. 4-19. 4 60-22. 8-0. 9-4. 6 ATCTGCATTAGTGCCATAAA 1367 SEQ ID NO : 3632 4. 4-21. 6 63. 7-24. 1-1. 9-7. 2 CAAGACTGAGAGGCCCCCTC 1501 SEQ ID NO : 3633 4. 4-29. 2 78. 3-31. 8-1. 8-8. 2 CCAGTGTGCACGAGAGGCCC 2039 SEQ ID NO : 3634 4. 4-30. 8 82. 1-34. 5 0-9. 1 AGAGGCTCAGTAATATGTCC 2411 SEQ ID NO : 3635 4. 4-23. 1 69. 5-27. 5 0-4. 5 AAAAAAAGCACTGTATTAAA 2828 SEQ ID NO : 3636 4. 4-12. 7 44. 4-17. 1 0-4. 1 GAAAAAAAGCACTGTATTAA 2829 SEQ ID NO : 3637 4. 4-14 47-18. 4 0-4. 1 AAGCATTTTGGATAAGGGAT 3542 SEQ ID NO : 3638 4. 4-19. 9 60-24. 3 0-4. 1 AGGTGGAAAATGAAAACTTG 104 SEQ ID NO : 3639 4. 5-15. 8 50. 4-20. 3 0-2. 6 AAGAAACAGAAGTTTTAAAA 210 SEQ ID NO : 3640 4. 5-12. 4 44. 1-15. 1-1. 8-6. 6 CCGTTCCTTTCACGAAGTTG 789 SEQ ID NO : 3641 4. 5-24. 9 69. 2-28. 6-0. 6-4. 1 ACAACGGTTCTTGCGGCAGC 1181 SEQ ID NO : 3642 4. 5-27. 2 74. 4-31-0. 5-7. 7 TGAGACAGGTAGCTGCGAAA 1540 SEQ ID NO : 3643 4. 5-22. 7 65. 3-26. 4-0. 6-2. 6 CCAGCTGCTTACACACAAAT 2012 SEQ ID NO : 3644 4. 5-23. 2 65. 7-27. 2 0-8. 1 ACAAAAAATGGGAAAACCCC 3771 SEQ ID N0 : 3645 4. 5-18. 5 53. 4-21. 4-1. 5-5. 8 AAAAATCCAAAATCCGAAAT 3826 SEQ ID NO : 3646 4. 5-14. 6 46. 8-19. 1 0-2. 8 CTAATCCAAAAATCCAAAAT 3833 SEQ ID NO : 3647 4. 5-15. 2 48. 4-19. 7 0-1. 1 74 GCCCGGGCGGTGGCAGGGAG 4. 6-34. 7 88. 3-35. 7-3. 1-15 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 3648 AAGCAATAGCAGAGGCTCCA 283 SEQ ID NO : 3649 4. 6-24. 9 70. 8-27. 8-1. 7-8. 1 TGTGGATGTCGGCCCCTTCA 849 SEQ ID NO : 3650 4. 6-30. 5 82-35. 1 0-6. 2 AGCCTTCTACACAGGGCCTC 2120 SEQ ID NO : 3651 4. 6-29. 1 82-31. 9-1. 8-7. 3 CAAAGCAGGCTGAGCAGCTG 2142 SEQ ID NO : 3652 4. 6-25. 5 72. 1-28. 3-1. 8-10. 4 CCAAATGGAGAGGCTCAGTA 2419 SEQ ID NO : 3653 4. 6-23. 6 68-27-1. 1-5. 3 CATCCAAACAGAAAGAGGGT 2464 SEQ ID NO : 3654 4. 6-20. 7 60. 4-25. 3 0-3. 6 TGCATATACACATACACCAT 2481 SEQ ID NO : 3655 4. 6-21. 2 62. 1-25. 8 0-4. 7 AAATATTTCAAAGAGGAAAA 2844 SEQ ID NO : 3656 4. 6-12. 5 44. 2-16. 6-0. 2-5. 8 AAGCCTCAGTTTTGTAAAAT 3033 SEQ ID NO : 3657 4. 6-19. 4 59-23. 5-0. 2-4. 2 CAGCCATAAAAAGTCCAACC 3290 SEQ ID NO : 3658 4. 6-21. 9 61. 5-26. 5 0-3. 2 TGAAACACTTCTGGTTCCAA 3560 SEQ ID NO : 3659 4. 6-21. 5 63-24-2. 1-5. 8 CTCAGACAGATCCCCTTTTT 1162 SEQ ID NO : 3660 4. 7-25. 8 73. 3-30. 5 0-4. 5 TGCATTAGTGCCATAAAGGG 1364 SEQ ID NO : 3661 4. 7-22. 7 65. 6-25. 5-1. 9-7. 2 AGCTGCTTACACACAAATCT 2010 SEQ ID NO : 3662 4. 7-21. 8 64. 2-26. 5 0-6. 7 AACTAAGAAGAAATAGAAAC 2571 SEQ ID NO : 3663 4. 7-11. 6 42. 6-16. 3 0-2. 9 CTCAGCCATAAAAAGTCCAA 3292 SEQ ID NO : 3664 4. 7-21 60. 6-25. 7 0-3. 2 AGAAGCACACAATTGGCTTG 3471 SEQ ID NO : 3665 4. 7-21. 6 63. 3-23. 7-2. 6-10. 1 CCAAAAATCCAAAATCCGAA 3828 SEQ ID NO : 3666 4. 7-18 52. 3-22. 7 0-2. 8 ACACCATCCAAACAGAAAGA 2468 SEQ ID NO : 3667 4. 8-20. 2 58. 5-25 0-2. 2 TAATAACTAAGAAGAAATAG 2575 SEQ ID NO : 3668 4. 8-10. 9 41. 4-15. 7 0-2. 5 CTATATAAAAAAAAAAGTCC 3208 SEQ ID NO : 3669 4. 8-11. 3 41. 9-16. 1 0-3. 3 GAGCCGCCGGGAGGCAAGGA 10 SEQ ID NO : 3670 4. 9-31. 6 80. 7-32. 8-3. 7-13. 3 GCAGAGAAGGTGGAAAATGA 111 SEQ ID NO : 3671 4. 9-19. 7 58. 9-24. 6 0-3. 4 CTGGGGGACTGGAGGCAGAG 125 SEQ ID NO : 3672 4. 9-27. 5 77. 8-30. 7-1. 7-5. 2 TTTTAAAAAACAAAAACCAC 198 SEQ ID NO : 3673 4. 9-11. 7 42. 4-16. 6 0-6 CATCCACAAAATCTGCATCG 885 SEQ ID NO : 3674 4. 9-21. 6 61. 4-26. 5 0-4. 9 ATAGGGATAATAATAGTTGC 3015 SEQ ID NO : 3675 4. 9-17. 5 55. 6-22. 4 0-2. 6 TCAGTTTTGTAAAATAGGGA 3028 SEQ ID NO : 3676 4. 9-18. 1 57-22. 5-0. 2-4. 2 TGGTTATGTCTTCAGAAGTT 3424 SEQ ID NO : 3677 4. 9-21. 1 65. 9-26 0. 2-7. 1 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo GAGAAGCACACAATTGGCTT 3472 SEQ ID NO : 3678 4. 9-22. 2 64. 6-24. 7-2. 4-10. 1 TCTAAAATTTGAAACACTTC 3569 SEQ ID NO : 3679 4. 9-14. 8 49. 2-19. 7 0-5. 3 CCCTAATCCAAAAATCCAAA 3835 SEQ ID NO : 3680 4. 9-19. 9 56. 3-24. 8 0-1. 1 GAGAAGGTGGAAAATGAAAA 108 SEQ ID NO : 3681 5-15. 1 48. 9-20. 1 0-1. 2 AGGCAGAGAAGGTGGAAAAT 113 SEQ ID NO : 3682 5-20. 3 60. 3-25. 3 0-4 GTCAGTGCACTGGAAGGCAA 1130 SEQ ID NO : 3683 5-25. 2 72. 5-27. 1-1. 7-14. 4 TGCTATTACAACGGTTCTTG 1188 SEQ ID NO : 3684 5-21. 3 63. 2-26. 3 0-4. 7 TGTCGGAAGGACTTCTCACT 2168 SEQ ID NO : 3685 5-24 70-27. 4-1. 6-6. 8 CCATCCAAACAGAAAGAGGG 2465 SEQ ID NO : 3686 5-21. 5 61. 1-26. 5 0-3. 5 AAATAATCTAAAATTTGAAA 3575 SEQ ID NO : 3687 5-9. 9 39. 5-14. 9 0-5. 2 AAAATAATCTAAAATTTGAA 3576 SEQ ID No : 3688 5-9. 9 39. 5-14. 9 0-5. 2 TAATCCAAAAATCCAAAATC 3832 SEQ ID NO : 3689 5-14. 7 47. 7-19. 7 0-1. 1 GTGTGGAGGACATCCACAAA 895 SEQ ID NO : 3690 5. 1-23. 5 67. 4-23. 3-5. 3-11. 9 TGGAGTCAGTGCACTGGAAG 1134 SEQ ID NO : 3691 5. 1-24 70. 9-26-0. 4-14. 4 AAAAAAGCACTGTATTAAAT 2827 SEQ ID NO : 3692 5. 1-13. 4 45. 8-18. 5 0-4. 1 ATAATCTAAAATTTGAAACA 3573 SEQ ID NO : 3693 5. 1-12. 2 43. 7-17. 3 0-5. 2 GGAGCCCGGGCGGTGGCAGG 77 SEQ ID NO : 3694 5. 2-34. 7 88. 3-36. 1-2. 4-15. 7 AGAGAAGGTGGAAAATGAAA 109 SEQ ID NO : 3695 5. 2-15. 8 50. 5-21 0-1. 2 GTTAGAGCTATTCAAGAGAG 1953 SEQ ID NO : 3696 5. 2-19. 7 62-24. 4-0. 2-4. 5 TTAAAAAATGAACAGAAAAA 2343 SEQ ID NO : 3697 5. 2-8. 9 37. 7-14. 1 0-2. 4 CAGTAATATGTCCATTACCA 2404 SEQ ID NO : 3698 5. 2-21. 6 63. 8-25. 4-1. 3-5 ATATACACATACACCATCCA 2478 SEQ ID NO : 3699 5. 2-21. 8 63. 2-27 0-2. 4 TAAGAAGAAATAGAAACCAC 2568 SEQ ID NO : 3700 5. 2-14. 1 47. 1-19. 3 0-1. 2 TGTATTACATATGTCATAAC 2758 SEQ ID NO : 3701 5. 2-16. 8 54. 5-21. 5 0-8. 2 AAAATAGGGATAATAATAGT 3018 SEQ ID NO : 3702 5. 2-13. 5 46. 4-18. 7 0-1. 4 AATAATCTAAAATTTGAAAC 3574 SEQ ID NO : 3703 5. 2-10. 8 41. 2-16 0-5. 2 GAAGTTTTAAAAAACAAAAA 202 SEQ ID NO : 3704 5. 3-9. 7 39. 1-13. 1-1. 9-8. 8 TGGCCGACGGAGAGGTAGCA 442 SEQ ID NO : 3705 5. 3-28. 4 76. 5-33-0. 4-8. 2 AGCTCAGACAGATCCCCTTT 1164 SEQ ID NO : 3706 5. 3-27. 4 77. 2-32. 7 0-4. 5 1952 TTAGAGCTATTCAAGAGAGG 5. 3-19. 7 61. 4-24. 5-0. 2-5. 1 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter-, total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 3707 GGCACCCAGCTGCTTACACA 2017 SEQ ID NO : 3708 5. 3-29. 6 80. 3-33. 5-1. 3-8. 1 GCACATAATAACTAAGAAGG 2602 SEQ ID NO : 3709 5. 3-16. 6 52. 4-21. 9 0-3. 4 CAACCCTAATCCAAAAATCC 3838 SEQ ID NO : 3710 5. 3-20. 8 58. 3-26. 1 0-1. 1 TCAGTAATATGTCCATTACC 2405 SEQ ID NO : 3711 5. 4-21. 3 64-25. 3-1. 3-5 TAAGGGATACTCAACCTGTA 3530 SEQ ID NO : 3712 5. 4-21. 2 62. 9-25. 7-0. 7-4. 7 GCATTTTGGATAAGGGATAC 3540 SEQ ID NO : 3713 5. 4-20. 5 61. 9-25. 9 0-3. 4 TGAAAATAATCTAAAATTTG 3578 SEQ ID NO : 3714 5. 4-10. 6 40. 8-16 0-5. 2 CTCCAGAAACAGAGCAGAGG 268 SEQ ID NO : 3715 5. 5-23 66. 5-28. 5 0-4. 1 GGCTCCAGAAACAGAGCAGA 270 SEQsID NO : 3716 5. 5-24. 8 70. 4-27-3. 3-8 TATACACATACACCATCCAA 2477 SEQ ID NO : 3717 5. 5-21. 1 61. 3-26. 6 0-1. 5 AAACACGTCACTCATAGGGG 2627 SEQ ID NO : 3718 5. 5-22. 3 64. 4-27. 8 0-4. 6 TGGCACGATACAGATTAAAA 3387 SEQ ID NO : 3719 5. 5-18. 2 54. 9-23-0. 4-4 AATAATATGGGTTGAGCAAC 3854 SEQ ID NO : 3720 5. 5-18. 3 56. 4-23. 8 0-7. 3 CAGAGAAGGTGGAAAATGAA 110 SEQ ID NO : 3721 5. 6-17. 2 53. 3-22. 8 0-1. 6 AAAAAGCACTGTATTAAATC 2826 SEQ ID NO : 3722 5. 6-14. 5 48. 3-20. 1 0-3. 3 AATATTTCAAAGAGGAAAAA 2843 SEQ ID NO : 3723 5. 6-12. 5 44. 2-17. 2-0. 7-4. 9 AGAGAAGCACACAATTGGCT 3473 SEQ ID NO : 3724 5. 6-22. 1 64. 5-26. 8-0. 8-7. 4 CAACAAGACAAAAAATGGGA 3778 SEQ ID NO : 3725 5. 6-15. 2 48. 5-20. 8 0-2. 5 ACCAACAAGACAAAAAATGG 3780 SEQ ID NO : 3726 5. 6-15. 6 49. 1-20. 7-0. 2-3. 9 AAAATCCAAAATCCGAAATG 3825 SEQ ID NO : 3727 5. 6-15. 3 48. 1-20. 9 0-2. 8 GCCAGGGGCTGGGGGACTGG 133 SEQ ID NO : 3728 5. 7-32. 5 87. 5-35. 9-2. 3-8. 4 AAGTTTTAAAAAACAAAAAC 201 SEQ ID NO : 3729 5. 7-9. 3 38. 4-13. 1-1. 9-8. 8 AATAGCAGAGGCTCCAGAAA 279 SEQ ID NO : 3730 5. 7-22. 3 64. 7-26. 4-1. 5-5 GACAGATCCCCTTTTTGAAG 1158 SEQ ID NO : 3731 5. 7-23. 7 67. 6-28. 7-0. 4-5. 3 CTGAGAGGCCCCCTCCCAGG 1496 SEQ ID NO : 3732 5. 7-34. 3 87. 9-39. 5 0. 8-8. 6 CAGGCTGAGCAGCTGACAGC 2137 SEQ ID NO : 3733 5. 7-27. 7 79. 1-29. 3-2. 5-16. 4 TACACCATCCAAACAGAAAG 2469 SEQ ID NO : 3734 5. 7-19. 3 56. 8-25 0-2. 2 ATACACCATCCAAACAGAAA 2470 SEQ ID NO : 3735 5. 7-19. 3 56. 6-25 0-2. 2 CACTAAGCCTCAGTTTTGTA 3037 SEQ ID NO : 3736 5. 7-23 68. 6-28. 7 0-3. 2 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo CACCAACAAGACAAAAAATG 3781 SEQ ID NO : 3737 5. 7-15. 1 48. 1-20. 8 0-2. 1 CAAAAATCCAAAATCCGAAA 3827 SEQ ID NO : 3738 5. 7-15. 3 47. 9-21 0-2. 8 TCTGCATTAGTGCCATAAAG 1366 SEQ ID NO : 3739 5. 8-21. 6 63. 9-25. 5-1. 9-7. 2 GACTTCTCACTGAGGCTCAA 2159 SEQ ID NO : 3740 5. 8-24. 2 71. 4-30 0. 2-6 GAATCTCAGCCATAAAAAGT 3296 SEQ ID NO : 3741 5. 8-18. 9 57. 1-24. 7 0-3. 2 AGCATTTTGGATAAGGGATA 3541 SEQ ID NO : 3742 5. 8-20. 3 61. 5-26. 1 0-4. 1 AATCTAAAATTTGAAACACT 3571 SEQ ID NO : 3743 5. 8-13. 6 46. 4-19. 4 0-5. 2 CCAACAAGACAAAAAATGGG 3779 SEQ ID NO : 3744 5. 8-16. 6 50. 8-22. 4 0-3. 4 AATCCGAAATGCTCCAAAAT 3816 SEQ ID NO : 3745 5. 8-19. 4 55. 8-25. 2 0-3. 6 CCTAATCCAAAAATCCAAAA 3834 SEQ ID NO : 3746 5. 8-17. 2 51. 6-23 0-1. 1 TGAGCCGCCGGGAGGCAAGG 11 SEQ ID NO : 3747 5. 9-31 79. 3-32. 7-4. 2-13. 3 CTGGAGGCAGAGAAGGTGGA 117 SEQ ID NO : 3748 5. 9-25. 1 72. 5-30. 1-0. 8-4 TTTAAAAAACAAAAACCACC 197 SEQ ID NO : 3749 5. 9-13. 6 45. 4-19. 5 0-4 CCAGAAACAGAGCAGAGGAA 266 SEQ ID NO : 3750 5. 9-21. 6 62. 5-27. 5 0-4. 1 GCTCCAGAAACAGAGCAGAG 269 SEQ ID NO : 3751 5. 9-23. 6 68. 1-27-2. 5-7. 4 CTGCATTAGTGCCATAAAGG 1365 SEQ ID NO : 3752 5. 9-22. 4 65-26. 4-1. 9-7. 2 CCCAGCTGCTTACACACAAA 2013 SEQ ID NO : 3753 5. 9-25. 2 69. 1-30. 6 0-8. 1 GTAATATGTCCATTACCACA 2402 SEQ ID NO : 3754 5. 9-21. 8 64. 1-27-0. 5-4. 8 TGGAGAGGCTCAGTAATATG 2414 SEQ ID NO : 3755 5. 9-21. 3 64. 6-26-1. 1-5 CGAATCTCAGCCATAAAAAG 3297 SEQ ID NO : 3756 5. 9-18. 5 55. 1-24. 4 0-3. 2 GGGGGACTGGAGGCAGAGAA 123 SEQ ID NO : 3757 6-26. 5 74. 8-30. 8-1. 7-4. 7 TGGGGGACTGGAGGCAGAGA 124 SEQ ID NO : 3758 6-27. 2 77. 1-31. 5-1. 7-4. 7 GATAGCAGGAAGTCTTGCTG 1785 SEQ ID NO : 3759 6-23. 2 69. 3-27. 4-1. 8-9. 9 AGGCTCAGTAATATGTCCAT 2409 SEQ ID NO : 3760 6-23. 2 69-28. 7-0. 1-4. 1 ATAAGGGATACTCAACCTGT 3531 SEQ ID NO : 3761 6-21. 5 63. 4-26. 8-0. 5-3. 9 CAATAATATGGGTTGAGCAA 3855 SEQ ID NO : 3762 6-18. 8 57. 1-24. 8 0-4. 1 AAAAAACAAAAACCACCTCT 194 SEQ ID NO : 3763 6. 1-15. 9 49. 3-22 0 0 GACTTGCCCGGGCACCCTCA 1753 SEQ ID NO : 3764 6. 1-33. 5 85. 2-35. 4--1. 3-16. 6 CAAGACTTGCCCGGGCACCC 1756 SEQ ID NO : 3765 6. 1-31. 5 79. 7-33. 4-1. 3-16. 6 2413 GGAGAGGCTCAGTAATATGT 6. 1-22. 5 68. 1-27. 4-1. 1-5 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 3766 ATGTGGCTGAACCTCACTAA 3051 SEQ ID NO : 3767 6. 1-23. 3 67-28. 4-0. 9-5. 2 CAGCCAATAATATGGGTTGA 3859 SEQ ID NO : 3768 6. 1-21. 5 62. 6-26. 6-0. 9-5 ATATTTCAAAGAGGAAAAAA 2842 SEQ ID NO : 3769 6. 2-12. 5 44. 2-17. 8-0. 7-4. 9 TCAGCCATAAAAAGTCCAAC 3291 SEQ ID NO : 3770 6. 2-20. 3 59. 3-26. 5 0-3. 2 AAGAGAAGCACACAATTGGC 3474 SEQ ID NO : 3771 6. 2-20. 5 60. 6-26. 1-0. 3-7. 2 TAATCTAAAATTTGAAACAC 3572 SEQ ID No : 3772 6. 2-12. 4 44. 2-18. 6 0-5. 2 AAGACTTGCCCGGGCACCCT 1755 SEQ ID NO : 3773 6. 3-31. 7 80. 5-33. 8-1. 3-16. 6 GGGCCTCTTCGGAGCCAGCG 2107 SEQ ID NO : 3774 6. 3-32. 6 85. 4-35. 4-3. 5-10. 2 GGCTGAGCAGCTGACAGCCT 2135 SEQ ID NO : 3775 6. 3-29. 9 83. 3-30. 3-4. 3-20 CACTCATAGGGGAGGTGGCA 2619 SEQ ID NO : 3776 6. 3-26. 9 77. 1-32. 4-0. 6-4. 9 GGAAAAAAAGCACTGTATTA 2830 SEQ ID NO : 3777 6. 4-15. 9 50. 7-22. 3 0-4. 1 TCAACTGGTTATGTCTTCAG 3429 SEQ ID NO : 3778 6. 4-21. 4 66-27. 3-0. 1-6 ATCTAAAATTTGAAACACTT 3570 SEQ ID NO : 3779 6. 5-14. 4 48. 1-20. 9 0-4. 7 ATAATATGGGTTGAGCAACC 3853 SEQ ID NO : 3780 6. 5-21 62-25. 8-1. 6-10. 9 ACTAAGCCTCAGTTTTGTAA 3036 SEQ ID NO : 3781 6. 6-21. 6 65. 1-28. 2 0-2. 4 TTTGAAACACTTCTGGTTCC 3562 SEQ ID NO : 3782 6. 6-21. 7 64. 6-26. 2-2. 1-4. 8 TCCAGAAACAGAGCAGAGGA 267 SEQ ID No : 3783 6. 7-22. 7 65. 9-29. 4 0-4. 1 AGACTTGCCCGGGCACCCTC 1754 SEQ ID NO : 3784 6. 7-32. 8 84. 7-35. 4-1. 3-16. 3 CTCAGTAATATGTCCATTAC 2406 SEQ ID NO : 3785 6. 7-20. 2 62. 1-25. 9-0. 9-4. 6 GTGGCCGACGGAGAGGTAGC 443 SEQ ID NO : 3786 6. 8-28. 9 78. 8-35. 2 0-8. 2 CTTGTGGATGTCGGCCCCTT 851 SEQ ID NO : 3787 6. 8-30. 4 81. 5-37. 2 0-6. 2 CTAAGCCTCAGTTTTGTAAA 3035 SEQ ID NO : 3788 6. 8-20. 7 62. 3-27. 5 0-3. 2 AGCCATAAAAAGTCCAACCG 3289 SEQ ID NO : 3789 6. 8-22 60. 8-28. 8 0-3. 2 GGCACGATACAGATTAAAAC 3386 SEQ ID NO : 3790 6. 8-18. 4 55. 5-25. 2 0-4 GGCACGGAGCCCGGGCGGTG 82 SEQ ID NO : 3791 6. 9-34. 5 85. 4-36. 2-5. 2-16. 3 TTAAAAAACAAAAACCACCT 196 SEQ ID NO : 3792 6. 9 -14. 4 46. 7-21. 3 0-2 AAGGTGGAAAATGAAAACTT 105 SEQ ID NO : 3793 7-15. 1 48. 9-22. 1 O.-2. 6 GAGAGGCTCAGTAATATGTC 2412 SEQ ID NO : 3794 7-21. 7 67-28. 1-0. 3-5. 1 GACAAAAAATGGGAAAACCC 3772 SEQ ID NO : 3795 7-17. 1 51. 3-23. 4-0. 4-5. 4 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo CAGCTGCTTACACACAAATC 2011 SEQ ID NO : 3796 7. 2-21. 6 63. 5-28. 8 0-7. 2 AGTAATATGTCCATTACCAC 2403 SEQ ID NO : 3797 7. 2-21. 1 63. 1-26. 9-1. 3-5 AATCTCAGCCATAAAAAGTC 3295 SEQ ID NO : 3798 7. 2-18. 7 57. 1-25. 9 0-3. 2 AATTTGAAACACTTCTGGTT 3564 SEQ ID NO : 3799 7. 2-18. 6 57. 4-25. 2-0. 3-3. 8 CCAATAATATGGGTTGAGCA 3856 SEQ ID NO : 3800 7. 2-21. 5 62. 6-28. 2-0. 2-4. 5 GCACGGAGCCCGGGCGGTGG 81 SEQ ID NO : 3801 7. 3-34. 5 85. 4-37. 2-4. 4-16. 7 CGAGGCTGTAGCCGATCAAG 744 SEQ ID NO : 3802 7. 3-25. 8 70. 9-30. 6-2. 5-10. 5 ACATCCACAAAATCTGCATC 886 SEQ ID NO : 3803 7. 3-21 61. 5-28. 3 0-4. 9 GGTTCTTGCGGCAGCTCAGA 1176 SEQ ID NO : 3804 7. 3-28. 6 81. 4-34. 5-1. 3-8 TCCAAGCATTTTGGATAAGG 3545 SEQ ID NO : 3805 7. 3-21. 2 62. 5-25. 7-2. 8-7. 8 AATATGGGTTGAGCAACCCT 3851 SEQ ID No : 3806 7. 3-24. 2 68-27. 9-3. 4-14. 6 ATATGGGTTGAGCAACCCTA 3850 SEQ ID NO : 3807 7. 4-24. 6 69. 6-27. 9-4. 1-15. 3 ACCATCCAAACAGAAAGAGG 2466 SEQ ID NO : 3808 7. 5-20. 5 59. 3-28 0-3. 6 AAATTTGAAACACTTCTGGT 3565 SEQ ID NO : 3809 7. 5-17. 8 55. 3-24. 4-0. 7-5. 8 AAATCCGAAATGCTCCAAAA 3817 SEQ ID NO : 3810 7. 5-18. 7 54. 3-26. 2 0-3. 6 AAAATCCGAAATGCTCCAAA 3818 SEQ ID NO : 3811 7. 5-18. 7 54. 3-26. 2 0-3. 6 AGCAACCCTAATCCAAAAAT 3840 SEQ ID NO : 3812 7. 5-20. 2 57. 5-27. 7 0-4. 1 GAAGGTGGAAAATGAAAACT 106 SEQ ID NO : 3813 7. 6-15. 6 49. 8-23. 2 0-2. 6 TAAGCCTCAGTTTTGTAAAA 3034 SEQ ID NO : 3814 7. 6-19. 1 58. 4-26. 7 0-4 CGAAATGCTCCAAAATCCAA 3812 SEQ ID NO : 3815 7. 7-20. 1 56. 9-27. 8 0-3. 6 GGCCAGGGGCTGGGGGACTG 134 SEQ ID NO : 3816 7. 8-32. 5 87. 5-37. 9-2. 4-9. 1 ATACACATACACCATCCAAA 2476 SEQ ID NO : 3817 7. 8-20. 7 59. 9-28. 5 0-0. 9 TTGAAACACTTCTGGTTCCA 3561 SEQ ID NO : 3818 7. 8-22. 3 65. 4-28-2. 1-5. 8 GGAGTCAGTGCACTGGAAGG 1133 SEQ ID NO : 3819 7. 9-25. 2 73. 8-30. 3-0. 2-13. 8 GACAGGTAGCTGCGAAACTC 1537 SEQ ID NO : 3820 7. 9-23. 6 67. 8-29. 9-1. 5-3. 5 AACAAGACAAAAAATGGGAA 3777 SEQ ID NO : 3821 7. 9-13. 8 46-21. 7 0-2. 5 CAAAATCCGAAATGCTCCAA 3819 SEQ ID NO : 3822 7. 9-20. 1 56. 9-28 0-3. 6 CAAAGAGGAAAAAAAGCACT 2836 SEQ ID NO : 3823 8-15. 1 48. 5-23. 1 0-4. 1 CAGCTCAGACAGATCCCCTT 1165 SEQ ID NO : 3824 8. 1-28 77. 8-36. 1 0-4. 5 2471 CATACACCATCCAAACAGAA 8. 1-20. 7 59. 5-28. 8 0-2. 2 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 3825 AAGAGGAAAAAAAGCACTGT 2834 SEQ ID NO : 3826 8. 2-16. 3 51. 3-24. 5 0-4. 1 ATTTGAAACACTTCTGGTTC 3563 SEQ ID NO : 3827 8. 2-19. 7 60. 8-26. 2-1. 7-5. 5 ACAAGACAAAAAATGGGAAA 3776 SEQ ID NO : 3828 8. 2-13. 8 46-22 0-2. 5 GGCAGCTCAGACAGATCCCC 1167 SEQ ID NO : 3829 8. 3-30 82. 5-38. 3 0-5 TATTTCAAAGAGGAAAAAAA 2841 SEQ ID NO : 3830 8. 3-11. 8 42. 8-19. 2-0. 7-4. 9 TAAAATAGGGATAATAATAG 3019 SEQ ID NO : 3831 8. 3-12 43. 4-20. 3 0-1. 4 GCAACCCTAATCCAAAAATC 3839 SEQ ID NO : 3832 8. 4-20. 6 58. 5-29 0-3. 4 AGAAGGTGGAAAATGAAAAC 107 SEQ ID NO : 3833 8. 5-14. 7 48. 2-23. 2 0-1. 9 CGGTTCTTGCGGCAGCTCAG 1177 SEQ ID NO : 3834 8. 5-28. 8 79. 5-35. 9-1. 3-7. 8 TCAAAGAGGAAAAAAAGCAC 2837 SEQ ID NO : 3835 8. 5-14. 6 47. 8-23. 1 0-4. 1 TGGGTTGAGCAACCCTAATC 3847 SEQ ID NO : 3836 8. 5-24. 6 69. 5-29-4. 1-15. 3 AGAAACAGAAGTTTTAAAAA 209 SEQ ID NO : 3837 8. 6-12. 4 44. 1-19. 2-1. 8-6. 8 TTCAAAGAGGAAAAAAAGCA 2838 SEQ ID NO : 3838 8. 6-14. 5 47. 7-23. 1 0-4. 1 GTTCTTGCGGCAGCTCAGAC 1175 SEQ ID NO : 3839 8. 7-27. 6 79. 3-34. 9-1. 3-8 AAAGAGGAAAAAAAGCACTG 2835 SEQ ID NO : 3840 8. 7-14. 4 47. 4-23. 1 0-4. 1 GATAAGGGATACTCAACCTG 3532 SEQ ID NO : 3841 8. 8-20. 9 61. 7-28. 8-0. 7-4. 7 AGAGGAAAAAAAGCACTGTA 2833 SEQ ID NO : 3842 8. 9-16. 7 52. 4-25. 6 0-4. 1 AGCCAATAATATGGGTTGAG 3858 SEQ ID No : 3843 8. 9-20. 8 61. 7-28. 7-0. 9-4. 5 AAAGCAATAGCAGAGGCTCC 284 SEQ ID NO : 3844 9-23. 5 67. 5-30. 8-1. 7-8. 1 CATTTTGGATAAGGGATACT 3539 SEQ ID NO : 3845 9-19. 6 59. 7-27. 7-0. 7-3. 3 TAATATGGGTTGAGCAACCC 3852 SEQ ID NO : 3846 9-23 65. 6-28. 5-3. 3-14. 3 ATGGGTTGAGCAACCCTAAT 3848 SEQ ID NO : 3847 9. 1-24. 2 68-29. 2-4. 1-15. 3 AATGGTAAACTCTGAAAGGC 1278 SEQ ID NO : 3848 9. 2-18. 6 56. 7-27. 8 0-3. 8 AGAGGCCCCAGGCACCCAGC 2027 SEQ ID NO : 3849 9. 2-34. 7 89. 5-41. 4-2. 5-7. 8 GAGAGGCCCCAGGCACCCAG 2028 SEQ ID NO : 3850 9. 2-33. 5 86. 5-41-1. 7-7. 1 CAAACAGAAAGAGGGTCTAG 2460 SEQ ID NO : 3851 9. 2-18. 6 57. 1-27. 8 0-3. 4 ACTGGAGGCAGAGAAGGTGG 118 SEQ ID NO : 3852 9. 3-24. 7 71. 8-32. 3-1. 7-4. 7 TTGTGGATGTCGGCCCCTTC 850 SEQ ID NO : 3853 9. 3-29. 9 81. 4-39. 2 0-6. 2 TATGGGTTGAGCAACCCTAA 3849 SEQ ID NO : 3854 9. 3-23. 9 67. 5-29. 1-4. 1-15. 3 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo TAAAAAACAAAAACCACCTC 195 SEQ ID NO : 3855 9. 4-14. 7 47. 3-24. 1 0 0 GAGGCTCCAGAAACAGAGCA 272 SEQ ID NO : 3856 9. 4-24. 8 70. 4-30. 9-3. 3-8 AAAATTTGAAACACTTCTGG 3566 SEQ ID NO : 3857 9. 5-15. 9 50. 9-24. 5-0. 7-5. 8 GGGTTGAGCAACCCTAATCC 3846 SEQ ID NO : 3858 9. 6-26. 6 73. 1-32. 6-3. 4-14. 5 AGGCTCCAGAAACAGAGCAG 271 SEQ ID NO : 3859 9. 7-24. 2 69. 4-30. 6-3. 3-8 CAAGACAAAAAATGGGAAAA 3775 SEQ ID NO : 3860 9. 7-12. 9 44. 3-22. 6 0-2. 2 GAGCAACCCTAATCCAAAAA 3841 SEQ ID NO : 3861 9. 7-20. 8 58. 6-30. 5 0-4. 1 CTAAAATTTGAAACACTTCT 3568 SEQ ID NO : 3862 10-15. 3 49. 9-24. 4-0. 7-5. 8 TGAGCAACCCTAATCCAAAA 3842 SEQ ID NO : 3863 10-21. 5 60. 3-31. 5 0-4. 1 GAAACAGAAGTTTTAAAAAA 208 SEQ ID NO : 3864 10. 1-11. 7 42. 7-20-1. 8-6. 8 CTGTGGCCGACGGAGAGGTA 445 SEQ ID NO : 3865 10. 1-28 76-37. 5-0. 1-8. 2 GGTTGAGCAACCCTAATCCA 3845 SEQ ID NO : 3866 10. 1-26. 1 71. 7-34. 8-1. 2-10. 1 CAGCAATCCCGGCCGGTAAG 165 SEQ ID NO : 3867 10. 4-28. 9 74. 3-36. 3-0. 1-14. 2 TTCTTGCGGCAGCTCAGACA 1174 SEQ ID NO : 3868 10. 8-27. 1 76. 8-36. 7-1. 1-7. 8 GCCAATAATATGGGTTGAGC 3857 SEQ ID NO : 3869 11. 1-22. 6 65. 5-32. 7-0. 9-4. 5 GGATAAGGGATACTCAACCT 3533 SEQ ID NO : 3870 11. 4-22. 1 64. 3-32. 6-0. 7-4. 6 AGGCTGAGCAGCTGACAGCC 2136 SEQ ID NO : 3871 11. 5-29 81. 6-34. 6-4. 3-20 CACCATCCAAACAGAAAGAG 2467 SEQ ID NO : 3872 11. 5-20 58. 1-31. 5 0-2. 2 ATTTCAAAGAGGAAAAAAAG 2840 SEQ ID NO : 3873 11. 5-12. 1 43. 4-22. 7-0. 7-4. 9 GAGGCCCCAGGCACCCAGCT 2026 SEQ ID NO : 3874 11. 7-35. 6 90. 9-44. 8-2. 5-8. 7 CACATACACCATCCAAACAG 2473 SEQ ID NO : 3875 11. 8-21. 7 61. 8-33. 5 0-0. 9 TACACATACACCATCCAAAC 2475 SEQ ID NO : 3876 11. 9-20. 9 60. 4-32. 8 0-0. 9 AGGAAAAAAAGCACTGTATT 2831 SEQ ID NO : 3877 12. 1-16. 2 51. 4-28. 3 0-4. 1 TGTGGCTGAACCTCACTAAG 3050 SEQ ID NO : 3878 12. 1-23. 3 67. 3-34. 4-0. 9-5. 2 ATTTTGGATAAGGGATACTC 3538 SEQ ID NO : 3879 12. 1-19. 3 59. 8-30. 5-0. 7-3. 3 GGCCCCAGGCACCCAGCTGC 2024 SEQ ID NO : 3880 12. 2-36. 8 93. 3-46. 5-2. 5-12. 1 ACATACACCATCCAAACAGA 2472 SEQ ID NO : 3881 12. 2-21. 6 61. 8-33. 8 0-2 ACACATACACCATCCAAACA 2474 SEQ ID NO : 3882 12. 2-21. 9 62. 1-34. 1 0-0. 7 TTTCAAAGAGGAAAAAAAGC 2839 SEQ ID NO : 3883 12. 2-13. 9 46. 7-25. 6-0. 2-4. 4 3047 GGCTGAACCTCACTAAGCCT 12. 2-26. 8 73. 9-36. 8-2. 2-7. 1 kcal/kcal/kcal/ mol mol deg C mol kcal/mol kcal/mol duplex target Intra-Inter- total form-Tm of struc-molecular molecular position oligo binding ation Duplex ture oligo oligo SEQ ID NO : 3884 GTGGCTGAACCTCACTAAGC 3049 SEQ ID NO : 3885 12. 4-25. 1 71. 6-36. 6-0. 8-5. 1 TTTTGGATAAGGGATACTCA 3537 SEQ ID NO : 3886 12. 4-20 61. 1-31. 5-0. 7-4 TGTGGCCGACGGAGAGGTAG 444 SEQ ID NO : 3887 12. 6-27. 1 74. 4-39. 1-0. 1-8. 2 TCTTGCGGCAGCTCAGACAG 1173 SEQ ID NO : 3888 12. 7-27 76. 7-38. 3-1. 3-8. 7 TGGCTGAACCTCACTAAGCC 3048 SEQ ID NO : 3889 12. 8-25. 9 71. 9-36. 6-2. 1-6. 9 AGGCCCCAGGCACCCAGCTG 2025 SEQ ID NO : 3890 12. 9-35 89. 4-45. 4-2. 5-11. 8 TAAAATTTGAAACACTTCTG 3567 SEQ ID NO : 3891 12. 9-14. 4 48. 1-26. 4-0. 7-5. 8 CGGCAGCTCAGACAGATCCC 1168 SEQ ID NO : 3892 13-28. 8 78. 6-41. 8 0-5 ACGGTTCTTGCGGCAGCTCA 1178 SEQ ID NO : 3893 13. 1-29 79. 8-40. 7-1. 3-7. 8 GAGGAAAAAAAGCACTGTAT 2832 SEQ ID NO : 3894 13. 1-16. 7 52. 3-29. 8 0-4. 1 TTGAGCAACCCTAATCCAAA 3843 SEQ ID NO : 3895 13. 1-22. 3 62. 4-35. 4 0-4. 1 GCAGCTCAGACAGATCCCCT 1166 SEQ ID NO : 3896 13. 4-29. 7 81. 8-43. 1 0-4. 5 AAGACAAAAAATGGGAAAAC 3774 SEQ ID NO : 3897 13. 5-12. 4 43. 6-25. 9 0-2. 5 GTTGAGCAACCCTAATCCAA 3844 SEQ ID NO : 3898 13. 6-24. 2 67. 2-37. 8 0-6. 5 CTTGCGGCAGCTCAGACAGA 1172 SEQ ID NO : 3899 13. 7-27. 2 76. 3-39. 5-1. 3-8. 7 AGACAAAAAATGGGAAAACC 3773 SEQ ID NO : 3900 14. 2-15. 1 48. 2-29. 3 0-2. 9 AACGGTTCTTGCGGCAGCTC 1179 SEQ ID NO : 3901 14. 5-27. 6 76. 2-40. 7-1. 3-7. 8 TGGATAAGGGATACTCAACC 3534 SEQ ID NO : 3902 14. 5-21. 2 62. 3-34. 8-0. 7-4. 2 CAACGGTTCTTGCGGCAGCT 1180 SEQ ID NO : 3903 14. 6-27. 9 75. 6-41. 1-1. 3-7. 8 GCGGCAGCTCAGACAGATCC 1169 SEQ ID NO : 3904 15-28. 6 79. 4-42. 8-0. 6-7 TTGCGGCAGCTCAGACAGAT 1171 SEQ ID NO : 3905 16. 6-26. 3 74. 3-41. 5-1. 3-8. 7 TTTGGATAAGGGATACTCAA 3536 SEQ ID NO : 3906 17. 1-19. 2 58. 8-35. 4-0. 7-5 TGCGGCAGCTCAGACAGATC 1170 SEQ ID NO : 3907 17. 7-26. 6 75. 7-42. 9-1. 3-7. 8 TTGGATAAGGGATACTCAAC 3535 SEQ ID NO : 3908 19. 4-19. 3 59-37. 8-0. 7-4. 9 Example 15 Western blot analysis of EL protein levels

[00178] Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to EL is used, with a radiolabeled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGERTM (Molecular Dynamics, Sunnyvale CA).